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IntRoDuCtIon to hEPAtItIS C VIRuS InfECtIonS
Hepatitis C virus (HCV) infections have a major impact on global healthcare, since it 
is estimated that 130-150 million people are infected with HCV worldwide. The major 
long-term complication caused by the virus is liver cirrhosis, which can eventually lead 
to hepatocellular carcinoma (HCC), liver transplantation, or death[1]. 
HCV is a positive, single stranded RNA virus, which replicates in the hepatocyte. Around 
1010 to 1012 HCV particles can be generated per day and these particles remain available 
in the body for 2-3 hours. There is a high occurrence of resistant-associated substitu-
tions (RAS), which appear naturally or are caused by drug selective pressure. These RAS 
are caused by the high replication rate and the low fidelity of the HCV polymerase 
(prone to error)[2]. 
HCV is transmitted through blood-blood contact and only transferred among humans. 
The main routes for transmission are intravenous drug use or high risk sexual activity[3]. 
Other routes are mother-to-child transmission, medical procedures (e.g. dialysis), and 
transfusion of unscreened blood and blood products[1]. After infection, there is an acute 
phase in which approximately 20% of infected patients clear the virus. The other 80% of 
patients becomes chronically infected[3]. 
HCV causes permanent damage to the liver, which can eventually lead to cirrhosis. De-
velopment of cirrhosis is a slow process. Around 15-30% of patients develops cirrhosis 
within 20 years of infection[1]. Compensated cirrhosis is an asymptomatic phase in which 
there is already function loss of the liver (Child-Pugh [CP] class A). This can transfer to a 
state of decompensated cirrhosis (CP-B/C or Model for End-Stage Liver Disease [MELD] 
score >10) which includes complications such as ascites, hepatic encephalopathy, and 
portal hypertension[4, 5] (Figure 1). Decompensated patients with a MELD score >15 
have an indication for liver transplantation in the Netherlands[6]. Lastly, cirrhosis caused 
by a viral infection is a major risk factor for development of HCC[5]. 
Aside from hepatic disease, HCV patients can suffer from several extra hepatic com-
plications, such as insulin resistance (Type-2 diabetes mellitus [T2DM]), renal diseases 
(mixed cryoglobulinemia), depression, and/or cardiovascular events[7, 8] (Figure 1). 
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figure 1: overview of hepatic and extra hepatic complications of hCV infection. Data 
adapted from negro[7] and Moller et al[4].
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tREAtMEnt of thE hEPAtItIS C VIRuS
The goal of HCV treatment is to eradicate the virus and therefore preventing progression 
of liver disease and its complications. If the patient already has cirrhosis the progression 
to a worse state of disease is attempted to be prevented. Clearance of the virus 12 
weeks after completion of treatment is called sustained virological response (SVR12) 
and is the primary outcome measure in HCV treatment.
Treatment options and efficacy of HCV treatment has rapidly changed over the last 
years. As shown in Figure 2, a major increase in patients reaching SVR12 was accom-
plished with the introduction of telaprevir and boceprevir[9]. Telaprevir and boceprevir 
were used in combination with peg-interferon alfa 2a/2b (subcutaneous injection) and 
ribavirin. 
Telaprevir and boceprevir are oral drugs that directly target HCV and are therefore called 
direct-acting antivirals (DAAs). From 2014 onwards, more oral DAAs have become avail-
able with even higher response rates, shorter treatment duration (8-12 weeks instead 
of 24-48 weeks), and better safety profiles[10]. To date, the drugs listed in Table 1 are 
licensed in Europe[11-15] and the United States[16, 17].
table 1: overview of the available DAAs in 2017.
Class Drug name
Protease inhibitors Telaprevira, boceprevir, simeprevir, grazoprevir, 
paritaprevir/ritonavir
Nonstructural protein 5A (NS5A) inhibitors Daclatasvir, ledipasvir, elbasvir, velpatasvir, ombitasvir
Nonstructural protein 5B (NS5B) inhibitors Sofosbuvir, dasabuvir
aTelaprevir was withdrawn from the market by the manufacturer in 2015.
In general, patients are treated with at least two DAAs. The options are 1) an NS5B 
polymerase inhibitor in combination with an NS5A inhibitor and/or a protease inhibitor 
or 2) a protease inhibitor with an NS5A inhibitor (Figure 2, x-axis)[18]. 
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figure 2: overview of the various treatment regimens for chronic hCV genotype 1 infec-
tion, SVR-rates, and costs per month (based on genotype 1). 
Data adapted from EASL guidelines 2016[18] and http://www.medicijnkosten.nl (April 2017). 
IFN: Interferon; Peg-IFN: Peg-interferon alfa 2a or 2b; RBV: Ribavirin; BOC/TEL: Boceprevir or telaprevir; SOF: Sofos-
buvir; SIM: Simeprevir; DCV: Daclatasvir; LDV: Ledipasvir; PrOD: Paritaprevir/ritonavir, ombitasvir, and dasabuvir; 
GZR: Grazoprevir; EBR: Elbasvir; VEL: Velpatasvir.
SElECtInG thE RIGht CoMbInAtIon of DIRECt-ACtInG 
AntIVIRAlS
We could state that all combinations of DAAs are equally effective and in real-life 
SVR-rates >90% can be reached[19-21]. However, for selection of the right DAA regimen, 
the physician must deal with several aspects of DAA treatment. First, it is necessary to 
determine the genotype of the virus. There are 6 genotypes and various numbers of 
subtypes (a, b, c, etc.)[2] and only a few approved drugs are effective against all geno-
types (pan-genotypic). For example, dasabuvir can only be used in genotype 1 patients 
and velpatasvir is considered pan-genotypic[13, 17]. 
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Secondly, the physician must be informed whether the patient is treatment-experi-
enced and/or has cirrhosis. Both these characteristics influence the chance of reaching 
SVR. When treating these patients, it is recommended to prolong treatment from 12 to 
24 weeks or to add ribavirin (12 weeks of treatment). Of course, other patient charac-
teristics such as renal function and co-morbidities (hemophilia) must also be taken into 
account when selecting a regimen[18]. 
Another aspect that complicates treatment are (baseline) RAS which could influence 
treatment-outcome[22]. RAS testing could help us with selecting the right regimen, 
deciding on treatment duration, and adding ribavirin yes or no. However, the exact 
role in daily practice is still under debate as international guidelines give conflicting 
recommendations[18, 23].
The last aspect that I would like to discuss is the use of co-medication and the risk of 
drug-drug interactions (DDIs). These DDIs must be recognized and managed before 
initiation of DAA therapy, since drug-interactions could cause unnecessary toxicity or 
loss of efficacy[24, 25]. 
A final note is that novel DAA therapy is extremely expensive and that we are obliged to 
society to treat these patients effectively, both in terms of costs and treatment success 
(Figure 2). 
outlInE of thIS thESIS
As discussed, we have highly effective drugs, and if we use these drugs wisely we can 
probably eradicate HCV if the medical community is willing and able to detect all 
the infected individuals[26, 27]. However, there are still gaps in our knowledge when it 
comes to the optimal use of DAAs. Examples of knowledge gaps are: the use of DAAs 
in special patient populations, DAAs in combination with co-medication, and the use 
of ribavirin. As a pharmacist investigating the pharmacology of DAAs and ribavirin, I 
aimed to contribute to the optimization of HCV therapy and therefore eradication of 
the virus. The aim of this thesis was to answer pharmacological issues concerning current 
HCV therapy including novel DAAs and ribavirin, which can be used for the optimization of 
HCV treatment.
As a result, this thesis focuses on four major topics:
1) DDIs involving the DAAs. DAAs can both be victims and perpetrators of drug-
interactions and these interactions are relatively new in the field of hepatology. In 
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addition, despite studies described in the drug label, there is still information missing 
about drug-interactions and DAAs. 
2) Ribavirin pharmacokinetics and therapeutic drug monitoring (TDM). Ribavirin is still 
part of HCV therapy and the pharmacokinetics of ribavirin have not yet been studied 
with the novel DAAs. 
3) Treatment of HCV with DAAs in special patient populations. With introduction of 
the novel DAAs, little information about special patients was available and therefore 
studied in this thesis. 
4) A pharmacist’s contribution to eradicate HCV is the last part of this thesis and de-
scribes five special patients where we illustrate that knowledge of clinical pharmacol-
ogy is helpful to select the right treatment for individual patients.
Part 1: Drug-drug interactions involving direct-acting antivirals
DAAs are extensively metabolized by liver enzymes which makes them potential vic-
tims of drug-interactions. This means that the plasma concentration of the DAA can be 
affected by another drug (perpetrator, the cause of the drug-interaction). Altered drug 
levels could cause toxicity in case of increased drug levels, or loss of efficacy in case of 
decreased drug levels[24]. With respect to DAAs, lower exposure could mean that the 
HCV virus becomes resistant to the drug, probably leading to treatment failure and 
therefore harder to re-treat the infection in the future[22]. On the other hand, DAAs can 
also be perpetrators of DDIs themselves: they influence several drug-transporters and 
metabolizing enzymes altering plasma concentrations of co-medication[25].
Psychoactive drugs undergo extensive hepatic metabolism and are widely used in HCV-
infected patients. Use of psychoactive drugs in this population is high, as there is a high 
prevalence for mental disorders[28-30]. This makes it reasonable that both psychoactive 
drugs and DAAs are combined in HCV patients with a risk for DDIs as a consequence. 
For the various DAAs little information about DDIs with psychoactive drugs is available 
and therefore, we aimed to give an overview of the available information about DDIs 
between psychoactive drugs and DAAs in Chapter 1. 
When drugs are licensed by the regulatory agencies, drug labels become available. 
These labels contain information about pre-marketing studies concerning DDIs. This 
DDI information is derived from both in vitro and in vivo DDI studies. After release, the 
label is often the only source of DDI information for physicians and pharmacists. From 
a clinical, academic point of view, information in the drug label concerning DDIs is 
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discussed using two recently approved agents, i.e. grazoprevir plus elbasvir[16] and 
velpatasvir plus sofosbuvir[17] (Chapter 2). 
HCV and insulin resistance/type 2 diabetes mellitus are associated, so drugs for both 
diseases are commonly co-administered[31-34]. Daclatasvir is a DAA used for HCV treat-
ment and metformin is the first drug of choice for T2DM. Metformin is not metabolized 
but a substrate of various drug-transporters, namely plasma membrane monoamine 
transporter (PMAT), organic cation transporter (OCT) 1, 2 and 3 and multidrug and toxin 
extrusion protein (MATE) 1 and 2K[35]. When co-administered with daclatasvir, there 
might be a DDI as daclatasvir inhibits OCT1/2, at least in vitro[14]. This interaction had not 
been studied in vitro nor in vivo. In Chapter 3 we performed a randomized, cross-over 
study in healthy volunteers to determine the effect of daclatasvir on metformin phar-
macokinetics. Our hypothesis was that daclatasvir would increase metformin exposure.
An HIV/HCV co-infection is commonly seen[36]. HIV is treated with antiretroviral therapy, 
which includes different classes of drugs such as integrase inhibitors, protease inhibitors, 
and (non)-nucleoside reverse transcriptase inhibitors. Atazanavir is a protease inhibitor 
that is combined with the CYP3A4 boosters ritonavir or cobicistat[37, 38]. Daclatasvir is 
substrate of CYP3A4 and in combination with atazanavir/ritonavir[39, 37] the dose of da-
clatasvir must be reduced with 50% due to CYP3A4 inhibition of atazanavir/ritonavir[40]. 
However, we do not know what the impact of atazanavir/cobicistat is on daclatasvir[41]. 
Therefore, we conducted a randomized, cross-over study in healthy volunteers to study 
whether atazanavir/ritonavir and atazanavir/cobicistat have comparable influence on 
the pharmacokinetics of daclatasvir (Chapter 4).
As previously described, there is a genuine risk on DDIs when HCV patients, both mono- 
and co-infected, are treated with DAAs[42-44]. We studied these DDIs extensively and, on 
a daily basis, we help physicians managing these DDIs. However, we do not know what 
the actual risk is on DDIs in Dutch patients. We tried to answer this question retrospec-
tively analyzing data from a nationwide, real-life mono-infected cohort (Chapter 5) 
and an HIV/HCV co-infected cohort (Chapter 6). The question that follows, when our 
patients are at risk, what is the clinical relevance of these DDIs and are they handled ac-
curately? This question is answered in Chapter 7 using an HIV/HCV co-infected cohort.
Part 2: Ribavirin pharmacokinetics and therapeutic drug monitoring
The goal of TDM is to optimize a patient’s clinical outcome by managing the drug dose 
with the assistance of measured plasma drug concentrations[45]. These concentrations 
are interpreted by pharmacists and dose advises are given. 
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To decide whether TDM is useful for a particular drug, the drug must meet certain crite-
ria. For example, there must be an appropriate drug assay available, adequate pharma-
cokinetic data must be available, the drug has to have a narrow therapeutic range, and 
the drug should have a well-described concentration-effect relationship[46, 47]. Ribavirin 
meets these criteria and is therefore a possible candidate for TDM.
As said, an appropriate drug assay must be available. A number of analytical assays for 
ribavirin has been developed worldwide. To assure the quality of these assays, a quality 
control program was developed to evaluate the accuracy of these assays. In Chapter 8 
we present the first results of this worldwide quality control program involving ribavirin 
assays.
Another requirement for TDM is the need for a therapeutic range. The therapeutic 
range for ribavirin combined with peg-interferon and boceprevir/telaprevir was 2.2-
3.6 mg/L[48]. With the introduction of the modern DAAs, the need arose to redefine a 
therapeutic range. It is unclear if we should use the range of 2.2-3.6 mg/L for ribavirin 
plasma concentrations when combined with, for instance, sofosbuvir plus simeprevir/
daclatasvir/ledipasvir. Can we maybe strive to lower plasma concentrations as the new 
DAAs are highly active? This hypothesis is discussed in Chapter 9 where we present 
the results of a Dutch cohort in which ribavirin concentrations are studied in combina-
tion with modern DAA therapy. 
HIV/HCV co-infected patients usually have lower ribavirin plasma concentrations than 
mono-infected patients[49]. This was previously described in a Western cohort; however, 
this was never studied in Thai patients. Therefore, in collaboration with the HIV-NAT (HIV 
Netherlands, Australia, Thailand) research group a prospective study was conducted 
evaluating the current Thai treatment regimen of peg-interferon alfa plus ribavirin in 
HIV/HCV co-infected Thai patients. The results are presented in Chapter 10.
Part 3: Treatment of hepatitis C virus in special patient populations
Special patient populations are in this thesis defined as patients with a specific co-mor-
bidity which could alter the pharmacokinetics of an agent. For these patients in depth 
knowledge about the clinical pharmacology of drugs is necessary. For example, hepatic 
or renal impairment could influence the clearance of drugs which are eliminated by the 
liver or kidney, respectively[50, 51]. Both conditions can be related to HCV infection[50, 52] 
and potentially influence pharmacokinetics of various DAAs. In Chapter 11 we give an 
overview of data available in literature about the efficacy, safety, and pharmacokinetics 
of DAAs in context of these two special patient populations. 
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Physiology-based pharmacokinetic modeling (PBPK) is a technique where physico-
chemical properties and in vitro data of drugs are used to simulate absorption, distribu-
tion, metabolism, and excretion (ADME)[53, 54]. In other words, in vitro to in vivo extrapola-
tion (IVIVE) is used to predict the pharmacokinetics of a drug in a defined population, 
for instance healthy volunteers or cirrhotic patients. An advantage of these computer 
models is that there is less need for full pharmacokinetic studies in human subjects. 
It is known that cirrhotic patients have altered liver clearance, possibly affecting the 
pharmacokinetics of daclatasvir which is primarily hepatically metabolized[55]. A clinical 
study in cirrhotic subjects showed that patients receiving a single dose of daclatasvir 
had a decreased maximum plasma concentration compared with non-cirrhotic sub-
jects, but based on the unaffected unbound daclatasvir concentration the authors 
concluded that no dose adjustment was necessary[56]. In Chapter 12 we describe 
a PBPK model of daclatasvir in cirrhotic patients in which we aimed to simulate and 
confirm these in vivo findings. We used Simcyp®, a PBPK tool, that contains a model of 
physiological changes in cirrhotic patients[57, 55].
Part 4: A pharmacist’s contribution to eradicate hepatitis C
The last part of the thesis consists of four case reports (Chapter 13). These were all spe-
cial patients in which we used our pharmacological knowledge to optimize treatment.
Finally, I finish with a general discussion on the various topics discussed in this thesis. 
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AbStRACt
Treatment options for chronic hepatitis C virus (HCV) infection have drastically changed 
since the development and licensing of new potent direct-acting antivirals (DAAs). The 
majority of DAAs are extensively metabolized by liver enzymes and have the ability to 
influence cytochrome P450 (CYP) enzymes. Additionally, these same DAAs are both 
substrates and inhibitors of drug-transporters, which makes the DAAs both possible 
victims or perpetrators of drug-drug interactions (DDIs). There is a high prevalence of 
mental illnesses such as depression or psychosis, in HCV-infected patients; therefore, 
psychoactive medications are frequently co-administered with DAAs. The majority of 
these psychoactive medications are also metabolized by CYP enzymes but remarkably 
little information is available on DDIs between psychoactive medications and DAAs. 
Hence, the aim of this review is to provide an overview of the interaction mechanisms 
between DAAs and psychoactive agents. In addition, we describe, evidenced-based 
interactions between DAAs and psychoactive drugs and identify safe options for the 
simultaneous treatment of mental illnesses and chronic HCV infection.
KEy PoIntS 
•	 Escitalopram and citalopram have been studied in combination with most direct-
acting antivirals and either of these drugs can be safely combined with hepatitis C 
virus (HCV) treatment. 
•	 No formal interaction studies between psychoactive agents and sofosbuvir or ledi-
pasvir have been performed in humans. However, these DAAs are generally neither 
victims nor perpetrators of drug-interactions and can therefore be safely used in 
combination with psychoactive drugs. 
•	 Boceprevir, simeprevir, and the combination paritaprevir/ritonavir plus ombitasvir 
with dasabuvir are most likely to cause drug-interactions via the inhibition of 
cytochrome P450 (CYP) 3A4. Therefore, caution must be exercised when CYP3A4 
substrates such as midazolam and/or quetiapine are co-administered with these 
DAAs.
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1IntRoDuCtIon
One of the components previously used in the treatment regimen for hepatitis C virus 
(HCV) is peg-interferon; however, it has major adverse effects on mental health and 
depression was a commonly seen adverse event[1]. Since the development of novel 
direct-acting antivirals (DAAs), peg-interferon is no longer used in the treatment of 
HCV infections in resource-rich settings. However, the prevalence of mental disorders 
remains high among untreated HCV-infected patients[2]. For example, a retrospective 
study reported that 86% of HCV-infected patients had at least one psychiatric, drug-, or 
alcohol use-related disorder recorded in their patient charts. The most common condi-
tions were depressive disorders (50%), psychosis (50%), anxiety disorders (41%), post-
traumatic stress disorders (34%), and bipolar disorders (16%)[3]. Another study reported 
a prevalence of 41% for anxiety and 27% for depression in HCV-infected individuals 
(n = 395)[4]. One explanation for this high prevalence was that patients with mental 
disorders are more likely to have a drug addiction, because intravenous drug use is a 
major route of HCV transmission[5]. 
The results from a cross-sectional study were in agreement with the high prevalence of 
mental disorders. In that study, 16% of the HCV-infected patients were on antidepres-
sants and 10% were on antipsychotics (n = 3,716)[6]. This corresponds with data from 
a Dutch nationwide survey in which benzodiazepines, drugs used for treating opioid 
dependence, and selective serotonin reuptake inhibitors (SSRIs) were among the drugs 
most frequently used by chronic HCV-infected patients[7]. 
The use of antipsychotics and antidepressants during DAA therapy increases the risk 
of drug-drug interactions (DDIs). Both DAAs and psychoactive agents are extensively 
metabolized in the liver and have the ability to affect the activities of various enzymes 
(e.g., cytochrome P450 [CYP]) and drug-transporters (e.g., P-glycoprotein [P-gp]). This 
makes DAAs as well as psychoactive agents possible victims (objects of DDIs) and 
perpetrators (causes of DDIs) of drug-interactions, which could negatively affect treat-
ment outcomes as the result of adverse effects (increased plasma concentrations) or 
treatment failure (decreased plasma concentrations)[8, 9]. In order to interpret the DDIs 
between DAAs and psychoactive agents, it is important to have sufficient knowledge 
of their therapeutic ranges. Benzodiazepines, tricyclic antidepressants (TCAs), and 
antipsychotics have a narrow therapeutic range while SSRIs have a broad therapeutic 
range. Generally, drugs with narrow therapeutic ranges are more likely to have clinically 
relevant DDIs than drugs with large therapeutic ranges[10]. DAAs have a large therapeu-
tic range, which makes them less susceptible to the effects of an increase or decrease 
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in their plasma concentrations caused by, for example, CYP inhibition or induction. 
However, extremely low plasma concentrations could lead to virologic failure.
Little information is available on interactions between DAAs and psychoactive agents. 
Therefore, the aim of this review is to provide an overview of the interaction mecha-
nisms of DAAs and psychoactive agents. In addition, we describe evidenced-based 
interactions between DAAs and psychoactive drugs and identify safe options for treat-
ment of the simultaneous treatment of mental illnesses and HCV infection.
MEthoDS
We searched PubMed (1946-January 2016) and EMBASE (1947-January 2016) to identify 
peer-reviewed studies. The search covered all DAAs recommended in European and US 
guidelines[11, 12] and licensed by the European Medicines Agency (EMA) and US Food 
and Drug Administration (FDA). The DAAs included protease inhibitors (PIs) (bocepre-
vir, simeprevir, paritaprevir, and grazoprevir), NS5A inhibitors (daclatasvir, ledipasvir, 
ombitasvir, and elbasvir), and NS5B polymerase inhibitors (sofosbuvir and dasabuvir). 
Telaprevir was excluded from the review because it has limited use in current therapy. 
We also referred to the work published by Kiser and colleagues[13] for more information 
about telaprevir and DDIs between DAAs and psychoactive drugs.
The psychoactive agents included were SSRIs, TCAs, typical and atypical antipsychotics, 
benzodiazepines, monoamine oxidase inhibitors, lithium, and St John’s wort.
The Google and Google Scholar search engines, and ClinicalTrials.gov (http://www.
clinicaltrials.gov) website and the Liverpool drug-interaction database (http://www.
hep-druginteractions.org) were used to identify conference papers and abstracts. All 
searches were performed in English. The search items contained generic and/or brand 
names of the drugs and included terms such as antidepressant, antipsychotic, sedative, 
and tranquilizer. 
Information about the pharmacokinetics and metabolism of the DAAs and psychoactive 
agents were obtained from the Summary of Product Characteristics (SmPC) and FDA 
Prescribing Information for each drug as well as from the Lexicomp database (available 
via http://www.uptodate.com). Enzyme inhibitors and inducers were defined as being 
strong, moderate, or weak if they changed the area under the concentration-time curve 
(AUC) of a substrate by 5-fold, >2 to <5-fold, and <2-fold, respectively. Substrates were 
also grouped as being minor and major substrates of enzymes. These groupings were 
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1
based on the clinical relevance of the potential interaction described by Lexicomp 
(http://www.uptodate.com)[14, 15].
DRuG-DRuG IntERACtIon MEChAnISMS: DIRECt-ACtInG 
AntIVIRAlS
In this section, we elaborate on the mechanisms by which DAAs can be perpetrators 
and/or victims of DDIs. We focused on interactions through hepatic drug-metabolism 
and drug-transporters because this are the most important pathways underlying in-
teractions between DAAs and psychoactive agents. These mechanisms are illustrated 
using examples of drug-interactions between DAAs and psychoactive agents or non-
psychoactive drugs, which were studied in healthy volunteers. 
Tables 1 and 2 give an overview of the involvement of enzymes and drug-transporters 
in the metabolism of DAAs and psychoactive agents respectively. Table 3 shows the 
results of drug-interaction studies performed between DAAs and psychoactive drugs. 
Phase I and II reactions: direct-acting antivirals as perpetrators
Drugs that influence drug-metabolizing enzymes (perpetrators) such as CYP and 
uridine 5’-diphospho-glucuronosyltransferase (UGT) have the ability to affect the 
plasma concentration of substrates of the enzymes (victims). Inhibitors of CYP and UGT 
generally cause an increased plasma concentration of the victim, while inducers usually 
lower the plasma concentration of the victim.
Ritonavir is included in the fixed-dose combination with paritaprevir, ombitasvir, and 
dasabuvir to ‘boost’ the pharmacokinetic characteristics of paritaprevir through the 
inhibition of CYP3A4; this opens the door for DDIs to occur. For example, the AUC and 
maximum plasma concentration (Cmax) of orally administered midazolam, a CYP3A4 
substrate, increased ~26-fold and ~4-fold, respectively, when midazolam was co-
administered with ritonavir (note: the interaction between ritonavir and midazolam 
is studied in the absence of paritaprevir, ombitasvir, or dasabuvir)[16]. Increases in the 
plasma concentration of midazolam have also been observed when the drug was 
administered with boceprevir, simeprevir, and grazoprevir, which are also CYP3A4 
inhibitors. Boceprevir is a strong inhibitor of CYP3A4, while simeprevir and grazoprevir 
are mild CYP3A4 inhibitors (Table 1)[17-19]. 
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UGTs are inhibited by DAAs such as paritaprevir, ombitasvir, and dasabuvir. Lorazepam 
(benzodiazepine) is a UGT substrate; however, the interaction between lorazepam and 
DAAs has not has not been studied. Interaction studies between furosemide (UGT1A1 
substrate) and combination regimen paritaprevir/ritonavir, ombitasvir, and dasabuvir 
have indicated the importance of UGT inhibition. Results from these studies showed 
that the AUC and Cmax of furosemide were increased by 8 and 42%, respectively. As a 
result of this, a reduction in the dose of furosemide of up to 50% might be required if 
the drugs have to be co-administered[20].
Phase I and II reactions: direct-acting antivirals as victims
DAAs, e.g., daclatasvir, simeprevir, grazoprevir, and elbasvir are predominantly metabo-
lized by CYP3A4/5 in the liver and gastrointestinal tract. Thus, caution is needed when 
DAAs are administered with strong inducers or inhibitors of CYP3A4. A reduced plasma 
concentration of DAAs creates a potential risk of resistance of the virus to the adminis-
tered drug and/or virologic failure, while elevated drug concentrations increase the risk 
of adverse events. Most psychoactive agents do not strongly inhibit or induce CYP3A4 
and thus, we do not expect DAAs to be victims of psychoactive agents. St John’s wort, 
which is a psychoactive agent, is the exception; it is a strong CYP3A4 inducer. However, 
co-administration of boceprevir and St John’s wort showed only a slight decrease in the 
plasma concentration of boceprevir (9%)[21]. 
DAAs are not metabolized by UGT or other phase-II enzymes; therefore, phase-II medi-
ated DDIs with DAAs as victims are not usually expected.
Drug-transporters: direct-acting antivirals as perpetrators
DAAs inhibit various drug-transporters such as efflux transporters P-gp and breast 
cancer resistance protein (BCRP) (Table 1), which are, among other, located at the 
blood-brain barrier (BBB). Little information is available on DDIs between psychoactive 
agents and drug-transporters. However, it is known that amitriptyline and risperidone 
are P-gp substrates (Table 2). Accordingly, inhibition of these transporters increases 
substrate concentrations in the cerebrospinal fluid[26]. Since the pharmacological ac-
tion of psychoactive drugs takes place in the brain, inhibition of P-gp can result in an 
increased pharmacological effect. 
No formal interaction studies have been conducted between the P-gp substrates and 
DAAs. The effect of P-gp inhibition by DAAs has been studied using digoxin, which 
is a known P-gp substrate. Boceprevir had a minor influence on plasma digoxin con-
centrations (an increase in AUC and Cmax by 19 and 18%, respectively)[17]. Daclatasvir 
and simeprevir also affected digoxin plasma concentrations; the AUC of digoxin was 
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increased by 27 and 39%, and Cmax was increased by 65 and 31%, respectively[18, 22]. It 
should be noted that these interactions between the P-gp inhibitors and digoxin were 
driven by the concentration of digoxin in the intestinal lumen, which is high after oral 
intake. For psychoactive drugs, interactions with P-gp inhibitors take place at the BBB. 
This is affected by the systemic concentration of the P-gp substrate instead of the con-
centration in the lumen. Therefore, it is difficult to predict possible interactions between 
DAAs and psychoactive drugs from these results. Additionally, the clinical relevance of 
P-gp inhibition by DAAs depends on the inhibitory potential of the perpetrator and the 
therapeutic range of the victim.
Many DAAs are inhibitors of organic anion-transporting polypeptide (OATP) 1B1 and 
OATP1B3, which are uptake transporters. None of the psychoactive drugs is a substrate 
of OATPs; hence, these transporters are not discussed in this review.
Drug-transporters: direct-acting antivirals as victims
Most DAAs are substrates of P-gp and OATPs; therefore, DAAs are possible victims when 
psychoactive agents inhibit or induce these transporters. However, there is limited data 
available on psychoactive agents and transporters. An example demonstrating the im-
portance of a transporter-mediated interaction, is the contra-indication of grazoprevir 
with OATP1B1/3 inhibitors.
DRuG-DRuG IntERACtIon MEChAnISMS: PSyChoACtIVE 
AGEntS
Table 2 provides an overview of the enzymes and transporters involved in the me-
tabolism of psychoactive agents. In this section, we describe the mechanisms by which 
psychoactive agents can be victims and perpetrators of DDIs. 
Psychoactive agents as perpetrators
In general, psychoactive agents are more often victims of DDIs than perpetrators. For 
example, benzodiazepines have limited influence on drug-metabolizing enzymes and 
transporters (Table 2).
Various antipsychotics, SSRIs, and TCAs have the potential to inhibit CYP2D6, which 
makes these drugs perpetrators of drug-interactions. However, the currently available 
DAAs are not metabolized by CYP2D6 and therefore DDIs via this pathway are not 
expected (Tables 2, 3).
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1
Psychoactive agents as victims
Most benzodiazepines are substrates of various CYP enzymes, such as CYP3A4, CYP2B6, 
CYP2C19, and CYP1A2; therefore, benzodiazepines are potential victims of DDIs. Benzo-
diazepines have a narrow therapeutic range and a strong concentration-effect relation-
ship[27]; thus, increased plasma concentrations are likely to cause increased toxicity. 
Midazolam is a model substrate of CYP3A4; therefore, interactions between midazolam 
and DAAs have been extensively studied. For example, oral co-administration of 
midazolam and boceprevir resulted in an increase in the midazolam AUC of by 430% 
and an increase in its Cmax of 177%. As a result, co-administration of midazolam and 
boceprevir is contra-indicated[17]. Similarly, an increase in the plasma concentration of 
midazolam is expected when it is administered with paritaprevir/ritonavir, ombitasvir, 
and dasabuvir; therefore, this co-administration is also contra-indicated[20]. Interactions 
between midazolam and simeprevir or grazoprevir have both been studied and in-
creased midazolam AUC and Cmax values were observed; thus, caution is needed with 
co-administration[18, 19]. On the other hand, daclatasvir has been shown to have little 
effect on midazolam exposure[22]. 
SSRIs are hepatically metabolized by various CYP enzymes (e.g., CYP3A4, CYP2D6, 
CYP2C9, and CYP2C19), particularly CYP3A4. Theoretically, this puts patients at risk 
when they are also taking DAAs. However, SSRIs have a broad therapeutic range; 
therefore, increased plasma concentrations of SSRIs are not likely to result in significant 
toxicities[10]. For instance, the co-administration of escitalopram (CYP3A4 substrate) and 
DAAs such as boceprevir, simeprevir, or the combination of paritaprevir/ritonavir, om-
bitasvir, and dasabuvir did not result in a clinically relevant increase in the escitalopram 
plasma concentration[17, 18, 20]. 
Antipsychotics are metabolized in the liver by a variety of CYP enzymes, as given in 
Table 2. CYP3A4 and CYP2D6 are involved in this metabolism; however, they can be 
inhibited by DAAs. Most antipsychotics have a narrow therapeutic range. Therefore, 
DDIs involving antipsychotics can result in clinically relevant outcomes, especially with 
strong CYP3A4 inhibitors such as boceprevir and ritonavir. However, no interaction 
studies have been conducted so far.  
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ClInICAl GuIDAnCE
In this section, we provide guidance for clinical decision making regarding the use of a 
combined treatment of DAAs and psychoactive drugs. Most potential drug-interactions 
have not been subjected to rigid pharmacokinetic testing in humans, and recom-
mendations are often based on theoretical interpretations of the pharmacokinetic 
characteristics of drugs. 
We believe that a relevant interaction only occurs when a drug (victim) is metabolized 
to a ‘major’ or ‘moderate’ extent. Major or moderate substrate status is based on the po-
tential clinically relevant drug-interaction as described by Lexicomp[15]. A major status 
indicates that the regimen should be modified, whereas a moderate status implies that 
the therapy should be monitored. Consequently, a drug should have strong (>5-fold 
increase in substrate AUC) or moderate (2-to 5-fold increase in substrate AUC) influence 
on an enzyme/transporter (perpetrator) in order to cause an interaction (Tables 4, 5, 6, 
7, 8, 9, 10).
Protease inhibitors
Boceprevir
Table 4 shows benzodiazepines, antidepressants, and antipsychotics that are safe to 
combine with boceprevir. Of the currently available DAAs, boceprevir is one of the most 
potent CYP3A4 inhibitors. Therefore, we do not recommend combining boceprevir and 
drugs primarily metabolized by CYP3A4, especially if they have a narrow therapeutic 
range (a contra-indication).
Co-administration of midazolam and boceprevir (both oral and parenteral) is contra-
indicated since the midazolam AUC and Cmax are both significantly increased[17]. This 
exceptional increase was not observed with other DAAs, which emphasizes the strong 
inhibitory potential of boceprevir on CYP3A4. 
On the other hand, no dose adjustment is required when escitalopram is administered 
with boceprevir. This is unexpected as escitalopram is a CYP3A4 substrate. It is pos-
sible that there is involvement of other unknown enzymes or transporters; hence, the 
underlying mechanism cannot be explained[17]. 
Boceprevir is also a P-gp inhibitor. Theoretically, this inhibition could have an impact on 
P-gp substrates; however, it seems to have minimal clinical relevance due to the mild 
inhibition of P-gp by boceprevir[17, 26]. Boceprevir may not be a victim of any DDIs with 
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benzodiazepines, SSRIs, TCAs, or antipsychotics, as studies with midazolam and esci-
talopram have shown[17]. Additionally, interaction studies between St John’s wort and 
boceprevir showed no alterations in the plasma concentration of boceprevir; hence, 
this combination is safe to use[17, 21]. 
Finally, physicians should take care when prescribing boceprevir in combination with 
drugs that might prolong the QT interval and are metabolized by CYP3A4[17]. For in-
stance, SSRIs and TCAs may influence the QT interval and serious pharmacodynamic 
interactions may occur when they are administered with boceprevir (Table 4).
Simeprevir
Table 5 shows psychoactive medications that can be safely combined with simepre-
vir. Simeprevir inhibits intestinal CYP3A4 and therefore only interactions with orally 
administered medications are relevant. Thus, intravenous midazolam can be used 
safely with simeprevir but oral midazolam should be used with caution, as the AUC 
and Cmax of midazolam are increased by 45 and 31%, respectively, when the two are 
co-administered[18].
Studies have been conducted of escitalopram, and it can be safely used in combination 
with simeprevir[18]. 
Simeprevir inhibits P-gp and OATP1B1. Simeprevir has a higher impact than boceprevir 
on the transport activity of P-gp as indicated before. Therefore, inhibition of P-gp by 
simeprevir may lead to small increase in concentrations of P-gp substrates (e.g., risperi-
done and nortriptyline) in the brain. However, the clinical relevance seems limited[18].
Simeprevir is a possible victim of DDIs as it is primarily metabolized by CYP3A4[18]. St 
John’s wort may therefore cause a decrease in the plasma concentration of simeprevir 
as it is a CYP3A4 inducer. Nevertheless, this change might not be clinically relevant 
since simeprevir exhibits high inter- individual variability in its plasma concentrations[56].
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NS5A inhibitor
Daclatasvir
Daclatasvir has a negligible influence on the activities of CYP3A4 and other CYP en-
zymes and no dose adjustments were required when it was studied with midazolam[22]. 
Based on this information, it is expected that most benzodiazepines, antidepressants, 
and antipsychotics can be used safely in combination with daclatasvir, as given in Table 
6. Daclatasvir is metabolized by CYP3A4 and thus inducers and inhibitors of CYP3A4 
have the ability to affect the plasma concentrations of daclatasvir[22]. Most psychoactive 
drugs do not influence CYP3A4; with the exception of St John’s wort; therefore, co-
administration of St John’s wort and daclatasvir is contra-indicated[22]. 
NS5B polymerase inhibitor
Sofosbuvir
Sofosbuvir is an NS5B inhibitor and not a perpetrator of DDIs as it has no influence on CYP 
enzymes or drug-transporters; therefore, it has no impact on the plasma concentrations 
of psychoactive drugs[24]. However, an unexpected interaction has occurred involving 
sofosbuvir and the antiarrhythmic agent amiodarone[57, 58]. This indicates that not every 
DDI can be predicted based on the activities of CYP, UGT, or drug-transporters. The 
mechanism and the specific role of sofosbuvir in the interaction was uncertain because 
other DAAs (daclatasvir, simeprevir, and ledipasvir) were simultaneously administered 
and could have been involved in causing the interaction[57, 58]. Additionally, it could also 
be a pharmacodynamic interaction.
Sofosbuvir is metabolized in the liver and intestine; the drug is not a victim of enzymatic 
DDIs because it is not metabolized by, for example, CYPs or UGTs[24]. Sofosbuvir is a sub-
strate for P-gp and BCRP; hence, interactions may occur with inducers and inhibitors of 
P-gp. P-gp inducers, e.g., St John’s wort, could potentially decrease plasma concentra-
tions of sofosbuvir and result in a decrease in the pharmacological effects of sofosbuvir. 
Therefore, co-administration of the two drugs is contra-indicated. Trazodone is also a 
possible P-gp inducer and may affect the plasma concentration of sofosbuvir (Table 7). 
Inhibition of P-gp could increase the plasma concentration of sofosbuvir; however, the 
interactions studies have not been performed in humans[24]. Lastly, the main (inactive) 
metabolite of sofosbuvir (GS-331007) is not a P-gp substrate[24]. 
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Fixed-Dose combinations 
Ledipasvir and sofosbuvir
Ledipasvir inhibits P-gp and BCRP and may cause interactions with P-gp and BCRP sub-
strates (e.g., risperidone, and nortriptyline)[23]. P-gp inhibition at the BBB could poten-
tially increase the exposure of these P-gp substrates in the brain. No interaction studies 
have been performed between ledipasvir and psychoactive agents. Table 8 shows the 
psychoactive agents that can be safely used with or potentially interact with ledipasvir. 
The metabolism of ledipasvir is unknown but it is mainly excreted unchanged through 
bile. Thus, ledipasvir is not expected to be a victim of DDIs[23].
Paritaprevir/ritonavir, ombitasvir, and dasabuvir
Ritonavir is a strong CYP3A4 inhibitor but it also influences other CYP enzymes and 
drug-transporters. Consequently, caution is needed combining drugs metabolized by 
CYP3A4 with this fixed-dose regimen (paritaprevir/ritonavir, ombitasvir, and dasabuvir). 
Psychoactive agents such as duloxetine, escitalopram, zolpidem, alprazolam, and diaz-
epam can be safely administered with this regimen as previous studies have not given 
any clinically relevant interactions (Table 9)[20, 59, 54, 55]. 
The plasma concentrations of duloxetine did not alter when it was co-administered 
with the combination regimen[20]. Duloxetine is a substrate for CYP2D6 and CYP1A2, 
and ritonavir inhibits CYP2D6 and induces CYP1A2. As no effect was observed when 
combined with paritaprevir/ritonavir, ombitasvir and dasabuvir, it was suggested 
that the inhibition of CYP2D6 and induction of CYP1A2 occurred to similar extents. 
We recommend that this combination regimen is used with care in patients receiving 
medications that are metabolized by CYP2D6 and/or CYP1A2, especially as a previous 
interaction study on the co-administration of olanzapine (CYP1A2 and CYP2D6 sub-
strate) and ritonavir resulted in decreased olanzapine concentrations[60]. 
It is important to note that CYP2D6 inhibition by ritonavir is dose dependent[61]. Low-
dose ritonavir (100 mg twice daily) had only a mild effect on CYP2D6, as shown with 
the CYP2D6 substrate desipramine (26% increase AUC) but the therapeutic dose of 
ritonavir (600 mg twice daily) had a stronger effect (desipramine AUC increase of 145%)
[61-63]. However, this fixed-dose HCV regimen contains only 100 mg of ritonavir. There-
fore, we expect DDIs only with co-administered drugs that are primarily metabolized by 
CYP2D6 and that have a narrow therapeutic range. Such drugs are not contra-indicated 
with this combination regimen; however, drug plasma concentrations and adverse 
events should be monitored after co-administration[61].
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Ritonavir also inhibits P-gp; therefore, ritonavir may modify plasma concentrations of 
P-gp substrates such as risperidone and amitriptyline. 
Paritaprevir, ombitasvir, and dasabuvir are inhibitors of UGT and thus benzodiazepines 
(e.g., lorazepam, lormetazepam, and oxazepam) conjugated by UGT could be victims of 
interactions (Table 9)[20]. 
Grazoprevir and elbasvir
Table 10 shows safe options for psychoactive drugs that can be administered with grazo-
previr and elbasvir. Grazoprevir is a mild CYP3A inhibitor as it was observed to increase 
the plasma concentration of midazolam by only 30%[19]. Therefore, CYP3A4 substrates 
are not contra-indicated with grazoprevir. However, we recommend that prescribers be 
aware of possible interactions with drugs that are primarily metabolized by CYP3A4 and 
have a narrow therapeutic range. There are no reported studies on drug-interactions 
between the grazoprevir/elbasvir combination and psychoactive agents[19]. Grazoprevir 
and elbasvir are mainly metabolized by CYP3A4; thus, they should not be administered 
with St John’s wort and other CYP3A4 inducers or inhibitors[19] (Table 10).
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ConCluSIon
In this review, we have shown that there is a paucity of experimental data on drug-
interactions between psychoactive agents and DAAs. Many mechanisms are involved 
in the metabolism and transport of both classes of drugs, making it difficult to predict 
which drugs can be safely co-administered to patients. 
In our opinion, safe options for concomitant administration should be combinations 
that have actually been studied in humans, or combinations that are not based on 
theoretical pharmacokinetic interactions. In addition, all medications used at the start 
of and during HCV treatment should be inventoried, so that possible DDIs can be evalu-
ated before clinically relevant effects arise. Physicians should also be aware of possible 
interactions and their consequences. These may include adverse effects caused by 
increased plasma drug concentrations or reduced efficacy due to decreases in drug ex-
posure. These are of great importance as such issues may also affect adherence to both 
DAAs and psychoactive agents. Our final recommendation is that physicians contact 
pharmacists or clinical pharmacologists for support in managing these interactions.
This review provides an overview of the mechanisms of interactions between DAAs 
and psychoactive agents. Based on interaction studies, we give recommendations for 
the co-administration of DAAs and psychoactive agents. The administration of various 
combinations of drugs results in different potential interactions. It is therefore neces-
sary that theoretical predictions of DDIs be backed with actual drug-interaction studies, 
in order to obtain more conclusive and useful data for clinical applications.
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2
IntRoDuCtIon
During clinical development of medicines, manufacturers are obliged to assess the risk 
of drug-drug interactions (DDIs) with their new drug. There is no doubt that product 
labels of drugs that are nowadays introduced to the market contain much more infor-
mation on DDIs than in the past. Indeed, the drug label is often the first source for DDIs 
available to physicians and pharmacists. But how informative are the data presented in 
the drug labels?
thE IMPoRtAnCE of DRuG-DRuG IntERACtIonS
There is increased awareness of the importance of DDIs as they may be associated with 
clinical toxicity or treatment failure. This is fueled by a better understanding of mecha-
nisms of DDIs, particularly when drug-transporters are involved. Also, the recognition 
that increased medication use in our ageing patient population leads to poly-pharmacy 
which is associated with an elevated risk of DDIs. Regulatory authorities such as the 
US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) 
have issued guidelines to support manufacturers in evaluating DDIs of not yet licensed 
drugs[1, 2]. A snapshot of that information will be channeled to the description of a drug’s 
DDI potential in the product label. 
Here we briefly describe the process of pre-licensure DDI evaluation. Second, we ad-
dress four issues relating to DDI information in the product label from an academic/
clinical point of view. These issues have been discussed by other stakeholders[3]. We 
illustrate this by commenting on two recently FDA and EMA-approved drug labels of 
direct acting antivirals (DAAs) for the treatment of chronic hepatitis C virus (HCV) infec-
tion, i.e. grazoprevir/elbasvir (Zepatier®) and velpatasvir/sofosbuvir (Epclusa®). These 
examples were chosen as they (1) reflect the current state of DDI reporting; (2) belong 
to a group of drugs with a high risk of DDIs[4]; and (3) are used in the treatment of 
chronic HCV patients who are known to use multiple concomitant medications[5].
ASSESSInG A DRuG’S IntERACtIon PotEntIAl DuRInG DRuG 
DEVEloPMEnt
Generally speaking, the process of assessing a drug’s potential to be a victim or a per-
petrator of a (clinically significant) DDI during drug development involves three phases. 
DDIs can be assessed based on the plausible DDI mechanisms (via in vitro assessment 
or other knowledge) and also based on likely co-medications, or a combination of both 
a mechanistic and clinical relevance consideration. These three phases are not neces-
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sarily conducted sequentially, but for the purpose of this commentary we describe 
them separately.
First, in vitro studies are conducted to determine a drug’s substrate affinity and inhibi-
tory/inducer capacity guided by a predefined list of preferred agents in these test sys-
tems[1, 2, 6]. A summary of the findings of the tests for sofosbuvir, velpatasvir, grazoprevir 
and elbasvir is listed in Table 1.
table 1: Substrate affinity and inhibitory/inducer capacity of the DAAs discussed in this 
paper.
DAA
Victim (= substrate of) Perpetrator 
Metabolism
(enzyme)
transporter Metabolism (enzyme) transporter
Inhibitor Inducer Inhibitor Inducer
Sofosbuvir P-gp
BCRP
Velpatasvir CYP3A
CYP2B6
CYP2C8
P-gp
BCRP
OATP1B1/3
P-gp
BCRP
OATP1B1/3
Grazoprevir CYP3A OATP1B1/3 CYP3A BCRP
Elbasvir CYP3A BCRP
DAA: Direct acting antiviral; P-gp: P-glycoprotein; BCRP: Breast cancer resistance protein; OATP: Organic anion 
transporter polypeptide; CYP: Cytochrome P450.
A second stage consists of clinical DDI studies with co-medications that have the 
potential to interact with the drug, for which both (probe) substrates and established 
perpetrators are used. For example, with grazoprevir, elbasvir, and velpatasvir, which 
were found in vitro to be cytochrome P450 (CYP3A) substrates, in vivo DDI studies with 
the established CYP3A inhibitor ketoconazole have been conducted[7, 8]. Additionally, 
both grazoprevir and velpatasvir have been studied with the CYP3A inducer rifampin 
and grazoprevir/elbasvir was studied with the CYP3A substrate midazolam, as grazo-
previr is a weak CYP3A inhibitor[7, 8]. 
A third phase of DDI evaluations can be defined as a set of studies with frequently used 
co-medications in the target patient population for which the drug is being developed. 
Taking the DAAs again as examples, studies were planned with multiple antiretroviral 
agents and immunosuppressive agents, with the potential to examine both perpetra-
tors and victims of a DDI. 
Combining data from in vitro and clinical studies as part of physiologically-based 
pharmacokinetic (PBPK) modeling has also found its place into product labels, thereby 
extending our knowledge on DDIs without actually having to do all the clinical studies.
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After completing these three pre-licensing phases, several pages of the product label 
are now dedicated to DDI information. The presentation of DDI data in product labels 
can be a challenge. One way to do this is by using Forest plots in which geometric 
mean ratios for area under the concentration-time curve (AUC) and maximum plasma 
concentration (Cmax) are summarized from all DDI studies conducted.
One could also define a fourth, post-marketing, phase where yet undiscovered DDIs 
may be detected through clinical vigilance such as individual case reports and data 
mining of spontaneous reporting databases. In addition, controlled pharmacoepide-
miologic studies are performed to examine the health effects of DDIs. These and other 
studies could also be requested or required by the regulatory agencies. This may lead to 
revisions of the product label, as was recently the case with amiodarone and sofosbuvir-
based DAAs[9].
how InfoRMAtIVE IS thE DRuG-DRuG IntERACtIon 
InfoRMAtIon In thE PRoDuCt lAbEl?
The purpose of a drug label is to assist a prescriber in the use of a specific medicine. 
However, a seemingly ‘grey area’ is how physicians should use (new) medications in 
patients on concomitant medications that are not mentioned in the product label. We 
recognize that it is unrealistic to expect product labels to have information on all thera-
peutic agents. The (online) available product label is a relatively static document that, 
despite regular updates, can be soon be outdated once it is published, as new data be-
come available in the public domain. In our electronic age, we need to do better. Many 
healthcare providers will expect that the product label contains the relevant warnings 
for co-medications, and therefore assume that drugs not specifically mentioned in the 
label can be safely combined with the new drug. But to what degree is that true?
We now focus on four examples where we think that the drug label could be more 
informative:
1. In case a new drug is a CYP3A substrate, with which CYP3A inducers is an interac-
tion mentioned in the label?
2. In case of interaction with CYP3A inducers, when will this lead to a contra-indication 
or labeled as ‘not recommended’; in this the same or not?
3. In case a new drug is a (moderate) CYP3A inhibitor, which CYP3A substrates with a 
narrow therapeutic range are listed in the drug label?
4. New drugs are usually tested with relevant co-medication in the target patient 
population, but how is this set of ‘relevant’ medication selected?
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To address the first issue, we have noticed that there is a clear warning in the product 
labels of both grazoprevir/elbasvir and velpatasvir/sofosbuvir that (strong) CYP3A 
inducers are contra-indicated with both DAA combinations. Guidance is given by the 
FDA providing a list of strong and moderate enzyme inducers[6]. However, comparison 
of the product labels with this list reveals important discrepancies (Table 2)[6]. Although 
both product labels state that the list of not recommended co-medications is ‘not all 
inclusive’ and the FDA warns that their examples of CYP3A inducers is not ‘an exhaus-
tive list’ one wonders how many agents are missed? We acknowledge that there is no 
accepted list of CYP3A inducers, so this is an important knowledge gap. A well-known 
website (http://www.medicine.iupui.edu/clinpharm/ddis/) includes in addition to the 
drugs mentioned in Table 2 the following agents as CYP3A inducers: glucocorticoids, 
nevirapine, pioglitazone, and troglitazone. It must be noted that we could not find 
information how these agents have been selected and whether any external review 
process has been included.
table 2: CyP3A inducers mentioned in product labels of grazoprevir/elbasvir and velpa-
tasvir/sofosbuvir[7, 8] and in information provided by fDA[6].
Inducer Grazoprevir/
elbasvir fDA 
label
Grazoprevir/
elbasvir EMA 
label
Velpatasvir/
sofosbuvir fDA 
label
Velpatasvir/
sofosbuvir 
EMA label
fDA 
tableb
Phenytoin  Xa X X X X
Carbamazepine X X X X X
Rifampin X X X X X
St John’s wort X X X X X
Efavirenz X X X X X
Nafcillin X X
Bosentan X X X
Etravirine X X X
Modafinil X X X X
Phenobarbital X X
Oxcarbazepine X X
Rifabutine X X
Rifapentin X X
EMA guideline only reports rifampin as an inducer.
aMentioned in label/table. 
bRestricted to moderate and strong CYP3A inducers.
A second issue relates to what we think the goal of presenting DDI data in a product 
label is to assist clinicians in accurately weighing the risk/benefit ratio in view of the 
combination of drugs that a particular patient will be using. However, it is challenging 
for physicians to define such an individualized risk/benefit ratio. This is especially true 
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for combinations of drugs where information is often lacking or conflicting. In addition, 
the use of pharmacokinetic parameters and other mechanistic information in the label 
might be difficult to evaluate without some understanding of the concentration-effect 
relationship of a specific drug (pharmacokinetic-pharmacodynamic [PK-PD]). Therefore, 
terms such as ‘contra-indicated’,  ‘avoid use’, or ‘use with caution’ are used in the product 
labels; however, these are suboptimal surrogates for a quantifiable risk/benefit ratio. 
Although clearly this guidance is far better than none at all – one needs to keep in mind 
its limitations when determining criteria and exact terms used. For example, rifampin is 
‘contra-indicated’ with grazoprevir/elbasvir in both the EMA and FDA labels and velpa-
tasvir/sofosbuvir is contra-indicated with rifampin in the EMA label but it is ‘not recom-
mended’ in the FDA label. This is remarkable because trough levels of velpatasvir and 
grazoprevir are reduced by rifampin to a similar degree (i.e., 82 and 90%, respectively). 
Based on these pharmacokinetic results we would interpret the two terms as identical 
or should we see them as two different recommendations? Is there a suggestion that in 
some specific patients on rifampin velpatasvir/sofosbuvir might be used? 
A third example relates to a drug being a CYP3A inhibitor and the selection of CYP3A 
substrates to be named in the product label. Here we only use the data from the 
grazoprevir/elbasvir label as velpatasvir/sofosbuvir does not possess CYP3A inhibi-
tory capacity. Grazoprevir is a weak CYP3A inhibitor and premarketing in vivo studies 
demonstrated a 34% increase in midazolam AUC and a 43% increase in tacrolimus 
AUC[7]. How does this translate into warnings in the product label for other CYP3A 
substrates? At the time the grazoprevir/elbasvir file was reviewed, the FDA had speci-
fied a list of CYP3A substrates with narrow therapeutic ranges which are defined as 
‘those drugs where a small increase in exposure caused by CYP3A inhibition may lead 
to serious safety concerns’[6]. This list included the following marketed agents: alfentanil, 
ciclosporin, dihydroergotamin, ergotamin, fentanyl, pimozide, quinidine, sirolimus, and 
tacrolimus. We find it surprising that, with the exception of ciclosporin and tacrolimus, 
none of these CYP3A substrates with a narrow therapeutic range are included in the 
grazoprevir/elbasvir FDA and EMA labels[7].
More recently, the FDA website was updated and now a table is included with sensi-
tive CYP450 substrates being drugs that demonstrate an increase in AUC of ≥5-fold 
with strong index inhibitors of a given metabolic pathway in clinical DDI studies. As 
grazoprevir/elbasvir is not a strong index inhibitor of CYP3A, this table does not apply. 
A fourth and final comment relates to the selection of  ‘frequently used co-medications 
in the target patient population’. Antiretrovirals, immunosuppressive agents, statins, 
methadone, oral contraceptives, and acid-reducing agents are all part of common test 
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panels. But does this reflect the most widely used co-medication in the HCV patient 
population? To address this question, we used data from a paper by Lauffenberger et 
al who reviewed the most utilized medications in US patients with HCV from a large 
commercial insurance database[10]. It is remarkable that in the top-20 only omeprazole/
pantoprazole is mentioned in the grazoprevir/elbasvir and velpatasvir/sofosbuvir FDA 
and EMA labels (Table 3). 
table 3: References in grazoprevir/elbasvir and velpatasvir/sofosbuvir product labels to 
most utilized medications in uS patients with hCV based on a large commercial insurance 
database[10] .
Medication Grazoprevir/elbasvir label Velpatasvir/sofosbuvir label
Acetaminophen + combinations
Zolpidem
Levothyroxine
Alprazolam
Lisinopril
Oxycodone
Furosemide
Amlodipine
(Es)Omeprazole, Pantoprazole F, E F, E
Metformin
Escitalopram
Spironolactone
Hydrochlorothiazide
Bupropion
Tramadol
Metoprolol
Lorazepam
Azithromycin
Atenolol
Sertraline
F: FDA label; E: EMA label
how to MAnAGE DRuG-DRuG IntERACtIonS whEn PRoDuCt 
lAbElS Do not IntEnD to bE CoMPlEtE
DDI data are traditionally included in electronic prescribing systems for physicians and 
computerized drug-interaction surveillance systems for pharmacists. One could expect 
that these systems are up-to-date, which means that as soon as a new drug reaches the 
market contra-indicated drugs and warnings are added to these systems to guarantee 
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patient safety. This will be primarily based on the information provided by the drug 
label, as this is the only official communication on DDIs at such time point. 
Various online DDI sources are available, such as Micromedex, First databank, in addi-
tion to the drug labels. The Working Group on Pharmacotherapy and Drug Informa-
tion from the Royal Dutch Association for the Advancement of Pharmacy, take a step 
further by making predictions of DDIs based on similarities in pharmacokinetic profiles 
to other drugs not mentioned in the drug label[11]. In addition, the Interaction Check-
ers developed by the University of Liverpool (http://www.hiv-druginteractions.org & 
http://www.hep-druginteractions.org) have evolved to be an indispensable source for 
management of DDIs with antiretroviral agents and DAAs, and are now also included 
in international treatment guidelines. Over the years, >800 individual co-medications 
have been carefully evaluated and added to the websites. But one could also question 
why such external resources are necessary to fill a knowledge gap. Are all the evalua-
tions of DDIs in such web resources being done as rigorously as the FDA and EMA do 
when reviewing a new drug application? 
fInAl ConCluSIonS AnD RECoMMEnDAtIonS
We wish to stress that this commentary was not written to criticize either specific 
pharmaceutical companies who write drug labels or the regulatory authorities who 
approve these labels, but rather to start a discussion on how we can better inform 
healthcare providers about DDIs. We believe that more complete information on DDIs 
is important for safer patient management, and accept this is not only the responsibil-
ity of manufacturers and regulators. We suggest an initiative that includes all relevant 
stakeholders and addresses a systematic evaluation of DDI data, defines research gaps, 
and writes consensus documents. When will the Consortium for Optimal Management 
of drug-drug Interactions in patient Care (COMIC) see daylight?
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AbStRACt
Aim
The aim of this study was to evaluate the effect of the proposed organic cation trans-
porter (OCT) inhibitor daclatasvir on the pharmacokinetics and pharmacodynamics of 
the OCT substrate metformin. 
Methods
This was an open-label, two-period, randomized, cross-over trial in 20 healthy subjects. 
Treatment A consisted of metformin and treatment B consisted of metformin + dacla-
tasvir. Pharmacokinetic curves were recorded at steady-state. Geometric mean ratios 
(GMRs) with 90% confidence intervals (CIs) were calculated for metformin area under 
the concentration-time curve from 0 to 12 hours (AUC0-12), maximum plasma concen-
tration (Cmax), and final plasma concentration (Clast). An oral glucose tolerance test was 
performed, measuring insulin, glucose and lactate levels. 
Results
The GMRs (90% CI) of metformin AUC0-12, Cmax, and Clast (B versus A) were 109% (102-
116%), 108% (101-116%), and 112% (103-122%). The geometric mean AUC0-2 for insulin, 
glucose, and lactate during treatments A and B were 84 and 90 h.mE/L, 13.6 and 13.4 
h.mmol/L, and 3.4 and 3.5 h.mmol/L, respectively.
Conclusions
Bioequivalence analysis showed that daclatasvir does not influence the pharmaco-
kinetics of metformin in healthy subjects. Pharmacodynamic parameters were also 
comparable between treatments.
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IntRoDuCtIon
Chronic hepatitis C virus (HCV) infection is associated with insulin resistance, which 
might cause type 2 diabetes mellitus (T2DM)[1]. It is estimated that 150-170 million 
people are infected with HCV worldwide and 422 million people were living with T2DM 
in 2014[2, 3]. In addition, both conditions have a high impact on international healthcare 
because of the high morbidity and mortality rates of T2DM and HCV[4, 5]. 
The association between HCV and insulin resistance/T2DM has been studied exten-
sively[6, 7]. Compared with controls, there is an increased prevalence of diabetes mellitus 
(DM) in HCV patients[8]. T2DM is two- to threefold more prevalent in HCV-infected pa-
tients compared with hepatitis-B-infected individuals[1]. Insulin resistance itself causes 
liver disease[1], and in combination with HCV, patients have an increased risk of develop-
ing cirrhosis and hepatocellular carcinoma[8, 9]. Furthermore, insulin resistance in HCV 
patients is correlated with reduced efficacy of HCV treatment, and viral clearance is as-
sociated with improved insulin sensitivity[1, 10]. In the literature, there is consensus about 
the relationship between HCV and insulin resistance/T2DM; however, the mechanisms 
behind this relationship are still under debate[7].
Metformin is a biguanide used for the treatment of T2DM, as it has the ability to lower 
the blood glucose concentrations in these patients. In Western counties, metformin is 
the first choice in treatment of T2DM. It is not metabolized but it is a substrate of several 
membrane transporters – namely, plasma membrane monoamine transporter (PMAT), 
organic cation transporter (OCT) 1, 2 and 3, and multidrug and toxin extrusion protein 
(MATE) 1 and 2K. The oral absorption and hepatic uptake of metformin is mediated by 
PMAT, OCT1, and OCT3. However, the involvement of the OCTs in intestinal absorption 
remains controversial[11, 12]. Metformin is excreted renally through glomerular filtration 
(protein binding is negligible) and active tubular secretion[11]. Tubular secretion is facili-
tated by uptake into the tubular cells via OCT2 and excretion into the urine via MATE1 
and MATE2K[13]. Tubular reabsorption might be facilitated by OCT1 and PMAT[11, 14, 15]. As 
the renal clearance of metformin is higher than creatinine clearance, it is deduced that 
tubular secretion plays an important role in its excretion[16]. 
Drug-interactions influencing metformin pharmacokinetics (PK) are a result of inhibition 
or induction of the previously mentioned drug-transporters. The human immunodefi-
ciency virus (HIV) integrase inhibitor dolutegravir increases the metformin exposure by 
79%, probably via inhibition of OCT2[17]. Rifampicin, an OCT inducer, causes increased 
renal clearance and tubular secretion of metformin[18]. 
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Similarly, a potential interaction may exist between the nonstructural protein 5A (NS5A) 
inhibitor daclatasvir and metformin. Daclatasvir is used for the treatment of HCV in-
fection in combination with sofosbuvir and is licensed for the treatment of genotype 
1, 3, and 4[19]. It is metabolized by cytochrome P450 (CYP) 3A4 and is a substrate of 
P-glycoprotein (P-gp). It does not influence drug-metabolizing enzymes but, at least 
in vitro, it seems to inhibit the activity of several drug-transporters, such as P-gp, OCT1, 
OCT2, organic anion transporting polypeptide 1B1, and breast cancer resistance pro-
tein[19]. However, the clinical relevance of OCT1 and OCT2 inhibition was unknown at 
the time of the present study.
Our hypothesis is that daclatasvir could decrease metformin tubular excretion, through 
inhibition of OCT2, and therefore causes increased plasma concentrations and 
increased glucose-lowering activity. Inhibition of OCT1 in the liver could also lead to 
increased plasma concentrations of metformin. The proposed in vivo PK interaction and 
the net pharmacodynamic (PD) effect are unknown, and therefore we conducted a 
PK-PD study to evaluate the potential drug-drug interaction between daclatasvir and 
metformin.
MEthoDS
Study design
This was an open-label, two-period, randomized, cross-over trial in healthy subjects. 
Subjects were randomized in treatment sequences AB and BA. Treatment A (reference) 
consisted of 500 mg metformin twice daily (BID) on day 1 and 2 (Metformin HCL Actavis 
500 mg, Aurobindo Pharma - Milpharm Ltd, Middlesex, United Kingdom). The dose was 
increased to 1,000 mg BID on days 3-8. This gradual dose step-up was chosen to limit 
adverse events (AEs), as subjects used metformin without food for 8 days. 
Treatment B (test) consisted of 500 mg metformin BID (day 1-2) and 1,000 mg metformin 
BID (days 3-8). From day 1 to day 8, 60 mg daclatasvir once daily was added (Daklinza®, 
Bristol-Myers Squibb, Uxbridge, United Kingdom[20]). Between treatments there was a 
washout period of 13 days.
To study metformin and daclatasvir exposure, at day 8 of treatment (steady-state), 
blood samples for a PK curve were obtained up to 12 hours and 24 hours after intake 
of metformin and daclatasvir, respectively. Secondly, to study metformin excretion, 12-
hour urine was collected for the determination of metformin renal clearance. 
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The PD of metformin was studied using an oral glucose tolerance test (OGTT), which 
was also performed at day 8 of treatment. During this 2-hour test, venous blood was 
withdrawn to determine the plasma concentrations of glucose, lactate, and insulin.
Study participants
Healthy males and females were included. Subjects eligible for inclusion were 18-55 
years of age and had a body mass index (BMI) of 18-36 kg/m2. Subjects had to be in 
good age-appropriate health condition (physical examination, electrocardiography, 
biochemical, hematologic, and urinalysis testing). No concomitant medication was 
allowed, except for acetaminophen <2,000 mg/day. Main exclusion criteria were a 
positive HIV, hepatitis B, or HCV test, pregnancy, and estimated glomerular filtration 
rate (eGFR) <60 mL/min. 
Dosing and adherence
During study visits at days 1, 2, 3, 5, and 8, medication was administered at 08:00 hour, 
supervised by the study personnel. In between study visits, subjects took the medica-
tion at home, and adherence was assessed as follows: (1) tablets were counted by the 
trial nurses; (2) Medication Event Monitoring System (MEMS) caps (Aardex Ltd, Zug, 
Switzerland) were used to monitor the opening of the metformin-containing bottles; 
and (3) subjects were instructed to record the time of medication intake (and any AE) 
in a diary.
PK sampling and oral glucose tolerance test 
The study was conducted at the Clinical Research Centre Nijmegen in the Radboud 
university medical center, Nijmegen, the Netherlands.
At steady-state (day 8), blood samples were withdrawn to measure the plasma concen-
trations of metformin (A and B) and daclatasvir (B). Drugs were taken concomitantly 
after an overnight fast, and blood was withdrawn in ethylene diamine tetra-acid tubes 
at t = 0 (pre-dose), 0.5, 1, 1.5, 1.9, 2.5, 3, 4, 6, 8, 10, and 12 hours after metformin intake. 
During treatment B (daclatasvir), an additional sample was collected at 24 hours. Blood 
samples were stored in a refrigerator until centrifuged (5 minutes at 1,900 g). Plasma 
was transferred into polypropylene tubes and stored at -40°C until bioanalysis. To study 
metformin excretion at steady-state and to assess the renal clearance of metformin, 
urine was collected for 12 hours at intervals of 4 hours. Prior to the start of collection, 
morning urine was voided before the administration of metformin. Participants were 
asked to drink 200 mL water every 4 hours. Volume and pH of urine were noted, and it 
was stored at -40°C until further bioanalysis. 
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For the OGTT, the participants were instructed to avoid strenuous exercise and to follow 
a carbohydrate-controlled diet (at least 200-250 gram carbohydrates per day) for 3 days 
prior to day 8. The OGTT was performed after an overnight fast for at least 14 hours. 
At 10:00 hour, the subjects drank 75 g glucose in 200 mL water. Following the glucose 
intake, venous blood was withdrawn at t = 0 (pre-dose), 30, 60, 90, and 120 minutes to 
determine the plasma concentrations of glucose, lactate, and insulin.
Data were collected using Castor EDC (Castor Electronic Data Capture, Ciwit BV, Amster-
dam, the Netherlands).
Bioanalytical methods
Metformin and daclatasvir were analyzed in the laboratory of the Department of 
Pharmacy of the Radboud university medical center, Nijmegen, the Netherlands. 
Metformin in the plasma and urine were determined using two different validated 
ultra-performance liquid chromatography (UPLC) assays with ultraviolet (UV) detection 
(236 nm).
Metformin was extracted from 200 µL plasma using 80 µL 4M sodium hydroxide and 
3 mL 1-butanol/ (n-) hexane (50:50, v/v). This solution was vortexed for 1 minute at 
1,600 rpm and centrifuged for 5 minutes at 1,900 g. The aqueous phase was frozen 
for 1 minute at -40°C before the organic phase was poured into a vial. Metformin was 
then back-extracted from the organic phase by adding 200 µL 0.1% phosphoric acid. 
This solution was vortexed for 1 minute at 1,600 rpm and centrifuged for 5 minutes at 
1,900 g.
Metformin was extracted from 20 µL urine following the same procedures after add-
ing 200 µL blank plasma. After back-extraction, 100 µL of the water phase was diluted 
with 900 µL water before injection.
Chromatography was performed using an Acquity UPLC HSS T3 analytical column (1.8 
μm, 2.1 × 100 mm; Waters, Milford, MA, USA) with a mobile phase of 0.02 M phosphate 
buffer, pH 3.23. The flow rate was set on 0.6 mL/min. After every injection, the column 
was rinsed with a combination of eluent and acetonitrile (50:50, v/v) before equilibrat-
ing back to the initial eluent.
Accuracy across five metformin quality-control samples measured in three runs (n = 
15) over 2 days ranged from 101 to 103% in plasma and 98 to 101% in urine. Interday 
precision ranged from 0.0 to 2.4% in plasma and 0.0 to 3.9% in urine (n = 15). Intraday 
precision ranged from 1.2 to 5.8% in plasma and 2.3 to 8.9% in urine (n = 5). For met-
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formin in plasma, the calibration range was 0.01-5.00 mg/L and for urine the range was 
2.0-2,100 mg/L. 
Daclatasvir was measured using a validated UPLC method with UV detection (314 nm). 
Daclatasvir was extracted from 100 µL plasma using 200 µL acetonitrile/methanol 
(50:50, v/v) with 0.1% formic acid. This solution was vortexed for 5 minutes at 2,500 rpm 
and centrifuged for 5 minutes at 1,910 g. The supernatant (170 µL) was poured into a 
vial and centrifuged for 5 minutes at 1,910 g; 10 µL was then injected onto an Acquity 
UPLC BEH C18 analytical column (1.7 µm, 2.1 × 50 mm; Waters, Milford, MA, USA). The 
flow rate was set to 0.550 mL/min, and daclatasvir was eluted by using a gradient 0.05 
M phosphate buffer and 0.05 M phosphate buffer/acetonitrile 30/70 v/v.
Accuracy across five daclatasvir quality-control samples, measured in three runs over 2 
days, ranged from 98 to 107%. Interday precision ranged from 0.0 to 1.3% and intraday 
precision ranged from 1.3 to 6.0%. The calibration range of the method was 0.03-10 
mg/L. 
Insulin samples were collected in lithium-heparinized tubes and determined at the 
clinical chemistry laboratory of Radboud university medical center, Nijmegen, the 
Netherlands (random access analyzer, Roche E170 modular immunoassay, Roche Diag-
nostics International Ltd, Rotkreuz, Switzerland). Glucose and lactate (blood gas tube 
Pro-Vent 4646E, lithium-heparin coating, Smiths Medical, MN, USA) were determined 
directly after sampling, using a glucose enzymatic-amperometric method (Biosen C-
line GP, EKF-diagnostic GmbH, Barleben, Germany). 
Pharmacokinetic analysis
A non-compartmental approach was used (WinNonlin/Phoenix version 6.3, Pharsight 
Corporation, St. Louis, MO, USA) to assess the area under the concentration-time curve 
from 0 to 12 hours (AUC0-12) and 12-hour plasma concentration (C12) for metformin and 
from 0 to 24 hours (AUC0-24) and 24-hour plasma concentration (C24) for daclatasvir. 
In addition, maximum plasma concentration (Cmax), time to reach Cmax, and apparent 
elimination half-life of metformin and daclatasvir were determined. Metformin renal 
clearance was calculated by dividing the total amount metformin excreted (0-12 hours) 
by the AUC0-12. The secretion of metformin was calculated by subtracting the metfor-
min clearance from the creatinine clearance, which was calculated using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) formula:
eGFR (mL/min/1.73 m2) = 141 × minimum (Scr /κ)α × maximum (Scr /κ, 1)-1.209 × 0.993 
Age × 1.018 [if female] × 1.159 [if black]). 
Chapter 3
84
With Scr as standardized serum creatinine in mg/dL, α as -0.329 and -0.411 for females 
and males, κ as 0.7 and 0.9 for females and males, respectively, and age in years.
In addition, the geometric mean ratios (GMRs) with 95% confidence intervals (CIs) 
(treatment B versus A) for metformin secretion and eGFR were calculated.
Pharmacodynamic analysis
The plasma concentrations of glucose, lactate, and insulin were used to calculate the 
area under the concentration-time curve from 0 to 2 hours (AUC0-2) for which Win-
Nonlin/Phoenix was used. The insulin and glucose concentrations were also used to 
calculate the homeostatic model assessment insulin resistance (HOMA-IR) score, which 
is used to quantify insulin resistance (HOMA-IR = [glucose × insulin]/22.5).
Statistical analysis
The AUC0-12 values of metformin for treatments A and B were compared using the 
bioequivalence approach, which is recommended by the European Medicines Agency 
(EMA) to evaluate PK drug-interactions[21]. GMRs with 90% CIs of AUC0-12, Cmax, and C12 
were calculated for metformin, comparing treatment B and treatment A. We used a 
linear mixed-effect model with fixed parameters to calculate the GMR with 90% CI. 
Fixed parameters were treatment, period, sequence, and subjects within sequence 
according to EMA guidelines[21]. 
For bioequivalence between treatments A and B, the AUC0-12 GMR with 90% CI should 
fall within the range of 80-125%.
Based on a previously observed inter-subject coefficient of variation (CV%) of 22% 
for metformin AUC0-12[22], we expected the intra-subject CV% to be lower: 15%. For 
the sample-size calculation, we used a power calculation in SAS® 9.2 (SAS Institute 
Inc. 2011. Cary, NC, USA) using a paired t-test for lognormal distribution for showing 
equivalence). For 80% power to prove bioequivalence, a sample size of 17 subjects 
should be included in the study. To account for possible dropouts, 20 subjects were to 
be included.
Metformin renal clearance was log-transformed and compared between treatments 
using a paired t-test.
Glucose, lactate, and insulin AUC0-2 values were log-transformed and compared be-
tween treatments using a paired t-test. All statistical analyses were performed in IBM 
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SPSS Statistics (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. 
Armonk, NY: IBM Corp).
Safety and tolerability
During all study visits, AEs and laboratory safety (biochemistry and hematology) were 
monitored by the study nurses and physicians. AEs were graded using the Division of 
AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (‘DAIDS AE 
Grading Table’); version 1.0, December 2004, clarification August 2009[23]).
Ethics
The trial was approved by the Investigational Review Board of Radboud university 
medical center, Nijmegen, the Netherlands. The trial was conducted in accordance with 
Good Clinical Practice and the Declaration of Helsinki and registered at ClinicalTrials.
gov (NCT02565862). All participants signed informed consent forms before screening 
evaluations.
RESultS
Baseline characteristics 
Twenty subjects (nine male) were enrolled, and all subjects completed the study. All 
subjects were white; their median (range) age was 47.5 (20-55) years and the median 
(range) BMI was 26.6 (22.9-36.0) kg/m2. The subjects were in normal health, based on 
medical history, physical examination, vital signs, and biochemical and hematology 
data. 
In general, adherence to the study medication was good, as proven by pill count, moni-
toring of the MEMS caps and the registration in the diary. Two subjects took a double 
dose of daclatasvir, and three subjects forgot one or two tablets of 500 mg metformin. 
These deviations did not lead to exclusion of any of the study participants. 
Pharmacokinetics of metformin and daclatasvir
Steady-state geometric mean (GM) concentration-time curves of metformin are shown 
in Figure 1a and the PK parameters are given in Table 1. 
One subject vomited during treatment A; therefore, the results of 19 subjects are 
presented. The GMR with 90% CI of the metformin AUC0-12, Cmax, and C12 of metformin 
with and without daclatasvir (B versus A) were 109% (102-116%), 108% (101-116%), 
and 112% (103-122%), respectively. As the CIs of all parameters fell within the range of 
80-125%, absence of an interaction was confirmed.
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figure 1: Pharmacokinetic curves of metformin for both treatments (A). Pharmacokinetic 
curve of daclatasvir (and reference) (b). 
Data shown are geometric means with geometric coefficient of variation. Reference curves for daclatasvir were 
adapted from Gandhi et al[24]. 
A: Data of 19 subjects were used. 
B: Data of 20 subjects were used. 
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table 1: Steady-state pharmacokinetic parameters of metformin (n = 19) and daclatasvir 
(n = 20). 
Metformin treatment A (n = 19a) treatment b (n = 20) GMR % (90% CI)
AUC0-12 (h.mg/L) 12.41 (22) 13.54 (25) 109 (102-116)
Cmax (mg/L) 2.06 (23) 2.23 (23) 108 (101-116)
C12 (mg/L) 0.34 (32) 0.38 (29) 112 (103-122)
Tmax (h)b 1.9 (1-2.5) 1.9 (1-3.0) -
T1/2 (h)c 4.77 (19) 4.86 (22) -
Daclatasvir treatment b Referenced
AUC0-24 (h.mg/L) 18.38 (44) 12.7 (41); 13.8 (26)
Cmax (mg/L) 1.85 (40) 1.34 (38); 1.41 (28)
C24 (mg/L) 0.30 (63) 0.225 (54); 0.225 (36)
Tmax (h)a 1 (1-2.5) 2.0 (1.0; 6.0)
T1/2 (h)b 11.23 (23) -
Geometric means are presented with geometric coefficient of variation. Also, the geometric mean ratios of 
treatment B (with daclatasvir) versus treatment A (without daclatasvir) are presented.
aFor treatment A, 19 subjects are used for the pharmacokinetic analysis as 1 subject vomited during treatment.
bValues presented are medians (range).
cThe apparent T1/2 is calculated.
dThe reference values from Gandhi et al are presented[24].
AUC0-12: Area under the concentration-time curve from 0 to 12 hours; AUC0-24: Area under the concentration-
time curve from 0 to 24 hours; C12: 12-hour plasma concentration; C24: 24-hour plasma concentration; 90% CI: 
90% confidence interval; Cmax: Maximum plasma concentration; GMR: Geometric mean ratio; T1/2: Elimination 
half-life; Tmax: Time to reach Cmax.
Urine was collected to estimate renal metformin clearance. Treatment B included 19 
subjects because urine was not correctly stored for one subject. The GM (range) renal 
clearance of metformin for treatment A was 351 (148-646) mL/min and for treatment B 
was 333 (166-537) mL/min (p = 0.504). The GM (range) for metformin secretion during 
treatments A and B was 275 (25-538) mL/min and 269 (91-445) mL/min (p = 0.3822), 
respectively. The GMR (95% CI) for metformin secretion (B versus A) was 98% (70-137%) 
and 98% (95-101%), respectively, for eGFR (Figure 2). 
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figure 2: the 12-hour metformin secretion during treatments A and b shown per patient. 
The urine of one subject was discarded during the trial; therefore, the metformin secretion of 19 subjects is 
shown.
The GM concentration-time curve of daclatasvir and PK parameters are shown in Figure 
1b and Table 1, respectively, combined with references values[24]. The GMs with geo-
metric coefficient of variation (GCV%) AUC0-24, Cmax, and C24 values of daclatasvir were 
18.38 (44) h.mg/L, 1.85 (40) mg/L, and 0.30 (63) mg/L. 
Pharmacodynamics of metformin
The OGTT was used to study PD endpoints (insulin, lactate, glucose). Treatment A con-
tained data from 19 subjects as one subject was not able to tolerate the glucose drink 
during treatment A. The subject vomited and was excluded from the analysis. 
The GM (GCV%) for AUC0-2 for insulin for treatments A and B were 86 (49) and 87 (54) 
h.mE/L, respectively (p = 0.430). The glucose and lactate GM (GCV%) AUC0-2 values dur-
ing treatments A and B were 13.7 (10) and 13.4 (14) h.mmol/L and 3.4 (15) and 3.4 (18) 
h.mmol/L, respectively (p = 0.919; p = 0.779, respectively) (Figure 3). In Figure 4, we show 
the AUC0-2 ratios (treatment B/treatment A) per subject for glucose, insulin, and lactate.
The HOMA-IR score was calculated for the individual subjects (treatments A and B), 
showing the variation of insulin resistance in the study population. The HOMA-IR varied 
from 0.73 to 4.81 during treatment A and 0.94 to 4.19 during treatment B.
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figure 4: Ratios for treatment b/treatment A shown per subject for metformin area under 
the concentration-time curves from 0 to 12 hours, metformin maximum plasma concen-
tration, metformin 12-hour plasma concentration, all open circles. In addition, the closed 
circles show the ratio for treatment b/treatment A per subject for the glucose area under 
the concentration-time curves from 0 to 2 hours (AuC0-2), insulin AuC0-2, and lactate AuC0-2. 
One subject did not tolerate the oral glucose tolerance test during treatment A; therefore, the ratio of 19 sub-
jects is shown for glucose, insulin and lactate. 
AUC0-12: Area under the concentration-time curve from 0 to 12 hours; Cmax: Maximum plasma concentration; C12: 
12-hour plasma concentration; AUC0-2: Area under the concentration-time curve from 0 to 2 hours.
Safety and tolerability
A total of 129 AEs were reported during the trial, varying from three to 11 AEs per 
subject. No serious adverse events (SAEs) were reported. Only one grade 3 AE was 
reported: elevated amylase. The majority of the AEs were ‘probably’ related to the use of 
study medication (55%) and were reported during the combined treatment of metfor-
min and daclatasvir (59%). Six AEs (four subjects) were reported directly after the intake 
of the study medication.
Most commonly reported AEs were diarrhea (n = 26), stomach ache/stomach cramps 
(n = 15), nausea (n = 11), headache (n = 10), and fatigue (n = 9). The gastrointestinal AEs 
are most likely caused by metformin. Subjects recovered from all AEs after the end-of-
treatment. AEs reported (≥5%) per treatment are given in Table 2.
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table 2: Adverse events (AEs) reported during the trial, per treatment. only AEs that were 
reported ≥5.0 % per treatment are given.
 treatment A (total number AEs: 53)  treatment b (total number AEs: 76)
Subjects, n AEs, n AEs, % Subjects, n AEs, n AEs, %
Diarrhea 10 11 21 12 15 20
Fatigue 5 5 9 4 4 5
Stomach ache/cramps 5 5 9 6 10 13
Nausea 4 4 8 5 7 9
Sore throat 3 3 6 - - -
Vomiting 2 3 6 2 2 3
Common cold 3 3 6 - - -
Headache 2 2 4 7 8 11
Treatment A: 1,000 mg metformin twice daily.
Treatment B: 1,000 mg metformin twice daily and 60 mg daclatasvir once daily.
Toxicity grades were judged by the trial physician and graded using the Division of AIDS Table for Grading the 
Severity of Adult and Pediatric Adverse Events (‘DAIDS AE Grading Table’); version 1.0, December 2004, clarifica-
tion August 2009[23].
AEs: Adverse events.
DISCuSSIon
We studied the potential interaction between the NS5A inhibitor daclatasvir and the 
biguanide metformin in healthy volunteers. We hypothesized that the exposure to met-
formin could possibly be increased due to OCT1 and/or OCT2 inhibition by daclatasvir, 
with altered glucose plasma concentrations as a result.
The results of the PK analysis did not support this hypothesis: no interaction was ob-
served when metformin was administered with daclatasvir. In addition, there was no 
difference in metformin renal secretion between treatments. Therefore, we concluded 
that daclatasvir does not affect systemic exposure to metformin. Similarly, the PD analy-
sis showed no difference between treatments, so we concluded that there was no PD 
interaction between daclatasvir and metformin.
The apparent absence of an effect of daclatasvir on metformin PK is confirmed by in 
vitro studies that were carried out later. Comparing the maximum therapeutic concen-
tration of daclatasvir (Cmax) of 1.85 mg/L found in the present study with the reported 
half-maximum inhibitory concentration (IC50) showed that the in vivo unbound Cmax 
was indeed lower than the in vitro data, as daclatasvir is highly bound to plasma 
proteins (99%). The IC50 of daclatasvir for OCT2 was 7.3 µM[25] and for OCT1 it was 1.4 
µM[26], representing plasma concentrations of ~5.4 mg/L and ~1.0 mg/L, respectively, of 
unbound daclatasvir. We should note that, at the site of action (intestine, hepatocyte), 
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the daclatasvir concentration might be different to the Cmax used, as the latter is the 
plasma concentration after systemic absorption. Daclatasvir concentrations could 
be higher in the intestine and portal vein, possibly inhibiting OCTs. This could be an 
explanation for the statistically significantly increased metformin plasma concentration 
when combined with daclatasvir (GMR and CI >100%). We argue that this increase is 
not clinically relevant for patients with normal metformin clearance but it might be 
clinically relevant in special populations with reduced metformin clearance, such as 
patients with renal impairment.
In daily practice, metformin is administered with food. In the present trial, we deviated 
from this recommendation, as subjects had to fast overnight for the execution of the 
OGTT. The systemic exposure of metformin is decreased in a fed state (Cmax: 40%; AUC: 
25%)[27]. In our study, Cmax and AUC were elevated when compared with a previous 
study in healthy volunteers where metformin was taken with food: Cmax 1.32 mg/L and 
AUC0-24 20.5 h.mg/L[28]. The high number of metformin-related AEs could be explained 
by these increased metformin exposures. Intake of metformin without food might 
cause additional AEs[27]. 
We used an OGTT to study the PD effect of metformin on glucose regulation with and 
without daclatasvir. The OGTT was conducted because the PK drug-interaction was 
only clinically relevant when also the glucose regulation (PD) was be altered. In addi-
tion, we did not want to exclude the possibility that there was a PD effect without a PK 
effect. In the present study, we showed that both PK and PD were related, as neither 
the systemic metformin concentrations nor OGTT results were affected by daclatasvir. 
The relation between the OGTT and metformin PD was shown previously in healthy 
volunteers, whereas the blood glucose levels were not altered[18, 29, 30].
Daclatasvir PK was studied only in treatment group B, in the presence of metformin; 
therefore, the PK of daclatasvir was compared with literature (Table 1). Daclatasvir 
was not studied separately, as metformin was thought not to influence any drug-
metabolizing enzymes or transporters, and therefore we did not expect that metformin 
would influence daclatasvir PK[31]. Daclatasvir exposure was increased compared with 
reference values, as shown in Figure 1b[24]. In our study, subjects took daclatasvir while 
fasted, whereas daclatasvir was taken with food in the reference study. This might be an 
explanation for the elevated daclatasvir plasma concentrations because food decreases 
daclatasvir AUC by 23% and Cmax by 28%[20]. However, daclatasvir plasma concentrations 
were somewhat higher than we would expect based on the food effect alone. Dacla-
tasvir PK is increased solely by CYP3A4 and/or P-gp inhibitors, and metformin is neither 
of these. It could be that metformin induces other unidentified drug-transporters 
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or drug-metabolizing enzymes that contribute to the metabolism or distribution of 
daclatasvir[32]. Another explanation could be that the fasted healthy volunteers in our 
study had better absorption of daclatasvir, possibly caused by a more acidic gastric pH, 
increasing the solubility of daclatasvir.
No unexpected AEs or SAEs were reported in the present study. The study medica-
tion was well tolerated overall; however, almost all subjects reported diarrhea and/
or stomach ache/cramps, which were related to the use of metformin. One subject 
did not tolerate the glucose solution, but, overall, the OGTT was well tolerated by the 
fasted participants. However, we should point out that the number of AEs was 76 with 
combined treatment of daclatasvir and metformin, versus 53 when metformin was 
given alone. This might have been caused by the relatively high daclatasvir plasma 
concentrations combined with the small increase of metformin plasma concentrations. 
Therefore, our recommendation is that daclatasvir and metformin can be combined, 
although we recommend that physicians monitor for (altered) AEs during treatment. 
The limitations of our study were that daclatasvir PK was not studied separately and 
that we included healthy, white subjects who might not completely reflect the HCV/
T2DM patient population that will use these drugs. Therefore, we included subjects 
with a wide range of age, BMI, and insulin resistance (HOMA-IR). 
We did not determine OCT genotypes because all the PK curves for the subjects were 
in the same concentration range; we observed a low inter-subject variability for metfor-
min; and the sample size was limited.
In conclusion, the establishment of bioequivalence in the present study showed that 
daclatasvir did not influence the PK of metformin in healthy subjects. PD parameters 
were also comparable between treatments. An increased number of AEs was reported 
when daclatasvir was combined with metformin; however, no unexpected AEs were re-
ported. We recommend monitoring for altered AEs during treatment when daclatasvir 
and metformin are combined in HCV-infected patients with T2DM.
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AbStRACt
Background 
Atazanavir is boosted with cytochrome P450 (CYP) 3A4 inhibitor ritonavir. When com-
bined with the CYP3A4 substrate daclatasvir, the daclatasvir dosage should be reduced 
from 60 mg to 30 mg once daily. Recently, cobicistat was licensed as a CYP3A booster 
and used in combination with atazanavir. 
Objective
We studied if the fixed-dose combination of atazanavir/cobicistat has an influence on 
daclatasvir pharmacokinetics comparable to that of as seen with the separate agent’s 
atazanavir and ritonavir.
Methods
This was a prospective, open-label, two-period, randomized, cross-over trial was per-
formed in 16 healthy subjects (NCT02565888). Treatment consisted of 300/100 mg of 
atazanavir/ritonavir plus 30 mg of daclatasvir once daily (reference) and a second pe-
riod of 300/150 mg of 30 mg of atazanavir/cobicistat plus daclatasvir once daily (test). 
A 24-hour pharmacokinetic, steady-state curve was recorded for all drugs. Geometric 
mean ratios (GMRs) with 90% confidence interval (CI) were calculated for daclatasvir 
and atazanavir AUCtau and Cmax to compare the effect of both treatments (test versus 
reference). Laboratory safety and adverse events were evaluated throughout the trial. 
Results
All 16 healthy subjects completed the study. Median (range) age and Body Mass Index 
(BMI) were 48.5 (21-55) years and 24.5 (19.0-29.2) kg/m2, respectively. Pharmacokinetic 
parameters of ritonavir and cobicistat were comparable to those in the literature. The 
GMRs (90% CI) of daclatasvir AUCtau and Cmax (test versus reference) were 101% (92-
111%) and 97% (89-106%), respectively. Atazanavir GMRs (90% CI) of AUCtau and Cmax 
were 82% (75-79%) and Cmax 74% (68-81%), respectively. No serious adverse events 
were reported. 
Conclusions
Atazanavir/cobicistat and atazanavir/ritonavir had a similar influence on daclatasvir 
pharmacokinetics in healthy volunteers. Daclatasvir at 30 mg once daily is the correct 
dose when combined with atazanavir/cobicistat.
Daclatasvir 30 mg/day is the correct dose with atazanavir/cobicistat
99
4
IntRoDuCtIon
Combined treatment for infection with human immunodeficiency virus (HIV) and 
hepatitis C virus (HCV) is commonly applied in daily practice, because globally ~33% of 
HIV patients are co-infected with HCV[1, 2]. There are a number of combination regimens 
of specific antivirals available for both treatments.
Atazanavir is an HIV protease inhibitor (PI) that is mainly metabolized by cytochrome 
P450 (CYP) 3A4 in the liver. To improve the pharmacokinetics (PK) of atazanavir, the 
PI ritonavir is added as a ‘booster’. Ritonavir is a strong inhibitor of CYP3A4 and there-
fore breakdown of atazanavir is inhibited. This extends the elimination half-life (T1/2) 
of atazanavir (8.6 hour versus 6.5 hour[3]) and allows once daily dosing[3]. Apart from 
CYP3A4 inhibition, ritonavir inhibits CYP2D6 and P-glycoprotein (P-gp), and it induces 
e.g., CYP2C9, CYP1A2, and uridine 5’-diphospho-glucuronosyltransferase (UGT) 1A1[4].
Recently cobicistat became available as an alternative CYP3A booster and is approved 
to boost atazanavir, darunavir, and elvitegravir[5, 6]. Cobicistat is co-formulated with ata-
zanavir (300 mg/150 mg). This combination is equally effective as atazanavir/ritonavir 
at 300 mg/100 mg[7]. Cobicistat is a specific inhibitor of CYP3A, CYP2D6, and P-gp, but 
it lacks the inductive capacity of ritonavir[8]. In addition, cobicistat has a more favorable 
toxicity profile than ritonavir. For example, cobicistat does not adversely affect the lipid 
profile. 
Daclatasvir is part of a number of HCV regimens that target patients infected with 
genotypes 1, 3 and 4. Daclatasvir is a substrate of CYP3A4 and P-gp. This opens the 
door for a drug-drug interaction (DDI) with ritonavir and atazanavir. Atazanavir itself 
also inhibits drug-enzymes and transporters such as CYP3A4, CYP2D6, UGT1A1, and 
organic anion transporting polypeptides (OATPs). 
According to the label, the dose of daclatasvir should be reduced from 60 mg to 30 mg 
once daily when it is administered concomitantly with atazanavir/ritonavir[9]. However, 
the impact of atazanavir/cobicistat on daclatasvir PK is unknown. Because these drugs 
will be used in combination in HIV/HCV co-infected patients, we sought to examine 
whether atazanavir/cobicistat has the same impact on daclatasvir PK as atazanavir/
ritonavir. Our hypothesis is that 30 mg of daclatasvir is the sufficient dose when it is 
combined with atazanavir/cobicistat, because its CYP3A-inhibitory capacity is compa-
rable to atazanavir/ritonavir.
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PAtIEntS & MEthoDS
This prospective, open-label, two-period, randomized, cross-over trial included 16 
healthy subjects, aged 18-55 years. Main exclusion criteria were estimated glomerular 
filtration rate (eGFR) <60 mL/min, positive HIV, HCV or hepatitis B test, abnormal labora-
tory tests, and the use of medication or drugs (except acetaminophen [paracetamol] 
at ≤2 g/day). 
Subjects were equally randomized into two treatment groups (AB and BA). Treatment 
A (reference) consisted of 10 days daclatasvir 30 mg once daily (Daklinza®, Bristol-
Myers Squibb [BMS] Pharma EEIG) and the separate compounds atazanavir at 300 mg 
(Reyataz®, BMS) and ritonavir at 100 mg once daily (Norvir®, AbbVie Ltd). Treatment B 
(test) consisted of 10 days of daclatasvir at 30 mg once daily and the fixed-dose com-
bination atazanavir/cobicistat at 300/150 mg once daily (Evotaz®, BMS). Between the 
treatments, a washout period of 11 days was included (Figure 1). 
Day -28 to 0
Screening
Day 1-10
Atazanavir 300 mg QD
Ritonavir 100 mg QD
Daclatasvir 30 mg QD
Day 10-11
PK-day
Day 12-21
Washout period
Day 22-31
Atazanavir/cobicistat 300/150 mg QD
Daclatasvir 30 mg QD
Day 31-32
PK-day
End of trial
Treatment A
Treatment B
Day 1
Start of 
treatment
Day 3, 5, 8
Study visits
Day 22
Start of 
treatment
Day 24, 26, 29
Study visits
figure 1: overview of study design. 
The shown design is treatment AB. Treatment BA has the same design and treatments, but the sequence was 
reversed. 
QD: Once daily; PK: Pharmacokinetics. 
On day 10 of both treatments (steady-state) the drugs were taken with a standardized 
breakfast consisting of a glass of milk and two slices of buttered wheat bread with 
Dutch 48+ cheese (48+ means ~25% of saturated fats) and cervelat (396 kCal). A 24-
hour PK curve was recorded and blood samples were obtained at t = 0 (pre-dose) and 
0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours after intake of the study medication.
Atazanavir and ritonavir plasma concentrations were determined using a modification 
of a validated high performance liquid chromatography (HPLC) assay with ultraviolet 
(UV) detection[10]. Cobicistat was determined using a validated liquid chromatography 
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with tandem mass spectrometer (LC-MS/MS) method with a lower limit of quantification 
(LLOQ) of 0.031 mg/L. Daclatasvir was determined with a validated ultra performance 
liquid chromatography (UPLC) assay with UV detection (LLOQ: 0.03 mg/L). 
PK parameters (AUC0-tau, Cmax, Clast, Tmax, T1/2) were calculated for all drugs using non-com-
partmental analysis (WinNonlin 6.4, Phoenix 64). To determine bioequivalence between 
treatments, geometric mean ratios (GMRs) with 90% CI of AUC0-tau, Cmax, and Clast were 
calculated comparing the effect of atazanavir/ritonavir with the effect of atazanavir/
cobicistat on the PK of daclatasvir. Bioequivalence was demonstrated if the 90% CI of 
the GMR fell within 80-125%, which is in accordance with international guidelines[11, 12]. 
For sample size calculation we used power calculation in SAS® 9.2 (paired t-test for 
lognormal distribution for showing equivalence). We used the previously observed 
inter-subject variation of ~35% and intra-subject variation of ~10% for daclatasvir AUC 
in healthy subjects[13]. For 80% power a sample size of seven subjects needed to be 
included in the trial to detect bioequivalence for daclatasvir between treatments. To ac-
count for possible drop-outs and to follow the FDA guidelines (minimum of 12 subjects 
required), two groups of 8 subjects were included.
Secondarily, GMRs with 90% CI of atazanavir were calculated comparing the effects of 
cobicistat and ritonavir on atazanavir PK parameters. 
During every visit, safety was assessed by serum biochemistry and hematology and 
subjects were asked about the presence of adverse events (AEs). Data were collected 
using Castor EDC (Castor Electronic Data Capture, Ciwit BV, Amsterdam, the Nether-
lands).
Ethics
The study was conducted in Radboud university medical center, Nijmegen, the 
Netherlands and approved by the local Ethical Committee. The trial was conducted in 
accordance with Good Clinical Practice and the Declaration of Helsinki. All participants 
signed informed consent prior to screening evaluations (NCT02565888).
RESultS
All 16 healthy subjects (8 males, 16 Caucasian) completed the study. Median (range) 
age and BMI were 48.5 (21-55) years and 24.5 (19.0-29.2) kg/m2, respectively. 
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Table 1 displays daclatasvir PK parameters with atazanavir/ritonavir versus atazanavir/
cobicistat. Bioequivalence was established for daclatasvir between treatment groups, 
because GMRs 90% CI were all within the 80-125% range: AUC0-tau 101% (92-111%), Cmax 
97% (89-106%), and Clast 101% (89-115%). For atazanavir, exposure after boosting with 
cobicistat appeared to be lower than after boosting with ritonavir. The GMR values (B 
versus A) were: AUC0-tau 82% (75-79%), Cmax 74% (68-81%), and Clast 86% (76-98%). 
Figure 2 shows the PK curves of daclatasvir and atazanavir for both treatments. Figure 
3 shows the PK curves of cobicistat and ritonavir with reference curves obtained from 
the literature.
table 1: Steady-state pharmacokinetic (PK) parameters of daclatasvir, atazanavir, ritona-
vir, and cobicistat (n = 16). 
Daclatasvir treatment A treatment b GMR,% 
(90% CI)
Reference[9] Ritonavir Reference 
(GM)[14]
AUC0-tau 
(h.mg/L)
14.18 (33.72) 14.30 (36.73) 101 (92-111) 14.12 11.37 (37.48) 11.82
Cmax (mg/L) 0.97 (32.26) 0.94 (33.32) 97 (88-106) 1.53 1.87 (32.60) 1.75
Clast (mg/L) 0.38 (52.22) 0.38 (46.23) 101 (89-115) 0.232 0.03 (78.47) -
Tmax (h)a 3.0 (1.5-4.0) 1.75 (0.5-4.0) - 1-2 3.0 (1.0-4.0) 1.76
T1/2 (h)b 19.56 (46.23) 19.08 (27.19) - 12-15 4.04 (17.90) 3.29
Atazanavir treatment A treatment b GMR,% 
(90% CI)
Reference[14, 15]c Cobicistat Reference 
(mean)[15]
AUC0-tau 
(h.mg/L)
55.56 (34.44) 45.48 (40.68) 82 (75-89) ATV/r, mean: 46.72
ATV/c, GM: 34.84
11.32 (29.71) 8.91
Cmax (mg/L) 5.46 (25.27) 4.05 (29.70) 74 (68 - 81) ATV/r, mean: 4.90
ATV/c, GM: 4.10
1.46 (18.41) 1.35
Clast (mg/L) 1.04 (62.32) 0.90 (68.05) 86 ( 76 -98) ATV/r, mean: 0.66
ATV/c, GM:0.45
0.04 (106.87) -
Tmax (h)a 3.0 (1.5-4.0) 1.75 (0.5-4.0) - ATV/r, mean: 1.80
ATV/c, GM: 2.5
2.0 (1.0-4.0) 2.5
T1/2 (h)b 13.44 (52.57) 13.93 (60.90) - ATV/r, mean: 8.77
ATV/c, GM: 7.5
4.22 (30.04) 4.3
Geometric means are presented with coefficient of variation (CV%). Geometric mean ratios of treatment B (da-
clatasvir + atazanavir/cobicistat) versus treatment A (daclatasvir + atazanavir/ritonavir) are presented. 
aValues presented are medians (range).
bApparent elimination half-life (T1/2).
cReference data presented for atazanavir is without intake of food. 
GMR: Geometric mean ratio; GM: Geometric mean; 90% CI: 90% Confidence interval; ATV/r: Atazanavir/ritonavir; 
ATV/c: Atazanavir/cobicistat.
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figure 2: Daclatasvir (A) and atazanavir (b) plasma concentrations (mg/l) in 16 healthy 
volunteers. 
Values are medians and upper limits. 
A: Steady-state concentrations for 300 mg atazanavir once daily, 100 mg ritonavir once daily, and 30 mg dacla-
tasvir once daily. 
B: Steady-state concentrations 300/150 mg for atazanavir/cobicistat once daily and 30 mg daclatasvir once daily.
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figure 3: Cobicistat (A) and ritonavir (b) plasma concentrations (mg/l) in 16 healthy volun-
teers with reference curves obtained from literature. 
Values are medians and upper limits. 
A: Steady-state concentrations of cobicistat 150 mg once daily in combination with atazanavir 300 mg and 
daclatasvir 30 mg once daily. Reference curve for cobicistat is obtained from Sevinsky et al. 
B: Steady-state concentrations of ritonavir 100 mg once daily in combination with atazanavir 300 mg and dacla-
tasvir 30 mg once daily. Reference curve for ritonavir is obtained from Estévez et al. 
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No serious adverse events (SAEs) were reported in this trial. However, a total of 139 
AEs occurred and 23% were classified as grade 3/4. AEs were comparable between 
treatment groups. AEs reported (≥5%) are given per treatment in Table 2.
All subjects had at least grade 1 hyperbilirubinemia (>1.0 mg/dL). Ten subjects devel-
oped jaundice, of whom six had jaundice during both treatments. Bilirubin concentra-
tions normalized after cessation of atazanavir.
table 2: Adverse events (AEs) reported during the trial, per treatment. only AEs that are 
reported >5.0% are given. 
Patients, 
n
AEs, 
n
AEs, 
%
Grade 3/4, 
n
Patients, 
n
AEs, 
n
AEs, 
%
Grade 3-4, 
n
Asymptomatic 
hyperbilirubinemia
16 18 26.1 12 16 20 29.4 11
Jaundice 8 10 14.5 4 6 7 10.3 4
Headache 4 7 10.1  - 5 10 14.7 -
Fatigue / tired 5 6 8.7 - 4 5 7.4 1
Flatulence 4 4 5.8  - 3 5 7.4 -
Elevated amylase 3 4 5.8  - 1 1 1.5 -
Treatment A: Atazanavir 300 mg once daily, ritonavir 100 mg once daily, and daclatasvir 30 mg once daily.
Treatment B: Atazanavir/cobicistat 300/150 mg once daily and daclatasvir 30 mg once daily.
AEs: Adverse events.
Toxicity grades are judged by the trial physician and graded using the Division of AIDS 
Table for Grading the Severity of Adult and Pediatric Adverse Events (“DAIDS AE Grad-
ingTable”); version 1.0, December 2004, clarification August 2009.
DISCuSSIon
The primary objective of our trial was to compare the influences of atazanavir/ritonavir 
and atazanavir/cobicistat on daclatasvir plasma concentrations. Our hypothesis was 
confirmed and daclatasvir plasma concentrations were comparable, because bio-
equivalence was established. Additionally, the daclatasvir plasma concentrations were 
in line with previously published data in healthy volunteers[9]. Therefore, we argue that 
30 mg of daclatasvir is the right dose for HCV treatment when used in combination 
with atazanavir/cobicistat. 
The GMR values with 90% CI of atazanavir/cobicistat versus atazanavir/ritonavir (sec-
ondary research question) fell outside the range of 80-125%. Apparently, cobicistat 
administered at a dose of 150 mg once daily dose is a weaker booster than steady-state 
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ritonavir, since atazanavir plasma concentrations were lower when given with cobici-
stat than with ritonavir. Phase-III studies have produced comparable efficacy and safety 
data for both treatments[16]. So, these mildly reduced atazanavir levels appear not to 
have clinical relevance. This is supported by the fact that atazanavir Clast in both study 
arms was >0.15 mg/L, which is the proposed minimal effective concentration[17]. The 
conclusion that 150 mg of cobicistat is a somewhat weaker CYP3A booster than 100 
mg of ritonavir can also be found in a study that described the PK of darunavir/ritonavir 
and darunavir/cobicistat[18].
In both treatment groups, the PK parameters of atazanavir were increased compared 
with the reference values given in Table 1. We should notice, that the subjects in the 
study of Estévez et al[14] did not take atazanavir/ritonavir with food, which may explain 
this difference, as food intake increases the absorption of atazanavir[3]. The reference 
values of atazanavir/cobicistat where obtained from a study were the drugs were taken 
with a light meal (336 kCal), which is similar in our study[15]. 
Cobicistat and ritonavir exposures were both in line with the literature (Table 1). Refer-
ence values were obtained from studies in healthy volunteers treated with atazanavir/
ritonavir or atazanavir/cobicistat[14, 15].
During the trial, unconjugated hyperbilirubinemia was seen in all subjects and jaundice 
was reported by 10 subjects. This was an expected AE, caused by UGT1A1 inhibition 
of atazanavir. UGT1A1 is responsible for the conjugation of bilirubin, so less enzyme is 
available for bilirubin conjugation. This results in a decreased elimination of bilirubin 
and thus hyperbilirubinemia (Gilbert’s-like syndrome). After cessation of atazanavir 
bilirubin levels normalized in all subjects[3, 19]. 
ConCluSIonS
Atazanavir/cobicistat and atazanavir/ritonavir had a similar influence on the PK of 
daclatasvir in healthy volunteers and are considered to be bioequivalent. The recom-
mended dose of daclatasvir with atazanavir/ritonavir, 30 mg once daily, also applies 
cobicistat-boosted atazanavir. Since no unexpected side effects were reported in the 
trial, this combination can be used safely. 
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AbStRACt
Background
Direct-acting antivirals have improved treatment of chronic hepatitis C virus infection 
significantly. Direct-acting antivirals inhibit/induce and can also be substrates of, drug-
metabolizing enzymes and transporters. This increases the risk for drug-drug interac-
tions. 
Objective
The purpose of this study was to predict drug-drug interactions with co-medication 
used by hepatitis C virus- infected patients. 
Methods
We assembled a nationwide cohort of hepatitis C patients and collected cross-sectional 
data on co-medication use. We compiled a list of currently available direct-acting 
antiviral regimens and cross-checked for potential drug-drug interactions with used 
co-medication. 
Results
The cohort included 461 patients of which 77% used co-medication. We identified 260 
drugs used as co-medication. Antidepressants (7.4%), proton pump inhibitors (7.1%), 
and benzodiazepines (7.1%) were most frequently used. Of the patients, 60% were at 
risk for a clinically relevant drug-drug interaction with at least one of the direct-acting 
antivirals regimens. Interactions were most common with paritaprevir/ritonavir, ombi-
tasvir, and dasabuvir and least interactions were predicted with grazoprevir/elbasvir.
Conclusion
Co-medication use is rich in frequency and diversity in chronic hepatitis C patients. 
The majority of patients are at risk for drug-drug interactions which may affect efficacy 
or toxicity of direct-acting antivirals or co-medication. The most recently introduced 
direct-acting antivirals are associated with a lower risk of drug-drug interactions. 
The majority of HCV patients treated with DAAs  at risk for DDIs
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IntRoDuCtIon
Treatment of hepatitis C virus (HCV) infected patients has significantly improved with 
the introduction of direct-acting antivirals (DAAs). DAAs have the disadvantage that 
they can be involved in drug-drug interactions (DDIs) with patients’ co-medication. 
DDIs might increase the risk for toxicity or result in poorer efficacy[1, 2]. The mechanism is 
twofold: DAAs can both be victim and/or perpetrator of DDIs. Drugs are victims of DDIs 
when their plasma concentration is affected by another drug. In contrast, drugs are per-
petrators when they have the ability to influence plasma concentrations of drugs, for 
example by inhibiting or inducing metabolizing enzymes and/or drug-transporters[3, 4]. 
DAAs inhibit various cytochrome P450 (CYP) enzymes, responsible for drug-metabolism 
(Table 1). The clinical importance of DDIs was illustrated by the interaction between 
sofosbuvir-based DAA therapy and amiodarone, resulting in severe bradycardia[5, 6]. This 
report and other similar papers indicate that there is a genuine risk for relevant DDIs in 
patients treated with DAAs who use co-medication[5-11]. 
table 1: overview of enzymes and drug-transporters involved in the metabolism and 
transport of DAAs used for the treatment of hepatitis C.
Direct-acting antiviral Victim (= substrate of) Perpetrator
Inhibitor Inducer
Daclatasvir CYP3A4/5, P-gp P-gp, OATP1B1
Dasabuvir CYP2C8, CYP3A4, P-gp, BCRP UGT1A1, BCRP, P-gp
Elbasvir CYP3A, P-gp
Grazoprevir CYP3A, P-gp, OATP1B1/3 CYP3A (?)
Ledipasvir Pg-p, BCRP P-gp, BCRP
Ombitasvir - UGT1A1
Paritaprevir/ ritonavir CYP3A4/5, P-gp, OATP1B1/3, 
BCRP
CYP3A4/5, UGT1A1, 
CYP2D6(?),OATP1B1/3, OATP2B1, 
BCRP
CYP2C19 
Simeprevir CYP3A4/5 CYP3A4/5, CYP1A2, P-gp, 
OATP1B1/3
Sofosbuvir P-gp, BCRP
Velpatasvir P-gp, BCRP, CYP2B6, CYP2C8, 
CYP3A4
P-gp, BCRP, OATP1B1/2, OATP2B1
? Unknown of the inhibition/induction in clinically relevant.
DAA: Direct-acting antiviral; CYP: Cytochrome P450; BCRP: Breast cancer resistance protein; P-gp: P-glycoprotein; 
UGT: Uridine 5’-diphospho-glucuronosyltransferase; OATP: Organic anion-transporting polypeptide.
The toxicity profiles of the currently used interferon-free DAA combinations, improved 
significantly relative to the DAAs combined with peg-interferon and ribavirin. Nowadays, 
more HCV patients with complex co-morbidities and thus co-medication receive anti-
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viral treatment[12]. The combination of DAAs and many other drugs obviously increases 
the risk for DDIs. To date, limited data is available about the extent of co-medication 
use by HCV patients and the risk of DDIs as a consequence. Therefore, the aim of this 
study is to identify the co-medication use in a nationwide real-life HCV cohort in order 
to predict clinically relevant DDIs between co-medication and new DAA regimens.
MEthoDS
We performed this research in three steps: (1) we identified which co-medication 
were used by HCV-infected patients in a real-world cohort; (2) in order to predict DDIs 
we cross-checked the co-medication with DAAs in the database of the University of 
Liverpool (http://www.hep-druginteractions.org); and (3) we assessed the risk for DDIs 
per patient. 
For this type of study (retrospective) formal consent was not required. Formal evalu-
ation was waived by the institutional review board Arnhem-Nijmegen. Good Clinical 
Practice guidelines and the code of conduct for the use of data in health research were 
followed (http//www.federa.org).
Patients and use of co-medication
Data from a nationwide, real-life cohort were used[13]. This cohort included Dutch pa-
tients treated for a HCV genotype 1 mono-infection. Patients were identified based on 
local databases present in 45 hepatitis treatment centers in the Netherlands. Data col-
lection was performed between January 2014 – July 2015. Baseline data were extracted 
from the patient’s medical record and included patient characteristics, medical history, 
HCV genotype, and co-medication use prior to commencement of HCV treatment. 
Patients were excluded when data on co-medication use was missing and if patients 
had a co-infection with HIV or hepatitis B virus. In addition to prescribed medication, 
we included complementary and alternative medicine (CAM) when available in the 
medical record. Separate compounds of fixed-dose products were registered, except 
for CAMs, these were counted as one, even though they may have contained several 
chemical compounds. We did include drugs taken as part of a substance abuse disorder 
(e.g. methadone), although illicit drugs such as heroin or cocaine were not collected. 
We added Anatomical Therapeutic Chemical (ATC) codes to all co-medication reported 
in the patient’s medical record, and grouped the drugs by therapeutic/pharmacologi-
cal subgroups[14]. 
The majority of HCV patients treated with DAAs  at risk for DDIs
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Predicted drug-drug interactions with direct-acting antivirals
The co-medication was cross-checked with currently approved DAA regimens in Eu-
rope and USA through the University of Liverpool database in an effort to predict DDIs 
(July 2016). The University of Liverpool database is a commonly used resource to check 
for DDIs[4, 15]. For cross-checking we included approved DAA regimens effective against 
HCV genotype 1: simeprevir plus sofosbuvir, daclatasvir plus sofosbuvir, ledipasvir plus 
sofosbuvir, paritaprevir/ritonavir, ombitasvir plus dasabuvir, grazoprevir plus elbasvir, 
and velpatasvir plus sofosbuvir. Ribavirin and first generation protease inhibitors were 
not taken into account. Ribavirin is considered not to cause any DDIs in this population 
as is not metabolized by or influencing any of the drug-metabolizing enzymes and the 
included patients do not use nucleoside reverse transcriptase inhibitors (NRTIs)[16]. The 
first generation DAAs are considered outdated. 
We used four risk categories corresponding with the University of Liverpool database: 
1) No clinically significant interaction; 2) Potential interaction - may require close moni-
toring, alternation of drug dosage or timing of administration; 3) Contra-indication, i.e. 
drugs should not be co-administered; 4) Unknown, as not available in the Liverpool 
database. For these unavailable drugs, the pharmacists (ES and DB) judged if there 
might be risk of a DDI. Pharmacokinetic parameters of these drugs were used (US FDA 
Prescribing Information and MicroMedex®) to evaluate these interactions. Overall, we 
defined category 2 and 3 as the clinically relevant DDIs[17]. 
Risk for drug-drug interactions per patient
To assess the number of patients at risk for a clinically relevant DDI, we counted the 
patients with at least one predicted DDI between co-medication and one of the DAA 
regimens. Further, we compared the risk for DDIs between subgroups of patients: (1) 
patients aged <65 years versus ≥65 years[17], and (2) in patients with versus without 
cirrhosis. We used Fib-4 index >3.25 to classify patients as cirrhotic[18]. 
Analyses
Descriptive analyses were performed with frequency counts and proportions. For the 
subgroup analyses we used chi-square tests. All analyses were performed in SPSS (IBM 
SPSS Statistics 20).
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RESultS
Patients and use of co-medication
This cohort included 467 patients; we excluded 6 patients from the analysis because 
data on co-medication was missing. There were 313 males and the mean age was 51 
years (Table 2). 
table 2: Patient characteristics.
Characteristic overall 
(n = 461)
Age - mean (range), year 51 (19-77)
Age ≥65 years - n (%) 30 (7)
Male sex - n (%) 313 (68)
Caucasian - n (%)a 316 (90)
Treatment-naïve - n (%)b 269 (58)
Decompensated liver disease - n (%) 23 (5)
Fib-4 index >3.25 (cirrhosis) - n (%)c 115 (26)
Creatinine clearance <30 mL/min - n (%)d 3 (1)
aRace: available in 352 patients.
bPrevious response: available in 448 patients.
cFib-4 index: available in 437 patients.
dCreatinine clearance: available in 407 patients.
A total of 356 patients (77%) used co-medication at start of HCV therapy and 105 pa-
tients did not use any co-medication. The number of medications per patient ranged 
from 1-17 (median 2). Of the cohort, 12% used ≥6 medications at start of HCV therapy. 
Overall, the 356 patients had a total number of 1,329 prescriptions (including CAMs), 
which comprised 260 different drugs (Figure 1). 
Most frequently used co-medication were antidepressants, proton pump inhibitors 
(PPIs), benzodiazepine derivatives, and drugs for opioid dependence (Table 3). 
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table 3: Most frequently used (>2.0%) concomitant medications at start of hepatitis C 
treatment. 
Drug class AtC-code 
(4rd level)
number (%)a
Antidepressants (both tricyclic antidepressants and selective serotonin 
reuptake inhibitors e.g. amitriptyline, sertraline)
N06AA, N06AB, 
N06AX
98 (7.4)
Proton pump inhibitors (e.g. omeprazole) A02BC 94 (7.1)
Benzodiazepine derivatives (e.g. diazepam, flurazepam) N05BA, N05CD 94 (7.1)
Drugs used in opioid dependence (e.g. methadone) N07BC 74 (5.6)
Selective beta-2-adrenoreceptor agonists (respiratory systemic use and 
inhalants e.g. salbutamol)
R03AC, R03CC 55 (4.2)
Antipsychotics (e.g. olanzapine, risperidone) N05AA, N05AB, 
N05AD, N05AF, 
N05AH, N05AL, 
N05AN, N05AX
46 (3.5)
Vitamin D and analogues (e.g. colecalciferol) A11CC 38 (2.9)
Thiazides (e.g. hydrochlorothiazide) C03AA 34 (2.6)
Selective beta blocking agents (e.g. metoprolol) C07AB 32 (2.4)
ACE inhibitors (e.g. enalapril) C09AA 32 (2.4)
Glucocorticoids (respiratory system e.g. beclomethasone) R03BA 32 (2.4)
Biguanides (e.g. metformin) A10BA 27 (2.0)
Platelet aggregation inhibitors excl. heparin (e.g. acetylsalicylic acid) B01AC 26 (2.0)
Dihydropyridine derivatives (calcium channel blockers e.g. amlodipine) C08CA 26 (2.0)
aPercentage is calculated using the total number of prescriptions in this cohort (n = 1,329)
ACE: Angiotensin I converting enzyme; ATC: Anatomical Therapeutic Chemical.
Predicted drug-drug interactions with direct-acting antivirals
We used our cohort to predict DDIs between co-medication and DAA regimens. Figure 
1 presents the distribution of the DDI categories per DAA regimen for 260 different 
drugs. The combination of grazoprevir plus elbasvir and velpatasvir plus sofosbuvir had 
the lowest number of predicted DDIs in our mono-infected cohort. Grazoprevir plus 
elbasvir and daclatasvir plus sofosbuvir had no contra-indicated drugs (category 3) and 
no clinical significant interactions were predicted with 72% and 63%, respectively, of 
the concomitantly used drugs (category 1).
The combination of paritaprevir/ritonavir, ombitasvir plus dasabuvir had the most 
contra-indications (4%), followed by simeprevir (2%), and velpatasvir (1%). Category 
2 interactions were also mainly predicted with the regimen containing paritaprevir/
ritonavir, ombitasvir plus dasabuvir (33%) and simeprevir plus sofosbuvir (26%). Inter-
estingly, ~90% of these category 2 DDIs have not been studied in vivo. These potential 
interactions were predicted by the pharmacologist of the University of Liverpool data-
base, based on the characteristics of the drugs. The top 5 medications which can cause 
clinically relevant DDIs with at least one of the antiviral regimens are given in Table 4.
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figure 1: overview of concomitant medication and expected number of drug-drug inter-
actions between the direct-acting antiviral combinations of regimens and 260 different 
compounds.
Sofosbuvir (SOF), simeprevir (SIM), and daclatasvir (DCV) are licensed as separate compounds for hepatitis C 
virus (HCV) infected patients. These drugs are separately available in the Liverpool database. However, we pres-
ent these regimes together, because in clinical practice these drugs are used in combination. Drug-drug inter-
actions (DDI) with PTV/r, OBV plus DSV (paritaprevir/ritonavir, ombitasvir plus dasabuvir), ledipasvir (LDV) plus 
SOF, velpatasvir (VEL) plus SOF, and grazoprevir (GZR) plus elbasvir (EBR) were available per combination in the 
Liverpool database.
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table 4: top 5 concomitant medication causing clinically relevant interactions with at 
least one of the antiviral regimens.
Drug class AtC code number
DDI category 2 1. Benzodiazepines
2. Antidepressants
3. Proton pump inhibitors (such as omeprazole)
4. Glucocorticoids airway
5. Selective beta-blocking agents
N05BA
N06A
A02BC
R03BA
C07AB
61
43
42
30
29
DDI category 3 1.  Proton pump inhibitors (such as esomeprazole, 
pantoprazole)
2. HMG CoA reductase inhibitors (statins)
3. Antipsychotics
4.  Selective beta-2-adrenoreceptor agonists respiratory 
system
5. CAM
A02BC
C10AA
N05A
R03AC/
R03CC
no ATC
52
19
13
12
2
CAM: Complementary and alternative medicine; DDI: Drug-drug interaction; ATC: Anatomical Therapeutic 
Chemical.
The risk of DDIs could not be assessed in 60 of the 260 different drugs (category 4), be-
cause the drugs were not listed in the University of Liverpool database (July 2016). The 
top three of therapeutic subgroup (2nd ATC level) in Category 4 were antihemorrhagics 
(B02; e.g. coagulation factors), vitamins (A11; e.g. colecalciferol), and psycholeptics (N05; 
e.g. flunitrazepam) which were used by a total of 17, 33, and 13 patients, respectively.
The pharmacists (ES and DB) judged if there were potential interactions with these 
60 drugs and DAAs. We predicted that 11 drugs had a potential interaction, 30 drugs 
would not cause interactions, and for 19 drugs it is unknown if there is a potential 
interaction (for example: metabolism not known of the co-medication), data is given 
in Table 5.
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Risk for drug-drug interaction per patient
The majority of the patients in our cohort (60%) was at risk for a clinically relevant DDI 
with at least one of the DAA regimens: 93 patients (20%) used a drug that would be 
contra-indicated (category 3) and 184 patients (40%) had co-medication leading to a 
possible interaction (category 2), which would require close monitoring, alternation 
of drug dosage or timing of administration. Figure 2 shows the risk of a DDI per DAA 
regimen per patient. The risk for DDIs per patient did not differ in patients aged below 
or above 65 years (60 versus 67%, p = 0.45), nor between patients without cirrhosis and 
with cirrhosis (60 versus 64%, p = 0.50).
     






   
  
        
figure 2: Risk on a clinically relevant drug-drug interaction per patient, grouped per di-
rect-acting antiviral regimen (n = 461).
DDI: Drug-drug interaction; SIM: Simeprevir; SOF: Sofosbuvir; PTV/r: Paritaprevir/ritonavir; OBV: Ombitasvir; LDV: 
Ledipasvir; DCV: Daclatasvir; DSV: Dasabuvir; GZR: Grazoprevir; EBR: Elbasvir; VEL: Velpatasvir.
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DISCuSSIon
In this nationwide, real-life cohort study, we show that the majority of HCV-infected 
patients is at risk for having a clinically relevant DDI with new DAAs. This can have a 
negative influence on treatment outcomes and could potentially harm the patient[1]. In 
this cohort, patients with cirrhosis or ≥65 years old did not have a higher risk for a DDI 
when compared with patients <65 years old or without cirrhosis. This contrasts with 
a recently published study[17] and might be explained due to low number of elderly 
patients in our cohort and the lower mean age of patients ≥65 years (68 years, standard 
deviation [SD] 3). This shows that not only the elderly are at risk for a DDI. The psychoac-
tive agents such as antidepressants (7.4%) and benzodiazepines (7.1%) were the most 
frequently used drugs in our cohort, as well as in the literature[3]. This is relevant be-
cause these drugs increase the risk for DDIs: antidepressants and benzodiazepines are 
extensively metabolized through CYP enzymes, which can be inhibited by DAAs[21, 22]. 
This causes increased plasma concentrations of psychoactive agents increasing the 
likelihood of toxicity. 
PPIs were also responsible for many clinically relevant DDIs in our cohort, both as victim 
and perpetrator[15]. Omeprazole is a victim of paritaprevir/ritonavir, ombitasvir plus 
dasabuvir due to CYP2C19 induction of ritonavir, decreasing omeprazole exposure with 
40-50%[23]. In contrast, PPIs are the perpetrators of a DDI with ledipasvir and velpatasvir. 
PPIs increase gastric pH, which decreases exposure to DAAs due to its insolubility at 
higher pH ranges[24, 25]. The clinical relevance for DDIs between PPIs and ledipasvir is 
under debate[26, 27]. For velpatasvir, the product label states that co-administration of 
omeprazole or other PPIs is not recommended, and that esomeprazole and pantopra-
zole are contra-indicated[25]. 
Most frequently predicted DDIs were found with paritaprevir/ritonavir, ombitasvir plus 
dasabuvir, which fits with data from the published literature[11]. These interactions are 
predominantly caused by ritonavir, which strongly inhibits the most important drug-
metabolizing enzyme (CYP3A4) and various other enzymes and drug-transporters are 
influenced (e.g., CYP2D6, P-glycoprotein [P-gp])[28, 29]. The fewest interactions were seen 
with the newest regimens: velpatasvir plus sofosbuvir and grazoprevir plus elbasvir. 
Grazoprevir and elbasvir are substrates of P-gp and CYP3A and only strong CYP3A 
inhibitors or inducers lead to clinically relevant DDIs. Grazoprevir is also a (weak) CYP3A 
inhibitor, but no DDIs between this combination and CYP3A substrates are listed[30]. 
However, we recommend caution when combining elbasvir and grazoprevir with 
CYP3A substrates with a narrow therapeutic range, such as tacrolimus[31]. 
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The contra-indicated drugs count for up to 4% of the predicted interactions. This is a 
very clear signal to the physician: do not combine the co-medication with this DAA 
regimen. The dilemma is mostly present in the drugs categories in 2 and 4. In our study, 
~90% of category 2 DDIs have not been studied, but were predicted by the University 
of Liverpool group. However, some DDIs cannot be predicted on theoretical grounds 
but do occur in clinical practice. For example, the unexpected severe bradycardia 
that occurred in nine patients who were on amiodarone treatment and received a 
sofosbuvir-containing regimen. The mechanism of this DDI and the role of sofosbuvir 
is still unclear[6, 32-34]. Further, 23% (n = 60) of drugs used by patients from our cohort 
were not listed in the University of Liverpool database (category 4). We judged that 
11 of these drugs might cause an enzymatic interaction with the currently used DAAs. 
Prescribers should be aware that when the drug is not mentioned in the database, it 
does not mean there is no interaction. 
A strength of this study is that it is a nationwide multicenter cohort with a large number 
of patients. This cohort provides a representative overview of co-medication use in the 
Dutch HCV genotype 1 population with a treatment indication. Genotype 1 is globally 
the main genotype (60%) and we expect that the patients of the cohort reflect the 
patients who will be subjected to therapy[35, 36]. Further, we provide a risk assessment for 
drugs not available in the University of Liverpool database. Limitations of our study are 
the retrospective design and that our study describes predicted DDIs and not observed 
DDIs. Finally, the research question that led to this study was not the primary objective 
of data collection. 
In conclusion, co-medication use is rich in both frequency and diversity in chronic HCV-
infected patients. DDIs may result in subtherapeutic or increased drug concentrations 
of DAAs or co-medication, and can cause treatment failure or toxicity. Physicians should 
be aware that the majority of patients are at risk for clinically relevant DDIs. In that case, 
co-medication can be adjusted prior to DAA therapy or DAA treatment can be aligned 
with co-medication use. 
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AbStRACt
Background
To describe the use of non-antiretroviral co-medication and combination antiretroviral 
therapy (cART) in patients co-infected with HIV/hepatitis C virus (HCV), and to predict 
the potential for drug-drug interactions (DDIs) with direct-acting antivirals (DAAs) 
against HCV. 
Methods
This is a retrospective, cross-sectional study, using the Dutch nationwide ATHENA ob-
servational HIV cohort database. All patients with a known HIV/HCV co-infection on 1 
January 2015 were included. Co-medication and cART registered in the database were 
listed. The potential for DDIs between DAAs and co-medication/cART were predicted 
using http://www.hep-druginteractions.org. DDIs were categorized as: (1) no clinically 
relevant DDI; (2) possible DDI; (3) contra-indication; or (4) no information available. 
Results
We included 777 patients of whom 488 (63%) used non-antiretroviral co-medication. 
At risk for a category 2/3 DDI with non-antiretroviral co-medications were 299 patients 
(38%). Most DDIs were predicted with paritaprevir/ritonavir, ombitasvir ± dasabuvir 
(47% of the drugs) and least with grazoprevir/elbasvir (11% of the drugs).
Concerning cART, daclatasvir/sofosbuvir is the most favorable combination as no cART 
is contra-indicated with this combination. In genotype 1/4 patients, grazoprevir/elbas-
vir is least favorable, as 75% of the patients must alter their cART. 
Conclusions
This study showed that co-medication use in the aging HIV/HCV population is frequent 
and diverse. There is a high potential for DDIs between DAAs and co-medication/cART. 
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IntRoDuCtIon
Because of shared routes of transmission and overlapping at-risk populations, patients 
with HIV are commonly co-infected with hepatitis C virus (HCV). It is estimated that, 
worldwide, 2.3 million people live with an HIV/HCV co-infection[1]. In the Netherlands, 
12% of the HIV-infected patients tested were positive for HCV antibody or HCV RNA. 
Most of these patients are men who have sex with men (46%) or current or former drug 
users (31%)[2]. 
Both HIV (combination antiretroviral therapy [cART]) and HCV (direct-acting antivirals 
[DAAs]) treatments can be victims (substrates) and/or perpetrators (cause) of drug-
drug interactions (DDIs)[3]. For example, nevirapine is a strong inducer of cytochrome 
P450 (CYP) 3A4, and therefore interacts with velpatasvir (CYP3A4 substrate)[4]. On the 
other hand, the combination of paritaprevir/ritonavir, ombitasvir, with dasabuvir (PrOD), 
strongly inhibits CYP3A4, causing increased rilpivirine (CYP3A4 substrate) levels[5]. 
These examples demonstrate that DDIs could be a potential problem in HIV/HCV co-
infected patients. So far, this has been studied mainly focusing on cART/DAA interac-
tions[6-9]. However, treatment of co-infected patients is complicated in the aging HIV 
population, because these patients often have somatic or psychiatric co-morbidities 
for which co-medication is prescribed. Thus, besides cART, management of DDIs in HIV/
HCV co-infected patients should also focus on interactions between DAAs and these 
co-medications. Furthermore, earlier publications in general did not include evalua-
tions of the most modern DAAs, such as velpatasvir and grazoprevir/elbasvir, which are 
now recommended first-line agents.
We aimed to identify the use of co-medication and cART and predicted DDIs of these 
medications with all currently available DAAs in a Dutch nationwide HIV/HCV co-
infected cohort. 
MEthoDS
This retrospective, cross-sectional study used the ATHENA database managed by the 
HIV monitoring Foundation (http://www.hiv-monitoring.nl). In this Dutch, nationwide 
registry all HIV-infected patients in care who did not opt out are registered. All patients 
with a known HIV/HCV co-infection on 1 January 2015 were included (HCV RNA posi-
tive). These patients were not treated with DAAs before, as these drugs became avail-
able in the Netherlands on 1 January 2015. The included patients represent the total 
population of patients who could potentially be treated with DAAs and co-medication 
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and cART were thus not altered because of DDIs with DAAs. The reported co-medication 
and cART was used to predict DDIs using the database of the University of Liverpool 
(http://www.hep-druginteractions.org; September 2016).
This analysis was done in four steps: 1) identification of co-medication used in the co-
hort; 2) prediction of DDIs between co-medication and DAAs; 3) identification of cART 
used in the cohort; and 4) prediction of DDIs between cART and DAAs.
Identification of co -medication
All non-antiretroviral co-medication was extracted from the database, from which a list 
was compiled of all unique co-medications. 
Prediction of drug-drug interactions between co-medication and direct-
acting antivirals
The extracted list of co-medications was used for the prediction of DDIs. Each drug was 
cross-checked if DDIs exist with one of the DAA regimens. We included all DAA regi-
mens recommended in Dutch guidelines in November 2016[10]. DDIs were categorized 
as: (1) no clinically relevant DDI expected; (2) possible DDI expected, i.e. monitor the 
patient or alter drug dosage/timing; (3) contra-indication, do not co-administer; or (4) 
no information available in the Liverpool database. Category 2 and 3 DDIs were defined 
as clinically relevant. We reported per DAA regimen the number of co-medications with 
a potential DDI.
After determination of the DDIs between the unique co-medications and DAA regi-
mens, we assessed the number of patients, per genotype, at risk for a clinically relevant 
DDI. We counted the patients who had at least one predicted DDI with any of the DAA 
regimens. Dutch recommendations of November 2016 were used to determine which 
DAA regimen can be used per genotype[10]. Patients with an unknown HCV genotype 
were analyzed with pan-genotypic regimens: daclatasvir + sofosbuvir and velpatasvir + 
sofosbuvir. We reported per genotype, the frequency of patients at risk for a DDI.
In addition, patients with DDIs were counted for those (1) with or without cirrhosis, and 
those (2) <60 or ≥60 years. Cirrhosis (METAVIR F3/F4) was defined using a pathology or 
Fibroscan report (stiffness >9.5 kPa).
Identification of cART
Antiretroviral drugs registered in the database were extracted and a list of antiretroviral 
drugs per patient was compiled. 
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Prediction of drug-drug interactions between cART and direct-acting antivirals
The compiled list of antiretroviral drugs was used for the prediction of DDIs. To simplify 
the analysis, only patients with a double nucleoside reverse transcriptase inhibitors 
(NRTI) backbone and 1 additional drug were included. These additional drugs can 
be a (boosted) protease inhibitor (PI), (boosted) integrase inhibitor (INSTI), or a non-
nucleoside reverse transcriptase inhibitor (NNRTI). These additional drugs usually cause 
DDIs and therefore used in this analysis. Patients with other regimens were excluded. 
Per genotype and DAA regimen, the number of patients at risk for a DDI was reported.
Finally, patients using tenofovir disoproxil fumarate (TDF) and boosted PIs were identi-
fied. This combination interacts with ledipasvir and velpatasvir, causing possible renal 
toxicity. It is therefore recommended to discontinue TDF or the boosted PI before 
ledipasvir and velpatasvir therapy (category 2). 
Analyses were performed using IBM SPSS Statistics 20.
RESultS
The ATHENA database contained data on 777 HIV/HCV co-infected patients known to 
be in care on 1 January 2015. The majority of these patients were male (666; 86%). 
Median (range) age was 49.3 (23-80) years; 689 patients were <60 years and 88 were 
≥60 years. A METAVIR score F0/F1/F2 was reported for 438 (56%) patients and F3/F4 for 
181 (23%) patients (158 unknown). Genotype 1 and 4 were most prevalent, in 495 (64%) 
and 139 (18%) patients, respectively (Table 1).
table 1: baseline patient characteristics.
Characteristics number
Total HIV/HCV-infected patients with positive HCV RNA in carea 777
Patients on cART 762
Patients using co-medication 488
Age, median (range) 49.3 (23-80)
Sex
Male 666
Female 111
MEtAVIR score
F0, F1, F2 438
F3,F4 181
Unknown 158
Genotype
1 495
2 26
3 68
4 139
Unknown 49
aCohort in 2016, 7%, HCV RNA data were not documented (see http://www.hivmonitoring.nl).
HIV: Human immunodeficiency virus; HCV: Hepatitis C virus; cART: combination antiretroviral therapy.
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Identification of co-medication 
An overview of co-medication use is presented in Figure 1, showing that 488 patients 
used 156 unique non-antiretroviral co-medications. Medication use varied from 1 to 14 
prescriptions per patient (excluding cART), in total 1,245 prescriptions were reported. 
Most frequently used medications were drugs for opioid dependence (138; 11%), 
proton pump inhibitors (110; 9%), calcium supplements (77; 6%), selective serotonin 
reuptake inhibitors (56; 4%), platelet aggregation inhibitors (53; 4%), vitamin D (46; 4%), 
and statins (45; 4%). In Table 2 these drug classes are broken down to the drugs that 
were prescribed at least to 10 patients (single molecules).
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figure 1: flowchart of the study including the number of predicted drug-drug interac-
tions with various DAA regimens and co-medication. A total of 1,245 prescriptions were 
available for 488 patients. these prescriptions contained 156 unique drugs, which were 
used for the analysis.
The number of drugs for each category (1-4) are shown in parentheses.
DDI: Drug-drug interaction; HCV: Hepatitis C virus; PrOD: Paritaprevir/ritonavir, ombitasvir with dasabuvir; PrO: 
Paritaprevir/ritonavir, ombitasvir; SIM + SOF: Simeprevir and sofosbuvir; LDV + SOF: Ledipasvir and sofosbuvir; 
DCV + SOF: Daclatasvir and sofosbuvir; VEL+SOF: Velpatasvir and sofosbuvir: GZR + EBR: Grazoprevir and elbasvir.
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table 2: overview of drugs used by at least 10 hIV/hCV co-infected patients.
Drug name number of patients
Methadone 138
Calcium carbonate/colecalciferol 77
Omeprazole 50
Pantoprazole 48
Colecalciferol 43
Co-Trimoxazole 35
Valaciclovir 30
Diazepam 27
Metoprolol 27
Citalopram 24
Lisinopril 24
Carbasalate calcium 23
Pravastatin 23
Acetylsalicylic acid 22
Testosterone 22
Mirtazapine 21
Sildenafil 19
Alendronic acid 17
Olanzapine 17
Spironolactone 15
Escitalopram 14
Furosemide 14
Ranitidine 14
Metformin 13
Pregabaline 13
Quetiapine 13
Salmeterol/fluticasone 12
Tramadol 12
Clonazepam 11
Promethazine 11
Venlafaxine 10
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Prediction of drug-drug interactions between co-medications and direct-
acting antivirals
Grazoprevir/elbasvir and velpatasvir/sofosbuvir had the lowest number of predicted 
DDIs with the 156 co-medications. PrOD and simeprevir/sofosbuvir account for the 
highest number of predicted category 2 and 3 interactions with the used co-medica-
tion. Overall, the number of truly contra-indicated drugs is low, with a maximum of 10 
drugs for PrOD. We were not able to predict potential DDIs of 23 drugs (category 4), as 
these drugs were unavailable in the Liverpool database (Figure 1).
Converting the number of drugs (156) to the number of patients with a category 2 or 
3 DDI with any of the DAAs, we found that 299 patients were at risk. This concerns 205 
(41%) genotype 1, 34 (36%) genotype 2/3, 54 (39%) genotype 4, and 6 (12%) patients 
with an unknown genotype. Furthermore, 269 (40%) patients <60 years and 55 (77%) 
patients ≥60 years were at risk for a category 2 or 3 DDI with any of the DAA regimens. 
Similarly, 147 (34%) and 100 (55%) patients without and with cirrhosis, respectively, 
were at risk for a DDI. 
Identification of cART
A total of 762 (98%) patients were treated with cART. The NRTI backbone containing 
TDF + emtricitabine was used by 536 (70%) of patients, and 103 (14%) patients used 
abacavir + lamivudine. 
Most patients used 1 additional (e.g., PI, INSTI, NNRTI) antiretroviral drug (670; 88%) 
and 40 (5%) patients used more than 1 additional antiretroviral. Most frequently used 
additional drugs were NNRTIs (307; 46%), followed by the boosted PIs (247; 37%), and 
INSTIs (116; 17%). It should be noted that on the date of evaluation, 1 January 2015, 
dolutegravir had only been available for 2 months (Table 3).
Prediction of drug-drug interactions between cART and direct-acting 
antivirals
Per genotype, the predicted DDIs per patients are shown in Figure 2 (n = 669). None of 
the genotypes 1 and 4 patients would have to change their cART when treated with 
daclatasvir/sofosbuvir. However, the dosage of daclatasvir should be altered depending 
on some specific cART regimens. Ledipasvir and velpatasvir in combination with sofos-
buvir can be safely used with all third additional drugs. However, 199 (31%) patients 
with genotype 1 or 4 used TDF with boosted PIs, which makes it necessary to switch 
either TDF or the PI. Comparably, in combination with velpatasvir, patients infected 
with all genotypes using TDF with a boosted PI (n = 231; 29%), are recommended to 
switch either TDF or the PI.
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Grazoprevir/elbasvir causes the most category 3 DDIs, necessitating a change in DAA 
or cART regimen. Other regimens with category 3 interactions were sofosbuvir with 
velpatasvir or simeprevir and PrOD. For patients with genotype 2/3 or an unknown 
genotype, it is shown that sofosbuvir/daclatasvir can be used without switching the 
cART. 
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  
  
  
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figure 2: the number of patients predicted to have a drug-interaction between cARt and 
the various combinations of direct-acting antivirals shown per genotype. 
Only patients with one additional (third) drug are included in this analysis (n = 670). 
Genotype 6 is excluded from this analysis, as only one patient was listed with genotype 6 (n = 669).
Category 2 30 mg: reduce the daclatasvir dose to 30 mg.
Category 2 90 mg: increase the daclatasvir dose to 90 mg.
PrOD: Paritaprevir/ritonavir, ombitasvir with dasabuvir; PrO: Paritaprevir/ritonavir, ombitasvir; SIM + SOF: Simepre-
vir and sofosbuvir; LDV + SOF: Ledipasvir and sofosbuvir; DCV + SOF: Daclatasvir and sofosbuvir; VEL+SOF: Velpa-
tasvir and sofosbuvir: GZR + EBR: Grazoprevir and elbasvir.
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DISCuSSIon
This cohort represents all Dutch HIV/HCV co-infected patients in care in the Netherlands 
who might be treated with the novel DAAs. Most commonly used co-medications 
reflect the characteristics of the HIV/HCV patient population, such as the drugs used for 
opioid dependence[2]. Other drug classes in the top 5 are comparable with HCV mono-
infected patients in the Netherlands[11] and represent the aging HIV population with 
an increasing number of co-morbidities. This is supported by our subgroup analysis 
in which patients aged ≥60 years had a higher risk of DDIs than patients <60 aged 
years. Similarly, patients with cirrhosis had a higher predicted risk of DDIs than patients 
without cirrhosis. This is comparable to the findings in HCV mono-infected patients[12]. 
PrOD and sofosbuvir/simeprevir have the highest number of predicted DDIs with 
non-antiretroviral co-medication, which is in line with previous studies[6, 8, 9]. Both 
combinations contain inhibitors of CYP3A4 (i.e. ritonavir, simeprevir), which is the main 
drug-metabolizing enzyme[5, 13]. However, it should be mentioned that, in daily practice, 
these regimens are infrequently used, because side effects and DDIs caused by the 
protease inhibitors.
Grazoprevir/elbasvir had the lowest number of DDIs with co-medication because they 
have minimal influence on drug-enzymes and transporters[14]. One should notice that 
grazoprevir is a mild inhibitor of CYP3A4. Therefore, we recommend being careful 
with CYP3A4 substrates with a narrow therapeutic range. However, it remains unclear 
whether these DDIs are clinically relevant. 
Daclatasvir/sofosbuvir can be easily combined with cART, because of the possibility of a 
dose adaptation and no contra-indicated cART regimens. Although ledipasvir has only 
category 2 DDIs, it is less favorable, because ledipasvir is not recommended with the 
combination of a boosted PI and TDF, an issue that would require a switch in cART in 
31% of patients. This interaction, as well as the interaction with velpatasvir (29%), can 
also be avoided when switching from TDF to tenofovir alafenamide. Plasma concen-
trations of tenofovir alafenamide are not affected by ledipasvir[15]. In most countries, 
the separate agents, daclatasvir and sofosbuvir are in general a more expensive DAA 
regimen compared with the fixed-dose combinations with velpatasvir and ledipasvir 
and therefore prescribed in a lesser extent. In the Netherlands, the prices of DAAs are 
unknown and therefore not a criterion for selecting a DAA regimen[10].
It is striking that grazoprevir/elbasvir has the lowest number of interactions with non-
antiretroviral co-medication, but this combination has the highest number of DDIs 
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with cART. Grazoprevir/elbasvir (and simeprevir) is contra-indicated with all boosted 
PIs, NNRTIs (except rilpivirine), and elvitegravir/cobicistat; this makes it an unfavorable 
combination in this co-infected population because almost all patients would need to 
alter their cART regimen, if they are not already on raltegravir or dolutegravir. NNRTIs 
and PIs are most frequently used in our cohort, but with the introduction of dolutegra-
vir, the use of NNRTIs and PIs decreased[2]. 
A limitation of the analysis is that patients with the most complicated cART regimens 
(e.g., >1 additional drug, no NNRTI backbone) were excluded from the analysis pre-
sented in Figure 2. These patients are probably the most difficult-to-treat HIV patients, 
because they have deviating cART regimens, and therefore, switching cART is probably 
not an option in these cases (e.g., resistance, toxicity). For these patients, the treatment 
strategy is to use a DAA regimen with a least number of (possible) drug-interactions.
Finally, we must comment that the majority of the DDIs, which are discussed in this 
article, only are studied in healthy volunteers and not in HIV/HCV co-infected patients. 
These drug-interaction studies in healthy volunteers give a good indication of the 
direction of the DDI; however, as healthy volunteers substantially differ from HIV/HCV 
co-infected patients, the magnitude of the DDIs could also differ, for example, the 
exposure to DAAs and antiretroviral drugs is probably different in healthy volunteers 
and HIV/HCV patients[16].
Concluding, this study showed that co-medication use in the aging HIV/HCV population 
is frequent and diverse and that there is a high potential of DDIs between DAAs plus 
co-medication/cART. Combining the results from our analysis, from the perspective of 
potential DDIs with co-medication and/or cART, the most favorable regimen seems to 
be daclatasvir/sofosbuvir. 
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view board of all participating centers. It has subsequently become integral part of HIV 
care and includes pseudonymized data and stored plasma samples from HIV-infected 
patients living in the Netherlands and receiving care in one of the designated HIV treat-
ment centers. Patients can opt out after being informed by their treating physician of 
the purpose of collection of data and samples. Data from patients who opt out are 
not included in the ATHENA database. Pseudonymized data may be used for scientific 
purposes without further review. Patients are informed that in case of future requests 
for use of stored plasma samples for scientific research, they will be asked for prior con-
sent by their treating HIV physician. Data are pseudonymized before being provided to 
investigators. For the purpose of our analysis, only existing data have been used, and 
therefore no additional review or consent has been necessary.
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Academic Medical Center of the university of Amsterdam: HIV treating physicians: 
J.M. Prins*, T.W. Kuijpers, H.J. Scherpbier, J.T.M. van der Meer, F.W.M.N. Wit, M.H. Godfried, 
P. Reiss, T. van der Poll, F.J.B. Nellen, S.E. Geerlings, M. van Vugt, D. Pajkrt, W.J. Wiersinga, 
M. van der Valk, A. Goorhuis, J.W. Hovius. HIV nurse consultants: M.A.H. Bijsterveld, J. van 
Eden, A.M.H. van Hes, M. Mutschelknauss, H.E. Nobel, F.J.J. Pijnappel, A.M. Weijsenfeld. 
HIV clinical virologists/chemists: S. Jurriaans, N.K.T. Back, H.L. Zaaijer, B. Berkhout, M.T.E. 
Cornelissen, C.J. Schinkel, X.V. Thomas. Admiraal De Ruyter Ziekenhuis, Goes: HIV 
treating physicians: M. van den Berge, A. Stegeman. HIV nurse consultants: S. Baas, L. 
Hage de Looff. HIV clinical virologists/chemists: B Wintermans, J Veenemans. Catharina 
Ziekenhuis, Eindhoven: HIV treating physicians: M.J.H. Pronk*, H.S.M. Ammerlaan. 
HIV nurse consultants: E.S. de Munnik, E. van Beek. HIV clinical virologists/chemists: A.R. 
Jansz, J. Tjhie, M.C.A. Wegdam, B. Deiman, V. Scharnhorst. Elisabeth-tweeSteden 
Ziekenhuis, tilburg: HIV treating physicians: M.E.E. van Kasteren*, A.E. Brouwer. HIV 
nurse consultants: R. van Erve, B.A.F.M. de Kruijf-van de Wiel, S.Keelan-Pfaf, B. van der Ven. 
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Data collection: B.A.F.M. de Kruijf-van de Wiel, B. van der Ven. HIV clinical virologists/chem-
ists: A.G.M. Buiting, P.J. Kabel, D.Versteeg. Emma Kinderziekenhuis, Amsterdam: HIV 
nurse consultants: A. van der Plas, A.M. Weijsenfeld. Erasmus MC, Rotterdam: HIV treat-
ing physicians: M.E. van der Ende*, H.I. Bax, E.C.M. van Gorp, J.L. Nouwen, B.J.A. Rijnders, 
C.A.M. Schurink, A. Verbon, T.E.M.S. de Vries-Sluijs. HIV nurse consultants: N. Bassant, J.E.A. 
van Beek, M. Vriesde, L.M. van Zonneveld. Data collection: H.J. van den Berg-Cameron, 
F.B. Bruinsma-Broekman, J. de Groot, M. de Zeeuw-de Man. HIV clinical virologists/
chemists: C.A.B. Boucher, M.P.G Koopmans, J.J.A van Kampen, S.D. Pas. Erasmus MC-
Sophia, Rotterdam: HIV treating physicians: G.J.A. Driessen, A.M.C. van Rossum. HIV 
nurse consultants: L.C. van der Knaap, E. Visser. flevoziekenhuis, Almere: HIV treating 
physicians: J. Branger*, A. Rijkeboer-Mes. HIV nurse consultant and data collection: C.J.H.M. 
Duijf-van de Ven. hagaZiekenhuis, Den haag: HIV treating physicians: E.F. Schippers*, 
C. van Nieuwkoop. HIV nurse consultants: J.M. van IJperen, J. Geilings. Data collection: 
G. van der Hut. HIV clinical virologist/chemist: P.F.H. Franck. hIV focus Centrum (DC 
Klinieken), Amsterdam: HIV treating physicians: A. van Eeden*. HIV nurse consultants: 
W. Brokking, M. Groot, L.J.M. Elsenburg. HIV clinical virologists/chemists: M. Damen, I.S. 
Kwa. Isala, Zwolle: HIV treating physicians: P.H.P. Groeneveld*, J.W. Bouwhuis. HIV nurse 
consultants: J.F. van den Berg, A.G.W. van Hulzen. Data collection: G.L. van der Bliek, P.C.J. 
Bor. HIV clinical virologists/chemists: P. Bloembergen, M.J.H.M. Wolfhagen, G.J.H.M. Ruijs. 
leids universitair Medisch Centrum, leiden: HIV treating physicians: F.P. Kroon*, 
M.G.J. de Boer, H. Jolink, A.M. Vollaard. HIV nurse consultants: W. Dorama, N. van Holten. 
HIV clinical virologists/chemists: E.C.J. Claas, E. Wessels. Maasstad Ziekenhuis, Rot-
terdam: HIV treating physicians: J.G. den Hollander*, K. Pogany, A. Roukens. HIV nurse 
consultants: M. Kastelijns, J.V. Smit, E. Smit, D. Struik-Kalkman, C. Tearno. Data collection: 
M. Bezemer, T. van Niekerk. HIV clinical virologists/chemists: O. Pontesilli. Maastricht 
uMC+, Maastricht: HIV treating physicians: S.H. Lowe*, A.M.L. Oude Lashof, D. Posthou-
wer. HIV nurse consultants: R.P. Ackens, J. Schippers, R. Vergoossen. Data collection: B. 
Weijenberg-Maes. HIV clinical virologists/chemists: I.H.M. van Loo, T.R.A. Havenith. MCh-
bronovo, Den haag: HIV treating physicians: E.M.S. Leyten*, L.B.S. Gelinck. HIV nurse 
consultants: A.Y. van Hartingsveld, C. Meerkerk, G.S. Wildenbeest. HIV clinical virologists/
chemists: J.A.E.M. Mutsaers, S.Q. van Veen. MC Slotervaart, Amsterdam: HIV treating 
physicians: J.W. Mulder*, S.M.E. Vrouenraets, F.N. Lauw. HIV nurse consultants: M.C. van 
Broekhuizen, H. Paap, D.J. Vlasblom. HIV clinical virologists/chemists: P.H.M. Smits. MC 
Zuiderzee, lelystad: HIV treating physicians: S. Weijer*, R. El Moussaoui. HIV nurse 
consultant: A.S. Bosma. Medisch Centrum leeuwarden, leeuwarden: HIV treating 
physicians: M.G.A.van Vonderen*, D.P.F. van Houte, L.M. Kampschreur. HIV nurse consul-
tants: K. Dijkstra, S. Faber. HIV clinical virologists/chemists: J Weel. Medisch Spectrum 
twente, Enschede: HIV treating physicians: G.J. Kootstra*, C.E. Delsing. HIV nurse con-
sultants: M. van der Burg-van de Plas, H. Heins. Data collection: E. Lucas. noordwest 
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Ziekenhuisgroep, Alkmaar: HIV treating physicians: W. Kortmann*, G. van Twillert*, 
J.W.T. Cohen Stuart, B.M.W. Diederen, R. Renckens. HIV nurse consultant and data collec-
tion: D. Ruiter-Pronk, F.A. van Truijen-Oud. HIV clinical virologists/chemists: W. A. van der 
Reijden, R. Jansen. olVG, Amsterdam: HIV treating physicians: K. Brinkman*, G.E.L. van 
den Berk, W.L. Blok, P.H.J. Frissen, K.D. Lettinga W.E.M. Schouten, J. Veenstra. HIV nurse 
consultants: C.J. Brouwer, G.F. Geerders, K. Hoeksema, M.J. Kleene, I.B. van der Meché, 
M. Spelbrink, H. Sulman, A.J.M. Toonen, S. Wijnands. HIV clinical virologists: M. Damen, D. 
Kwa. Data collection: E. Witte. Radboudumc, nijmegen: HIV treating physicians: R. van 
Crevel*, M. Keuter, A.J.A.M. van der Ven, H.J.M. ter Hofstede, A.S.M. Dofferhoff. HIV nurse 
consultants:  M. Albers, K.J.T. Grintjes-Huisman, M. Marneef, A. Hairwassers. HIV clinical 
virologists/chemists:  J. Rahamat-Langendoen. HIV clinical pharmacology consultant:  D. 
Burger. Rijnstate, Arnhem: HIV treating physicians: E.H. Gisolf*, R.J. Hassing, M. Claas-
sen. HIV nurse consultants: G. ter Beest, P.H.M. van Bentum, N. Langebeek. HIV clinical 
virologists/chemists: R. Tiemessen, C.M.A. Swanink. Spaarne Gasthuis, haarlem: HIV 
treating physicians: S.F.L. van Lelyveld*, R. Soetekouw. HIV nurse consultants: L.M.M. van 
der Prijt, J. van der Swaluw. Data collection: N. Bermon. HIV clinical virologists/chemists: 
W.A. van der Reijden, R. Jansen, B.L. Herpers, D.Veenendaal. Medisch Centrum Jan van 
Goyen, Amsterdam: HIV treating physicians: D.W.M. Verhagen. HIV nurse consultants: M. 
van Wijk. universitair Medisch Centrum Groningen, Groningen: HIV treating physi-
cians: W.F.W. Bierman*, M. Bakker, J. Kleinnijenhuis, E. Kloeze, H. Scholvinck, Y. Stienstra, 
C.L. Vermont, K.R. Wilting. HIV nurse consultants: A. Boonstra, H. de Groot-de Jonge, P.A. 
van der Meulen, D.A. de Weerd. HIV clinical virologists/chemists: H.G.M. Niesters, C.C. van 
Leer-Buter, M. Knoester. universitair Medisch Centrum utrecht, utrecht: HIV treat-
ing physicians: A.I.M. Hoepelman*, J.E. Arends, R.E. Barth, A.H.W. Bruns, P.M. Ellerbroek, T. 
Mudrikova, J.J. Oosterheert, E.M. Schadd, M.W.M. Wassenberg, M.A.D. van Zoelen. HIV 
nurse consultants: K. Aarsman, D.H.M. van Elst-Laurijssen, E.E.B. van Oers-Hazelzet. Data 
collection: M. van Berkel. HIV clinical virologists/chemists: R. Schuurman, F. Verduyn-Lunel, 
A.M.J. Wensing. Vumc, Amsterdam: HIV treating physicians: E.J.G. Peters*, M.A. van Agt-
mael, M. Bomers, J. de Vocht. HIV nurse consultants: M. Heitmuller, L.M. Laan. HIV clinical 
virologists/chemists: C.W. Ang, R. van Houdt, A.M. Pettersson, C.M.J.E. Vandenbroucke-
Grauls. wilhelmina Kinderziekenhuis, uMCu, utrecht: HIV treating physicians: S.P.M. 
Geelen, T.F.W. Wolfs, L.J. Bont. HIV nurse consultants: N. Nauta. 
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AbStRACt
Objective
Direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection treatment 
can cause drug-interactions (DDIs), with combination antiretroviral therapy (cART) and 
non-antiretroviral co-medication. We mapped how physicians manage DDIs between 
DAAs and co-medication and analyzed treatment outcomes. 
Methods
Data was prospectively collected as part of the ATHENA HIV observational cohort and 
retrospectively analyzed. Dutch patients with HIV/HCV co-infection who initiated treat-
ment with DAAs between January 2015 and May 2016 were included. Co-medication 3 
months prior to and during DAA therapy was identified. Potential DDIs with the DAAs 
were checked using http://www.hep-druginteractions.org. DDIs were categorized 
as: (1) no interaction expected; (2) potential interaction; (3) contra-indication; (4) no 
recommendation. This was used to determine which patients switched or had a DDI 
during DAA therapy with co-medication.
Results
423 patients were treated with DAAs, of whom 418 (99%) used cART and 251 (59%) 
used non-antiretroviral co-medication. Before commencing DAA treatment, in 17/84 
(20%) patients the non-antiretroviral co-medication which could result in a category 2 
or 3 DDI, were discontinued before DAA initiation, including 2/6 (33%) prescriptions of 
category 3 drugs. 
196/418 (47%) patients had a category 2 or 3 DDI between their DAA regimen and 
cART. Category 2 or 3 DDIs were prevented by switching cART in 78/147 (53%) and 
47/49 (96%) patients. 367/423 (87%) patients have reached SVR (33 in follow-up).
Conclusions
Prescription patterns suggest physicians to be aware of potential DDIs between co-
medication and DAAs, in particular where it concerns DDIs with cART. Awareness is 
needed for category 3 interactions between non-antiretroviral co-medication and 
DAAs. 
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IntRoDuCtIon
Several drug classes used for the treatment of HIV (combination antiretroviral therapy 
[cART]) may cause drug-drug interactions (DDIs), especially the boosted protease inhibi-
tors (PIs) and most of the non-nucleoside reverse transcriptase inhibitors (NNRTIs). Both 
classes influence the activity of drug-metabolizing enzymes and/or drug-transporters 
and, in addition, they can also be a substrate of these enzymes and transporters[1]. 
Simultaneous treatment of both HIV and hepatitis C virus (HCV) infection increases the 
risk of DDIs, because the direct-acting antivirals (DAAs) against HCV are metabolized by 
the enzymes that are influenced by cART, and vice versa[2]. 
Earlier studies predicted a high risk of clinically relevant DDIs when patients are simul-
taneously treated for HIV and HCV[3-5]. For instance, it was previously predicted that 51% 
of HIV/HCV co-infected patients had a cART regimen that would be contra-indicated 
with simeprevir/sofosbuvir or grazoprevir/elbasvir[5]. Co-medication other than cART 
can also be involved in DDIs[6]. This has already been shown for HCV mono-infected 
patients[4, 7-10]. Vermehren et al predicted that 60% of HCV mono-infected patients using 
non-antiretroviral co-medication had a DDI with at least one DAA regimen and that 
patients ≥65 years had an increased risk for DDIs[9]. 
Therefore, when DAAs are co-administered with cART and non-antiretroviral medica-
tions there is a risk of clinically relevant DDIs. Various tools are available that provide 
information for clinical decision making and preventing DDIs, such as electronic 
medication warnings during the process of drug prescription or the website of the Uni-
versity of Liverpool (http://www.hep-druginteractions.org)[11]. However, two important 
questions have remained largely unanswered so far: how do physicians handle these 
potential DDIs in clinical practice, and does this affect the outcome of HCV treatment? 
Modifying cART to prevent a DDI may not be without risk, and could result in new 
drug toxicity or HIV virological failure. Therefore, this analysis was conducted to analyze 
how physicians managed potential DDIs between DAAs and either non-antiretroviral 
co-medication or cART co-medication and how this affected subsequent HIV and HCV 
virological treatment outcomes in a nationwide cohort of HIV/HCV co-infected patients 
in the Netherlands.
MEthoDS 
Data were used from the ATHENA database managed by the HIV monitoring Founda-
tion (http://www.hiv-monitoring.nl). This is a registry of all Dutch HIV patients in care, 
except a small minority who opt out of having their data registered (2%). 
Chapter 7
152
All HIV/HCV co-infected patients initiating treatment with DAAs between January 
2015 and May 2016 were included. DAAs available during that time in the Netherlands 
were simeprevir, daclatasvir, sofosbuvir, ledipasvir/sofosbuvir, and the combination of 
paritaprevir/ritonavir, ombitasvir and dasabuvir.
Patient characteristics were extracted from the database three months before DAA 
treatment was started. We identified which non-antiretroviral and cART co-medication 
was used by the patients three months before and during DAA therapy. 
Potential DDIs between cART and other co-medication and the selected DAA 
regimen were checked using the website of the University of Liverpool (http://www.
hep-druginteractions.org; September 2016). DDIs were categorized as defined by the 
Liverpool database: (1) no interaction expected (green); (2) potential interaction, i.e. 
monitor the patient or alter drug dosage/timing (amber); (3) contra-indication, do not 
co-administer (red); or (4) no clear data, so no recommendation is given. We defined 
category 2 and 3 as clinically relevant, given that according to the website, action is 
needed when the drugs are combined. For patients with a category 2 or 3 DDI between 
DAA and non-antiretroviral co-medication and DAAs and cART, the information about 
DDIs before commencing DAA therapy was evaluated. Information about any modifica-
tion of the cART regimen both before starting and during DAA treatment was available 
in the database. However, for non-antiretroviral co-medications information was only 
available concerning whether therapy was stopped or continued.
Data on sustained  virological response 12 weeks after the end of HCV therapy (SVR12) 
and HIV viral load were also extracted; (HIV RNA <100 copies/mL was defined as un-
detectable to exclude blips). We performed descriptive analyses (frequency counts, 
proportions) using SPSS (IBM SPSS Statistics 20).
RESultS
Data from 423 HIV/HCV co-infected patients were analyzed. The median (interquartile 
range [IQR]) age at time of DAA initiation was 50 (45-55) years, 377 (89%) patients were 
male, 118 (28%) patients had METAVIR score ≥F3 (liver stiffness ≥9.5 kPa). The majority of 
patients were infected with HCV genotype 1 (288; 68%). 
Most frequently prescribed regimens were ledipasvir/sofosbuvir (213; 50%), daclatasvir/
sofosbuvir ± ribavirin (115; 27%) and simeprevir/sofosbuvir ± ribavirin (59; 14%). In 
total, 418 (99%) patients were being treated for their HIV infection with cART, of whom 
405/418 (96%) had an undetectable plasma HIV-1 RNA level at start of DAA treatment. 
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The majority of patients were treated with a nucleoside reverse transcriptase inhibitor 
(NRTI) backbone consisting of tenofovir disoproxil fumarate (TDF) plus emtricitabine 
(298/418; 70%) or lamivudine plus abacavir (63/418; 15%). Boosted PIs, NNRTIs, and 
integrase inhibitors (INSTIs) were used by 125/418 (30%), 175/418 (41%), and 76/418 
(18%) patients, respectively. 
In conjunction with starting DAA treatment, 166/418 (40%) patients switched their 
boosted PI, NNRTI, or INSTI and 57/418 (14%) of the patients switched their NRTI back-
bone. The majority of these patients switched from a boosted PI or NNRTI to INSTIs such 
as raltegravir or dolutegravir (Table 1). Supplementary Table 1 shows that switching 
cART did not influence HIV suppression.
table 1: baseline patient characteristics (n = 423).
Characteristic number
Male, n (%) 377 (89)
Age, median (IQR) 50 (45-55)
Genotype, n (%)
1 57 (14)
1a 202 (48)
1b 29 (7)
2 13 (3)
3 30 (7)
4 76 (18)
6 1 (0)
Missing 15 (4)
MEtAVIR score, n (%)
F0, F1, F2 (liver stiffness <9.5 kPa) 255 (60)
F3, F4 (liver stiffness ≥9.5 kPa) 118 (28)
Missing 50 (12)
Creatinine µmol/L, median (IQR) 87 (24)
DAA regimen, n (%)
PrOD 17 (4)
Daclatasvir containinga 116 (27)
Simeprevir containingb 67 (16)
Ledipasvir/sofosbuvir 213 (50)
Sofosbuvir, peg-interferon alfa, ribavirin 10 (2)
cARt, n (%) before DAA treatment After DAA treatment
Tenofovir disoproxil fumarate + emtricitabine 298 (70) 271(64)
Lamivudine + abacavir 63 (15) 85 (20)
Lamivudine + zidovudine 8 (2) 2 (1)
Lamivudine + zidovudine + abacavir 0 (0) 3 (1)
Other NRTI 30 (7) 33 (8)
No NRTI backbone 19 (5) 27 (6)
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table 1: baseline patient characteristics (n = 423). (continued)
Characteristic number
Boosted PI 125 (30) 66 (16)
NNRTI 175 (41) 103 (24)
INSTI 76 (18) 204 (48)
Other 35 (8) 40 (10)
No PI, NNRT, INSTI 7 (2) 5 (1)
No cART 5 (1) 2 (1)
hIV RnA, n (%)
Undetectable (<100 IU/mL) 405 (96) 379 (90)
Detectable (>100 IU/mL) 18 (4) 13 (3)
Missing 31 (7)
aRegimens containing daclatasvir: daclatasvir + sofosbuvir ± ribavirin or daclatasvir + peg-interferon ± ribavirin.
bRegimens containing simeprevir: simeprevir + sofosbuvir ± ribavirin, simeprevir + daclatasvir, or simeprevir + 
peg-interferon ± ribavirin.
DAA: Direct-acting antiviral; PrOD: Paritaprevir/ritonavir, ombitasvir, dasabuvir; cART: combination antiretroviral 
therapy; NRTI; Nucleoside reverse transcriptase inhibitor; NNRTI: Non-nucleoside reverse transcriptase inhibitor; 
PI: Protease inhibitor; INSTI: Integrase inhibitor.
At least one non-antiretroviral co-medication was used by 251 (59%) patients (range: 
1-11 drugs per patient). In total 570 unique prescriptions were used by these 251 
patients. Most frequently used non-antiretroviral co-medication was methadone (39 
prescriptions), followed by the fixed-dose combination of calcium carbonate/colecal-
ciferol (38 prescriptions), colecalciferol (26 prescriptions), omeprazole (24 prescriptions), 
and pantoprazole (22 prescriptions). The top 20 of the most frequently prescribed non-
antiretroviral co-medications are presented in Table 2.
Drug-drug interactions
In Figure 1 an overview is given of the category 2 and category 3 interactions before 
and during DAA treatment. This figure includes all co-medication: non-antiretroviral 
co-medication as well as cART. Three months before DAA treatment, 199/423 (47%) 
patients were at risk for a category 2 DDI of which 55/199 (28%) patients would have 
had a DDI with non-antiretroviral co-medication, 121/199 (61%) with cART, and 23/199 
(12%) with both non-antiretroviral and cART co-medication. This number was reduced 
to 125/423 (30%) during DAA treatment, mainly as a result of the fact that 53/199 (27%) 
patients had modified their cART regimen prior to starting DAAs. 
Comparably, 47/423 (11%) patients were at risk for a category 3 DDI prior to DAA treat-
ment, the majority was at risk for an interaction between their DAA regimen and cART. 
Only six (1%) patients continued their category 3 drug during DAA treatment, of which 
4/6 (1%) patients continued contra-indicated non-antiretroviral co-medications. Two 
out of these six patients had both a category 2 and category 3 DDI.
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Drug-drug interactions between direct-acting antivirals and non-
antiretroviral co-medication
Table 3 provides an overview of all category 2 and 3 DDIs between non-antiretroviral 
co-medication and the DAA regimens which were used.
Before commencing DAA treatment, 78/423 (18%) patients were at risk for a category 
2 DDI between their DAA regimen and non-antiretroviral co-medication (90 prescrip-
tions). These category 2 DDIs were mostly caused by proton pump inhibitors (PPIs; 
omeprazole, pantoprazole) and statins (atorvastatin, pravastatin). Of the 90 interact-
ing prescriptions, 21/90 (23%) were discontinued before DAA initiation. Ledipasvir/
sofosbuvir had most category 2 DDIs with non-antiretroviral co-medications: 45/78 
(58%) patients accounting for 57 prescriptions, of which 27 prescriptions included acid-
reducing agents such as PPIs and H2-antagonists (e.g. ranitidine). Seventeen patients 
continued their acid-reducing agent during HCV therapy with ledipasvir/sofosbuvir; 
14/17 (82%) achieved SVR12; 1/17 patient did not achieve SVR, and 2/17 are still in 
follow-up for their SVR (Figure 2).
table 2: top 20 prescriptions co-medication (total number of prescriptions is 570) used 
by 251 patients.
Drug number prescriptions
Methadone 39
Calcium carbonate /colecalciferol 38
Colecalciferol 26
Omeprazole 24
Pantoprazole 22
Lisinopril 18
Valaciclovir 18
Pravastatin 14
Testosterone 14
Co-Trimoxazole 11
Metoprolol 11
Acetylsalicylic acid 10
Citalopram 10
Sildenafil 10
Carbasalate calcium 9
Metformin 9
Ranitidine 8
Escitalopram 7
Hydrochlorothiazide 7
Alendronic acid 6
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In 2 out of 6 (33%) patients who used non-antiretroviral co-medication that had a 
category 3 DDI with ledipasvir and paritaprevir/ritonavir, ombitasvir plus dasabuvir, the 
interacting drug was discontinued before DAA initiation. The other four (67%) patients 
who continued the interacting drug were able to complete the DAA therapy and all 
reached SVR.
In September 2016, 23 non-antiretroviral drugs were not included on the Liverpool 
website. These drugs were used by 91 patients, varying from one to three drugs per 
patient (105 prescriptions). None of these drugs were discontinued before HCV treat-
ment. The most common of these drugs were calcium carbonate/colecalciferol (38 
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figure 1: number of patients that had an interaction between the used direct-acting an-
tivirals (DAAs) and non-antiretroviral and cARt co-medication before and during DAA 
treatment. 
Number represents the number of patients that have a category 2 or 3 interaction.
Before: drug-drug interactions before DAA treatment.
During: drug-drug interactions during DAA treatment.
cART: combination antiretroviral therapy.
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prescriptions), colecalciferol (26 prescriptions), and testosterone (14 prescriptions) for 
which no interactions were expected with any of the DAAs which were prescribed.
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figure 2: Sustained virological response (SVR) rates shown for the total cohort, patients 
with and without a drug-drug interaction, and patients treated with an acid-reducing 
agent and ledipasvir.
SVR: sustained virological response rate of the total cohort.
DDI: SVR-rate for patients with a DDI during treatment.
No DDI: SVR-rate for patients without a DDI during treatment.
Acid-reducing agent & LDV: SVR-rate for patients simultaneously treated with an acid-reducing agent and le-
dipasvir.
Drug-drug interactions between direct-acting antivirals and cART
In Figure 3, the interacting cART regimens per DAA regimen are presented. In the figure 
only the boosted PI, NNRTI, and INSTI are shown, as there are no DDIs with the NRTI 
backbone. The exception is the potential interaction when ledipasvir is combined with 
TDF and a boosted PI or boosted elvitegravir which is presented separately in Figure 3.
In total, 196 (47%) of 418 patients had a category 2 (147/418; 35%) or 3 (49/418; 12%) 
potential DDI between their prescribed DAA regimen and cART prior to initiation of 
DAA treatment. 
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figure 3: overview of cARt regimens used (third drugs) that caused category 2 and 3 
drug-drug interactions 3 months prior to treatment.
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NNRTIs (e.g., efavirenz, etravirine, and nevirapine) and boosted PIs (atazanavir and 
darunavir boosted with ritonavir) were the most commonly used third drugs which 
were also responsible for the majority of the category 2 DDIs (91 [22%] patients). Of the 
147 patients with a category 2 DDI, 78 (51%) switched to a non-interacting cART regi-
men. The majority of these patients switched to a regimen with an INSTI (75/78; 96%), 
as raltegravir and dolutegravir have no DDIs with the DAAs. At start of DAA therapy 
39/213 (18%) patients treated with ledipasvir used a boosted PI and TDF, while during 
DAA treatment this number was reduced to 13/213 (7%). The creatinine clearance of 
the patients that continued TDF and the boosted PI in combination with ledipasvir, 
remained stable during DAA therapy (supplementary Table 1).
The patients that did not switch cART, usually continued their potentially interacting 
regimen with a NNRTI or a boosted PI. However, we must comment that the daclatasvir 
dose can be easily adapted to 30 mg with enzyme inhibitors (atazanavir/ritonavir) or to 
90 mg with enzyme inducers (e.g., efavirenz, etravirine). Information concerning such 
dose alterations were however not available in the database.
Another interesting but unexpected finding was that five patients who used a non-
interacting cART regimen before starting DAA treatment, were switched during treat-
ment to a potentially interacting cART regimen (Figure 3). 
Category 3 cART regimens were used by 49/418 (12%) of the patients. Only 2/49 (4%) 
patients continued these interacting regimens during DAA treatment. 
Efficacy of direct-acting antiviral treatment
Figure 2 shows the SVR12 rate of the cohort. At the time of our analysis, 367/423 (87%) 
patients had reached SVR (33 patients were still in follow-up). There was no difference in 
SVR-rates between patients with and without a potential DDI (84% and 88%, respectively). 
The SVR-rate of the patients that continued their PPI during ledipasvir treatment was 82%.
figure 3: overview of cARt regimens used (third drugs) that caused category 2 and 3 
drug-drug interactions 3 months prior to treatment. (continued)
aTwo patients did not have an interacting cART regimen before DAA treatment but switched during DAA treat-
ment to an interacting regimen.
bThree patients did not have an interacting cART regimen before DAA treatment but switched during DAA treat-
ment to an interacting regimen.
Before: drug-drug interactions before DAA treatment.
During: drug-drug interactions during DAA treatment.
PI: Protease inhibitor; INSTI: Integrase inhibitor; NNRTI: Non-nucleoside reverse transcriptase inhibitor; TDF: Te-
nofovir disoproxil fumarate.
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DISCuSSIon
This is the first study describing the outcome of clinicians managing possible DDIs 
with DAAs in a nationwide cohort of HIV/HCV co-infected patients. Not surprisingly, we 
showed that a high number of HIV/HCV co-infected patients were at risk for a clinically 
relevant DDI with both non-antiretroviral and cART co-medication before initiating HCV 
therapy. Analysis of the prescribing patterns of physicians showed that Dutch physi-
cians are well aware of DDIs and are keen on preventing them. Especially, interactions 
between DAAs and cART are managed accurately. 
Interacting non-antiretroviral co-medications were less often appropriately discontin-
ued before HCV treatment was started (Table 2). Drugs with a category 3 DDI are contra-
indicated and must be substituted; however, 4/6 of these drugs were not discontinued. 
Therefore, it can be stated that management of category 3 DDIs is suboptimal for 
non-antiretroviral co-medications. 
Many category 2 DDIs between DAAs and non-antiretroviral co-medication can be 
handled by monitoring the patient, separating drug intake, or adjusting the drug dose. 
However, for some of these category 2 DDIs in daily practice, we strongly recommend 
to discontinue the non-antiretroviral co-medication during DAA therapy. For example, 
when statins are combined with several DAAs such as simeprevir, daclatasvir, and 
ledipasvir[12-14]. DAAs inhibit a number of uptake transporters, such as organic anion-
transporting polypeptide 1B1/3 at the surface of hepatocytes, which can lead to in-
creased plasma concentrations of the statins. Elevated plasma concentrations of statins 
might result in severe myopathy or even rhabdomyolysis[12-15]. 
Another example are PPIs and other acid-reducing agents. Due to low solubility of 
ledipasvir at higher pH, acid-reducing agents are not recommended to be combined 
with ledipasvir[14]. There is an ongoing debate whether the use of acid-reducing agents 
affects SVR[16-18]. This uncertainty is reflected in our cohort showing that PPIs were either 
continued or discontinued before ledipasvir was started. SVR was achieved in 82% of 
the patients (6% no SVR, 12% missing SVR data) who continued an acid-reducing agent 
in combination with ledipasvir.
Noticeable was that for category 2 interactions between cART and DAAs, 51% of patients 
switched their cART regimen. These interactions included the interactions with daclatas-
vir and ledipasvir which can be handled by adjusting the daclatasvir dose or monitor-
ing renal function during ledipasvir therapy with TDF and a boosted PI or elvitegravir/
cobicistat. Also, all interactions with the combination of paritaprevir/ritonavir, ombitasvir 
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and dasabuvir were avoided. It seems that physicians are more willing to switch cART to 
avoid interactions with the DAAs. This has become rather simple now that the integrase 
inhibitor dolutegravir and the NNRTI rilpivirine, which in contrast to older NNRTIs, has 
no cytochrome P450 (CYP) induction potential, are available in once daily regimens[19-22]. 
Of note however, dolutegravir, raltegravir, and rilpivirine do have a limited number of 
potential drug-interactions with non-antiretroviral co-medication. Switching cART did 
not affect the short-term viral suppression of HIV. Still, some physicians were cautious 
with switching cART because not all patients can switch, due to HIV drug resistance, 
adherence problems, or adverse events. DAA regimens which do not require modifying a 
patient’s cART regimen would represent an additional future advance.
Strength of this study is that it was conducted within the framework of a nationwide 
cohort which is very much representative of all HIV/HCV-infected patients treated with 
DAAs in the Netherlands. We were able to identify possible DDIs at the beginning of DAA 
treatment and how the DDIs were managed. A limitation is that we were not able to 
identify toxicities or inefficacy of non-antiretroviral co-medications as a result of potential 
interactions, in case these did not result in discontinuation of such co-medications. In 
addition, we were not able to detect whether category 2 interactions were monitored 
or dosages adjusted, as we could only identify discontinued drugs. Lastly, the website 
of the University of Liverpool is recently updated with a yellow category. This category 
represents an interaction of weak intensity for which additional action/monitoring or 
dosage adjustment is unlikely to be required. At the time of prescribing this category was 
not yet available and therefore could not be used for the present data analysis. 
In conclusion, DDIs are a significant potential problem when combining treatment for 
HIV and HCV. Despite the high risk of DDIs, Dutch HIV physicians seem well aware of 
possible DDIs and manage to prevent the large majority of these. Especially, cART regi-
mens are appropriately switched to non-interacting regimens before DAA treatment 
in case of both category 2 and 3 DDIs. There is however room for improvement where 
it concerns modifying potentially interacting non-antiretroviral co-medication. Finally, 
the limited number of patients who continue category 3 contra-indicated medications 
deserves further study. 
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EthICS StAtEMEnt
At initiation, the ATHENA observational cohort was approved by the institutional re-
view board of all participating centers. It has subsequently become integral part of HIV 
care and includes pseudonymised data and stored plasma samples from HIV-infected 
patients living in the Netherlands and receiving care in one of the designated HIV treat-
ment centers. Patients can opt out after being informed by their treating physician of 
the purpose of collection of data and samples. Data from patients who opt out are 
not included in the ATHENA database. Pseudonymised data may be used for scientific 
purposes without further review. Patients are informed that in case of future requests 
for use of stored plasma samples for scientific research they will be asked for prior con-
sent by their treating HIV physician. Data are pseudonymised before being provided 
to investigators. For the purpose of our analysis only existing data have been used and 
therefore no additional review or consent has been necessary.
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ClInICAl CEntERS
* denotes site coordinating physician
Academic Medical Center of the university of Amsterdam: HIV treating physicians: 
J.M. Prins*, T.W. Kuijpers, H.J. Scherpbier, J.T.M. van der Meer, F.W.M.N. Wit, M.H. Godfried, 
P. Reiss, T. van der Poll, F.J.B. Nellen, S.E. Geerlings, M. van Vugt, D. Pajkrt, W.J. Wiersinga, 
M. van der Valk, A. Goorhuis, J.W. Hovius. HIV nurse consultants: M.A.H. Bijsterveld, J. van 
Eden, A.M.H. van Hes, M. Mutschelknauss, H.E. Nobel, F.J.J. Pijnappel, A.M. Weijsenfeld. 
HIV clinical virologists/chemists: S. Jurriaans, N.K.T. Back, H.L. Zaaijer, B. Berkhout, M.T.E. 
Cornelissen, C.J. Schinkel, X.V. Thomas. Admiraal De Ruyter Ziekenhuis, Goes: HIV 
treating physicians: M. van den Berge, A. Stegeman. HIV nurse consultants: S. Baas, L. 
Hage de Looff. HIV clinical virologists/chemists: B Wintermans, J Veenemans. Catharina 
Ziekenhuis, Eindhoven: HIV treating physicians: M.J.H. Pronk*, H.S.M. Ammerlaan. 
HIV nurse consultants: E.S. de Munnik, E. van Beek. HIV clinical virologists/chemists: A.R. 
Jansz, J. Tjhie, M.C.A. Wegdam, B. Deiman, V. Scharnhorst. Elisabeth-tweeSteden 
Ziekenhuis, tilburg: HIV treating physicians: M.E.E. van Kasteren*, A.E. Brouwer. HIV 
nurse consultants: R. van Erve, B.A.F.M. de Kruijf-van de Wiel, S.Keelan-Pfaf, B. van der Ven. 
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Data collection: B.A.F.M. de Kruijf-van de Wiel, B. van der Ven. HIV clinical virologists/chem-
ists: A.G.M. Buiting, P.J. Kabel, D.Versteeg. Emma Kinderziekenhuis, Amsterdam: HIV 
nurse consultants: A. van der Plas, A.M. Weijsenfeld. Erasmus MC, Rotterdam: HIV treat-
ing physicians: M.E. van der Ende*, H.I. Bax, E.C.M. van Gorp, J.L. Nouwen, B.J.A. Rijnders, 
C.A.M. Schurink, A. Verbon, T.E.M.S. de Vries-Sluijs. HIV nurse consultants: N. Bassant, J.E.A. 
van Beek, M. Vriesde, L.M. van Zonneveld. Data collection: H.J. van den Berg-Cameron, 
F.B. Bruinsma-Broekman, J. de Groot, M. de Zeeuw-de Man. HIV clinical virologists/
chemists: C.A.B. Boucher, M.P.G Koopmans, J.J.A van Kampen, S.D. Pas. Erasmus MC-
Sophia, Rotterdam: HIV treating physicians: G.J.A. Driessen, A.M.C. van Rossum. HIV 
nurse consultants: L.C. van der Knaap, E. Visser. flevoziekenhuis, Almere: HIV treating 
physicians: J. Branger*, A. Rijkeboer-Mes. HIV nurse consultant and data collection: C.J.H.M. 
Duijf-van de Ven. hagaZiekenhuis, Den haag: HIV treating physicians: E.F. Schippers*, 
C. van Nieuwkoop. HIV nurse consultants: J.M. van IJperen, J. Geilings. Data collection: 
G. van der Hut. HIV clinical virologist/chemist: P.F.H. Franck. hIV focus Centrum (DC 
Klinieken), Amsterdam: HIV treating physicians: A. van Eeden*. HIV nurse consultants: 
W. Brokking, M. Groot, L.J.M. Elsenburg. HIV clinical virologists/chemists: M. Damen, I.S. 
Kwa. Isala, Zwolle: HIV treating physicians: P.H.P. Groeneveld*, J.W. Bouwhuis. HIV nurse 
consultants: J.F. van den Berg, A.G.W. van Hulzen. Data collection: G.L. van der Bliek, P.C.J. 
Bor. HIV clinical virologists/chemists: P. Bloembergen, M.J.H.M. Wolfhagen, G.J.H.M. Ruijs. 
leids universitair Medisch Centrum, leiden: HIV treating physicians: F.P. Kroon*, 
M.G.J. de Boer, H. Jolink, A.M. Vollaard. HIV nurse consultants: W. Dorama, N. van Holten. 
HIV clinical virologists/chemists: E.C.J. Claas, E. Wessels. Maasstad Ziekenhuis, Rot-
terdam: HIV treating physicians: J.G. den Hollander*, K. Pogany, A. Roukens. HIV nurse 
consultants: M. Kastelijns, J.V. Smit, E. Smit, D. Struik-Kalkman, C. Tearno. Data collection: 
M. Bezemer, T. van Niekerk. HIV clinical virologists/chemists: O. Pontesilli. Maastricht 
uMC+, Maastricht: HIV treating physicians: S.H. Lowe*, A.M.L. Oude Lashof, D. Posthou-
wer. HIV nurse consultants: R.P. Ackens, J. Schippers, R. Vergoossen. Data collection: B. 
Weijenberg-Maes. HIV clinical virologists/chemists: I.H.M. van Loo, T.R.A. Havenith. MCh-
bronovo, Den haag: HIV treating physicians: E.M.S. Leyten*, L.B.S. Gelinck. HIV nurse 
consultants: A.Y. van Hartingsveld, C. Meerkerk, G.S. Wildenbeest. HIV clinical virologists/
chemists: J.A.E.M. Mutsaers, S.Q. van Veen. MC Slotervaart, Amsterdam: HIV treating 
physicians: J.W. Mulder*, S.M.E. Vrouenraets, F.N. Lauw. HIV nurse consultants: M.C. van 
Broekhuizen, H. Paap, D.J. Vlasblom. HIV clinical virologists/chemists: P.H.M. Smits. MC 
Zuiderzee, lelystad: HIV treating physicians: S. Weijer*, R. El Moussaoui. HIV nurse 
consultant: A.S. Bosma. Medisch Centrum leeuwarden, leeuwarden: HIV treating 
physicians: M.G.A.van Vonderen*, D.P.F. van Houte, L.M. Kampschreur. HIV nurse consul-
tants: K. Dijkstra, S. Faber. HIV clinical virologists/chemists: J Weel. Medisch Spectrum 
twente, Enschede: HIV treating physicians: G.J. Kootstra*, C.E. Delsing. HIV nurse con-
sultants: M. van der Burg-van de Plas, H. Heins. Data collection: E. Lucas. noordwest 
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Ziekenhuisgroep, Alkmaar: HIV treating physicians: W. Kortmann*, G. van Twillert*, 
J.W.T. Cohen Stuart, B.M.W. Diederen, R. Renckens. HIV nurse consultant and data collec-
tion: D. Ruiter-Pronk, F.A. van Truijen-Oud. HIV clinical virologists/chemists: W. A. van der 
Reijden, R. Jansen. olVG, Amsterdam: HIV treating physicians: K. Brinkman*, G.E.L. van 
den Berk, W.L. Blok, P.H.J. Frissen, K.D. Lettinga W.E.M. Schouten, J. Veenstra. HIV nurse 
consultants: C.J. Brouwer, G.F. Geerders, K. Hoeksema, M.J. Kleene, I.B. van der Meché, 
M. Spelbrink, H. Sulman, A.J.M. Toonen, S. Wijnands. HIV clinical virologists: M. Damen, D. 
Kwa. Data collection: E. Witte. Radboudumc, nijmegen: HIV treating physicians: R. van 
Crevel*, M. Keuter, A.J.A.M. van der Ven, H.J.M. ter Hofstede, A.S.M. Dofferhoff. HIV nurse 
consultants:  M. Albers, K.J.T. Grintjes-Huisman, M. Marneef, A. Hairwassers. HIV clinical 
virologists/chemists:  J. Rahamat-Langendoen. HIV clinical pharmacology consultant:  D. 
Burger. Rijnstate, Arnhem: HIV treating physicians: E.H. Gisolf*, R.J. Hassing, M. Claas-
sen. HIV nurse consultants: G. ter Beest, P.H.M. van Bentum, N. Langebeek. HIV clinical 
virologists/chemists: R. Tiemessen, C.M.A. Swanink. Spaarne Gasthuis, haarlem: HIV 
treating physicians: S.F.L. van Lelyveld*, R. Soetekouw. HIV nurse consultants: L.M.M. van 
der Prijt, J. van der Swaluw. Data collection: N. Bermon. HIV clinical virologists/chemists: 
W.A. van der Reijden, R. Jansen, B.L. Herpers, D.Veenendaal. Medisch Centrum Jan van 
Goyen, Amsterdam: HIV treating physicians: D.W.M. Verhagen. HIV nurse consultants: M. 
van Wijk. universitair Medisch Centrum Groningen, Groningen: HIV treating physi-
cians: W.F.W. Bierman*, M. Bakker, J. Kleinnijenhuis, E. Kloeze, H. Scholvinck, Y. Stienstra, 
C.L. Vermont, K.R. Wilting. HIV nurse consultants: A. Boonstra, H. de Groot-de Jonge, P.A. 
van der Meulen, D.A. de Weerd. HIV clinical virologists/chemists: H.G.M. Niesters, C.C. van 
Leer-Buter, M. Knoester. universitair Medisch Centrum utrecht, utrecht: HIV treat-
ing physicians: A.I.M. Hoepelman*, J.E. Arends, R.E. Barth, A.H.W. Bruns, P.M. Ellerbroek, T. 
Mudrikova, J.J. Oosterheert, E.M. Schadd, M.W.M. Wassenberg, M.A.D. van Zoelen. HIV 
nurse consultants: K. Aarsman, D.H.M. van Elst-Laurijssen, E.E.B. van Oers-Hazelzet. Data 
collection: M. van Berkel. HIV clinical virologists/chemists: R. Schuurman, F. Verduyn-Lunel, 
A.M.J. Wensing. Vumc, Amsterdam: HIV treating physicians: E.J.G. Peters*, M.A. van Agt-
mael, M. Bomers, J. de Vocht. HIV nurse consultants: M. Heitmuller, L.M. Laan. HIV clinical 
virologists/chemists: C.W. Ang, R. van Houdt, A.M. Pettersson, C.M.J.E. Vandenbroucke-
Grauls. wilhelmina Kinderziekenhuis, uMCu, utrecht: HIV treating physicians: S.P.M. 
Geelen, T.F.W. Wolfs, L.J. Bont. HIV nurse consultants: N. Nauta. 
CooRDInAtInG CEntER
Director: P. Reiss. Data analysis: D.O. Bezemer, A.I. van Sighem, C. Smit, F.W.M.N. Wit, T.S. 
Boender. Data management and quality control: S. Zaheri, M. Hillebregt, A. de Jong. Data 
monitoring: D. Bergsma, A. de Lang, S. Grivell, A. Jansen, M.J. Rademaker, M. Raethke, R. 
Meijering, S. Schnörr. Data collection: L. de Groot, M. van den Akker, Y. Bakker, E. Claessen, 
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ConflICtS of IntERESt
EJS, CS, CTMMK and ASMD declare that they have no conflicts of interest that are 
directly relevant to the content of this manuscript. JEA joins advisory boards of Ab-
bvie, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, ViiV Healthcare 
and Merck. He received sponsorship of Bristol-Myers Squibb, ViiV Healthcare, Abbvie, 
and Merck. KB joins advisory board of Gilead Sciences, Bristol-Myers Squibb, Janssen, 
Abbvie, ViiV Healthcare, and Roche. BR received research grants from MSD and Gilead 
Sciences, travel grants from ViiV Healthcare, MSD, Bristol-Myers Squibb, Gilead Sciences, 
and Janssen-Cilag. He received speakers fee from Bristol-Myers Squibb, Gilead Sciences, 
and Janssen-Cilag and personal fees from Bristol-Myers Squibb, Gilead Sciences, and 
Janssen-Cilag. MV joins advisory boards of Abbvie, Bristol-Myers Squibb, Gilead, Jans-
sen, ViiV Healthcare and Merck. He received sponsorship and research grants of Gilead, 
Janssen and Merck. PR through his institution received independent scientific grant 
support, unrelated to the content of this manuscript, from Gilead Sciences Sciences, 
Janssen Pharmaceuticals Inc, Merck & Co, Bristol-Myers Squibb and ViiV Healthcare; he 
has served on a scientific advisory board for Gilead Sciences and a data safety monitor-
ing committee for Janssen Pharmaceuticals Inc; he chaired a scientific symposium by 
ViiV Healthcare, for which his institution has received remuneration. DMB joins advisory 
boards of Abbvie, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, ViiV 
Healthcare and Merck. He received sponsorship and research grants of Bristol-Myers 
Squibb, Janssen Pharmaceuticals, ViiV Healthcare and Merck.
funDInG
No funding was received for this project.
Management of DDIs with DAAs in HIV/HCV patients: adequate but not perfect
167
7
REfEREnCES
 1.  Burger DM, Hoetelmans RMW, Koopmans PP, Meenhorst PL, Mulder JW, Hekster YA et al. Clinically 
relevant drug interactions with antiretroviral agents. Antiviral Therapy. 1997;2(3):149-65
 2.  El-Sherif O, Khoo S, Solas C. Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfec-
tion. Curr Opin HIV AIDS. 2015;10(5):348-54
 3.  Cope R, Pickering A, Glowa T, Faulds S, Veldkamp P, Prasad R. Majority of HIV/HCV Patients Need to 
Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals. AIDS Patient Care STDS. 
2015;29(7):379-83
 4.  Poizot-Martin I, Naqvi A, Obry-Roguet V, Valantin MA, Cuzin L, Billaud E et al. Potential for Drug-Drug 
Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV 
Coinfected Patients. PLoS One. 2015;10(10):e0141164
 5.  Martinello M, Dore GJ, Skurowski J, Bopage RI, Finlayson R, Baker D et al. Antiretroviral Use in the CEASE 
Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/
Hepatitis C Virus Coinfection. Open forum infectious diseases. 2016;3(2):ofw105
 6.  Patel N, Nasiri M, Koroglu A, Amin R, McGuey L, McNutt LA et al. Prevalence of drug-drug interactions 
upon addition of simeprevir- or sofosbuvir-containing treatment to medication profiles of patients 
with HIV and hepatitis C coinfection. AIDS Res Hum Retroviruses. 2015;31(2):189-97
 7.  Patel N, Nasiri M, Koroglu A, Bliss S, Davis M, McNutt LA et al. A Cross-Sectional Study Comparing the 
Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medi-
cation Profiles of Hepatitis C Monoinfected Patients. Infectious Diseases and Therapy. 2015;4(1):67-78
 8.  Smolders EJ, Berden FA, Kanter de CTMM, Huizinga W, Kievit W, Drenth JP et al. High risk on drug-
drug interactions during hepatitis C treatment: a nationwide cohort [poster #45]. 17th International 
Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; Washington DC, USA
 9.  Vermehren J, Peiffer KH, Welsch C, Grammatikos G, Welker MW, Weiler N et al. The efficacy and safety of 
direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients 
with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2016;44(8):856-65
 10.  Honer Zu Siederdissen C, Maasoumy B, Marra F, Deterding K, Port K, Manns MP et al. Drug-Drug 
Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. Clin 
Infect Dis. 2015;62(5):561-7
 11.  Liverpool Uo. HEP Drug Interaction Checker. 2016. http://www.hep-druginteractions.org/.
 12.  EMA. Olysio: Summary of Product Characteristics. 2014. http://ec.europa.eu/health/documents/
community-register/2014/20140514128513/anx_128513_en.pdf. Accessed February 15 2015.
 13.  EMA. Daklinza: Summary of Product Characteristics. 2015. http://www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf. Accessed Feb-
ruary 15 2015.
 14.  EMA. Harvoni: Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/docu-
ment_library/EPAR_-_Product_Information/human/003850/WC500177995.pdf. Accessed February 
15 2015.
 15.  Kanter CT, Luin M, Solas C, Burger DM, Vrolijk JM. Rhabdomyolysis in a hepatitis C virus infected 
patient treated with telaprevir and simvastatin. Annals of hepatology. 2014;13(4):452-5
Chapter 7
168
 16.  Afdhal N, Bacon B, Curry M, Dieterich D, Flamm SL, Guest L et al. No Effect of Proton Pump Inhibi-
tor (PPI) Use on SVR with Ledipasvir/ Sofosbuvir (LDV/SOF): Real-World Data from 2034 Genotype 1 
Patients in the TRIO Network. J Hepatol. 2016;64(2):S222
 17.  El-Sherif O, Stewart S, Bergin C, McKiernan S, Crosbie O, Khoo S et al. SAT-233 - Determination of 
Ledipasvir Concentrations in Patients with Decompensated Cirrhosis Receiving Low Dose Proton 
Pump Inhibitors during Sofosbuvir-Ledipasvir Treatment for HCV Genotype 1 Infection. Journal of 
Hepatology. 2016;64(2, Supplement):S805-S6
 18.  Terrault N, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros P, Frazier LM et al. Oral presentations: Treatment 
Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis 
C Infection: Analysis of a Multicenter Prospective, Observational Study Hepatology. 2015;6232A-92A
 19.  EMA. Edurant; Summary of Product Characteristics. 2014.
 20.  EMA. Stocrin; Summary of Product Characteristics. 2014. http://www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Product_Information/human/000250/WC500058946.pdf.
 21.  EMA. Viramune 200 mg tablets; Summary of Product Characteristics. 2014. http://www.ema.europa.
eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000183/WC500051481.
pdf. 2013.
 22.  EMA. Intelence; Summary of Product Characteristics. 2014. http://www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Product_Information/human/000900/WC500034180.pdf.
Management of DDIs with DAAs in HIV/HCV patients: adequate but not perfect
169
7
Supplementary table 1: Creatinine levels for patients that were treated with ledipasvir, 
tenofovir disoproxil fumarate, and a protease inhibitor and hIV RnA levels for patients 
that switched cARt.
ledipasvir with tDf and  
boosted PI  
(n = 13)
ledipasvir without tDf and 
boosted PI  
(n = 198a)
Before During Before During
Creatinine µmol/L, 
median (IQR)
82 (12) 85 (28) 90 (23) 93 (24)
Switch cARt 
(n = 166)
no switch cARt 
(n = 257)
Before During Before During
HIV RNA undetectable 159 152 246 227
HIV RNA detectable 7 6b 11 7c
aCreatinine levels were missing for 2 patients.
bFollow up HIV RNA was missing for 8 patients.
cFollow up HIV RNA was missing for 23 patients.
TDF: Tenofovir disoproxil fumarate; PI: Protease inhibitor; cART: combination antiretroviral therapy.
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To the editor,
A chronic hepatitis C virus (HCV) infection is nowadays treated with combination 
therapy of novel direct-acting antivirals. These drugs are very effective, and high sus-
tained virological response rates are achieved in patients without cirrhosis (>90%)[1]. 
Cirrhotic patients are more difficult-to-treat, which could be due to by physiological 
changes caused by scarring of the liver. Therefore, ribavirin is added to direct-acting 
antiviral therapy, which improves HCV treatment response and gives an opportunity to 
shorten treatment duration from 24 to 12 weeks[1]. 
Ribavirin has a strong concentration-effect relationship, and therapeutic drug monitor-
ing (TDM) can be used to individualize the dose of ribavirin[2]. Therefore, several labora-
tories developed ribavirin assays. These methods are generally validated internally for 
validation parameters such as accuracy, precision, selectivity, sensitivity, reproducibility, 
and stability according to international guidelines[3, 4]. To ensure the accuracy of these 
bioanalytical methods and to alert laboratories to previously undetected problems, 
we developed an international external quality control (QC) or proficiency testing (PT) 
program for measurement of ribavirin. 
The aim of this report was to describe the results of the first year of this ribavirin PT 
program.
In 2015, we dispatched two samples per round (two rounds in total) to the participating 
laboratories. For these samples, bovine serum was spiked with low and high concentra-
tions of ribavirin. These samples were freeze dried and were shipped by regular mail. 
For two participants, the samples were shipped on dry ice because they participated in 
another program requiring shipment on dry ice. The concentrations chosen resembled 
the range of concentrations measured in patients treated with a normal dose of riba-
virin (patient weight <75 kg = 1,000 mg/day and ≥75 kg = 1,200 mg/day)[5]. The target 
range for ribavirin plasma concentrations at steady-state is 2.2-3.6 mg/L[2]. 
Details of similar programs have been described previously[6-8]. Participants were in-
formed about their performance in measuring ribavirin concentrations. Accuracy was 
considered to be acceptable if measurements were within the 80-120% limits of the 
spiked (weighed-in) ‘expert’ concentrations. This 20% threshold was based on guide-
lines for method validation for bioanalysis of drugs used as fixed criterion for inaccuracy 
at the lowest level of quantification and on maximum allowable error specifications 
for drug measurements according to the US Clinical Laboratory Improvement Amend-
ments (CLIA) of 1988[9-11]. 
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Eight laboratories participated in the program, of which two participants completed one 
round. Most participants (n = 7) used liquid chromatography with mass spectrometry 
detection to determine ribavirin concentrations. One center used high performance 
liquid chromatography with an ultraviolet detector. 
In round 1, 81% of the samples (i.e., 13 out of 16 samples) were determined accurately, 
and the variation in accuracy of samples with low concentrations was 86-336%. The 
samples spiked with high ribavirin concentrations varied from 55 to 160% inaccuracy 
(Table 1, Figure 1).
table 1: overall performance of the 8 laboratories. 
Round, 
Concentration
# 
samples
Expert 
concentration, 
(mg/l)
Measured 
concentration, 
median mg/l 
(range mg/l)
Median 
inaccuracy, 
median % 
(range %)a
number and 
percentage of
measurements with 
acceptable accuracy, 
n (%)
1, High 8 3.64 3.66 (2.00-5.84) 8.2 (0.8-60.4) 6/8 (75)
2, High 6 2.18 2.25 (2.12-3.22) 4.1 (0.9-47.7) 4/6 (67)
1, Low 8 0.82 0.80 (0.70-2.74) 6.4 (1.8-236.2) 7/8 (88)
2, Low 6 0.51 0.55 (0.49-1.54) 7.5 (1.6-203.2) 5/6 (83)
aInaccuracy is percentage bias from the true concentration. 
Measured/expert concentration >100%: inaccuracy = (100 x measured concentration / true concentration) – 100%. 
Measured/expert concentration <100%: inaccuracy = 100% - (100 x measured concentration / true concentration).
In round 2, a total of 75% samples (i.e., 9 out of 12) were determined accurately within 
80-120% of the weighed-in concentrations. Accuracy for samples with low and high 
concentrations varied from 97 to 303% and from 97 to 148%, respectively.
The median inaccuracy for all measurements was 6.1% (range: 0.8-236.2%). It was 6.7% 
(range: 1.6-236.2%) and 6.1% (range: 0.8-60.4%) for low and high ribavirin concentra-
tions, respectively.
Of the eight participating laboratories, five had all samples analyzed within 80-120% 
limits of the weighed-in concentrations, three reported at least one inaccurate result, of 
which one participant reported all four samples inaccurately (>120%).
The aim of a PT program is to provide external validation of bioanalytical assays to assure 
and improve quality. Participating laboratories were informed about their performance 
and their ability to measure the correct analyte concentrations. This may help them to 
improve their laboratory performance. The analysis of this small sample set showed 
that 6/28 of the ribavirin samples were measured inaccurately, which was in line with 
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first rounds of similar QC programs[6-8]. The laboratories with a poor performance should 
improve their analyses. In the specific case of the laboratory that inaccurately reported 
all four concentrations, intra laboratory validation was possibly incorrect, or other errors 
might have been involved, such as methodological, clerical, or technical errors. 
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figure 1: Measured concentration relative to expert value, 80-120% ranges. 
Each symbol represents a participating laboratory (A-H) and each point represents a single measured ribavirin 
concentration, shown as percentage of the ribavirin expert (weighed-in) concentration. Accuracy was accept-
able if measurements fell within 80-120% limits of the expert (weighed-in) concentrations (red lines). 
1 = round 1, high spiked concentration. 
2 = round 2, high spiked concentration. 
3 = round 1, low spiked concentration. 
4 = round 2, low spiked concentration.
The impact of reporting inaccurate high ribavirin plasma concentrations is that dos-
ages might be reduced unnecessarily, possibly leading to subtherapeutic ribavirin 
concentrations and potentially causing virologic failure. For concentrations reported 
with an accuracy <80%, this might lead to increased dosages, causing unnecessary 
adverse advents such as anemia. 
Ribavirin is important for HCV treatment in cirrhotic patients. To ensure safety and ef-
ficacy, TDM may be used in daily practice. TDM is especially relevant in specific patient 
populations such as patients with renal failure or patients receiving hemodialysis. Thus, 
for treatment of HCV patients it is critical that laboratories are able to measure the cor-
rect plasma concentrations, which is ensured by our external quality control program. 
Laboratories measuring ribavirin are encouraged to participate in our PT program 
(http://www.kkgt.nl).
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AbStRACt
Background
In the era of highly effective direct-acting antivirals (DAAs) for treatment of patients 
with chronic hepatitis C virus (HCV) infection, ribavirin is still considered beneficial in 
certain patients. 
Aim
To assess the association between ribavirin steady-state plasma levels and sustained 
virological response (SVR).
Methods
Consecutive HCV-infected patients treated with DAAs plus ribavirin from four Dutch 
academic medical centers were enrolled. Ribavirin steady-state plasma levels were 
prospectively measured at treatment week 8 using validated assays. Logistic regression 
analyses were performed to assess influence of ribavirin steady-state plasma level on 
SVR, and ribavirin therapeutic range was explored using Area Under the ROC curve 
analyses. 
Results
A total of 183 patients were included, of whom 85% had one or more difficult-to-cure 
characteristics (i.e. treatment-experienced, HCV genotype 3, cirrhosis). The majority was 
treated with a sofosbuvir-based regimen and 163 (89%) patients achieved SVR. Median 
ribavirin dose was 12.9 (interquartile range 11.2-14.7) mg/kg/day and median ribavirin 
steady-state plasma level was 2.66 (1.95-3.60) mg/L. In multivariable analyses, higher 
ribavirin steady-state plasma level (adjusted Odds Ratio 1.79 [95% CI 1.09-2.93]) was an 
independent predictor of SVR. With regard to the optimal ribavirin therapeutic range, 
2.28 mg/L was the optimal lower cut-off for achieving SVR and 3.61 mg/L was the up-
per cut-off for preventing significant anemia (hemoglobin <10 g/dL). 
Conclusion
In this cohort of mainly difficult-to-cure patients treated with DAAs plus ribavirin, higher 
ribavirin steady-state plasma level was an independent predictor of SVR. 
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IntRoDuCtIon
Chronic hepatitis C virus (HCV) infection is a major global health problem with an 
estimated 130-150 million infected individuals worldwide[1]. Until 2013, peg-interferon 
alfa (Peg-IFN) based treatment was the standard of care for HCV infection. Ribavirin, a 
guanosine analogue, was considered an important additive to increase the efficacy of 
Peg-IFN. Studies performed with Peg-IFN and ribavirin found a clear association be-
tween virological relapse and ribavirin dose reduction or discontinuation[2, 3]. The intro-
duction of direct-acting antivirals (DAAs) has changed the HCV therapeutic landscape 
completely, and currently, in more than 90% of patients, viral clearance is achieved with 
these highly effective agents[4-7]. 
Despite this development, and in contrast to Peg-IFN, ribavirin has not left the therapeu-
tic arena and is still used as an additive under certain circumstances such as presence of 
cirrhosis, genotype 3 infection, presence of resistance-associated substitutions, previ-
ous antiviral treatment failure, and/or in specific DAA regimens to increase treatment 
efficacy[8]. Unfortunately, ribavirin is also associated with serious side effects, of which 
the most concerning is hemolytic anemia[9]. Moreover, a high ribavirin plasma level is 
known to be associated with anemia[10]. Despite weight-based dosing of ribavirin, the 
measured plasma levels vary widely between individuals[11], whereas variability within 
an individual is minimal[12].
Studies investigating the association between ribavirin steady-state plasma level and 
sustained virological response (SVR) in HCV mono- and HIV/HCV co-infected patients 
show contradictory results, possibly due to their small sample sizes and retrospective 
nature[13-16]. Moreover, studies on ribavirin steady-state plasma levels in DAA-treated 
patients are scarce. Therefore, in a large cohort of HCV-infected patients treated with 
DAAs in combination with ribavirin, we assessed if there is an association between 
ribavirin steady-state plasma levels and SVR. 
MEthoDS
Study design and participants 
This prospective cohort study was conducted in four Dutch academic medical centers 
(Erasmus MC University Medical Center Rotterdam, University Medical Center Utrecht, 
Radboud university medical center, and University Medical Center Groningen). Con-
secutive adult patients with chronic HCV infection (i.e. positive HCV RNA >6 months), 
in whom interferon-free treatment with DAAs (except telaprevir and boceprevir) and 
ribavirin was initiated from January 2015 until May 2016, were included. 
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Selection of DAA regimen and treatment duration were at the discretion of the phy-
sician and according to international and national guidelines[17-19]. Ribavirin dosages 
were weight-based (<75 kg: 1,000 mg/day and ≥75 kg 1,200 mg/day) and administered 
twice daily with meals. There were no strict rules of action following therapeutic drug 
monitoring at week 8 and ribavirin dose adjustment or discontinuation was at the 
decision of the physician. Ribavirin plasma samples were obtained and analyzed at 
treatment week 8 or later. Clinical and demographic data were prospectively collected. 
Furthermore, patient-reported adherence and adverse events (AEs) were collected 
from the electronic patient file.
The study protocol was conducted in accordance with the Declaration of Helsinki and 
Good Clinical Practice guidelines and was approved by the local ethics review boards.
Definitions
SVR was defined as the absence of HCV RNA ≥12 weeks after completing antiviral 
treatment. Ribavirin steady-state plasma level was defined as ribavirin plasma level ≥ 
treatment week 8. The lower cut-off for the ribavirin therapeutic range was determined 
by the optimal value for predicting SVR, and the upper cut-off was the optimal value 
for preventing significant anemia (i.e. plasma hemoglobin <10 g/dL)[20]. The presence of 
either cirrhosis, being treatment-experienced (all genotypes), and/or having HCV geno-
type 3 infection were considered difficult-to-cure characteristics. Cirrhosis was assessed 
by liver histology (F4 according to METAVIR) or transient elastography (Fibroscan®; 
cut-off value ≥12.5 kPa[21]). A Child-Pugh score ≥7 was considered decompensated 
cirrhosis. Estimated glomerular filtration rate (eGFR) was based on the Modification of 
Diet in Renal Disease equation: 186 x (serum creatinine [µmol/L] / 88.4) – 1.154 x age 
(years) – 0.203 (x 0.742 if female). Renal function was classified according to interna-
tional guidelines: eGFR >90 normal, 50–89 mild to moderate, and <50 mL/min/1.73 m2 
moderate to severe renal impairment[22]. 
Measurement of ribavirin
Plasma ribavirin levels were measured by the pharmacy laboratories of the four par-
ticipating centers. While four different analytical methods were used, all were validated 
using international standards[23, 24]. Moreover, all four centers participate in the Dutch 
external quality control proficiency testing program for measurement of ribavirin, to 
ensure accuracy and comparability of these bioanalytical methods[25, 26]. All assays were 
able to measure ribavirin steady-state plasma levels within a 90-110% limit of the spiked 
(weighed-in) ‘expert’ concentration. This is within the 20% threshold that is frequently 
used to describe accuracy in international external quality control or proficiency testing 
programs[27, 28]. Used analytical methods were: 1) high pressure liquid chromatography 
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with ultraviolet detection (detection limit: 0.03-12.0 mg/L)[23]; 2) liquid chromatography 
(LC) with tandem mass spectrometry detection (MS/MS) (detection limit: 0.2-30 mg/L)
[24]; 3) LC-MS/MS (detection limit: 0.1-10 mg/L), and 4) LC-MS/MS (detection limit: 0.5-7.5 
mg/L)[23]. 
Statistical analysis
Differences in characteristics were described with the chi-square test or Fisher’s exact 
test for qualitative data and the Mann–Whitney U test or Kruskal Wallis test for quan-
titative data. Correlations were assessed by Spearman’s rank correlation coefficient. 
Predictors of SVR were analyzed using binary univariable logistic regression analyses, 
with subsequent multivariable logistic regression analyses for all covariates with a p-
value <0.10. Multicollinearity analyses with all covariates were performed to determine 
whether confounding was present. Included covariates were: ribavirin steady-state 
plasma level, age, gender, ethnic descent, medical center, baseline creatinine, treatment 
experience, cirrhosis, average ribavirin dose, hepatitis B and HIV co-infection. Receiver 
Operating Characteristic (ROC) plots were created to determine optimal cut-off values 
of ribavirin steady-state plasma level, for prediction of SVR and significant anemia. One-
way ANOVA analyses were done to compare geometric means of ribavirin plasma levels 
between eGFR groups. Finally, the coefficient of variance was calculated for ribavirin 
steady-state plasma level. A two-sided p-value <0.05 was considered statistically sig-
nificant. SAS version 9.4 (SAS Institute Inc., Cary, NC, USA), SPSS version 24 (SPSS Inc., 
Chicago, IL, USA), and GraphPad Prism version 7.02 (GraphPad Software, La Jolla, CA, 
USA) were used for statistical analyses. 
RESultS
Study population characteristics
From January 2015 until May 2016, a total of 185 chronic HCV-infected patients started 
interferon-free treatment with a combination of DAAs and ribavirin. In two patients, SVR 
could not be determined due to lost to follow-up and they were therefore excluded 
(Figure 1). The characteristics of the 183 included patients are given in Table 1. Median 
age in the study population was 57 (interquartile range [IQR] 52-64) years, 79% was 
male, and the majority was of Caucasian (74%) or North African/Middle Eastern (12%) 
descent (Table 1). The majority of patients had cirrhosis (60%), 6% of these patients 
had decompensated cirrhosis (all Child-Pugh B), and 24 (13%) were liver transplant 
recipients. HCV genotypes 1a (38%), 1b (21%), and 3 (23%), were the most prevalent, 
and median baseline HCV RNA was 6.20 (5.82-6.54) log10 IU/mL. 
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table 1: baseline characteristics of the study population according to treatment response.
number non-SVR 
(n = 20)
SVR
(n = 163)
p-value
Age (years) 56 (53-59) 57 (52-64) 0.38
Male gender 17 (85%) 128 (79%) 0.50
Body Mass Index (kg/m2) 28 (22-32) 26 (23-29) 0.52
Ethnic descent
Caucasian
Asian 
Sub-Sahara African 
North African/Middle Eastern
Other
14 (70%)
0
0
2 (10%)
4 (20%)
120 (74%)
4 (3%)
2 (1%)
20 (12%)
17 (10%)
0.90
0.48
0.62
0.77
0.54
hCV genotype
1a
1b
2
3
4
6
5 (25%)
1 (5%)
1 (5%)
12 (60%)
1 (5%)
0
65 (40%)
38 (23%)
10 (6%)
30 (18%)
19 (12%)
1 (1%)
0.20
0.06
0.84
<0.001
0.37
0.73
HCV RNA (log10 IU/mL) 6.17 (5.8-6.7) 6.2 (5.8-6.5) 0.89
treatment-experienced
PR
PR + 1st generation NS3/4A PI
Other
13 (65%)
12 (92%)
1 (8%)
0
96 (60%)
76 (79%)
8 (5%)
12 (13%)
0.62
0.26
0.99
0.21
Cirrhosis
Decompensated cirrhosisa
16 (80%)
3 (15%)
95 (58%)
8 (5%)
0.06
0.07
Liver transplantation 1 (5%) 23 (14%) 0.26
liver biochemistry
Total bilirubin (µmol/L)
ALT (U/L) 
Albumin (g/L)
Platelet count (x10/L)
17 (14-23)
89 (42-157)
39 (30-42)
104 (75-213)
12 (9-17)
75 (45-130)
41 (35-45)
169 (111-203)
0.01
0.81
0.17
0.14
Creatinine (µmol/L) 69 (60-85) 70 (59-83) 0.84
HIV co-infection 2 (10%) 8 (5%) 0.34
HBV co-infection 1 (5%) 3 (2%) 0.36
DAA regimenb 
DCV/SOF
SIM/SOF
LDV/SOF
PTV/r/OBV
PTV/r/OBV/DSV
SOF
4 (2%)
4 (2%)
1 (0.5%)
0
0
11 (6%)
74 (40%)
38 (21%)
24 (13%)
3 (2%)
5 (3%)
19 (10%)
0.03
0.74
0.23
0.54
0.43
<0.001
Data are expressed as median (IQR) or n (%). 
aDefined as Child-Pugh score ≥7.
bAll regimens include weight-based ribavirin.
HCV; Hepatitis C virus; PR: Peg-interferon/ribavirin; PI: Protease inhibitor; ALT; Alanine aminotransferase; HIV; Hu-
man immunodeficiency virus; HBV: Hepatitis B virus; DAA: Direct-acting antiviral; SOF: Sofosbuvir; DCV: Daclatas-
vir; SIM: Simeprevir; LDV: Ledipasvir; OBV: Ombitasvir; PTV/r: Paritaprevir/ritonavir; DSV: Dasabuvir. 
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Treatment characteristics 
Distribution of applied DAA regimens is given in Table 2. The majority of patients had 
either one (34%) or more (51%) difficult-to-cure characteristics, with only 15% having 
none of these characteristics (Table 2). In 157 (86%) patients, adherence to ribavirin 
was reported. Median patient-reported adherence was 100% (range 75-100%), with 
only one patient reporting adherence <80%. Median ribavirin start dose was 13.6 (IQR 
12.1-15.2) mg/kg/day, 13.1 (11.6-14.7) mg/kg/day at week 8, and 13.0 (11.2-14.7) mg/
kg/day at end-of-treatment, as a result of ribavirin dose reductions and/or discontinu-
ation. In 50 (27%) patients, ribavirin dose was adjusted, and in 16 (9%), ribavirin was 
discontinued. Main reasons for dose reduction were anemia (50%), other AEs (16%), or 
therapeutic drug monitoring (32%). 
Regarding ribavirin start dose and dose reductions/discontinuations there was no 
statistically significant difference between non-cirrhotic patients and patients with 
compensated or decompensated cirrhosis (p = 0.50; p =  0.29; p = 0.53, respectively) 
(Supplementary table 1).  
A total of 32 patients had anemia (hemoglobin <10 g/dL) of which 9 had a hemoglobin 
<8 g/dL. 
Median ribavirin steady-state plasma level in the full cohort was 2.66 (IQR 1.95-3.60)
mg/L, and the inter-patient coefficient of variation (CV) for ribavirin steady-state plasma 
level was 50.5%. There was no significant correlation between average ribavirin dose 
and ribavirin steady-state plasma level (R = 0.03, p = 0.706).
Included patients
n = 183
Center 1
n = 18
Center 4
n = 56
Center 3
n = 18
Treated patients
n = 185
2 patients excluded, SVR not 
determined
Center 2
n = 93
figure 1: flowchart of the study population consisting of hepatitis C patients treated with 
direct-acting antivirals plus ribavirin in four tertiary centers in the netherlands.
SVR: Sustained virological response.
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Factors associated with sustained virological response
In total, 163 (89%) patients achieved SVR. Patients with adherence <100% and those 
that experienced ribavirin dose adjustments had similar SVR-rates of 92% and 89%, re-
spectively. In univariable logistic regression analyses, there was no association between 
SVR and gender, ethnic descent, medical center, cirrhosis status, mean ribavirin dose, 
treatment experience, serum creatinine, and hepatitis B and HIV co-infection status. 
On the contrary, ribavirin steady-state plasma level (unadjusted Odds Ratio (OR) 1.86 
[95% confidence interval (CI) 1.14-3.04]), was significantly associated with SVR (Table 
3). Moreover, in multivariable logistic regression analyses, higher ribavirin steady-state 
plasma level (adjusted OR 1.79 [1.09-2.93], p = 0.021) remained an independent predic-
tor of SVR. 
table 2: Antiviral treatment characteristics of the study population.
number 183
Difficult-to-cure characteristicsa
0
1
2
3
27 (15%)
63 (34%)
81 (44%)
12 (7%)
DAA regimenb 
DCV/SOF
SIM/SOF
LDV/SOF
PTV/r/OBV
PTV/r/OBV/DSV
SOF
78 (43%)
42 (23%)
25 (14%)
3 (2%)
5 (3%)
30 (16%)
RBV start dose (mg/kg/day) 13.6 (12.1-15.2)
Mean RBV dose TW8 (mg/kg/day) 13.1 (11.6-14.7)
Mean RBV dose EOT (mg/kg/day) 12.9 (11.2-14.7)
RBV steady-state plasma level (mg/L) 2.66 (1.95-3.60)
SVR 163 (89%)
Data are expressed as median (IQR) or n (%). 
aPresence of cirrhosis, being treatment-experienced, and hepatitis C genotype 3: score from ‘0’ to ‘3’, where every 
factor is scored as 1 point, and presence of none of the factors is scored as 0 points. 
bAll regimens include weight-based ribavirin.
DAA: Direct-acting antiviral; SOF: Sofosbuvir; DCV: Daclatasvir; SIM: Simeprevir; LDV: Ledipasvir; OBV: Ombitasvir; 
PTV/r: Paritaprevir/ritonavir; DSV: Dasabuvir; RBV: Ribavirin; TW: Treatment week; EOT: End-of-treatment; SVR: 
Sustained virological response 12 weeks after treatment completion.
RBV plasma level is a predictor for SVR in HCV patients treated with DAAs
189
9Therapeutic range for ribavirin steady-state plasma levels
Ribavirin steady-state plasma levels were significantly higher in patients who achieved 
SVR (n = 163) than in those without SVR (n = 20): geometric mean 2.69 (95% CI 2.80-
2.91) versus 2.02 (1.66-2.47) mg/L, p = 0.019 (Figure 2). The optimal ribavirin steady-state 
plasma level cut-off value for predicting SVR was ≥2.28 mg/L (Figure 3a: AUC 0.70, p = 
0.004), with a sensitivity of 70% (95% CI 63-76%), a specificity of 60% (38-81%), a positive 
predictive value (PPV) of 93% (89-96%), and a negative predictive value (NPV) of 19% 
(14-26%). 
The geometric mean of ribavirin steady-state plasma level was not significantly higher 
in the 32 patients with significant anemia than in the 151 patients without (3.04 [95% 
CI 2.49-3.70] versus 2.52 [2.33-2.73] mg/L, p = 0.061). The optimal ribavirin steady-state 
plasma level cut-off to prevent significant anemia was ≤3.61 mg/L (Figure 3b: AUC 0.61, 
p = 0.042), with a sensitivity of 44% (95% CI 27-62%), specificity of 81% (74-87%), PPV 
of 10% (23-46%), and NPV of 61% (84-90%). The ribavirin therapeutic range was, thus, 
defined as a ribavirin steady-state plasma level between 2.28-3.61 mg/L. 
table 3: unadjusted and adjusted odds ratios for sustained virological response (n = 183).
Covariate unadjusted odds Ratio
(95%CI)
p-value Adjusted odds 
Ratio
(95% CI)
p-value
RBV steady-state plasma level (mg/L) 1.86 (1.14-3.04) 0.013 1.79 (1.09-2.93) 0.021
Cirrhosis, vs. no 0.35 (0.11-1.09) 0.070 0.33 (0.10-1.10) 0.072
Mean RBV dose (mg/kg/day) 1.16 (0.98-1.36) 0.084 1.19 (0.99-1.42) 0.059
Male gender, vs. female 1.55 (0.43-5.59) 0.504
Ethnic descent, vs. Caucasian
Asian 
Sub-Sahara African 
North African/Middle Eastern
Caribbean/Hispanic
-
-
1.02 (0.32-3.26)
-
1.0
-
-
0.978
-
Medical center, vs. A
B
C
D
2.13 (0.33-13.86)
-
0.65 (0.14-3.13)
0.345
0.431
-
0.591
Treatment-experienced, vs. naïve 0.78 (0.30-2.07) 0.622
Creatinine (µmol/L) 1.00 (0.99-1.01) 0.533
HIV co-infection, vs. no 2.15 (0.42-10.93) 0.355
HBV co-infection, vs. no 2.81 (0.28-28.35) 0.382
aAdjusted for HCV genotype, DAA regimen, and cirrhosis. 
bAll regimens include ribavirin.
OR: Odds Ratio; RBV: Ribavirin; HCV: Hepatitis C virus; DAA: Direct-acting antiviral; HIV: Human immunodefi-
ciency virus; HBV: Hepatitis B virus. 
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A total of 119 (65%) patients had a ribavirin steady-state plasma level ≥2.28 mg/L of 
which 42 (35%) had a ribavirin steady-state plasma level >3.61 mg/L. This translates into 
77 (42%) patients being in the therapeutic range. Of these patients, 69 (90%) achieved 
SVR and 9 (12%) developed significant anemia. Of the 64 patients with a ribavirin 
steady-state plasma level below the therapeutic range, 52 (81%) achieved SVR and 9 
(14%) developed significant anemia. Lastly, in the 42 patients with a ribavirin steady-
state plasma level above the therapeutic range, all (100%) achieved SVR but 14 (33%) 
developed significant anemia (Figure 4).
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figure 2: Ribavirin steady-state plasma levels (geometric mean and 95% confidence in-
terval) stratified by treatment response in hepatitis C patients treated with direct-acting 
antivirals plus ribavirin.
RBV: Ribavirin; SVR: Sustained virological response.
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figure 3: Receiver operating Characteristics (RoC) curves for ribavirin steady-state plas-
ma levels as predictors of sustained virological response (A) and significant anemia (b) in 
hepatitis C infected patients treated with direct-acting antivirals plus ribavirin. the arrow 
represents cut-off point. 
Significant anemia (hemoglobin <10 g/dL)
AUC: Area under the curve.
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Renal function and ribavirin levels
Baseline eGFR was available in 177 patients (97%), of whom 103 had an eGFR ≥90, 64 
eGFR 50-89, 9 eGFR <50, and only one patient had an eGFR <30 mL/min/1.73m2. Re-
markably, no significant difference was seen in ribavirin start dose between the groups. 
At treatment week 8, patients with an eGFR <50 had significantly more ribavirin dose 
reductions (Table 4: 20% vs. 14% vs. 3%, p <0.0001). Nevertheless, ribavirin steady-state 
plasma level geometric means were 2.13, 2.95, and 3.47 mg/L for eGFR ≥90, 50-89, 
and <50 mL/min/1.73m2 respectively (p <0.0001) (Figure 5). This went parallel to lower 
hemoglobin levels at treatment week 8, with a significant higher proportion in the 
eGFR <50 group that developed significant anemia (80% vs. 31% vs. 4%, p <0.0001). 
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figure 4: bar charts showing proportions (%) of sustained virological response and ane-
mia in hepatitis C infected patients treated with direct-acting antivirals plus ribavirin and 
having ribavirin steady-state plasma levels below, in, and above therapeutic range (2.28-
3.61 mg/l).   
RBV: Ribavirin; SVR: Sustained virological response.
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figure 5: boxplots showing the distribution (geometric mean and 95% confidence inter-
val) of ribavirin steady-state plasma levels stratified by renal function in hepatitis C pa-
tients treated with direct-acting antivirals plus ribavirin.
RBV: Ribavirin; eGFR: estimated glomerular filtration rate.
table 4: treatment characteristics in patients stratified by renal function.
eGfR (ml/min/1.73m2)
<50
(n = 10)
50-89
(n = 64)
≥90
(n = 103)
p-value
RBV start dose (mg/kg/day) 12.3 (11.4-17.4) 13.5 (12.0-15.4) 13.6 (12.3-15.0) 0.696
RBV TW8 dose (mg/kg/day) 9.9 (8.1-12.4) 12.0 (9.0-14.0) 13.5 (12.2-14.9) <0.0001
RBV dose reduction 2 (20%) 9 (14%) 3 (3%) 0.011
RBV steady-state plasma level (mg/L) 3.47 (2.81-5.25) 2.95 (2.33-4.07) 2.13 (1.90-3.01) <0.0001
Baseline hemoglobin (g/dL) 12.5 (11.8-13.5) 14.3 (13.1-15.5) 15.1 (13.9-16.0) <0.0001
TW8 hemoglobin (g/dL) 10.2 (8.5-10.5) 11.4 (10.2-12.7) 12.7 (11.8-14.2) <0.0001
Hemoglobin <10 g/dL 8 (80%) 20 (31%) 4 (4%) <0.0001
Data are expressed as geometric mean (IQR), median (IQR) or n (%).
eGFR: estimated glomerular filtration rate; RBV: Ribavirin; TW: Treatment week.
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DISCuSSIon
In this prospective study, the influence of ribavirin steady-state plasma level on achiev-
ing SVR in HCV-infected patients treated with a combination of DAAs and ribavirin was 
determined. The main finding of this study is that a higher ribavirin steady-state plasma 
level is an independent predictor of achieving SVR. In addition, the optimal ribavirin 
steady-state plasma therapeutic range that balances SVR with risk of anemia was found 
to be 2.28-3.61 mg/L. 
Despite the great successes of DAAs, some patients remain difficult-to-cure[29]. Adding 
ribavirin to DAAs in these patients can increase SVR-rates[8, 30]. Studies in the interferon-
era established that higher ribavirin steady-state plasma levels were positively corre-
lated with SVR[12, 23, 31, 32]. We similarly found that higher ribavirin steady-state plasma 
levels led to a 1.8-fold increase in SVR in DAA-treated patients. This demonstrates that 
higher ribavirin plasma levels are effective to improve response rates, particularly in 
difficult-to-cure patients with a lower a priori chance of achieving SVR. Possibly, thera-
peutic drug monitoring can help achieving these high ribavirin plasma levels. 
A recent study including patients treated with sofosbuvir/ribavirin found no association 
between ribavirin steady-state plasma levels and SVR[13]. However, this study had a small 
sample size of 47 treatment-naïve, predominantly genotype 1-infected, non-cirrhotic 
patients, and retrospectively analyzed ribavirin plasma samples. Moreover, SVR-rates 
were low (55%), probably because sofosbuvir/ribavirin is a suboptimal treatment for 
genotype 1[18, 17] and these results should, therefore, be carefully interpreted. Our study, 
however, represents a large real-world cohort of mainly difficult-to-cure patients on 
various DAA combinations with prospectively analyzed plasma samples and SVR-rates 
similar to clinical trials and real-world cohorts[17, 18]. 
In case the addition of ribavirin is considered beneficial and is administered, it is impor-
tant to balance efficacy and side effects. Although side effects of ribavirin in combina-
tion with DAAs are generally considered very mild, almost one in five of our patients 
developed significant anemia. This study found an optimal ribavirin steady-state plasma 
level therapeutic range of 2.28-3.61 mg/L. Interestingly, this study as well as studies 
with triple-therapy including a first-generation DAA[32, 33], found somewhat higher 
therapeutic ranges compared with studies done with Peg-IFN/ribavirin alone[23, 34, 35]. 
The most likely explanation for this is that Peg-IFN contributes to anemia through bone 
marrow suppression and as such augments the toxicity of ribavirin at any given dose/
concentration. Another explanation for this could be that with the excellent safety 
profile of DAAs, sicker patients than those in the Peg-IFN/ribavirin era can now be 
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treated[36]. A significant proportion of our patients had (decompensated) cirrhosis, were 
liver transplant recipients and/or had renal impairment, which could result in higher 
ribavirin levels. Finally, to significantly increase the likelihood of achieving SVR in the 
context of the already highly effective DAAs, a more pronounced increase in ribavirin 
exposure is necessary. 
Still, the question remains if and how ribavirin therapeutic drug monitoring should be 
implemented in the treatment of patients without difficult-to-cure characteristics. With 
current DAA regimens lasting only 12 weeks[18, 17], when reaching ribavirin steady-state 
plasma level, only 4 weeks of treatment are left to adjust ribavirin dosage. Thus, for 
most patients, ribavirin exposure could perhaps best be monitored based on toxic-
ity instead of ribavirin steady-state plasma levels. However, re-treatment of patients 
who fail therapy is considerably more expensive than therapeutic drug monitoring, 
and reaching adequate ribavirin plasma levels is not a certainty when relying on toxic-
ity alone. Co-morbidities, hepatic and/or renal dysfunction, and ITPA gene polymor-
phism[37, 38] can affect ribavirin pharmacokinetics and thus ribavirin steady-state plasma 
levels without evident toxicity[39]. For example, if a patient has a stable hemoglobin 
level, it is uncertain whether ribavirin steady-state plasma level will be in or below the 
therapeutic range. Assessment of ribavirin plasma level at week 8 of treatment (ribavirin 
steady-state plasma level) may be too late for intervention. An option for therapeutic 
drug monitoring and intervention at an earlier stage is measuring ribavirin plasma 
levels at treatment week 2. Van Vlerken and colleagues reported that a week 2 ribavirin 
level of ≥1.29 mg/L predicted adequate ribavirin steady-state plasma levels at week 8 
in patients treated with Peg-IFN/ribavirin[23]. Future studies are needed to determine if 
this also applies to patients treated with DAAs. 
Especially in patients with impaired renal function, therapeutic drug monitoring is im-
portant. This study found that despite the Food and Drug Administration and European 
Medicines Agency recommending ribavirin dose reduction in patients with eGFR <50 
mL/min[40, 41], they still received usual weight-based start dosages. As a result, these 
patients required more dose adjustments, resulting in lower average ribavirin doses, 
but still higher ribavirin steady-state plasma levels and high anemia rates. This study 
indicates that patients with a renal function <90 mL/min (especially those ≤50 mL/min) 
should be monitored closely during treatment, so that ribavirin can be timely adjusted 
when necessary. 
To the best of our knowledge, this is the largest prospective study analyzing the as-
sociation between ribavirin steady-state plasma level and SVR in the current DAA era. 
Nevertheless, some limitations are present. First, all four participating centers used 
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different assays to measure plasma ribavirin. However, we expect the influence of the 
different assays to be very limited, since all assays are validated according to interna-
tional standards and have undergone strict evaluation and comparison in the Dutch 
quality control program. In addition, logistic regression analyses did not show a center 
effect. Second, due to the real-life nature of the study, ribavirin dose adjustment and 
selection of DAA regimen were at the discretion of the treating physician, thus lead-
ing to variation. Nonetheless, DAA regimens were selected according to international 
and national guidelines. In hindsight, while previously recommended by guidelines[42], 
sofosbuvir/ribavirin is now considered a suboptimal treatment for genotype 3 patients 
with cirrhosis, which has led to a high proportion of relapsers within this population. 
Therefore, DAA regimen and HCV genotype were excluded in our logistic regression 
model. However, even in sensitivity analyses where DAA regimen, HCV genotype (as a 
combined variable or as separate variables), or both variables were added to the model, 
ribavirin steady-state plasma level still remained an independent predictor of SVR. For 
dose adjustments and other factors that could have influenced ribavirin exposure, we 
tried to account by adjusting for average ribavirin dose during the entire treatment, 
presence of cirrhosis, and creatinine levels in our logistic regression models. Lastly, 
influence of ITPA gene polymorphism was not assessed. 
In conclusion, a higher ribavirin steady-state plasma level is an independent predictor 
of SVR in patients treated with DAAs. 
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Supplementary table 1: treatment characteristics in patients stratified by Child-Pugh 
class.
Cirrhosis severity
no cirrhosis
(n = 72)
CP-A
(n = 100)
CP-b
(n = 11)
p-value
RBV start dose (mg/kg/day) 13.9 (12.4-15.3) 13.3 (12.2-15.0) 12.9 (9.1-14.9) 0.50
RBV TW8 dose (mg/kg/day) 13.2 (10.7-14.8) 13.1 (12.0-14.6) 12.3 (8.9-14.7) 0.51
RBV dose reduction 21 (29%) 24 (24%) 5 (46%) 0.29
RBV discontinuation 6 (8%) 10 (10%) 0 (0%) 0.53
RBV steady-state plasma level (mg/L) 2.8 (2.2-3.7) 2.5 (1.9-3.4) 2.5 (2.1-4.3) 0.48
Data are expressed as median (IQR) or n (%).
CP-A: Child-Pugh class A; CP-B: Child-Pugh class B; RBV: Ribavirin; TW: Treatment week. 
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AbStRACt
Aim
In Thailand, 7.2% of HIV patients are co-infected with the hepatitis C virus (HCV) and 
these patients are treated with peg-interferon + ribavirin (PR) for their HCV-infection. 
This study evaluates efficacy and safety of PR treatment and pharmacokinetics of riba-
virin in this population. 
Methods
HIV/HCV co-infected Thai patients were treated with PR for 24 or 48 weeks. Ribavirin 
plasma concentrations were measured during treatment. Sustained virological re-
sponse 24 weeks after end-of-treatment (SVR24) was used to describe efficacy. (Labora-
tory) safety and ribavirin concentrations were evaluated during study visits. Ribavirin 
concentrations were compared for patients with and without anemia (hemoglobin <10 
g/dL) and SVR24. 
Results
101 HIV/HCV co-infected patients were included. The majority of patients were male (n 
= 88) and infected with genotype 3 (n = 46). The median ribavirin start dose was 14.28 
mg/kg/day. SVR24-rate was 56%. All patients reported at least 1 (serious) adverse event, 
of which 28% of patients developed anemia. Seven patients discontinued treatment 
due to toxicity issues. Geometric mean ribavirin concentration was 1.81 mg/L at week 
8 of treatment. At week 8, patients with anemia had higher ribavirin levels (2.29 versus 
1.63 mg/L; p = 0.002) while patients without SVR had somewhat lower levels (1.74 
versus 1.91 mg/L; p = 0.378). 
Conclusions
PR treatment has comparable response rates and toxicity profile in Thai HIV/HCV co-
infected patients as in Western HIV/HCV patients. Ribavirin plasma concentrations were 
lower than reported in previously published studies in HCV mono-infected patients. 
Patients without SVR tend to have lower ribavirin plasma concentrations. 
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IntRoDuCtIon
Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are both transmitted 
through blood-blood contact, explaining why it is estimated that globally 2.3 million 
people live with a co-infection[1]. In Thailand, it has been estimated that 7.2% of HIV pa-
tients have a co-infection with HCV (estimated number inhabitants 68 million). The HIV 
infection of these patients originated mostly from heterosexual contact, homosexual 
contact, or intravenous drug use[2]. 
In Thai patients, HCV genotype 3 is most prevalent (43%), followed by genotype 1b 
(13%)[3]. Genotype 3 demonstrates a better response to treatment with peg-interferon 
plus ribavirin (PR) therapy compared with genotype 1[4, 5]. Contradictory, when HCV is 
treated with all oral therapy consisting of direct-acting antivirals (DAAs), genotype 3 is 
the less favorable genotype. 
In HIV/HCV co-infected patients, HIV has a negative influence on the prognosis of HCV 
infection, because these patients develop cirrhosis more rapidly than mono-infected 
patients[6]. This is especially true when they have a detectable HIV viral load[7]. In addi-
tion, co-infected patients have lower sustained virological response (SVR) rates when 
treated with PR. For genotype 1 and 4 SVR-rates of 14-29% and 44-73% for genotypes 
2 and 3[4] are previously reported for HIV/HCV co-infect patients in literature. Compared 
with SVR-rates of 42-56% for genotype 1 and 75-84% for genotype 3 in mono-infected 
patients[4]. With DAA therapy, HIV/HCV co-infected patients have similar response rates 
as mono-infected patients.
One explanation of lower response rates in HIV/HCV co-infected patients on PR 
treatment could be that these patients have lower and suboptimal ribavirin plasma 
concentrations when compared to mono-infected patients. This has been described 
by Deenen et al, who reported that the mean ribavirin plasma concentrations at week 
12 of treatment were 2.62 mg/L and 2.14 mg/L in mono- and co-infected Western 
patients, respectively[8]. 
Despite the advantages of DAA treatment in co-infected patients, even for genotype 3, 
Thai patients are still treated with PR, as DAAs remain to be expensive and are currently 
not widely accessible in Thailand. 
The current study was conducted to develop an appropriate HCV treatment program 
to improve the quality of life for HIV/HCV co-infected patients in Thailand. This was a 
cooperation between the National Health Security Office and the Thai AIDS society. 
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This is the first report describing the efficacy and safety of HCV treatment with PR in 
Thai patients along with the pharmacokinetics of ribavirin. 
MEthoDS
Study design and participants
This was an open-label, prospective, multi-center study performed in three centers in 
Thailand. HIV/HCV co-infected patients were included from April 2014 to August 2015. 
Patients were included and treated with PR, regardless of HCV genotype. Patients with 
HCV genotype 2 or 3, a METAVIR score <F3, and a negative HCV RNA at week 4 of 
treatment were treated for 24 weeks. Genotype 2 and 3 patients with a METAVIR score 
>F3 or any other genotype were treated for 48 weeks. Patients with a positive HCV RNA 
at week 4, needed a drop in HCV RNA of at least 2 log10 at week 12, otherwise treatment 
was discontinued. Patients who continued PR and had an undetectable HCV RNA at 
week 24, received 48 weeks of treatment. If the HCV RNA load was detectable at week 
24 the treatment was discontinued. The study treatment algorithm is shown in Figure 1. 
All patients continued antiretroviral treatment for HIV during HCV therapy.
Patients had to be at least 18 years of age and had a CD4 count >350 cells/µL. Cirrhotic 
patients were included with a Child-Pugh score ≤6, without ascites, hepatic encepha-
lopathy, or bleeding varices. Both males and females had to use adequate contracep-
tion during treatment and up to 24 weeks after treatment. Patients were excluded from 
this study if they had severe depression or any other psychiatric illness, significant liver 
disease other than cirrhosis, hemoglobin <11 g/dL for women or <12 g/dL for men, ALT 
and AST >10 times the Upper Limit of Normal (ULN), creatinine >1.5 times the normal 
ULN, neutrophil count <1,500 cells/mm3, platelet count <90,000 cells/mm3, thyroid 
dysfunction, use of didanosine, or evidence of severe retinopathy or any other severe 
illness not related to HIV/HCV co-infection (judged by the physician). In addition, it was 
judged by the study physician if active drugs use or alcohol consumption potentially 
compromised treatment safety. Lastly, pregnant women or women breastfeeding were 
also excluded (confirmed by pregnancy test at screening).
Before enrolment, written informed consent was obtained from all patients. The study 
was approved by a local ethics committee and executed in accordance with the prin-
cipals of the Declaration of Helsinki and Good Clinical Practice (BIDI IRB P005h/57 and 
HIV-NAT/Chulalongkorn Hospital IRB 478/56). 
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Treatment and study procedures
At screening, baseline patient characteristics such as age, weight, and several labora-
tory parameters were determined (Table 1). A Fibroscan® was performed to determine 
the liver stiffness (kPa) and a METAVIR score[9, 10].
After inclusion, the patients were treated with peg-interferon alfa 2a (Pegasys®, Hoff-
mann- La Roche Inc, South San Francisco, CA) 180 mcg per week or peg-interferon alfa 
2b (PegIntron®, Merck Sharp & Dome Corp, Whitehouse Station, NJ), which was dosed 
weight-based: 1.5 mcg/kg/week. It was at the discretion of the physician whether peg-
interferon alfa 2a or 2b was used. The dose of peg-interferon alfa 2a was adjusted based 
on absolute neutrophil count (ANC) and platelet count according to the drug label. 
Ribavirin (Rebetol®, Merck Sharp & Dome Corp, Whitehouse Station, NJ) was taken twice 
daily with food and also dosed weight-based according to the label: <65 kg: 800 mg/
day, 65-80 kg: 1,000 mg/day, 81-105 kg: 1,200 mg/day, and >105 kg: 1,400 mg/day. The 
ribavirin dose was adjusted based on side effects (anemia [hemoglobin <10 g/dL]) and 
ribavirin plasma concentrations (therapeutic drug monitoring [TDM]).
There were study visits at baseline and week 1 (optional), 2, 4, 8, 12, 16, 20, 24, 30, 36, 
42, 48, and week 72. Twenty-four weeks after end-of-treatment (week 48 or 72) the 
patients came to the study center for determination of HCV RNA. SVR was defined as 
undetectable HCV RNA 24 weeks post treatment (SVR24). Week 24 or 48 were both end-
of-treatment visits. Patients that were treated for 24 weeks were dismissed for further 
visits, except the week 48 visit for determination of SVR. Safety (adverse events) and 
laboratory safety were evaluated during all study visits. 
Laboratory safety included hemoglobin, lymphocytes, neutrophils, platelets, white 
blood cell count (WBC), hematocrit, creatinine, ALT, and AST. Creatinine was measured 
as ribavirin is mainly renally cleared and when the renal function alters this is reflected 
in the ribavirin plasma concentrations. HCV RNA was measured (RealTime HCV, Abbott 
Molecular) at week 0, 4, 12, 24, and 48 of treatment. 
If the patients gave consent, additional blood was drawn to determine the ribavirin 
plasma concentrations at week 1, 2, 4, 8, 12, 24, and 48. Preferably, trough samples were 
taken (C12), however, considering the very long elimination half-life of ribavirin (300 
hours), this was not mandatory and other sampling times were not excluded from the 
analysis. 
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Blood samples were sent to laboratory of the HIV-NAT research collaboration im-
mediately. The samples were centrifuged at 3,220 g for 10 minutes at 20°C. Plasma 
was divided and transferred to labeled polypropylene tubes and stored at -20°C until 
analysis. Total sample processing was performed within 2 hours after collection. Riba-
virin plasma concentrations were determined by a validated high performance liquid 
chromatography (HPLC) with ultraviolet detection (UV) method[11], with a lower limit 
of quantification of 0.300 mg/L. The ribavirin calibration curve was linear over the con-
centration range of 0.300 to 12.000 mg/L. The within-run and between-run variation 
(precision) was less than 5% and the accuracy results were between 95-105%.
Statistical analysis
First, patient characteristics, laboratory parameters, and ribavirin plasma concentrations 
were analyzed using descriptive statistics (medians with interquartile range [IQR]). The 
total population that completed follow up was included in the percentage of patients 
with SVR. Non-responders or treatment failures were dismissed from treatment visits, 
but were included in the efficacy analysis. Dose adjustments of peg-interferon and riba-
virin were reported. All biological parameters were log-transformed (e.g., hemoglobin, 
and ribavirin plasma concentrations) and geometric means or medians were reported. 
Geometric mean ribavirin plasma concentrations were calculated for week 1, 2, 4, 8, 12, 
24, and, 48 of treatment. Intra- and inter-subject variation of ribavirin plasma concentra-
tions were expressed as coefficient of variation (CV%). Second, independent samples 
t-tests were performed to evaluate whether patients with and without SVR24 or anemia 
had different ribavirin plasma concentrations (all weeks). 
All statistical analyses were performed in IBM SPSS Statistics, version 22. 
RESultS
A total of 106 patients were screened of whom 101 were eligible for inclusion (Figure 2). 
In Table 1 the baseline characteristics of the cohort are presented. The majority of pa-
tients were male (n = 88; 87%) and most patients were infected with HCV genotype 3 (n 
= 46; 46%) or 1 (n = 38; 38%). Median (IQR) age and weight were 43 (38-50) years and 60 
(53-70) kg, respectively. Median (IQR) baseline HCV viral load was log10 6.13 (5.42-6.58) 
IU/mL. Before treatment, 68 patients had an undetectable HIV RNA load (of 25 patients 
HIV RNA was missing), the median (IQR) liver stiffness obtained with Fibroscan® was 11.9 
(8.75-24.8) kPa and ALT and AST were 77 (49-115) and 64 (42.5-100.5) U/L, respectively.
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table 1: baseline characteristics of the study population (n = 101).
Characteristic baseline, median (IQR) week 48, median (IQR)
Patientsa 101 74
Age, years 43 (38-50) 44 (38-50)
Gender, malea 88 (87%) 66 (89%)
Weight, kg 60.3 (52.9-69.95) 58.20 (50.83-68.01)
Hemoglobin, g/dL 14.7 (13.4-16.0) 12.2 (11.13-12.9)
Creatinine, mg/dL 0.86 (0.78-1.00) 0.79 (0.74-0.89)
Platelet count, 103/uL 202 (154-246) 176 ( 132-213)
Neutrophil count, 103/uL 3.02 (2.27-3.75) 1.55 (1.09-2.46)
HIV RNA undetectablea 70 (69%)b -
CD4 count, cells/µL 595 (435-732) -
Log10 HCV RNA, IU/mL 6.13 (5.42-6.58) -
hCV genotypea
1 38 (38%) 27 (36%)
3 46 (49%) 35 (47%)
6 14 (14%) 10 (14%)
Mixed genotyped 3 (3%) 2 (3%)
Liver stiffness (Fibroscan®), kPa 11.9 (8.75-19.1) 8.25 (5.7-21.1)
ALT, U/L 77 (49-115) 31 (23-46)
AST, U/L 64 (42.5-100.5) 32 (23-45)
aNumber of patients is given.
b25 patients missing, HIV RNA undetecable <50 copies/mL.
c1 woman and 1 man had a hemoglobin <11 and 12 g/dL, respectively.
dMixed genotypes include: 1,3; 1,3,4; 1,4.
IQR: Interquartile range; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.
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Screening  
n = 106  
SVR evaluation at 
week 72 
n = 95 
Included 
n = 101 
AE / toxicity 
n = 7 
Non-response 
n = 13 
Death 
n = 3 
48 weeks of 
treatment 
n = 74 
Lost to follow up 
n = 3 
24 weeks of 
treatment 
n = 1 
figure 2: overview study participation.
AE: Adverse event; SVR: Sustained virological response.
Treatment
With the exception of 1 patient, all responders were treated for 48 weeks (genotype 3 
patients with detectable HCV RNA at week 4 or >F3 cirrhosis at baseline). 
A total of 57 patients reached SVR24 (56%), of whom 18 (47%) had genotype 1, 29 (63%) 
genotype 3, 8 (57%) genotype 6, and 2 (67%) had a mixed genotype. Liver enzymes 
recovered for the patients with SVR, median (IQR) AST and ALT of these patients at 24 
weeks of follow up were 29 (23-36) and 31 (23-42) U/L, respectively. 
Peg-interferon alfa 2a was used by 6 patients (6%) and 2b was used by 95 patients 
(94%). All patients received, according to protocol, weight-based ribavirin (Table 2). 
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table 2: overview hCV treatment. 
hCV drug number Dosage-median (IQR)
Start dose: Peg-interferon alfa 2a 6 180 mcg/week
# patients discontinued 1 -
# patients needed dose reduction 3 -
Week 48 dose 5 180 (135-180) mcg/week
Peg-interferon alfa 2b 95 1.43 (1.33-1.50) mcg/kg/week
# patients discontinued 26b -
# patients needed dose reduction 52(1-4a) -
Week 48 dose 69b 1.37 (1.06-1.53) mcg/kg/week
Ribavirin 101 14.28 (13.33-15.22) mg/kg/day
# patients discontinued 27 -
# patients needed dose adjustment  38b, d (1-4a) -
Week 48 dose 74b 13.84 (12.39-15.05) mg/kg/day
aNumber of dose reductions varied from 1 to 4 dose reductions per patient.
b1 patient was treated for 24 weeks.
c1 patient needed a dose increase.
HCV: Hepatitis C virus; IQR: Interquartile range.
The median (IQR) start dosage of ribavirin was 14.28 (13.33-15.22) mg/kg/day. During 
treatment, 38 patients needed a dose reduction and 1 patient received an increased 
dose of ribavirin due to weight gain. Overall, this resulted in a lower week 48 median 
(IQR) ribavirin dosage: 13.84 (12.39-15.05) mg/kg/day (Table 2, Figure 3). During treat-
ment, anemia was reported by 28 patients (28%).
For peg-interferon 2b the median start dose (IQR) was 1.43 (1.33-1.50) mcg/kg/week 
and 52 patients needed a dose reduction, resulting in a median (IQR) week 48 dose of 
1.37 (1.06-1.53) mg/kg/day. For peg-interferon 2a, all patients started with a dose of 
180 mcg/week and the dose was reduced for two patients to 90 mcg/week and for one 
patient to 135 mcg/week. 
In Figure 3, the course of ribavirin dosage, plasma hemoglobin, and serum creatinine 
concentrations during treatment are presented. The median (IQR) hemoglobin concen-
tration dropped from 14.70 (13.40-16.00) g/dL at baseline to 12.20 (11.13-12.90) g/dL at 
week 48 of treatment. Median (IQR) serum creatinine remained stable: 0.86 (0.78-1.00) 
mg/dL at baseline and 0.79 (0.74-0.89) mg/dL at week 48 of treatment.
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A total of 752 adverse events (AEs) were reported by 101 patients of which 20 serious 
adverse events (SAEs). The number of AEs varied from 1 to 22 AEs per patient. A total of 
20 patients discontinued treatment, of which 7 patients due to (serious) adverse events 
([S]AEs). During the study, three patients deceased. One due to a heroin overdose 
(unrelated to study medication), one to pulmonary tuberculosis (unrelated to study 
medication), and one to thrombocytopenia which was probably related to the study 
medication.
The majority of AEs were graded to be mild or moderate  severity: 383 (51%) and 306 
(41%), respectively. AEs were judged severe and potentially life threatening in 48 (6%) 
and 10 (1%) of the cases, respectively (Table 3). 
            










 
 
  
  
figure 3: Course of hemoglobin levels, ribavirin dosages, and creatinine levels during hCV treat-
ment. 
Median (interquartile range) values are shown and data  from all available patients were used (Figure 1).
Error bars represent interquartile ranges.
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table 3: Safety analysis: overview of the reported (serious) adverse events during the study.
times 
reported
count
Grade 
severe 
count
Grade 
moderate
count
Grade 
mild
count
Serious adverse event 
n = 11
20
Anemia 5 2 3 0
Thrombocytopenia 1 1 0 0
Hemoptysis 1 1 0 0
Neutropenia 1 1 0 0
Hyperglycemia 1 1 0 0
Uncontrolled diabetes mellitus 1 1 0 0
Schizoaffective disorder 1 0 1 0
Hypokalemia 1 0 1 0
Pulmonary Tuberculosis 1 0 1 0
Vomiting 1 0 1 0
Headache 1 0 1 0
Fever 1 0 1 0
Cataract surgery 1 0 1 0
Death due to overdose 1 - - -
Death due to thrombocytopenia 1 - - -
Death due to pulmonary tuberculosis 1 - - -
Adverse event (≥10 times reported) 
n = 101
732
Fever 107 0 15 92
Neutropenia 62 27 29 6
Alopecia 41 1 10 30
Fatigue 34 2 12 20
Weight loss 27 3 18 6
Myalgia 25 0 11 14
Pain/rash at injection site 24 1 7 16
Anemia 23 0 2 21
Elevated AST 21 5 16 0
Decreased lymphocytes 20 2 18 0
Anorexia 18 0 8 10
Dizziness 18 0 3 15
Nausea 17 0 6 11
Thrombocytopenia 14 0 14 0
Insomnia 14 0 6 8
Flu-like symptoms 13 1 4 8
Loss of appetite 12 0 4 8
Depression 12 0 8 4
AST: Aspartate aminotransferase.
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Ribavirin pharmacokinetics
In Figure 4, we present the results of the pharmacokinetics of ribavirin. Ribavirin plasma 
concentrations were available for 39 up to 64  patients, from week 2 to week 48 respec-
tively. Visual inspection of the data reveals that ribavirin steady-state plasma concentra-
tions were reached at week 8 of treatment and the geometric mean (IQR) ribavirin 
plasma concentration at that time point was 1.81 (1.42-2.32) mg/L. The inter-subject 
CV% was 34, 57, and 29% at week 8, 12, and 24 respectively. The intra-subject CV% was 
much smaller: 18% (week 8, 12, 24). 
      



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
      
  




 


 





 



figure 4: Ribavirin plasma concentrations per patient in each visit. 
Dose: Geometric mean ribavirin dose in mg/kg/day. 
Concentration: Geometric mean ribavirin plasma concentration in mg/L.
The bars are show the 95% confidence intervals.
Pharmacodynamics
Sustained virological response
Table 4 shows the geometric mean ribavirin plasma concentration per week of treat-
ment for patients with and without SVR24. It was observed that patients with SVR24 
had slightly higher ribavirin plasma concentrations throughout treatment. This differ-
ence only reaches statistical significance at week 24 of treatment.
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table 4: Ribavirin plasma concentrations per week presented for patients with and with-
out sustained virological response and anemia. 
treatment 
week
number Ribavirin plasma 
concentration, mg/l (SD)
number Ribavirin plasma 
concentration, mg/l (SD)
p-value
SVR no SVR
2 22 1.25 (1.58) 13 1.07 (1.51) 0.326
4 28 1.57 (1.73) 19 1.53 (1.48) 0.883
8 32 1.91 (1.45) 19 1.74 (1.43) 0.378
12 35 2.12 (1.58) 17 1.76 (1.41) 0.145
24 39 1.97 (1.38) 21 1.59 (1.41) 0.020
48 45 1.69 (1.46) 19 1.51 (1.58) 0.293
Anemia no anemia
2 15 1.45 (1.43) 24 1.05 (1.52) 0.017
4 19 2.01 (1.45) 33 1.34 (1.59) 0.002
8 17 2.29 (1.37) 38 1.63 (1.43) 0.002
12 17 2.56 (1.56) 39 1.76 (1.44) 0.002
24 16 2.00 (1.49) 46 1.77 (1.37) 0.216
48 17 1.36 (1.67) 47 1.75 (1.40) 0.028
Results of the independent t-tests are given. Values are geometric means of the ribavirin plasma concentrations.
SVR: Sustained virological response; SD: Standard deviation.
Anemia
Table 4 demonstrates that patients suffering from anemia had higher ribavirin plasma 
concentrations than patients without anemia. Until week 24, all patients with anemia 
had statistically significant higher ribavirin plasma concentrations than patients with-
out anemia. Strikingly, at week 48 patients with anemia had lower ribavirin plasma 
concentrations. 
DISCuSSIon
This is the first Thai prospective cohort study describing efficacy and safety of PR 
treatment in combination with pharmacokinetics of ribavirin in HIV/HCV co-infected 
patients. In this study, an overall SVR24 rate of 56% was achieved after 48 weeks of 
PR treatment. The overall SVR-rate was relatively low, but comparable with the SVR24 
rates described in genotype 2 and 3 Western co-infected patients treated with PR[4]. 
This could be explained by the fact that in our cohort the majority of patients was 
infected with genotype 3, of whom slightly more patients achieved SVR24 compared 
to genotype 1 (63% versus 47%). The SVR24 rate of 56% is lower than in mono-infected 
patients[4]. It remains unclear why co-infected patients have lower response rates with 
PR treatment than mono-infected patients. Possibly HIV increases HCV replication, 
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induces hepatic inflammation and the release of pro-inflammatory cytokines, increases 
hepatic apoptosis, and leads to an impaired HCV specific immune response[12]. Remark-
ably, these differences in SVR-rates disappeared with the introduction of interferon-free 
therapy[7]. As mentioned before, lower ribavirin plasma concentrations in co-infected 
versus mono-infected patients may play a role too. 
As expected with PR treatment, many AEs were reported. Most commonly reported 
AEs were fever, neutropenia, alopecia, fatigue, weight loss, and myalgia. These are in 
line with previously reported studies and resemble the known toxicity profile of PR[13, 14]. 
Depression and other mental disorders were only reported 21 times during this study, 
possibly because patients with psychiatric illnesses were excluded from this study[13, 14]. 
A total of three patients died during treatment, two of these deaths were unrelated 
to PR treatment; one patient had severe thrombocytopenia (without bleeding), which 
was probably related to PR treatment (peg-interferon alfa dose was previously re-
duced). Lastly, anemia was the most reported SAE (n = 5). All but one of these patients 
experiencing anemia as a SAEs needed dose reductions of peg-interferon alfa and/or 
ribavirin. 
We showed that at week 8 of treatment, ribavirin steady-state plasma concentrations 
were reached, which fits the long elimination half-life of 300 hours[15]. The steady-state 
ribavirin plasma concentrations found in this study were in the same range as previ-
ously published in Western HIV/HCV co-infected patients[8, 16, 17]. However, these ribavirin 
plasma concentrations remained lower than reported ribavirin plasma concentrations 
in mono-infected patients[8, 18]. We showed that hemoglobin concentrations dropped 
inversely with the raise of ribavirin plasma concentrations. In addition, when steady-
state was achieved hemoglobin concentrations remained stable. 
These findings fit the observation that patients with anemia had significantly higher 
ribavirin plasma concentrations than patients without anemia (until week 12). At week 
24, ribavirin plasma concentrations dropped in patients with anemia, which could be 
explained by the high number of dose reductions that were necessary because of low 
hemoglobin concentrations, resulting in reduced week 48 daily dosages and ribavirin 
plasma concentrations. In addition, creatinine concentrations, and thus renal function, 
remained stable during treatment. So, ribavirin renal clearance was not altered, giving 
an extra argument that the altered ribavirin plasma concentration is caused by the dose 
alterations.
Only at week 24, ribavirin plasma concentrations were higher for responders than for 
non-responders. This could be driven by the increasing number of patients of which 
Chapter 10
218
ribavirin plasma concentrations were available towards week 48. The relation between 
ribavirin plasma concentrations and SVR remains controversial, as both negative and 
positive results have been published on this topic[16, 17, 19, 20, 21]. These inconsistent results 
might be caused by, for example, differences in treatment, heterogeneity of popula-
tions, variation in analytical assays, and small sample sizes. 
A limitation of this study is that the number of ribavirin samples were varying and the 
number was increasing during the study. This could potentially influence the (statistical) 
analysis. In addition, this was not a randomized trial comparing efficacy and safety in 
mono and co-infected patients. Lastly, the drugs used in this trial are considered outdated 
in high income countries, because of the availability of DAAs which have better safety 
and efficacy profiles. However, to date, access to these expensive DAAs is still limited, 
but could greatly improve SVR-rates among HIV/HCV co-infected individuals[7]. Espe-
cially, velpatasvir combined with sofosbuvir (Epclusa®, Gilead Sciences, Foster City, CA) 
as this combination is highly active against genotype 3[22]. The introduction of (generic) 
velpatasvir in Thailand would not only greatly improve SVR-rates, it will shorten treatment 
duration and there will be less toxicity, compared with the current treatment of PR[22]. 
ConCluSIon
PR treatment in Thai HIV/HCV co-infected patients resulted in an overall SVR-rate of 
56%, including hard-to-treat genotype 1 patients. As known from PR therapy, toxicity 
was severe, but only a limited numer of patients dropped out because of toxicity issues. 
Ribavirin plasma concentrations were comparable with previously published studies in 
HIV/HCV co-infected patients, but were lower than in mono-infected patients. 
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AbStRACt
Hepatitis C virus (HCV) infected patients often suffer from liver cirrhosis, which can be 
complicated by renal impairment. Therefore, in this review we describe the treatment 
possibilities in HCV patients with hepatic and renal impairment. 
Cirrhosis alters the structure of the liver, which affects drug-metabolizing enzymes 
and drug-transporters. These modifications influence the plasma concentration of 
substrates of drugs metabolized/transported by these enzymes. The direct-acting 
antivirals (DAAs) are substrates of, for example, cytochrome P450 enzymes in the liver. 
Most DAAs are not studied in HCV-infected individuals with decompensated cirrhosis, 
and therefore awareness is needed when these patients are treated. Most DAAs are 
contra-indicated in cirrhotic patients; however, patients with a Child-Pugh class of B or 
C can be treated safely with a normal dose sofosbuvir plus ledipasvir or daclatasvir, in 
combination with ribavirin. 
Patients with renal impairment (Glomerular Filtration Rate [GFR] <90 mL/min) or who 
are dependent on dialysis often tolerate ribavirin treatment poorly, even after dose 
adjustments. However, most DAAs can be used at the normal dose because DAAs are 
not renally excreted. To date, grazoprevir plus elbasvir is the preferred DAA regimen in 
patients with renal impairment, as data are pending for sofosbuvir patients with GFR 
<30 mL/min (as for ledipasvir and velpatasvir). However, sofosbuvir has been used in a 
small number of patients with severe renal impairment and, based on these trials we 
recommend sofosbuvir 400 mg every day, when no other DAA regimen is available. Le-
dipasvir and velpatasvir are not recommend in patients with severe renal impairment.
KEy PoIntS
•	 All drugs used in hepatitis C virus (HCV) treatment can be used in patient with 
compensated liver cirrhosis (Child-Pugh class A).
•	 All drugs used in HCV treatment can be used in patients with moderate renal insuf-
ficiency (Glomerular Filtration Rate [GFR] ≥30 mL/min). 
•	 In patients with GFR ≤29 mL/min or advanced liver disease, HCV drugs might be 
contra-indicated or dosage adjustments may be necessary.
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IntRoDuCtIon
Chronic hepatitis C virus (HCV) related liver cirrhosis is the leading cause of liver 
transplantation in many countries[1-3]. Eventually, 15-30% of chronically infected HCV 
patients develops liver cirrhosis[4, 5]. Symptoms of decompensated cirrhosis are portal 
hypertension (with increased risk for variceal bleedings), ascites, hepatic encephalopa-
thy, and hepato-renal syndrome. In addition, cirrhotic patients have an enhanced risk of 
hepatocellular carcinoma, which is an important cause of mortality[6, 7].
HCV is associated with both renal and hepatic impairment, and care must be taken 
when prescribing direct-acting antivirals (DAAs) in these patients. The drugs described 
in this review are ribavirin and the novel DAAs.
Impaired kidney or liver function may result in altered drug concentrations, causing 
either toxicity or subtherapeutic levels, because these organs are mainly responsible 
for metabolizing and excreting drugs. For instance, patients with reduced renal func-
tion have a decreased ability to eliminate water soluble agents[8] and patients with 
impaired liver function have reduced expression of drug-metabolizing enzymes and 
thus reduced metabolizing capacity[6]. 
There is only limited information on the pharmacokinetics, safety, efficacy, and dosage 
in these special populations. Moreover, this information is often difficult to find and not 
presented in a comprehensive manner. Therefore, the aim of this review is to give an 
overview of the pharmacokinetics, efficacy, and safety of drugs used for HCV treatment 
in patients with renal or hepatic impairment and to provide dose recommendations for 
prescribing these drugs in these special populations. 
MEthoDS
An extensive search was performed using PubMed (1946-October 2015) and Embase 
(1947-October 2015) to identify peer-reviewed studies containing information on 
pharmacokinetics, efficacy, and safety in patients with impaired renal or hepatic func-
tion and HCV medication. Search terms contained generic and brand names. Various 
general search terms were used describing impaired renal and hepatic function, e.g., 
‘end stage renal disease’ (ESRD), ‘dialysis’, ‘cirrhosis’, and ‘hepatic impairment’.
Google, Google Scholar, and ClinicalTrials.gov were used to identify conference papers 
and abstracts. All searches were performed in the English language. Additional articles 
and primary sources were identified with citation snowballing. Lastly, the Summary of 
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Product Characteristics (SmPC) approved by the European Medicines Agency (EMA) 
and the US Food and Drug Administration (FDA) Prescribing Information were main 
sources of information for this review.
This review focuses on the novel DAAs, e.g., simeprevir, paritaprevir, asunaprevir, grazo-
previr, daclatasvir, ombitasvir, ledipasvir, elbasvir, velpatasvir, sofosbuvir, and dasabuvir. 
To date, velpatasvir is not yet licensed. The included DAAs are used in international 
guidelines[9, 10] or were submitted for registration up to November 2015 by the EMA 
and/or FDA. Ribavirin is also discussed, because it is still a component of the therapy 
in cirrhotic patients. We omitted telaprevir and boceprevir from the review, as their 
current use is limited. Additionally, we do not describe peg-interferon alfa as we believe 
it should not be used in patients with cirrhosis or renal impairment. 
PhARMACoKInEtICS
This section summarizes the pharmacokinetics of drugs used in HCV treatment, in 
both healthy subjects and in patients with impaired renal or hepatic function: DAAs 
(protease inhibitors [PIs], NS5A inhibitors, NS5B polymerase inhibitors, and fixed-dose 
regimens) and other antivirals (ribavirin). The clinical consequences and dosage recom-
mendations based on these observations are summarized in Tables 1 and 2. Figure 1 
gives an overview of the hepatic and renal metabolism of these drugs. 
Protease inhibitors
Simeprevir
Simeprevir is a second wave, first generation PI and is prescribed at a dose of 150 
mg once daily (QD). Simeprevir is highly bound to plasma proteins (>99.9%) and is a 
substrate of various drug-transporters such as P-glycoprotein (P-gp), organic anion-
transporting polypeptide (OATP) 1B1, OATP1B2, OATP2B1, and multidrug resistance 
protein (MRP) 2, and different cytochrome P450 (CYP) enzymes (intestinal CYP3A4, 
CYP2C19, and CYP2C8). The plasma concentration of simeprevir was two- to three-fold 
higher in HCV-infected patients than in healthy subjects[11].
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Compared with healthy individuals, simeprevir steady-state area under the concentra-
tion-time curve (AUC) was 2.4- and 5.2-fold higher in Child-Pugh class B (CP-B) and C 
(CP-C) patients, respectively. Therefore, the manufacturer recommends that simeprevir 
should not be used CP-C patients and that caution should be taken in CP-B patients[11]. 
Another trial reported similar results: non-HCV CP-B patients had twofold increased 
exposure compared with healthy individuals and CP-C patients had twofold higher 
exposure to simeprevir than CP-B patients[12]. After a dose of 150 mg, Sekar and co-
authors[13] observed equal exposure and protein binding between non-HCV Child-Pugh 
class A (CP-A) and CP-B subjects.
The steady-state AUC of simeprevir increased (62%) in patients with severe renal impair-
ment (Glomerular Filtration Rate [GFR]: 15-29 mL/min). This may indicate that exposure 
may increase in patients with severe renal impairment and ESRD (GFR ≤15 mL/min). 
Thus, caution is needed in these patients. However, the label states that simeprevir 
can be used by patients with all grades of renal impairment. At last, simeprevir is not 
removed by dialysis[11]. 
Asunaprevir
Asunaprevir is a PI that has activity against multiple genotypes. It is used at a dose of 
100 mg twice daily (BID), is metabolized by the liver (CYP3A4), and mainly excreted 
through the biliary system. Asunaprevir is 98.8% bound to serum proteins[14, 15]. 
The pharmacokinetics of asunaprevir were studied in non-HCV infected subjects with 
CP-A/B/C and compared with healthy volunteers; they were comparable in CP-A sub-
jects and controls. Maximum plasma concentration (Cmax) and AUC increased 10- and 
5-fold in CP-B subjects and 23- and 32-fold in CP-C subjects, respectively. Therefore, it is 
not recommended that CP-B/C patients be treated with asunaprevir. Protein binding in 
all groups was >99.5% and the unbound fraction was ± 0.004[14].
Asunaprevir was studied in non-HCV subjects dependent on dialysis compared with 
healthy controls. Protein binding, Cmax, AUC, and trough concentration (Ctrough) were not 
affected by dialysis[16]. Comparable results were presented in an open-label study in 
HCV-uninfected subjects with normal (GFR >90 mL/min), mild (GFR 50-89 mL/min), 
moderate (GFR 30-49 mL/min), or severe (GFR <30 mL/min) renal disease or patients 
dependent on dialysis. Subjects received asunaprevir, daclatasvir, and beclabuvir (NS5B 
inhibitor). ESRD subjects had slightly decreased asunaprevir concentrations. Subjects 
with moderate and severe renal impairment had increased Cmax (65 and 100%) and AUC 
(50 and 76%) values, respectively, compared with controls[17]. 
PK, efficacy, and safety of HCV drugs in patients with liver and/or renal impairment
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NS5A inhibitors
Daclatasvir
Daclatasvir is an NS5A inhibitor that is administered at a dosage of 60 mg QD. Daclatas-
vir is highly bound to plasma proteins (99%). It is hepatically metabolized (CYP3A4) and 
is a substrate of P-gp. Biliary excretion is the major route of elimination. 
Compared with healthy volunteers, Cmax, and AUC (total daclatasvir = unbound and 
bound drug) values were lower in non-HCV patients with CP-A/B/C after a single dose 
of daclatasvir 30 mg. However, there was no influence on the unbound fraction of 
daclatasvir when CP-B/C patients were compared with HCV-infected controls[19, 33].
Patients with mild, moderate, severe, or end-stage renal disease had increased unbound 
daclatasvir AUCs of 18, 39, 51, and 20%, respectively, compared with normal renal func-
tion. A similar trend was seen in total daclatasvir exposure. Although the exposure was 
affected, the authors concluded that no dose adjustments are necessary in patients 
with renal impairment and that these differences are within the high inter- individual 
variability of daclatasvir pharmacokinetics[19, 34].
The steady-state pharmacokinetics of daclatasvir 60 mg have been studied in com-
bination with asunaprevir and beclabuvir in patients with moderate and severe renal 
impairment, showing increased exposure of daclatasvir (Cmax 35 and 45%, and AUC 50 
and 65%, respectively). Patients undergoing dialysis had comparable pharmacokinetic 
parameters as healthy subjects[17]. 
NS5B polymerase inhibitors
Sofosbuvir
Sofosbuvir is an NS5B polymerase inhibitor that is administered at 400 mg QD. Sofos-
buvir is intracellular metabolized into the active metabolite GS-461203, followed by 
dephosphorylation resulting in the inactive compound GS-331007. GS-331007 is pri-
marily renally excreted (78% of the administered dose). Sofosbuvir is a substrate of P-gp 
and Breast Cancer Resistance Protein (BCRP) and is 61-65% bound to plasma proteins. 
GS-331007 is minimally bound to plasma proteins[21, 35]. 
In a study of the pharmacokinetic properties of sofosbuvir, the steady-state AUC of 
400 mg sofosbuvir following a 7-day dosing in CP-B and CP-C patients increased 126 
and 143%, respectively, relative to control subjects. The GS-331007 AUC was slightly in-
creased: 18 and 9%[20]. Lawitz and co-authors[36] reported increased Cmax and AUC values 
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of sofosbuvir 80 and 130%, respectively, in patients with hepatic impairment (CP-B and 
CP-C) compared with non-cirrhotic controls. The pharmacokinetics of GS-331007 were 
similar in these three groups. 
In patients with mild, moderate, and severe renal insufficiency sofosbuvir, AUC values 
were elevated by 61, 107, and 171% compared with controls. GS-331007 AUC values 
were 55, 88, and 451% higher in these patients. Administration before and after dialysis 
influenced the exposure to GS-331007 as it is removed during dialysis. After 4 hour 
of dialysis, 18% of the administered dose had been removed[20, 37]. A study comparing 
sofosbuvir 400 mg every day or only on the day of dialysis showed that there was no 
accumulation of sofosbuvir or GS-331007 in both treatment groups[38]. Gane and co-
authors treated patients with severe renal impairment with daily sofosbuvir 200 mg 
and low-dose ribavirin. Compared with historical controls the patients had comparable 
sofosbuvir exposure and fourfold higher GS-331007 concentrations[39]. A recently pre-
sented study of ten patients describing the steady-state pharmacokinetics of sofosbuvir 
in patients with a GFR <30 mL/min (mean creatinine clearance 26.2 mL/min) showed 
comparable results. Exposure to GS-331007 and sofosbuvir increased 6- and 1.4-fold, 
respectively, compared with patients with normal renal function[40].
The manufacturer does not recommend using sofosbuvir in patients with severe renal 
impairment or ESRD, since studies are still ongoing (NCT01958281[41]). The main issue 
might be the increased exposure to GS-331007 (AUC 451%). This is caused by decreased 
clearance of GS-331007. However, increased exposure of GS-331007 is not associated 
with increased toxicity[42]. 
Several small studies and case reports have shown that both low-dose (200 mg) and 
normal-dose (400 mg) sofosbuvir were overall well-tolerated[38, 43]. Pending more defi-
nite results of ongoing studies, we recommend patients be treated with sofosbuvir 400 
QD (GFR <30 mL/min or ESRD) in case there is no safer DAA option available. We base 
this advice on a number of arguments. First, accumulation of sofosbuvir does not take 
place in patients dependent on dialysis, suggesting that a standard dosage of 400 QD 
will produce similar concentrations of active intracellular metabolites independent of 
renal function[38]. Secondly, (interim) analyses of small studies show that sofosbuvir at 
standard doses is well-tolerated in these patient groups. Lastly, data are available for 
the sustained virological response at week-12 (SVR12) of patients treated with half-dose 
sofosbuvir, which varied from 40 to 90%[40, 44]. Patients treated with sofosbuvir 400 QD 
reached SVR12 in 60-100% of cases[40, 45]. These results suggest that a reduced dose 
of the prodrug sofosbuvir may result in lower concentrations of active intracellular 
metabolites.
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Fixed-Dose regimens
Ledipasvir/sofosbuvir
Ledipasvir is an NS5A inhibitor available in a fixed-dose tablet with sofosbuvir contain-
ing sofosbuvir 400 mg and ledipasvir 90 mg. The metabolism of ledipasvir is unknown 
but unchanged ledipasvir is mainly found in feces, indicating biliary excretion. It is a 
substrate of P-gp and BCRP and it is >99.8% bound to plasma proteins[21].
No relevant differences were seen in between pharmacokinetics of control patients 
with normal hepatic function and CP-C patients after a dose of ledipasvir 60 mg[21]. 
Single and multiple doses of ledipasvir 30 mg (in combination with 200 mg of the 
investigational PI vedroprevir) resulted in a reduction of the Cmax (36%) and an extended 
elimination half-life (T1/2) in CP-C patients (84.4 versus 45.7 hours in healthy subjects). 
The free fraction of ledipasvir increased in patients with severe hepatic impairment 
(0.21 versus 0.11% in healthy subjects). No significant changes were seen between CP-B 
patients and control subjects[46].
No pharmacokinetic differences were observed between healthy subjects and patients 
with severe renal impairment, although no safety data are available for patients with 
GFR <30 mL/min or ESRD[21, 47]. 
The pharmacokinetics of sofosbuvir in patients with impaired renal and hepatic func-
tion are discussed previously.
Velpatasvir/sofosbuvir
Velpatasvir is a novel NS5A inhibitor that will probably be licensed in a fixed-dose tablet 
with sofosbuvir (100 mg/400 mg)[22, 48]. Velpatasvir is primarily metabolized by the liver 
and excreted through the biliary system. Velpatasvir is substrate of P-gp and OATPs, and 
strong inducers or inhibitors of CYP influence the plasma concentration of velpatasvir, 
suggesting it is a substrate of CYP enzymes[49, 50].
Non-HCV subjects with CP-B and CP-C received a single dose of velpatasvir 100 mg and 
the AUC from time zero to infinity (AUC∞) was comparable with subjects with normal 
hepatic function: AUC∞ decreased 17% and increased 14%, respectively. However, Cmax 
in both groups decreased ~50% and the unbound fraction increased with decreasing 
hepatic function[51]. 
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A study in HCV-uninfected subjects with GFR <30 mL/min showed that renal insuffi-
ciency had a modest influence on the pharmacokinetics of velpatasvir (single dose 100 
mg). Cmax was increased 11% and AUC∞ increased 50%[52]. Further studies are ongoing 
and the results are still pending (NCT02185794[53]). 
Grazoprevir/elbasvir
Grazoprevir (PI) and elbasvir (NS5A inhibitor) are newly licensed in the USA and data 
from phase-III studies were recently published. Grazoprevir is a substrate of CYP3A4, 
P-gp, and OATPs and prescribed in a dosage of 100 QD[54]. Exposure to grazoprevir was 
approximately one- to two-fold higher in HCV patients than in healthy controls[55-57]. 
Elbasvir is prescribed in a dose of 50 QD. It is a substrate of CYP3A4, P-gp, and OATP[58]. 
Both elbasvir and grazoprevir are highly hepatically metabolized and less than 1% is 
renally extracted[54, 59].
Jacobson and co-authors[60] presented pharmacokinetic data of grazoprevir plus elbas-
vir in HCV patients with CP-B. CP-B patients received grazoprevir 50 mg and elbasvir 50 
mg and healthy controls received normal-dose grazoprevir and elbasvir. Despite the 
reduced dose, grazoprevir AUC and Ctrough values were increased 30 and 73%, respec-
tively, compared with controls. Elbasvir exposure was comparable between these two 
groups[60]. However, the fixed-dose combination is only available in a dose of grazopre-
vir 100 mg and elbasvir 50 mg; therefore, and due to a lack of safety and efficacy data, 
the combination is contra-indicated for CP-B and CP-C patients[26].
Pharmacokinetic data are available in non-HCV patients with GFR <30 mL/min and in 
patients dependent on dialysis. Dialysis did not influence the steady-state pharmaco-
kinetics of both grazoprevir and elbasvir. Grazoprevir was slightly removed by dialysis 
(<0.5%) and elbasvir was not removed. Subjects with GFR <30 mL/min (not on dialysis) 
had increased grazoprevir and elbasvir exposure. AUC and Ctrough values of grazoprevir 
were elevated 65 and 60%, compared with controls (GFR >80 mL/min). Elbasvir phar-
macokinetics showed similar results: AUC was 86% higher and Ctrough was 107% higher. 
The unbound fraction of grazoprevir was comparable between the three treatment 
groups. The unbound fraction of elbasvir was below the limit of detection[26, 44]. 
Paritaprevir/ritonavir, ombitasvir, and dasabuvir
The fixed-dose combination of paritaprevir (75 mg), ritonavir (50 mg), and ombitasvir 
(12.5 mg) is administered as two tablets QD with or without dasabuvir 250 mg BID. 
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Paritaprevir is a second-generation PI, which is a substrate of CYP3A4/5, P-gp, OATP1B1, 
and OATP1B3. Ritonavir is added to improve the pharmacokinetics of paritaprevir by 
inhibiting CYP3A4 (‘boosting’). Paritaprevir itself also inhibits various drug-transporters 
and is 97-98.6% bound to plasma proteins. After hepatic metabolism paritaprevir is 
excreted through the biliary system. CP-C patients had 3.2- and 9.5-fold higher Cmax 
and AUC values than control subjects[27, 28]. Paritaprevir is contra-indicated in CP-B/C 
patients. The unbound fraction was 1.1% in subjects with normal hepatic function and 
0.78, 0.75, and 1.2% by patients with CP-A, CP-B, and CP-C, respectively. 
In patients with mild, moderate, and severe renal insufficiency, the AUC of paritaprevir 
increased by 19, 33, and 45%. Cmax was comparable with control subjects[27]. 
Ombitasvir is an NS5A inhibitor and highly metabolized: only 8.9% of the unchanged 
drug is excreted and a total of 13 metabolites were identified. Amide hydrolysis and 
oxidative metabolism are responsible for its biotransformation. Ombitasvir is >99.9% 
bound to plasma proteins and biliary excretion is the major elimination pathway. In 
CP-C patients, ombitasvir reduced the AUC and Cmax values by 68 and 54%, respectively. 
The unbound fraction of ombitasvir increased from ~0.020% in control subjects and 
CP-A/B patients to 0.047% in CP-C patients[27, 28]. Ombitasvir exposure was not affected 
by any degree of renal insufficiency[27].
Dasabuvir is an NS5B polymerase inhibitor and a substrate of CYP2C8, CYP3A4, P-gp, 
BCRP, and organic cation transporter (OCT) 1. Dasabuvir is hepatically metabolized into 
seven metabolites, of which M1 accounts for 21% of the administered dose. However, 
unchanged dasabuvir accounts for 60% of the exposure. Dasabuvir is >99.5% and M1 
94.5% bound to plasma proteins. The AUC values of dasabuvir and M1 were equal in 
healthy controls and CP-A patients. CP-B patients had reduced dasabuvir and M1 AUC 
values (16 and 57% respectively). CP-C patients had elevated AUCs for dasabuvir and 
M1: 325 and 77%, respectively[28, 31]. Dasabuvir unbound fractions were lower in patients 
with CP-A, CP-B, and CP-C: 0.29, 0.28, and 0.42% respectively (control subjects: 0.61%). 
The unbound fraction of M1 in control subjects was 5.8% and was 5.1, 5.4 and 6.8% in 
CP-A, CP-B and, CP-C patients[28]. Due to the elevated AUC of dasabuvir (and M1) in CP-C 
patients, dasabuvir is contra-indicated in these patients.
The AUC of dasabuvir decreased in patients with mild (21%), moderate (37%), and 
severe (50%) renal insufficiency. As exposure slightly declines in patients with renal 
impairment, no dose adjustments are required in these patients[31].
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To conclude, paritaprevir/ritonavir plus ombitasvir with or without dasabuvir can be 
used safely in patients with any stage of renal impairment. Due to a recent FDA an-
nouncement, the label for this combination regimen has been updated, stating that 
paritaprevir/ritonavir, and ombitasvir with or without dasabuvir is contra-indicated for 
both CP-B and CP-C patients. These changes have been made based on results from 
post-marketing surveillance showing liver decompensation and liver failure in patients 
with advanced cirrhosis (CP-B/C) (n = 26) after 1-4 weeks of treatment[29, 30]. 
Other antivirals
Ribavirin
Ribavirin is a guanine analog with activity against a range of RNA and DNA viruses. 
Ribavirin is always prescribed as part of a combination therapy. In general practice, 
ribavirin is administered in a weight-based dose (<75 kg = 1,000 mg/day; ≥75 kg = 
1,200 mg/day), although this may differ by genotype and commercial product[32, 61]. The 
T1/2 of ribavirin is ~300 hours and approximately 61% of the administered dose is renally 
excreted, of which 17% was unchanged ribavirin. The site of metabolism is unknown but 
two metabolizing pathways are involved: (1) a reversible phosphorylation pathway: and 
(2) a degradative pathway involving deribosylation and amide hydrolysis[61]. It is notable 
that the ratio of whole blood:plasma is 60:1 and the volume of distribution (Vd) 5,000 
L, which is caused by the extensive accumulation of ribavirin in the erythrocytes[32, 61]. 
The SmPC states that the pharmacokinetics of ribavirin are similar in control subjects 
and patients with CP-A/B/C and therefore no dose adjustments were deemed necessary 
in patients with cirrhosis[32]. By contrast, a single-dose study described an increased Cmax 
with increasing severity of cirrhosis (the AUC was not significantly different between 
those patient groups)[62]. 
Patients with moderate or severe renal impairment had 20 to 30% higher ribavirin 
exposure despite adjusted daily doses of 600 and 400 mg, respectively. ESRD patients 
had 20% lower ribavirin plasma exposure when given 200 mg daily, than did subjects 
with GFR >80 mL/min receiving the standard dose[32].
Brennan and co-authors[63] studied steady-state plasma concentrations in patients with 
renal impairment. Data were hard to interpret, because many dose adjustments were 
necessary due to toxicity in patients with moderate and severe renal insufficiency. At 
week 12 of treatment, these patients had 36 and 25% higher AUCs, with adjusted daily 
doses of 600 and 400 mg, respectively, compared with control subjects. The apparent 
total clearance of ribavirin from plasma (CL/F) was 20.0 L/h in patients with normal 
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renal function but decreased in patients with renal insufficiency, ranging from 5 to 6 
L/h[63]. In a single-dose study, increased AUC and decreased clearance were linearly 
correlated with the severity of renal dysfunction (single dose of 400 mg)[64]. 
Taking into account the information from the literature and our clinical experience with 
ribavirin[65, 66], we recommend a weight-based loading dose of ribavirin, followed by 
200 mg QD in patients with severe renal dysfunction or ESRD. We also recommend 
alternating 200 and 400 mg QD in patients with moderate renal function. Steady-state 
plasma concentrations of ribavirin are directly achieved using a loading dose, which is 
necessary due to the long T1/2. Ribavirin is not removed by dialysis and these patients 
often have lower hemoglobin levels. Caution is needed due to accumulation of riba-
virin in the erythrocytes causing hemolysis. If available, therapeutic drug monitoring 
can be helpful to individualize treatment with ribavirin in patients with impaired and/
or variable renal function.
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EffICACy AnD SAfEty
HCV therapy consists of combinations of drugs, and therefore efficacy and safety are 
mostly evaluated in patients using combination therapy, making data hard to interpret 
for only one drug. Efficacy and safety data are given in Table 3 for CP-A/B/C patients. 
Table 4 presents the data for patients with mild, moderate, severe, and end-stage renal 
disease; only multiple-dose studies performed in HCV patients are included. 
Protease inhibitors
Simeprevir
Adverse events (AEs) were retrospectively reported in 22% of CP-A/B HCV genotype 
(GT) 1 patients (n = 119) treated with simeprevir and sofosbuvir ± ribavirin. SVR was 
reached in 78% of the CP-A/B patients (n = 84), of whom 29% were CP-B patients[70]. 
Another retrospective study, in which CP-B/C patients were treated with sofosbuvir and 
simeprevir, reported that 9% of patients discontinue due to AEs (CP-A = 1% discontin-
ued). These patients were hospitalized more often than CP-A patients. Furthermore, 
91% of the CP-A patients reached SVR versus 73% of the CP-B/C patients[71]. Both the 
EMA and FDA have warned for possible safety issues with CP-B/C patients because 
simeprevir safety data are lacking[11, 18]. 
In an observational study including ESRD patients with or without dialysis (n = 17) 
treated with simeprevir and sofosbuvir, 23% of the patients reported AEs. No patient 
discontinued treatment due to an AE[45]. Trials describing treatment with a reduced 
dose of sofosbuvir and simeprevir are discussed below[72, 73]. 
Asunaprevir
An open-label, randomized, uncontrolled trial with daclatasvir 30 mg, asunaprevir 200 
mg, and beclabuvir 75 mg, all BID, reported SVR-rates of ~94% in naive cirrhotic patients. 
Treatment-experienced patients had SVR-rates ≥87%. Ribavirin increased treatment 
response. Nine patients experienced a serious AE (SAE) and three patients discontinued 
the study due to AEs. The authors concluded that most AEs were caused by ribavirin 
and that there were no significant differences between cirrhotic and non-cirrhotic 
patients[74]. In a trial including genotype 1- and 4-infected cirrhotic patients (METAVIR 
score F3/4; n = 223), an SVR of 84% was reported after treatment with daclatasvir and 
asunaprevir. Pooled analyses of four phase-II/III studies showed that SVR was reached 
in 84% of genotype 1b cirrhotic patients (n = 229). No meaningful differences in safety 
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were described between cirrhotic and non-cirrhotic patients. Overall, most reported 
AEs were headache, fatigue, nausea, and diarrhea (≥10%)[75].
An SVR of 96% was reached in dialysis-dependent genotype 1 patients when treated 
with daclatasvir 60 mg and asunaprevir 100 mg (n = 21). Of these patients, 97% expe-
rienced any AE. Anemia (29%) and nasopharyngitis (29%) were most the commonly 
reported AEs[67].
NS5A inhibitors
Daclatasvir
The safety and efficacy of daclatasvir in cirrhotic patients was studied in combination 
with asunaprevir or sofosbuvir ± ribavirin. In combination with sofosbuvir 400 mg, an 
SVR of 83% was reached in CP-A/B/C patients (phase-III trial). SVR-rates in CP-B/C pa-
tients were lower: 56%. In this trial anemia (20%), fatigue (18%), and nausea (17%) were 
the most commonly reported AEs, of which 18% were grade 3-4[76]. Another open-label, 
phase-III study included patients with cirrhosis/advanced fibrosis (genotype 3) who 
were treated with sofosbuvir 400 mg and daclatasvir 60 mg (n = 50). These patients 
most commonly reported insomnia (30%), headache (24%), and fatigue (20%) as AEs[77]. 
No SVR was reported in this preliminary analysis. 
Daclatasvir, in combination with asunaprevir and beclabuvir, was overall well-tolerated 
by patients with renal impairment. SAEs were reported in 67% of the patients and SVR 
was ≥96% (n = 21)[67]. 
NS5B polymerase inhibitors
Sofosbuvir
No SAEs were reported in a multiple-dose study where 400 mg of sofosbuvir was ad-
ministered to HCV-infected CP-B/C patients (n = 17)[36]. Sofosbuvir-containing regimens 
were in general well-tolerated in patients with advanced cirrhosis. Fatigue, nausea, 
headache, and anemia were the most frequently reported AEs (≥10%)[78, 79]. SVR-rates 
varied from 29 to 91%, depending on genotype, Child-Pugh score, and other DAAs 
(Table 3)[70, 71, 78, 79]. 
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Sofosbuvir was well-tolerated in dialyses-dependent patients treated with sofosbuvir 
200 mg daily or 400 mg every day or on the day of dialysis[38]. However, as discussed, the 
SVR12 of patients treated with half-dose sofosbuvir, varied from 40 to 90%[40, 44, 72, 73]. Two 
other recently presented studies (n = 17 and 10) concluded that full-dose sofosbuvir 
(400 QD) had good tolerability and was safe in patients with GFR <30 mL/min with 
and without dialysis. SVR12 was reached in 60-100% of the patients[40, 45]. There was 
no evidence of an elevated risk of sofosbuvir-related toxicity. No cardiac toxicity was 
reported[40]. A longitudinal, observational cohort reported SVR-rates of 85% (n = 18), 
81% (n = 63), and 88% (n = 168) in patients with severe, moderate, and mild renal 
insufficiency, respectively, who were treated with sofosbuvir-containing regimens[43].
Fixed-Dose regimens
Ledipasvir/sofosbuvir
A phase-II study with ledipasvir and sofosbuvir ± ribavirin reported AEs in 98% of the 
CP-B (n = 59) and 100% of the CP-C (n = 49) patients. Of these patients, 22 and 35%, 
respectively, experienced an SAE. SVR was reached in ≥82% and ≥91% of the CP-B and 
CP-C patients, respectively[80]. A randomized, double-blind, placebo controlled trial 
reported >96% SVR. These patients had a CP-score of 5-7. Asthenia (52%) and headache 
(34%) were the most common AEs in this trial[81]. 
Studies in patients with renal impairment and ledipasvir are still ongoing (NCT01958281[41]). 
Velpatasvir/sofosbuvir
A randomized, double-blind, placebo-controlled trial described the use of velpatasvir 
in HCV patients with CP-B in combination with sofosbuvir (genotype 1-6). Different 
treatment regimens were used (Table 3) and SVRs ≥83% were reported. Overall, this 
combination was well-tolerated. The most reported AEs were fatigue, nausea, and 
headache (≥20%). In total, nine patients discontinued treatment due to an AE[23].
No studies have been published yet describing the safety of velpatasvir in HCV patients 
with renal insufficiency.
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Grazoprevir/elbasvir
The safety and efficacy of grazoprevir plus elbasvir ± ribavirin in CP-A patients was 
studied in a phase-II trial. SVR was reached in more than 90% of the patients (n = 253). 
More discontinuations due to AEs (2 versus 0%) and drug-related AEs (71 versus 54%) 
were seen in the patients treated with grazoprevir, elbasvir, and ribavirin. The regimen 
was well-tolerated by the patients[82]. Another phase-II trial showed that a reduced dose 
of grazoprevir (50 mg) and normal-dose elbasvir was well tolerated in CP-B patients 
(n = 30) despite the increased exposure. Fatigue (30%) was the most reported AE and 
end-of-treatment (EOT) response was 100% (n = 25/30)[60]. 
As described earlier, increased exposure to grazoprevir and elbasvir was reported in pa-
tients with a GFR <30 mL/min without dialysis. A phase-III study presented safety data 
for grazoprevir 100 mg and elbasvir 50 mg in patients with GFR ≤29 mL/min (n = 111). 
High rates of AEs were reported (76%), but these were comparable with the placebo 
group (84%). SAEs and laboratory abnormalities were also comparable between groups. 
Taking these results in combination with high SVR-rates (~95%) it was concluded that 
this regimen is safe and effective for the use in patients with renal insufficiency[59]. 
Paritaprevir/ritonavir, ombitasvir, and dasabuvir
The fixed-dose combination of paritaprevir/ritonavir, ombitasvir, and dasabuvir plus rib-
avirin in CP-A patients was studied by Poorded et al[83]. Of these patients, 91% reported 
AEs, of whom 6% had an SAE. Only 2% of patients discontinued the study due to AEs. 
More AEs were seen during 24 weeks of treatment than during 12 weeks of treatment 
(phase-III trial) and SVR-rates were approximately 94% (n = 380). As discussed, the label 
of this combination regimen was adjusted due to information that became available 
during post-marketing surveillance.
During a phase-I trial, this combination was studied in patients with severe renal insuf-
ficiency (n = 20). An interim analysis shows, that EOT response was 100% (n = 14/20). All 
patients completed the trial but experienced AEs such as anemia (40%), fatigue (30%), 
nausea (25%), and diarrhea (25%)[68]. 
Other antivirals
Ribavirin
In the past, ribavirin was frequently used in combination with peg-interferon alfa, but 
it is used now as part of DAA regimens. Anemia was frequently reported in trials where 
cirrhotic patients were treated with ribavirin, varying from 2 to 40% dependent on the 
combination treatment[70, 72, 76, 85, 86]. 
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Patients with severe and moderate renal impairment who were treated with peg-inter-
feron alfa and a daily dose of ribavirin 400 or 600 mg, respectively, frequently needed 
dosage reductions (71 and 54%). Dosage reductions were required in 22 and 23% of 
ESRD patients treated with a daily dose of ribavirin 200 mg and subjects with normal 
renal function, respectively. ESRD patients had a safety profile comparable with that of 
subjects with normal renal function[32, 63].
DISCuSSIon 
Influence of hepatic impairment on drug pharmacokinetics
Liver cirrhosis is the main complication of chronic HCV infection. Cirrhosis changes 
the liver architecture, into one with nodules causing reduction in hepatic blood flow, 
portal systemic shunting, capiliarization of sinusoids, and loss in number and function 
of hepatocytes. The liver is the main metabolizing organ, and therefore these changes 
have a profound influence on metabolism and elimination of drugs[6].
Cirrhosis curtails the metabolizing capacity of the liver, due to decreased levels of CYP 
enzymes. Various CYP enzymes are affected (e.g., CYP3A4, CY2A6, CYP2C9), but the sus-
ceptibility depends of the type and severity of the liver disease. For example, CYP1A2 
and CYP2C19 are sensitive to liver disease, whereas CYP2E1 is less susceptible. These 
changes in CYP enzymes may cause increased drug concentrations of enzyme sub-
strates. This explains the increased exposure of grazoprevir and paritaprevir in cirrhotic 
patients, because these drugs are metabolized by CYP3A4. Likewise, the increased so-
fosbuvir concentration or increased T1/2 of ledipasvir might be related to the reduced 
capacity of the liver to metabolize drugs by enzymes other than CYP enzymes, e.g., 
uridine 5’-diphospho-glucuronosyltransferase (UGT) conjugation is affected in cirrhotic 
livers. In addition, efflux transporters may be upregulated, while uptake transporters 
may be downregulated. These alterations are not yet fully understood[87]. However, 
they provide an explanation of increased simeprevir and grazoprevir concentrations, 
because OATP uptake transporters may be down-regulated, causing decreased uptake 
from the circulation into hepatocytes, resulting in increased plasma concentrations. 
Reduced hepatic metabolism affects the first-pass effect. This pre-systemic metabolism 
is responsible for metabolizing orally administered drugs prior to entering the systemic 
circulation. Decreased pre-systemic metabolism results in elevated bioavailability, as 
seen with paritaprevir and grazoprevir. In addition, portal shunting affects hepatic 
blood flow. Blood bypasses the liver, leading to an increased systemic drug concentra-
tion, as a result of decreased hepatic metabolism.
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In cirrhosis, the liver produces less drug-binding proteins (albumin, alpha1-acid glyco-
protein). Fewer proteins are available, and thus the unbound fraction of drugs may be 
elevated. Only this unbound fraction of drugs is available for uptake in the tissues and 
therefore is responsible for the pharmacological effect of a drug. The increased unbound 
fraction might even cause toxicity despite the total exposure being decreased. This 
was seen in ombitasvir: the unbound fraction increased twofold in patients with severe 
hepatic impairment but the total AUC was decreased[28]. On the other hand, the AUC 
of total daclatasvir was decreased, but the unbound fraction of daclatasvir remained 
unchanged in patients with cirrhosis due to increased clearance of free daclatasvir. This 
means that no differences were found in the active concentration of daclatasvir and 
therefore there was no need for dose modifications[33].
Finally, the ribavirin Cmax was increased in patients with cirrhosis compared with con-
trols. Ribavirin is renally cleared and extensively metabolized (site unknown). These 
changes in Cmax may be caused by alterations in, for example, hepatic drug-transporter 
activity; however, these findings could also be caused by the higher inter-individual 
variability of ribavirin. Since other pharmacokinetic parameters were not affected, no 
dose adjustments are necessary when using ribavirin in cirrhotic patients.
Figure 2 summarizes the physiological alterations during cirrhosis that influence drug 
concentrations and Table 1 shows the recommended doses or contra-indications for 
CP-A/B/C patients. 
Influence of renal impairment on drug pharmacokinetics
The prevalence of HCV in dialysis patients in Europe and the USA varies from 3 to 20%. 
In 2002, 8% of the dialyzed patients in the USA were infected with HCV[88]. HCV is both 
a cause and a consequence of renal impairment: first, patients on dialysis have an 
increased infection risk due to medical procedures and, secondly, HCV causes patho-
logical changes to the kidneys[88, 89].
Renal dysfunction influences the renal clearance of drugs. Glomerular filtration, tubular 
secretion, and tubular reabsorption are responsible for renal clearance of drugs. The 
clearance may be altered due to damage to glomeruli or by altered activity of drug-
transporters in tubular cells. In general, renal impairment results in increased drug 
concentrations of renally cleared drugs. 
Patients with ESRD are often dependent on dialysis. An important factor that affects the 
clearance of drugs is the molecular weight of the drug in relation to the pore size of the 
membrame in the dialyzer. Other parameters influencing drug clearance during hemo-
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dialysis are protein binding, Vd, water solubility, and plasma clearance. Characteristics 
of the dialyzer are also important for the pharmacokinetics of drugs, e.g., the flow of 
the blood and dialysate, and the concentration gradient. As described previously most 
HCV drugs are highly bound to plasma proteins, which explains why these drugs are 
not removed by dialysis (Table 4) as only unbound drugs can be removed by dialysis. 
Additionally, most drugs are metabolized by the liver, and therefore the contribution of 
hemodialysis to the clearance of drugs is relatively low[90]. 
In general, DAAs are hepatically cleared, meaning no dose modifications are necessary 
in patients with renal impairment. However, sofosbuvir and ribavirin, which are primar-
ily renally eliminated, are exceptions.
Exposure to GS-331007 increased with a decreasing GFR, but -as explained earlier- dose 
modification may not always be advisable. Sofosbuvir is removed during dialysis and 
thus it is recommended that it is administered after dialysis[20].
Ribavirin is mainly situated in the erythrocyte and not effectively cleared from the body 
during hemodialysis[63]. This causes increased plasma concentrations, which are related 
to (severe) anemia. However, while higher ribavirin plasma concentrations are related 
to anemia, they are also associated with improved SVR. Plasma concentrations of riba-
virin can explain toxicity or give information regarding whether the ribavirin exposure 
is sufficient. In other words: is the patient treated with the right dose[66, 91-93]? Due to 
toxicity, dose modifications are needed in ribavirin-treated patients who have a GFR 
≤50 mL/min and in ESRD patients. 
A second consideration is that non-renal clearance is affected in patients with renal 
disease. It should be noted that this phenomenon is mostly studied in patients with 
ESRD. CYP enzymes, UGT enzymes, and drug-transporters have altered activity in pa-
tients with renal insufficiency, but protein-binding may also decrease. One hypothesis 
is that the uremic toxins cause these alterations in drug-transporters and enzymes; di-
alysis then removes these toxins, which improves CYP3A- and transporter-related clear-
ance[94]. These alterations in hepatic function may affect hepatically cleared drugs such 
as daclatasvir, grazoprevir, and elbasvir. Daclatasvir exposure (bound and unbound) was 
elevated in patients with decreasing renal function[34]. Similarly, grazoprevir and elbasvir 
exposure increased significantly in patients with a GFR <30 mL/min[26, 44].
In conclusion, it is hard to predict what the influence of renal function on the exposure 
of drugs is. This should be taken into account when interpreting the dose recommen-
dations in Table 2.
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Studies in patients with renal and hepatic impairment during clinical 
development
The effect of renal- or hepatic impairment on the pharmacokinetics of HCV drugs is 
often studied in single-dose studies in HCV-negative patients with renal insufficiency 
or liver cirrhosis. These studies give an idea of the pharmacokinetics in these patient 
groups, but the influence of HCV is missing. The virus itself may also influence drug-
metabolism, as inflammation and infection are known to affect CYP activity in the 
liver[95, 96].
Therefore, studies in HCV-infected patients with renal or hepatic impairment are per-
formed after licensing and post-marketing surveillance takes place (e.g., collecting AEs). 
These findings might then be used to change the Prescribing Information. For example, 
the labels of both simeprevir and paritaprevir/ritonavir, plus ombitasvir with or without 
dasabuvir were recently changed due to information that became available after licens-
ing. In our opinion, these studies should be part of the pre-registration process, since 
HCV patients suffer from these conditions and therefore they will be treated with the 
novel DAAs. In comparison, sofosbuvir is contra-indicated for patients with a GFR <30 
mL/min, because no safety studies have been performed and data are missing. This 
might exclude patients unnecessarily from treatment. 
ConCluSIon
This review described the pharmacokinetics, efficacy, and safety of HCV drugs in pa-
tients with renal and hepatic dysfunction. All of the available drugs for the treatment 
of HCV can be used in patients with CP-A and in those with a GFR ≥30 mL/min. Some 
drugs are contra-indicated in patients with advanced liver disease (CP-B or CP-C), and 
sofosbuvir plus ledipasvir or daclatasvir are the best options for this group. Patients 
with GFR <30 mL/min can be treated with grazoprevir plus elbasvir or paritaprevir/
ritonavir, and ombitasvir with or without dasabuvir. Sofosbuvir is an important part 
of HCV therapy, and therefore data on its use renally impaired patients is essential 
information; however, data on sofosbuvir are still pending. Lastly, it would be helpful if 
more pharmacokinetics, efficacy, and safety data became available for the treatment of 
patients with advance liver disease or severe renal impairment. These patients might 
benefit the most from therapy, possibly preventing the need for liver transplantation.
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AbStRACt
Daclatasvir is an NS5A inhibitor used for the treatment of chronic hepatitis C virus 
(HCV) infection. Being a substrate of cytochrome P450 (CYP) 3A4 and P-glycoprotein 
(P-gp), hepatic metabolism and biliary excretion are important for daclatasvir clearance. 
Since HCV eventually leads to liver cirrhosis, physiology-based pharmacokinetic (PBPK) 
modeling was used to describe daclatasvir pharmacokinetics (PK) in healthy volunteers 
and cirrhotic patients. The Simcyp population-based PBPK modeling platform was used 
to investigate performance of a daclatasvir PBPK model. PK was simulated following 
single dosages (SD; 10, 30, 100 mg) and multiple dosages (MD; 30, 60 mg) in healthy 
volunteers. MD simulations were also performed in presence of CYP3A4 inhibitors da-
runavir/ritonavir and atazanavir /ritonavir. Simulated data were compared to reported 
clinical values. AUC-ratios (simulated/observed) of SD daclatasvir in healthy subjects 
varied from 0.74-0.89 and Cmax-ratios varied from 0.93-1.13. MD simulations and interac-
tion studies resulted in AUC and Cmax-ratios which were considered acceptable, ranging 
from 0.37-0.87 and 0.72-1.43, respectively. Subsequently, SD of 30 mg daclatasvir were 
simulated in the Simcyp virtual Child-Pugh class A, B, and C populations. However, we 
were not able to recover in vivo exposure in cirrhotic patients with this model. Given the 
involvement of intestinal and hepatic drug-transporters in daclatasvir clearance, and 
the fact that changes in transporter expression levels are not captured in the current 
(patho)physiological PK model, a more detailed charting of the impact of cirrhosis on 
these aspects of daclatasvir disposition appears required before its PK and drug-drug 
interactions may be simulated reliably within this patient population.
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IntRoDuCtIon
Hepatitis C virus (HCV) infection is transmitted through blood-blood contact and is 
nowadays effectively treated with direct-acting antivirals (DAAs). Daclatasvir is a DAA 
and, in combination with sofosbuvir, high cure rates are achieved (>90%). Daclatasvir 
is, among others, a substrate of cytochrome P450 (CYP) 3A4, P-glycoprotein (P-gp), 
and organic cation transporter (OCT) 1. It is actively and passively transported into the 
hepatocyte where it is metabolized. Daclatasvir is mainly cleared from the body via 
biotransformation and biliary excretion, as a mass-balance study showed a recovery of 
88% of a single oral dose in feces of which 53% was the unchanged drug[1, 2].
HCV replicates in hepatocytes, ultimately leading to hepatocyte cell death, causing 
chronic liver injury which may subsequently progress to liver cirrhosis. Patients with cir-
rhosis have abnormal liver structure caused by scarring of the liver tissue. Cirrhosis leads 
to reduced liver blood flow (e.g. portal-systemic shunting) and reduced liver function 
(e.g., decreased number of hepatocytes and production of albumin). These changes 
could eventually lead to clinical manifestations such as ascites and encephalopathy[3-5]. 
According to international guidelines, the treatment goal of HCV treatment is reduction 
of HCV transmission and decreasing the mortality caused by liver diseases (cirrhosis 
and hepatocellular carcinoma)[6, 7].
The liver is the main drug-metabolizing organ and loss of hepatic function influences 
the pharmacokinetics (PK) of a compound that is subject to biotransformation and/or 
biliary excretion; for example, in cirrhotic patients, metabolism by CYP enzymes, first 
pass effect, protein binding, and hepatic uptake by transporters may be altered[8-12]. As a 
result, drugs that are likely to be used in cirrhotic patients, or that are >20% metabolized 
in the liver must be studied in cirrhotic patients, during drug development or post-
marketing studies. The importance of this is recognized by the regulatory authorities: 
both the US Food and Drug Administration (FDA) and European Medicines Agency 
(EMA) recommend to study drugs in patients with Child-Pugh (CP) class A, B and C[13, 14]. 
There are some concerns when studying DAAs in cirrhotic patients. First of all, it is 
challenging to recruit HCV-infected patients with compensated or decompensated 
liver disease, i.e. covering the range of CP classifications. In addition, studying PK of 
these drugs in these patients, could also be considered unethical, as exposure to the 
compound could possibly be sub- or supratherapeutic, causing viral resistance or toxic-
ity, respectively. Therefore, non-HCV-infected cirrhotic patients are usually included in 
these kind of PK studies, which are, of course, also vulnerable patients exposed to a 
compound from which they will not benefit.
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A tool that can help to better understand the exposure of compounds in cirrhotic pa-
tients, without any in vivo study, is physiology-based pharmacokinetic (PBPK) modeling. 
This is a mechanistic approach in which absorption, distribution, metabolism, and ex-
cretion (ADME) as well as the resulting clinical pharmacokinetic profile of a compound 
can be predicted by combining physicochemical and in vitro pharmacokinetic data 
from a compound, with human anatomical and (patho)physiological information in a 
mathematical model[9, 11]. In vitro to in vivo extrapolation (IVIVE) of PK is also mentioned 
by the EMA for these patients, whereas the FDA has drafted a white paper, outlining 
the requirements of such models in order to use the approach in pharmaceutical drug 
development[14, 15].
We now explored a mechanistic model to simulate the PK of daclatasvir in healthy 
volunteers and cirrhotic patients. The objective was to simulate and predict the PK 
of total and unbound daclatasvir in these patient populations, including drug-drug 
interactions (DDI) taking place at the level of CYP3A4. Secondly, we aimed to identify 
knowledge gaps that hamper a more accurate PBPK modeling and simulation effort of 
daclatasvir PK in cirrhotic patients. 
MAtERIAlS & MEthoDS
PBPK modeling platform
Simcyp Population-Based Pharmacokinetic Simulator version 15, release 1 (Simcyp 
Limited, a Certara company, Sheffield, UK) was used as a PBPK platform. Simulations 
were performed using Simcyp virtual populations of healthy volunteers, as well as CP-A, 
B, and C liver cirrhotic patients. For each simulation, the number of patients, gender, 
and age range of the virtual population were matched with clinical data sets used for 
validation.
PBPK workflow
Two available populations in the database of Simcyp were used: healthy volunteers 
and cirrhotic patients. Simulations in healthy volunteers were done to determine the 
performance of the model. We used single dosages of daclatasvir (10, 30, and 100 mg) 
and multiple dosage of daclatasvir (30 mg and 60 mg once daily [QD]). In addition, we 
used 30 mg daclatasvir in combination with two strong CYP3A4 inhibitors to confirm 
robustness of the model and to test the influence of alterations in CYP3A4/5 metabo-
lism (1) darunavir/ritonavir (800/100 mg QD) and (2) atazanavir/ritonavir (300/100 mg 
QD). The effect of these interactions on daclatasvir systemic exposure were studied at 
steady-state concentrations. 
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After establishing adequately simulated daclatasvir plasma concentrations in single dose, 
multiple dose, and DDI studies in healthy volunteers, we moved to the simulation of 30 
mg daclatasvir in CP-A, B, and C patients. Subsequently, we simulated the PK of CYP3A4 
(probe) substrate midazolam in the same populations (15 mg oral QD). We included 
midazolam for comparison purposes as midazolam is cleared via biotransformation only, 
in contrast to daclatasvir which is also actively transported by hepatic drug-transporters. 
The midazolam model available in Simcyp was used for these simulations.
Physicochemical and in vitro pharmacokinetic parameters of daclatasvir
For this study, we used a modified model which was previously presented[16, 17], but which 
was modified in order to accommodate an active liver sinusoidal uptake transport step. 
The physicochemical and in vitro PK parameters of daclatasvir used to parameterize the 
model are presented in Table 1. Main assumptions were that next to CYP3A4, CYP2C8 
contributed to metabolic clearance, as fraction of the dose metabolized could not be 
explained by bottom-up CYP3A4 clearance only. In order to estimate daclatasvir distribu-
tion, we assumed the drug followed general lipid:water partitioning, as well as protein, 
phospholipid binding rules[18], except for distribution to the liver where transporters were 
assumed to be involved in daclatasvir hepatic uptake. In addition, P-gp was included in 
the model, being involved in intestinal absorption and biliary efflux[16, 17].
P-gp canalicular efflux in the liver was described to be 88 pmol/min/million cells with 
a Km of 8.16 µM and a relative activity factor/relative expression factor (RAF/REF) of 1.6. 
The previously published model did not include active sinusoidal uptake into the 
liver, despite that both passive and active uptake is described in the product label[1]. 
Therefore, we added a sinusoidal hepatic uptake clearance of 177 µL/min/million cells, 
based on the mean of two reported in vitro uptake experiments with hepatocytes. The 
involved transporters remain unknown from the experiment[1]. We used a passive dif-
fusion uptake clearance of 0.0412 mL/min/million cells based on observed uptake in 
an experiment in hepatocytes in which active uptake processes via OCT1 and organic 
anion transporter (OAT) 2 were assumed to be fully blocked with pyrimethamine and 
probenecid, respectively[1]. 
For simulations, we used a full PBPK distribution model with an Advanced Dissolution, 
Absorption, and Metabolism model (ADAM) absorption module and permeability-
limited liver model. Volume of distribution at steady-state (Vss) was calculated using the 
prediction method described by Rodgers and Rowland[18]. This overestimated Vss was 
subsequently scaled to the clinically observed value of 0.5507 L/kg (Kp scalar 0.1565)
[16, 17]. 
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table 1: Physicochemical and in vitro pharmacokinetic parameters of daclatasvir.
Parameters Values Ref[16, 17]
Physicochemical and blood binding  
Molecular Weight 738.96  
log Po:w 4.05  
Compound Type Diprotic base  
pKa 1 5.6  
pKa 2 4.9  
Blood:plasma ratio 0.8  
fu 0.006  
Absorption: ADAM model    
Predicted fugut 0.0007854  
Predicated permeability 8.9783  
PAMPA (x10-6 cm/s) 49  
Distribution: full PbPK Model    
Predicted Vss (l/kg) 0.5507 (Method 2: Rodgers and 
Rowland)
Kp Scalar 0.1565  
Elimination: enzyme kinetics, recombinant    
Unidentified CYP: CYP2C8  
CLint (µL/min/pmol) 0.32  
fumic 0.35  
CYP3A4    
Vmax (pmol/min/pmol) 0.575  
Km (µM) 2.53  
CYP3A5    
Vmax (pmol/min/pmol) 0.0957  
Km (µM) 9.14  
Available for re-absorption (%) 80  
transport – liver    
CLpd (ml/min/million cells) 0.0412 [1]
Canalicular efflux liver: P-gp    
Jmax (pmol/min/million cells) 88  
Km (µM) 8.16  
RAF/REF 1.6  
Sinusoidal uptake liver [1]
CLint (µL/min/1x x10-6 cells) 177  
fuinc 1  
RAF/REF 1  
CYP: Cytochrome P450; CLint: Intrinsic clearance; CLpd: Passive diffusion; fu: Fraction unbound; fuinc: Fraction un-
bound in the incubation medium; fumic: Fraction unbound microsomes; Jmax: Maximum observed flux; ka: Ab-
sorption rate constant; Ki: Inhibitory constant; Log P: Partition coefficient; PAMPA: Parallel artificial membrane 
permeability assay; P-gp: P-glycoprotein; pKa: Acid dissociation constant; Vss: Volume of distribution at steady-
state; Km: Michaelis-Menten constant; Vmax: Maximum rate; RAF/REF: Relative activity factor / relative expression 
factor; Ref: Reference.
PBPK model of daclatasvir in cirrhotic patients
275
12
Simulation of drug-drug interactions
To study the interactions of daclatasvir with darunavir/ritonavir and atazanavir/ritonavir, 
four compound files were created. Two compound files were created for ritonavir, one 
in addition with darunavir, and another in addition with atazanavir, as ritonavir PK pa-
rameters are different when ritonavir is combined with either darunavir or atazanavir[19]. 
We used the 50% inhibitory concentrations (IC50) of darunavir, atazanavir, and ritonavir 
against the different CYP enzymes and transporters in order to mechanistically simulate 
the influence of these compounds on daclatasvir metabolic clearance. Note that in 
this respect we adopted a semi-mechanistic approach as we did not build full PBPK 
models for the interacting drugs, and we only aimed to describe the influence of these 
inhibitors on daclatasvir PK. 
For the compound file of darunavir and ritonavir we used information described by our 
group before[20]. We included in vitro data on drug-metabolizing enzymes and trans-
porters, in order to simulate the interaction with daclatasvir PK (Table 2)[20]. Secondly, 
compound files of both atazanavir and ritonavir were created using data available in 
the public domain (Table 3).
Liver cirrhosis virtual populations
Disease severity of cirrhotic patients is clinically classified using the CP-score, which 
contains three classes of severity: CP-A, B, and C. This system was developed to deter-
mine short term prognosis in cirrhotic patients and one must consider that this classifi-
cation is not based on etiology of the liver disease. The CP-score is calculated using five 
clinical parameters: albumin, prothrombin time, bilirubin, ascites, and encephalopathy. 
CP-A patients have a score of 7-9 (well compensated disease), CP-B a score of 10-15 
(functional compromised disease), and CP-C a score >15 (decompensated disease)[35]. 
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table 2: Physicochemical and in vitro pharmacokinetic parameters of darunavir/ritonavir.
Parameters Darunavir 
values
Ref Ritonavir 
values
Ref
Physicochemical and blood binding 
Molecular Weight 548 [21] 720.95 [22]
log Po:w 1.8 [23] 4.3 a
Compound Type Monoprotic base Monoprotic base
pKa 1 2.39 [23] 2 a
Blood:plasma ratio 0.64 [24, 25] 0.587 a
fu 0.06 [24, 25] 0.02
Absorption ADAM First-Order 
Absorption 
Model
fa – 1 a 
ka (1/h) – 0.24 CV%:30 a
fugut 0.05 [20] 0.02 a
Qgut – 11.16 a
Predicted permeability 3.40 3.10
Caco-2 (10-6 cm/s)
Apical pH 6.5: basolateral pH 7.4 (Passive & Active)
18.9 [26] –
Distribution Full PBPK model Minimal PBPK 
model
Vss (l/kg); CV% Predicted: 1.24 
(method 2)
0.41; 30 a
Kp Scalar 6 [20] –
Elimination: In vivo clearance
CLpo (L/h); CV (%) – 16; 30 [27]
CLr (L/h) – 0.32 [20]
CLiv (L/h); CV (%) 5.9; 30 [28]
Available for re-absorption (%) 80 [20]
Interaction
Competitive inhibition
CYP2B6 (Ki (µM); fumic) 24; 1 [25] –
CYP2C9 (Ki (µM); fumic) 24; 1 [25] 4; 0.29 [20]
CYP3A4 (Ki (µM); fumic) 0.4; 1 [25] 0.03; 0.976 [20]
CYP2D6 (Ki (µM); fumic) 24; 1 [25] 10; 0.29 [20]
CYP2C19 (Ki (µM); fumic) 24; 1 [25]
Mechanism-based inhibition
CYP3A4 (Kapp; kinact (1/h); fumic) – 0.1; 0.32; 0.91 [29]
Induction 
CYP3A4 (IndC50^ (µM; CV%; fuinc) – 0.5; 30; 1 a
Transporter
OATP1B1 (Ki (µM); fuinc) – 1.4; 1 [30, 20]b
OATP1B3 (Ki (µM); fuinc) – 2.5; 1 [30, 20]b
P-gp (Ki (µM); fuinc) – 0.2; 0.233 [31]
aSimcyp compound library.
bBased on reported Ki for organic anion transporting polypeptide 1B3 (2.5 µM).
CLpo: Oral clearance; CLr: Renal clearance; CLiv: Intravenous clearance; CYP: Cytochrome P450; fa: Fraction ab-
sorbed; fu: Fraction unbound; fuinc: Fraction unbound in the incubation medium; fumic: Fraction unbound mi-
crosomes; IndC50: The concentration that yields half of the maximum fold induction; ka: Absorption rate constant; 
Kapp: Apparent absorption; Ki: Inhibitory constant; kinact: Maximum inactivation rate; Log P: Partition coefficient; 
P-gp: P-glycoprotein; pKa: Acid dissociation constant; Vss: Volume of distribution at steady-state; Ref: Reference.
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table 3: Physicochemical and in vitro pharmacokinetic parameters of atazanavir/ritonavir.
Parameters Atazanavir 
values
Ref Ritonavir values Ref
Physicochemical and blood binding 
Molecular Weight 704.856 [32] 720.95 [22]
log Po:w 4.08 [33] 4.3 a
Compound Type Monoprotic Base Monoprotic base
pKa 1 4.2 [33] 2 a
Blood:plasma ratio Predicted: 0.55 0.587 a
fu 0.14 [33] 0.02
Absorption: first-order Absorption Model
fa Predicted: 0.998 1 a 
ka (1/h) Predicted: 3.07 0.24 CV%:30 a
fugut 1 a 0.02 a
Qgut Predicted: 14.78 11.15705 a
Predicted permeability 7.46 a 3.096
MechPeff model: Ptrans, 0 (10-6 cm/s) 1188.166 a –
Distribution: Minimal PBPK model
Vss (l/kg); CV% 1.44 CV Vss%: 35 [34]b 0.7; 29.3 [34]b
Elimination: In vivo clearance
CLpo (L/h); CV (%) 5.41; 26 [34]b 8.83; 29.4 [34]b
CLr (L/h) – 0.32 [20]
Interaction
Competitive inhibition
CYP1A2 (Ki (µM); fumic) 12; 1 [32] –
CYP2C9 (Ki (µM); fumic) 12; 1 [32] 4; 0.29 [20]
CYP3A4 (Ki (µM); fumic) 2.35; 1 [32] 0.03; 0.976 [20]
UGT1A1(Ki (µM); fumic) 1.9; 1 [32] –
CYP2D6 (Ki (µM); fumic) – 10; 0.29 [20]
P-gp 29; 1 [32] – –
Mechanism-based inhibition
CYP3A4 (Kapp; kinact (1/h); fumic) – 0.1; 0.32; 0.91 [29]
Induction 
CYP3A4 (IndC50^ (µM; CV%; fuinc) – 0.5; 30; 1 a
Transporters
OATP1B1 (Ki (µM); fuinc) – 1.4; 1 [30, 20]c
OATP1B3 (Ki (µM); fuinc) – 2.5; 1 [30, 20]c
P-gp (Ki (µM); fuinc) – 0.2; 0.233 [31]
aSimcyp compound library.
bData on file.
cBased on reported Ki for organic anion transporting polypeptide 1B3 (2.5 µM).
CLpo: Oral clearance; CLr: Renal clearance; CV: Coefficient of variation; CYP: Cytochrome P450; fa: Fraction ab-
sorbed; fu: Fraction unbound; fuinc: Fraction unbound in the incubation medium; fumic: Fraction unbound mi-
crosomes; IndC50: The concentration that yields half of the maximum fold induction; ka: Absorption rate constant; 
Kapp: Apparent absorption; Ki: Inhibitory constant; kinact: Maximum inactivation rate; Log P: Partition coefficient; 
P-gp: P-glycoprotein; pKa: Acid dissociation constant; UGT: Uridine 5’-diphospho-glucuronosyltransferase; Vss: 
Volume of distribution at steady-state; Ref: Reference.
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Three virtual populations available in Simcyp correspond to these three CP-classes of 
cirrhotic patients. The virtual populations were based on the demographic, genetic, ana-
tomic, and physiological parameters described in literature. In brief, the parameterization 
of the cirrhotic populations were used: demographics were adapted for cirrhotic patients. 
Because liver cirrhosis is more prevalent in males than in females, so the proportion of 
males was set on 66%. Secondly, decreased liver size is described for cirrhotic patients, 
and thus the availably of functional hepatocytes. Therefore, the liver volume of CP-A, B, 
and C patients was set on 81, 65, and 53% compared with the controls (100%). Important 
for daclatasvir metabolism is the expression of CYP enzymes which alters with increas-
ing severity of cirrhosis. The CYP3A4 activity in the control population was set on 137 
pmol/mg. For CP-A, B, and C patients this was reduced to 80.8, 53.2, and 34.2 pmol/mg. 
Comparable for CYP2C8, the activity in the control population was 24 pmol/mg which 
reduced to 7.9 pmol/mg in CP-C patients. The amount of CYP3A4 in nmol per total gut 
was lowered: from 70 to 59, 40 and 25 for respectively controls, CP-A, B, and C subjects. 
Albumin plasma concentrations were 40 g/L in the control group and declined to 26.3 
g/L in the CP-C patients. Also, alpha1-acid glycoprotein, hematocrit, cardiac output, 
portal blood flow, and glomerular filtration rate (GFR) decreased with severity increasing 
CP-class. Hepatic arterial blood flow and villous blood flow increased with severity of cir-
rhosis. When no data was available on possible changes in physiological and biochemical 
parameters, data from Caucasian healthy volunteers were used[11].
Evaluation of model performance
The performance of the model was checked by visual inspection of the PK curves 
and the simulated PK parameters area under the concentration-time curve (AUC) and 
maximum plasma concentration (Cmax) were compared with in vivo data from literature. 
Acceptance criteria for the model were defined as follows: both the geometric mean of 
Cmax and AUC should not deviate more than 2-fold from the observed PK parameters, as 
is commonly applied in assessing PBPK model performance. We calculated an AUC and 
Cmax-ratio by dividing the simulated data with the observed data. The simulated data 
are presented as geometric mean (GM) with 95% confidence intervals (CI) of both un-
bound and total (bound + unbound) daclatasvir concentrations. The fraction unbound 
(fu) is calculated dividing the unbound concentration with the total concentration.
All the simulated data were compared with in vivo (observed) data available in literature. 
Daclatasvir simulations of single dosages 10 and 100 mg were compared with Wang et 
al[16, 17] and 30 mg with Bifano et al[36]. Multiple dose simulations were compared with 
data from Wang et al[16, 17] (30 and 60 mg). Daclatasvir PK parameters with darunavir/
ritonavir and atazanavir/ritonavir were compared with results from the study of Gandhi 
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et al[37] and Smolders et al[34], respectively. The simulations of daclatasvir in the cirrhotic 
population, were compared with the studies from Bifano et al[36] and Lawitz et al[38]. 
RESultS
Simulation of daclatasvir pharmacokinetics single and multiple dose in 
healthy volunteers
Daclatasvir simulations of single dosages of 10, 30, and 100 mg were done and presented 
in Table 4 and Figure 1. The simulated PK parameters and the shape of the curves for all 
dosages were comparable with the observed in vivo PK results of total daclatasvir in healthy 
subjects[16, 17, 36]. The AUC-ratios varied from 0.74-0.89 and Cmax-ratios varied from 0.93-1.13 
for these three dosages of daclatasvir. These results were within our acceptance criteria.
table 4: Pharmacokinetic parameters calculated from single and multiple dose simula-
tions of daclatasvir. 
Dosage Simulated
AuC 
(h.mg/l)
Ref
AuC
(h.mg/l)
AuC-ratioa Simulated
Cmax 
(mg/l)
Ref
Cmax 
(mg/l)
Cmax-
ratioa
Single dose
10 mg
Total 1.78 
(1.67-1.91)
2.05[16, 17] 0.89 0.22 
(0.21-0.22)
0.20[16, 17] 1.10
Unbound 0.011 – – 0.0013 – –
30 mg
Total 5.36 
(5.01-5.73)
7.29[36] 0.74 0.65 
(0.62-0.67)
0.70[36] 0.93
Unbound 0.033 – – 0.0038 – –
100 mg
Total 17.95
(16.77-19.22)
22.24[16, 17] 0.78 2.16 
(2.08-2.25)
1.92[16, 17] 1.13
Unbound 0.11 – – 0.013 – –
Multiple dose
30 mg
Total 5.43 
(5.06-5.82)
6.27[16, 17] 0.87 0.71 
(0.68-0.75)
0.74[16, 17] 0.96
Unbound 0.037 – – 0.0042 – –
60 mg
Total 10.89
(10.15-11.69)
15.66[16, 17] 0.70 1.43
(1.37-1.49)
1.58[16, 17] 0.91
Unbound 0.073 – – 0.0084 – –
aRatio was calculated as: simulated/reference with an acceptance range of 50-200%.
Reported values are geometric mean with 95% confidence intervals. Healthy volunteer populations, Caucasian, 
age 20-49, 50% females, 6 trials of 14 subjects. Single dose represents 72 hours sampling and multiple dose 380 
hours sampling.
AUC: Area under the concentration-time curve; Cmax: Maximum plasma concentration; Ref: Reference.
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figure 1: Simulations of single dosages 10 mg (A), 30 mg (b), and 100 mg (C) daclatasvir 
in healthy subjects.
Lines: simulations showing total daclatasvir concentrations.
Dashed lines: 95% confidence interval
Data points reflect the observed data by Wang et al[17, 16] and Bifano et al[36].
Healthy volunteer populations, Caucasian, age 20-49, 50% females, 6 trials of 14 subjects. Single dose represents 
72 hours sampling.
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Multiple dose simulations (Table 4, Figure 2) were done and the shape of the PK curve 
and the visual time to reach steady-state concentrations were comparable with the in 
vivo results[16, 17]. The AUC and Cmax-ratio for 30 mg QD daclatasvir were 0.87 and 0.96, 
respectively. For 60 mg QD the AUC-ratio was 0.70 and Cmax 0.94. These results were 
within our acceptance criteria. Bioavailability (F) was simulated at approximately 97% 
for both the single and multiple dose simulations, which was an overestimation as in 
vivo was determined at 67%[2].
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figure 2: last dose intervals of the multiple dosage simulations of 30 mg (A) and 60 mg 
(b) daclatasvir once daily (QD) in healthy subjects.
Lines: simulations showing total daclatasvir concentrations.
Data points reflect the observed data by Wang et al[17, 16].
Healthy volunteer populations, Caucasian, age 20-49, 50% females, 6 trials of 14 subjects.
Multiple dose represents 380 hours sampling.
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Simulation of daclatasvir pharmacokinetics in combination with CYP3A4 
inhibitors in healthy volunteers
To validate the performance of the model, we simulated the interaction with daclatasvir 
at steady-state in combination with darunavir/ritonavir (Table 5, Figure 3a) and atazana-
vir/ritonavir (Table 5, Figure 3b).
The darunavir AUC and Cmax-ratios of 800 mg darunavir in combination with 100 mg 
ritonavir were 1.77 and 1.43, respectively. For ritonavir, these values were 1.47 and 1.12. 
Together with darunavir/ritonavir, the shape of the simulated daclatasvir PK curve was 
comparable with in vivo data[37]. The ratio for AUC and Cmax were 0.63 and 1.43, respec-
tively, for 30 mg daclatasvir QD. 
The atazanavir AUC and Cmax-ratio were 1.05 and 0.73 respectively. For ritonavir, these 
values were 1.11 and 0.43, respectively. Daclatasvir PK parameters with atazanavir/
ritonavir were compared with values obtained from the clinical study by Smolders et 
al[34]. The shape of the curve and value of Cmax were comparable, however the AUC of 30 
mg daclatasvir was more than 2-fold lower (AUC-ratio: 0.37). 
table 5: Pharmacokinetic parameters calculated for 30 mg once daily (QD) daclatasvir in 
combination with 800/100 mg QD darunavir/ritonavir (11 days) and 300/100 mg QD ata-
zanavir/ritonavir (8 days). 
Drug and dosage Simulated
AuC 
(h.mg/l)
Ref
AuC 
(h.mg/l)
AuC-
ratioa
Simulated
Cmax 
(mg/l)
Ref
Cmax 
(mg/l)
Cmax-
ratioa
800 mg darunavir/ 100 mg ritonavir
Darunavir 141.52 80.0[39] 1.77 10.68 7.45[39] 1.43
Ritonavir 8.36 5.69[40] 1.47 0.84 0.75[40] 1.12
Daclatasvir 30 mg
Total 5.22 
(4.56-5.97)
8.29[37] 0.63 0.70 
(0.63-0.77)
0.49[37] 1.43
Unbound 0.082 – – 0.0058 – –
300 mg atazanavir/ 100 mg ritonavir
Atazanavir 58.38 55.56[34] 1.05 3.98 5.46[34] 0.73
Ritonavir 12.65 11.37[34] 1.11 0.82 1.87[34] 0.43
Daclatasvir 30 mg 
Total 5.27 
(4.63-5.99)
14.18[34] 0.37 0.70 
(0.64-0.77)
0.97[34] 0.72
Unbound 0.071 – – 0.0056 – –
aRatio was calculated as: simulated/reference with an acceptance range of 50-200%.
Reported values are geometric mean with 95% confidence intervals. 
Healthy volunteer population, Caucasian, age 20-49, 50% females, 1 trial of 14 subjects.
AUC: Area under the concentration-time curve; Cmax: Maximum plasma concentration; Ref: Reference.
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figure 3: last dose intervals of the multiple dosage simulations of 30 mg once daily (QD) 
daclatasvir in combination with 800/100 mg QD darunavir/ritonavir (11 days, A) and 
300/100 mg QD atazanavir/ritonavir (8 days, b). 
Lines: simulations showing total daclatasvir concentrations. 
• reflect the observed daclatasvir concentrations in the presence of the interacting drugs by Gandhi et al[37] and 
Smolders et al[34]. ° reflect the 30 mg daclatasvir concentrations adapted from Wang et al[16, 17].
Simulation of daclatasvir and midazolam pharmacokinetics in cirrhotic 
patients
Bifano et al[36] published data on 30 mg single dose daclatasvir exposure in non-HCV-
infected CP-A, B, and C patients, which were used as a comparison for the performance 
of our model. The simulated exposure of daclatasvir (for 30 mg single dose) was higher 
than observed exposure (Table 6, Figure 4). With increasing severity of cirrhosis, the 
simulated/observed AUC-ratio of total daclatasvir increased, starting at a ratio of 1.85 in 
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CP-A patients and ending with a ratio of 4.66 in CP-C patients. This was in line with the 
decreasing apparent clearance (CL/F) from the simulated data starting at 24 mL/min to 
9 mL/min in CP-A and CP-C patients, respectively. Along the same line, the in vivo data 
showed CL/F values of 120 mL/min and 108 mL/min in these  patients. Comparable 
results are shown for the unbound AUC values of daclatasvir. Cmax-ratios were 1.74 and 
1.81 for CP-A patients for total and unbound daclatasvir, 1.88 and 1.60 for CP-B patients, 
and 1.99 and 2.45 for CP-C patients, respectively. 
Midazolam simulations were included for comparison purposes as midazolam is only 
cleared via biotransformation, in contrast to daclatasvir which is also being actively 
transported by hepatic drug-transporters. Midazolam exposure was simulated and 
compared with a study of Andersen et al[41]. This study included CP-A, B, and C patients 
who received 15 mg midazolam QD (Table 6). The AUC and Cmax in the cirrhotic patients 
increased with increasing severity of disease and these patients had higher exposure 
than healthy volunteers. The simulated AUC and Cmax for healthy volunteers were 0.22 
h.mg/L and 0.07 mg/L. For CP-A patients the simulated AUC is 0.31 h.mg/L and Cmax 
0.08 is mg/L resulted in a AUC-ratio of 2.03 and a Cmax-ratio of 1.81. CP-B patients had a 
simulated AUC and Cmax of 0.69 h.mg/L and 0.12 mg/L resulting in a AUC-ratio of 1.68 
and a Cmax-ratio of 1.33, respectively. CP-C patients had a simulated AUC of 1.09 h.mg/L 
and a Cmax of 0.14 mg/L resulting in a AUC-ratio of 2.66 and a Cmax-ratio of 1.55.
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figure 4: Simulations of single dosages 30 mg daclatasvir in Child-Pugh class A, b, and C patients.
Lines: simulations showing total daclatasvir concentrations. 
Data points reflect the observed data of Bifano et al[36].
Cirrhotic populations, Caucasian, age 20-49, 50% females, 1 trial of 14 subject
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table 6: Pharmacokinetic parameters for single dosages 30 mg daclatasvir and 15 mg 
midazolam in cirrhotic patients. 
Dosage Simulated
AuC
(h.mg/l)
Ref
AuC 
(h.mg/l)
AuC-
ratioa
Simulated
Cmax 
(mg/l)
Ref
Cmax 
(mg/l)
Cmax-
ratioa
Simulated 
Cl/fb
(ml/min)
Ref
Cl/fb
(ml/min)
CP-A
Daclatasvir
Total 7.74 
(7.72-8.31)
4.17 1.85 0.66 
(0.63-0.69)
0.38 1.74 24 120
Unbound 0.052 0.0256 2.03 0.0042 0.00233 1.81 – –
Midazolamc
Total 0.31 0.41d[41] 0.76 0.08 0.09d[41] 0.88 – –
CP-B
Daclatasvir
Total 14.69 
(13.81-16.20)
4.55 3.23 0.72 
(0.70-0.76)
0.382 1.88 14 110
Unbound 0.127 0.04157 3.05 0.0056 0.00349 1.60 – –
Midazolam
Total 0.69 0.41d[41] 1.68 0.12 0.09d[41] 1.33 – –
CP-C
Daclatasvir
Total 19.85 
(18.23-21.62)
4.649 4.66 0.63 
(0.60-0.66)
0.317 1.99 9 108
Unbound 0.229 0.0401 6.08 0.0066 0.00273 2.45 – –
Midazolam
Total 1.09 0.41d[41] 2.66 0.14 0.09d[41] 1.55 – –
aRatio was calculated as: simulated/reference with an acceptance range of 50-200%.
bCL/F = Clearance of the drug from plasma after oral administration; CL = CLtotal/F and CLunbound/F.
cReference values healthy volunteers: AUC: 0.143 h.mg/L and Cmax: ~0.045 mg/L[42]; simulated values healthy 
volunteers: AUC: 0.22 h.mg/L Cmax: 0.07 mg/L; AUC-ratio: 1.54 Cmax-ratio: 1.55.
dMixed group of patients; CP-A, B, and C.
Cirrhotic populations, Caucasian, age 20-49, 50% females, 1 trial of 14 subjects.
Reported values are geometric mean with 95% confidence intervals. 
CP: Child-Pugh class; AUC: Area under the concentration-time curve; Cmax: Maximum plasma concentration; Ref: 
Reference.
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DISCuSSIon
We evaluated a mechanistic model to predict daclatasvir exposure in healthy subjects 
and patients with CP-A, B, or C cirrhosis.
We were able to adequately recover the exposure in healthy volunteers compared with 
the data from literature. This was the case for both the single and multiple dose simula-
tions and the simulation in combination with the CYP3A4 inhibitors. We must notice 
that both the metabolism by CYP2C8 and canalicular efflux by P-gp in our model, 
were based on sensitivity analysis/fitting as presented in the previously published pa-
pers[16, 17]. These aspects improved the performance of the model. CYP2C8 contributes 
in the model to the metabolism of daclatasvir (CLint = 0.32 µL/min/pmol CYP). It has 
been described that in vitro CYP2C8 has only minor contribution in the formation of 
daclatasvir metabolite M1 and that CYP3A4 is the main metabolizing enzyme (in vitro 
and in vivo)[1]. 
The interactions between daclatasvir and darunavir/ritonavir and atazanavir/ritonavir 
were studied to test the susceptibility of the daclatasvir model for impaired CYP3A4 ac-
tivity. In vivo studies demonstrated the need for combining darunavir/ritonavir with 60 
mg daclatasvir, whereas atazanavir/ritonavir is to be combined with 30 mg daclatasvir. 
This was remarkable as it was expected that both boosted protease inhibitors would 
increase daclatasvir plasma concentrations, resulting in a need for a dose reduction. 
The different influence of darunavir/ritonavir and atazanavir/ritonavir on daclatasvir ex-
posures, is probably caused by  different in vivo ritonavir concentrations (Table 5). When 
ritonavir is combined with darunavir, the Cmax and AUC of ritonavir were ~2-fold lower, 
compared when combined with atazanavir[34, 37]. Another explanation can be that next 
to being a CYP3A inhibitor, darunavir may also induce CYP3A (Table 2).
We were able to simulate ritonavir AUCs adequately with both dosing regimens, al-
though the increased Cmax of ritonavir when combined with atazanavir was not captured 
(Cmax-ratio was 0.43). This is of importance as exposure to the interacting drug clearly 
determines the magnitude of the effect on daclatasvir exposure and we were therefore 
probably not able to capture the different effect on daclatasvir PK by darunavir/ritonavir 
and atazanavir/ritonavir. The interaction studies resulted in a daclatasvir AUC-ratio of 
0.63 and 0.37 and Cmax-ratio of 1.43 and 0.72 when combined with respectively daruna-
vir/ritonavir and atazanavir/ritonavir. Despite the deviations of the simulated daclatasvir 
concentrations with observed values, we considered these simulations to be appropri-
ate for current purposes. 
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The simulations of daclatasvir in the cirrhotic population showed increased daclatasvir 
exposure with increasing severity of cirrhosis, which is in line with the simulated findings 
of midazolam. For midazolam, these findings were comparable with observed clinical 
findings[8, 11, 41, 42]. For daclatasvir the model overestimated the daclatasvir exposure 
compared with observed findings by Bifano et al[36], as exposure decreased in cirrhotic 
patients compared to healthy individuals. When the results of the model are compared 
with another study, also presenting in vivo PK data in CP-A and CP-B patients[38], the 
model also overpredicts exposure. However, these authors showed that for CP-B pa-
tients with HCV infection at steady-state daclatasvir AUC and Cmax were approximately 
1.2-fold higher than these parameters in CP-A patients with HCV infection, an increase 
in plasma concentration which is in the same direction shown by the simulations of 
the model[38]. The evaluation of PK in the study of Lawitz et al, was part of studying 
efficacy and safety of triple therapy with simeprevir, sofosbuvir and daclatasvir[38]. These 
results must be interpreted with care in respect to our simulations, as simeprevir is an 
inhibitor of intestinal CYP3A4 which increases AUC, Cmax, and Cmin of daclatasvir by 96, 
50, and 168% in vivo, respectively[2]. The discrepancies in outcome between the two 
clinical studies hampered the evaluation of our model in cirrhotic patients. Despite 
this, it appeared that predictions for daclatasvir were less accurate than simulation of 
midazolam PK in cirrhotics.
In the study of Bifano et al, 30 mg QD daclatasvir was studied in non-HCV CP-A, B, and 
C patients[36] and the study of Lawitz et al studied 60 mg multiple dose in HCV CP-A and 
CP-B patients. The discrepancy in outcome points out the variation of in vivo studies, and 
shows that non-HCV and HCV cirrhotic patients are a different population. Especially, 
when PK parameters are evaluated we must be careful by extrapolating these results to 
other populations. The differences were previously described by Morcos et al showing 
that the HCV infection itself also has influence on the metabolism of midazolam[43], 
however, in vivo daclatasvir PK was not different in healthy volunteers compared with 
non-cirrhotic HCV-infected patients[2]. So, when we extrapolate non-HCV cirrhotic 
simulations to cirrhotic HCV populations we should take these differences between 
patients into account.
As with drug-metabolizing enzymes, the cause of cirrhosis (e.g., alcohol induced or HCV) 
also has influence on the expression drug-transporters[44, 45]. Daclatasvir is a substrate 
of OCT1, P-gp and other unidentified transporters. It is described that both P-gp and 
OCT are down-regulated (assessed via quantitative proteomics) during HCV induced 
cirrhosis[44]. P-gp is, among others, important for the canalicular efflux of daclatasvir, 
and thus the biliary clearance of the drug and OCT is responsible for the uptake into 
the hepatocyte. 
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However, hepatic transporter expression is not well captured in the cirrhotic patho-
physiological PK model. This may be a contributing factor in the disposition of dacla-
tasvir, but not midazolam, and in line with the fact that the changes in midazolam PK in 
cirrhotic patients were better predicted, whereas the changes in daclatasvir exposure 
were not. Secondly, transporters are of course also located on membranes of cells in 
other organs[46, 47]. As it has been previously described that fibrotic rats have upregulated 
P-gp and CYP expression (mRNA) in the intestine compared with non-fibrotic rats[48]. 
Still, there is only limited and sometimes conflicting evidence for this process which 
makes it difficult to include these aspects in the PBPK model[48, 49]. At the same time this 
stresses the fact that more detailed experimental data on transporter expression across 
various CP classes would be valuable in order to improve predictions.
Note that it is common to use the CP classification system to identify severity of cir-
rhosis. However, this system is based on clinical parameters instead of etiology of liver 
cirrhosis. As said, etiology of the disease (e.g., non-alcoholic steatohepatitis [NASH], 
alcoholic steatohepatitis [ASH], HCV) might differently affect the relevant determinants 
of drug disposition (e.g., transporters, CYPs). Hence, this may result in additional varia-
tion in PK which may add to differences found between the in vivo and in silico findings, 
when the latter are based the characteristics obtained from overall CP-classes, while the 
former are obtained in a patient group with specific disease etiology. 
The EMA describes that PBPK modeling can be a tool for the evaluation of the PK of a 
drug in patients with hepatic impairment. We believe, that PBPK is a valuable tool in 
this population, as these are vulnerable and compromised (especially CP-C) patients 
which you preferably do not expose to a full drug-interaction study. We used Simcyp 
to gather more information about the influence of cirrhosis on the PK of daclatasvir. 
However, with the available cirrhotic model, we were not able to recover in vivo find-
ings due some discussed shortcomings. Clearly, the use of the hepatically impaired 
population in e.g. Simcyp for registration purposes could be useful for hypothesis 
finding and understanding PK of a compound. For other purposes, such as DDI studies 
in healthy volunteers for which the substrates/inhibitors are verified and robust, PBPK 
can be a useful additional tool during drug development. In this respect, predictions 
for drugs that are only subject to biotransformation are generally in better agreement 
with observed PK profiles than we found for daclatasvir, a drug that is also subject to 
active transport.
In conclusion, we were able to adequately model daclatasvir PK in healthy volunteers 
using a PBPK model that included both hepatic metabolism as well as hepatic drug-
transporters. However, there remained a discrepancy between the observed and simu-
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lated daclatasvir exposure in cirrhotic patients. We propose that future studies address 
hepatic and intestinal transporter mediated daclatasvir disposition in more detail, with 
a particular focus on the influence of cirrhosis on transporter expression and function.
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IntRoDuCtIon
Patients chronically infected with hepatitis C virus (HCV) in the Netherlands are treated 
according to a national guideline[1]. This guideline is periodically updated using several 
international guidelines such as EASL[2] and AASLD[3]. Information is given about which 
direct-acting antivirals (DAAs) can be used for which genotype, but also information 
about dose adaptations in renal- and hepatic impairment and drug-drug interactions 
(DDIs) are given. However, it is not possible to treat all patients according to these 
guidelines, for example due to complex DDIs or other special conditions. 
Here, we describe five patients who could not be treated according to the guideline, 
but were all in need of HCV treatment. Knowledge of pharmacology and DDIs were 
necessary to optimally treat these patients. 
SIxty MIllIGRAM DAClAtASVIR IS thE RIGht DoSE foR 
hEPAtItIS C VIRuS tREAtMEnt In CoMbInAtIon wIth 
EtRAVIRInE AnD DARunAVIR/RItonAVIR
Patient and treatment
In May 2015, a 54-year-old Ethiopian man with a 20-year history of HIV infection pre-
sented with progressive pulmonary hypertension and ascites. These symptoms were 
attributed to his liver cirrhosis (Child-Pugh class B [CP-B]; alanine transaminase [ALT] 
37 U/l; aspartate transaminase [AST] 27 U/l; γ-glutamyl transpeptidase [γGT] 54 U/l). 
Cirrhosis was caused by an HCV genotype 4 infection, for which he had been treated 
unsuccessfully with peg-interferon (Peg-IFN) and ribavirin in 2006. Treatment with 
diuretics led to progressive kidney function loss, after which was decided to initiate 
HCV therapy.
The proposed 12-week HCV treatment was a daily regimen containing 400 mg sofosbu-
vir, 800 mg ribavirin, and daclatasvir, in line with international[4] and Dutch guidelines[1]. 
For his HIV infection, he received 400 mg etravirine and 800/100 mg darunavir/ritonavir 
once daily (QD), after experiencing mitochondrial and other toxicity on nucleoside 
reverse transcriptase inhibitor-based combinations. Thus, the HIV regimen could not be 
changed. His HIV viral load was undetectable.
We examined potential DDIs that could arise from both regimens. Etravirine and 
darunavir/ritonavir induce and inhibit cytochrome P450 (CYP) 3A4, respectively, and 
daclatasvir is a CYP3A4 substrate. Experimental studies have shown that daclatasvir 
pharmacokinetics is minimally affected by darunavir/ritonavir, obviating the need for 
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dose adjustment. Co-administration of daclatasvir with etravirine may lead to decreased 
daclatasvir concentrations[5, 6]. Although this has not been shown in humans, the US 
Food and Drug Administration (FDA) advises increasing daclatasvir dose to 90 QD when 
co-administered with etravirine[6]. The normal daclatasvir dosage is 60 QD.
In view of the uncertain interaction between daclatasvir, etravirine, and darunavir/
ritonavir, we started treatment with 60 mg QD daclatasvir reasoning that CYP3A4 
induction by etravirine would be compensated by inhibition of this enzyme by da-
runavir/ritonavir. However, no dose adjustment of daclatasvir is necessary; CYP3A4 is 
inhibited by darunavir/ritonavir. The area under the concentration-time curve (AUC) 
and maximum plasma concentration (Cmax) of daclatasvir decreased with 41 and 23% 
when co-administered, respectively[5].
The pharmacokinetic curve of daclatasvir was recorded on steady-state. Blood samples 
were taken at t = 0 (pre-dose), 2, 6, 8, and t = 24 hours (Ctrough) after daclatasvir intake. 
Plasma concentrations were determined with a validated liquid chromatography-mass 
spectrometry (LC-MS) method and pharmacokinetic parameters were calculated using 
WinNonlin[7]. 
Figure 1 shows the pharmacokinetic curve and parameters of daclatasvir from our 
patient. Cmax and AUC0-tau were 59 and 20% decreased and Ctrough was 11% increased, 
compared with reference values obtained from literature[8]. The elimination half-life 
(T1/2) was 12.6 hours, which is similar to literature[8]. 
The patient completed a 12-week course of treatment and after follow-up sustained 
virological response (SVR12) was achieved in January 2016.
AUC and Ctrough are the most important pharmacokinetic parameters to attain antiviral 
efficacy and both were similar with reference values[9-11]. Ctrough should be high enough 
to maintain viral inhibition throughout the complete dose interval, whereas a decreased 
Ctrough potentially leads to viral failure or induction of resistant strains. 
Cmax was reduced in our patient, which is comparable with a trial describing decreased 
Cmax and AUC in CP-B patients. Additionally, the unbound daclatasvir fraction was 
equivalent between non-cirrhotic HCV and CP-B patients, meaning exposure to 
pharmacological active daclatasvir was unaffected[12]. Extrapolating these results to our 
patient; we believe the patient is treated with the right dose daclatasvir.
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figure 1: Pharmacokinetic curve 60 mg daclatasvir QD in combination with 400 mg etra-
virine QD and 800/100 mg darunavir/ritonavir QD.
Cmax: 707 ng/mL; AUC0-tau: 12,037 h.ng/mL; Ctrough: 284 ng/mL; Tmax: 8.0 hours; T1/2: 12.6 hours. 
Reference values in HCV patients without cirrhosis derived from Nettles et al: Cmax: 1,726 ng/mL; AUC0-tau: 15,121 
h.ng/mL; Ctrough: 254 ng/mL: Tmax: 1-2 hours; T1/2: 12-15 hours[8].
Our pharmacokinetic data suggest that the inducing effect of etravirine can be 
mitigated by darunavir/ritonavir. This is analogous to the interaction between mara-
viroc (CYP3A4 substrate), efavirenz (CYP3A4 inducer), and protease inhibitors (CYP3A4 
inhibitors). Boosted protease inhibitors mitigated the inducing effect of efavirenz on 
maraviroc, and hence the dose of maraviroc should be based on the presence of the 
boosted protease inhibitor[13]. 
Based on the pharmacokinetic parameters and the achievement of SVR12, we believe that 
exposure to daclatasvir was adequate. This fuels our hypothesis that CYP3A4 induction by 
etravirine can be compensated through CYP3A4 inhibition by darunavir/ritonavir. Dacla-
tasvir should be administered in a dose of 60 mg QD when combined with etravirine and 
darunavir/ritonavir.
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EffECtIVE tREAtMEnt of hEPAtItIS C VIRuS InfECtIon wIth 
SofoSbuVIR AnD DAClAtASVIR 90 MG In A PAtIEnt wIth 
SEVERE EPIlEPSy on oxCARbAZEPInE
Patient and treatment
A 63-year-old, treatment-naïve male patient was seen because of a chronic genotype 
1b HCV-infection. He had treatment-resistant epilepsy that ultimately stabilized with 
lacosamide 100 mg two times daily (BID), oxcarbazepine 600 mg three times daily plus 
300 mg before sleeping, and clobazam 5 mg BID.
Liver function test were slightly abnormal with an ALT of 100 U/L and a γGT of 258 U/L. 
Baseline HCV RNA was 1.5x106 IU/mL (RealTime HCV Genotype II, m2000sp instrument, 
Abbot Molecular Inc, Des Plaines, USA). Biopsies showed extensive fibrosis and some 
focal slight cirrhosis. The patient’s METAVIR score was F3-F4.
Potential drug-interactions were checked and all available regimes were contra-indi-
cated with oxcarbazepine. The patient could not switch to another anticonvulsant in 
view of the severity of his epilepsy. After careful consideration, the proposed treatment 
consisted of sofosbuvir, daclatasvir, and ribavirin. 
Oxcarbazepine is a P-glycoprotein (P-gp) and CYP3A4 inducer and is contra-indicated 
with sofosbuvir and daclatasvir because these DAAs are substrates of P-gp and CYP3A4, 
respectively[14, 15]. Therefore, oxcarbazepine potentially decreases daclatasvir and sofos-
buvir plasma concentrations. Reduced levels of DAAs may lead to virological failure 
and/or resistance because they might affect the ability of the drugs to maintain viral 
inhibition throughout the complete dose interval.
Therefore, we increased the daclatasvir dosage to 90 mg (normal dose, 60 mg)[15] based 
on a study with efavirenz, a moderate CYP3A inducer[15]. We did not alter the sofosbuvir 
dosage because only 400 mg tablets were available and we did not want to crush or 
split tablets. Furthermore, the patient had good prognostic factors (e.g., genotype 1b, 
treatment-naïve) and we added ribavirin 500 mg BID (patient weight, 58 kg) to enhance 
the potency of the regimen.
The patient started his 12-week treatment and at steady-state (week 7) an intensive 
pharmacokinetic curve was recorded. Blood samples were taken at t = 0 (pre-dose), 0.5, 
1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, and 24 hours after dosing of daclatasvir and sofosbuvir. 
Plasma concentrations of daclatasvir, sofosbuvir, and the main metabolite of sofosbuvir 
(GS-331007) were determined using a validated LC-MS method[16]. Pharmacokinetic 
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parameters for both DAAs were calculated using Phoenix WinNonlin (Certara USA, Inc., 
Princeton, NJ). 
The AUC, as well as the Cmax and Ctrough, of daclatasvir, were 54, 45, and 37% decreased 
compared with reference values despite the increased dose (Figure 2a). Sofosbuvir 
exposure was comparable with literature; however, Cmax was increased approximately 
three-fold. The AUC and Cmax of GS-331007 were both increased ca. 53% (Figure 2b). 
Lastly, the oxcarbazepine concentration was within references values during treatment 
(19 mg/L; reference: 7-35 mg/L).
During treatment, ALT and γGT decreased to 22 and 85 U/L (week 1) and 14 and 44 
U/L (week 4), respectively. Twelve weeks after finishing DAA treatment, the patient had 
undetectable HCV RNA, meaning that he reached SVR12 (ALT: 16 U/L; γGT: 84 U/L). 
The interaction study between daclatasvir and efavirenz showed that daclatasvir Cmax, 
Ctrough, and AUC were 17, 59, and 32% decreased in combination with efavirenz. To com-
pensate for this reduced exposure, daclatasvir 90 mg is recommended[15]. However, our 
patient had still decreased daclatasvir exposure compared with reference values. This 
suggests that CYP3A4 induction of oxcarbazepine was not completely abolished by in-
creasing the daclatasvir dose to 90 mg[8]. On the other hand, a previous study showed that 
in patients with cirrhosis, daclatasvir exposure was reduced compared with non-cirrhotic 
patients. Also, the unbound (active) fraction of daclatasvir was unaffected[12]. This could 
mean that in our patient the reduced exposure of total daclatasvir fits his cirrhosis, and 
that the unbound fraction of daclatasvir could be adequate. One could also argue that an 
even higher dose should be administered when daclatasvir is combined with moderate 
enzyme inducers (e.g., 120 mg QD or 60 mg BID), but this warrants further studies.
Sofosbuvir is a substrate of P-gp, but GS-331007 is not a substrate of P-gp and therefore 
is not affected by oxcarbazepine[14]. Apparently, in this patient sofosbuvir levels were 
unaffected by oxcarbazepine. This could be explained by the fact that oxcarbazepine is 
a mild/moderate inducer of P-gp. 
This case report suggests that daclatasvir 90 mg and sofosbuvir 400 mg were the correct 
dosages for this patient in combination with oxcarbazepine. Sufficient sofosbuvir concen-
trations were reached, but daclatasvir exposure was reduced in this patient. Alternatively, 
daclatasvir dose could be increased in patients with moderate enzyme inducers. However, 
we advise prescribers to be cautions until this is confirmed with a drug-interaction study. 
Nevertheless, our patient achieved SVR12, so it can be defended to use daclatasvir 90 mg in 
combination with sofosbuvir 400 mg and ribavirin in similar patients.
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figure 2: Pharmacokinetic curve of daclatasvir 90 mg (A) and sofosbuvir and GS-331007 
(b) in combination with oxcarbazepine. Reference curve shows daclatasvir 60 mg and the 
reference values show Cmax of both sofosbuvir and GS-331007.
A: Tmax: 1.4 hours; Cmax: 960: ng/mL; Ctrough: 162 ng/mL; T1/2: 32 hours; AUC0-tau: 7,069 h.ng/mL. 
Reference values and curve adapted from Nettles et al. Daclatasvir 60 mg QD (steady-state concentrations) 
hepatitis C virus (HCV) genotype 1-infected patients without cirrhosis: Tmax: 1-2 hours; Cmax: 1,726 ng/mL; Ctrough: 
254 ng/mL; T1/2: 12 hours; AUC0-tau: 15,120 h.ng/mL[8]. 
B: Tmax: 0.92 hours; Cmax: 1,574 ng/mL; Ctrough: 8 ng/mL; T1/2: 0.48 hours; AUC0-tau: 1,063 h.ng/mL. GS-331007: Tmax: 3.9 
hours; Cmax: 895 ng/mL; Ctrough: 251 ng/mL; T1/2: 39 hours; AUC0-tau: 11,033 h.ng/mL. 
Reference values adapted from Kirby et al. Sofosbuvir 400 mg QD treatment-naïve HCV genotype 1-infected 
subjects without cirrhosis. Sofosbuvir: Tmax: 0.5-1.5 hours; Cmax: 511 ng/mL; AUC0-tau: 1,030 h.ng/mL. GS-331007: 
Tmax: 2-4 hours; Cmax: 582 ng/mL; AUC0-tau: 7,120 h.ng/mL[14]. 
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DECREASED tACRolIMuS PlASMA ConCEntRAtIonS DuRInG 
hCV thERAPy: A DRuG-DRuG IntERACtIon oR IS thERE An 
AltERnAtIVE ExPlAnAtIon?
Patient 1 and treatment
The first patient was a 56-year-old male with a chronic HCV-infection genotype 3. He 
was diagnosed in 2009 and received prior treatment with Peg-IFN and ribavirin but 
failed to respond (2010 and 2011). He rapidly progressed to cirrhosis and end-stage 
liver disease, resulting in a liver transplantation (LT) in 2012. He received 2 mg tacroli-
mus QD (target value: 2-3 µg/L) and 500 mg mycophenolic acid BID. These doses had 
been stable since August 2013. In 2015, he was re-treated for his HCV-infection with 
400 QD sofosbuvir and 600 mg ribavirin BID for 24 weeks. At start of therapy, tacrolimus 
Ctrough was 5.5 µg/L (estimated Glomerular Filtration Rate [eGFR] 61 mL/min), followed 
by a decreased Ctrough of 2.4 µg/L at week 4. This required an increase of tacrolimus 
dosage to 2.5 mg QD. At week 8, the Ctrough was 2.5 µg/L and tacrolimus dosage was 
further elevated to 3 mg QD, resulting in an increased Ctrough of 3.8 µg/L. The dosage was 
subsequently lowered to 2.5 mg QD. 
The patient remained on that dosage during the rest of HCV treatment. The patient reached 
SVR after 12 weeks after completing treatment. His tacrolimus plasma concentration has 
been stable since, and the patient is still treated with a dosage of 2.5 mg QD (Figure 3).
Patient 2 and treatment
Patient 2 was a 74-year-old male with a chronic HCV genotype 1b infection. He was 
treated twice with Peg-IFN and ribavirin (2002 and 2004) and relapsed both times. Cir-
rhosis was diagnosed in 2008 and he developed hepatocellular carcinoma for which he 
received chemoembolization and radio frequent ablation. In June 2010, he underwent 
his first liver transplantation, which was complicated by a grade 2 rejection. A second 
liver transplantation was performed in August 2010. Since his transplantation, he has 
been on mycophenolic acid 1,000 mg BID and tacrolimus 4 mg QD (target value: 5-10 
µg/L). In May 2015, he developed mild ascites and HCV therapy was initiated (eGFR: 60 
mL/min). He received sofosbuvir 400 mg QD, daclatasvir 60 mg QD, and ribavirin 500 
mg BID for 12 weeks. His tacrolimus Ctrough was 17.9 µg/L at start of therapy and had 
decreased to 5.3 µg/L at week two of therapy. His tacrolimus dosage was increased to 
5 mg QD but at week 4 his Ctrough had dropped to 3.1 µg/L and dosage was increased 
again to 6 mg QD. From this moment on, his tacrolimus Ctrough rose gradually to 7.2 
µg/L at the end of therapy (Figure 3). His treatment was complicated due to anemia 
(hemoglobin 6.1 g/dL) necessitating blood transfusions and temporary withdrawal of 
ribavirin. In November 2015, he achieved SVR12.
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figure 3: tacrolimus plasma concentrations and tacrolimus dosages during hepatitis C 
virus (hCV) treatment for patients 1 and 2.
The figure shows the tacrolimus plasma concentration (µg/L) (left y-axis) and the tacrolimus dosage in mg/day. 
The weeks of treatment are shown on the x-axis. Patient 1 was treated for 24 weeks (follow-up data are missing). 
Patient 2 was treated for 12 weeks; follow-up data are shown at week 24. The estimated glomerular filtration rate 
(eGFR) remained stable during treatment in both patients.
DISCuSSIon
This part describes two liver transplant recipients receiving tacrolimus who have been 
treated for HCV successfully. Tacrolimus is a substrate for CYP3A4 and P-gp. It has a 
narrow therapeutic range and pharmacokinetics show a high inter-patient variability 
requiring close TDM with dose adjustment. 
At start of treatment, no DDIs between tacrolimus, sofosbuvir, daclatasvir, and ribavirin 
had been described. However, to maintain target tacrolimus Ctrough plasma concentra-
tions, we found that the tacrolimus dosage had to be increased during HCV treatment. 
This was an unexpected observation, in view of the fact that none of the DAAs influ-
enced CYP3A4, the main metabolizing enzyme of tacrolimus. 
We hypothesize that decreased tacrolimus plasma concentrations resulted from repres-
sion of drug-metabolizing enzymes, such as CYP3A4, by an inflammatory/infectious 
Clinical pharmacology in individual patients
309
13
stimulus. Pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis 
factor-alpha (TNF-α), inhibit CYP3A4 enzymes[17, 18]. This has been studied both in vi-
tro[17, 18] and in vivo and is described in infectious (HIV[19]) and inflammatory (rheumatoid 
arthritis[20]) conditions. Morcos et al[21] found decreased midazolam (CYP3A4 substrate) 
metabolism in HCV-infected patients compared with healthy volunteers. The midazol-
am metabolic ratio for HCV treatment-naïve patients was 37% lower and was even 54% 
lower in null-responders compared with healthy subjects. This is in line with increased 
midazolam plasma levels seen in chronically HCV-infected patients[21].
Additional evidence for this concept comes from trials, which show that the DAAs 
simeprevir and grazoprevir reach higher blood concentrations in HCV patients com-
pared with healthy volunteers[22, 23]. This is also described for the HIV protease inhibitors, 
which are all CYP3A4 substrates[24]. 
Table 1 shows the results of previously published studies showing a similar decrease in 
tacrolimus plasma concentrations during HCV therapy[25-30]. For example, the study of 
Saab et al[25] described that there was a statistically significant decrease in tacrolimus 
daily dose adjusted per weight and tacrolimus serum levels during HCV therapy with 
novel DAAs. In addition, van den Berg et al showed in liver transplant patients with and 
without HCV that patients with recurrent HCV infection after transplantation needed 
a lower dose of tacrolimus as trough levels remained high (20% compared with liver 
transplant patients without HCV)[31]. 
Lastly, tacrolimus plasma concentrations were determined using a validated liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) method with a quantitative 
range of 1.0-25 µg/L. Repeatability varied from 5.7 to 8.2% and reproducibility varied 
from 4.5 to 7.3%. As this is a validated assay with good precision and little variation, we 
believe that the decrease in Ctrough was not caused by any variability of the analytical as-
say. Second, as the plasma concentrations dropped ca. 50%, this was not thought to be 
caused by intra-subject variability of tacrolimus trough levels (coefficient of variation: 
13.4% in healthy subjects[32]).
The current cases are in line with previous reported studies and we argue that before 
DAA treatment was initiated in these two patients, CYP3A4 activity was reduced under 
the influence of the infection. The tacrolimus dosage was titrated under these infec-
tious conditions using TDM. During HCV treatment with DAAs, HCV RNA becomes 
rapidly undetectable (<4 weeks), which is shown in different studies[33]. Similarly, ALT 
decreased quickly in our patients. The ALT level in patient 1 was 40 U/L at the start of 
therapy and was decreased to 31 U/L at week 2 and to 25 U/L at week 12. For patient 
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2, baseline ALT was 41 U/L and decreased to 16 U/L at week 2 (upper limit normal: <45 
U/L). Normalization of the liver enzymes in our patients is undeniably due to clearance 
of the virus and a consequent decrease in liver cell damage. This potentially leads to 
normalized CYP3A4 activity because the infectious stimulus that downregulates CYP 
enzymes becomes absent, resulting in increased metabolism and thus decreased 
tacrolimus plasma concentrations.
In the Netherlands, it is clinical practice to adjust the tacrolimus dosage based on Ctrough 
concentrations. In general, the AUC is a more reliable value for the determination of 
drug exposure. However, the relationship between tacrolimus AUC and Ctrough is still 
under debate and therefore Ctrough is still used in TDM[34].
Novel HCV therapies have become easier and more available. Therefore, we believe that 
awareness among clinicians for the dynamics of tacrolimus levels during DAA therapy is 
necessary. Not only could tacrolimus levels be influenced, but mycophenolic acid levels 
might also be altered, as this is a uridine 5’-diphospho-glucuronosyltransferase (UGT) 
substrate. Other substrates of liver enzymes with narrow therapeutic ranges might also 
require dose adjustments. 
In conclusion, the plasma concentration of drugs that are extensively metabolized by 
the liver might be influenced by DAA therapy even when there is no DDI. We suggest that 
physicians treating patients with DAAs are aware of the dynamics of CYP substrates such 
as tacrolimus. Patients receiving tacrolimus starting with DAA treatment should be closely 
monitored. TDM of tacrolimus is an effective option to monitor the plasma concentration so 
that dosage adjustments can be made.
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table 1: overview from literature. Previously published studies showing a decrease in 
tacrolimus plasma concentration during hepatitis C virus (hCV) therapy.
Author Study design number
of lt 
patients
hCV therapy tacrolimus dose and plasma levels
Saab et al, 
2016[25].
Retrospective 
cohort.
Dosages were 
collected 3 
months before 
DAA therapy 
and 3 months 
after HCV 
therapy.
52 All-oral HCV 
therapy
Total daily dose was decreased in 41%, 
equivalent in 36% and increased in 23% 
when compared before and after start of 
DAA treatment.
Comparable tacrolimus serum levels were 
decreased in 80%, equivalent in 0%, and 
increased in 21% of the patients.
Ueda and 
Uemoto, 
2016[26].
Case series.
Patients treated 
with asunaprevir 
and daclatasvir.
10 Asunaprevir,
daclatasvir
Before DAA treatment: 3.95 ng/mL per mg
Week 1: 5.2 ng/mL per mg
Week 2: 2.975 ng/mL per mg
Five patients needed a dose increase
Raschzok et al,
2016[27],
Cohort 21 Sofosbuvir,
simeprevir/
daclatasvir
±ribavirin
Dose ratios are given.
Start of DAA treatment: 4.68
Week 12: 2.72.
Tacrolimus dose start: 1.8 mg/day
Tacrolimus dose week 12: 1.7 mg/day
Kawaoka et al, 
2016[28].
Case report 3 Asunaprevir,
daclatasvir
Patient 1:
Start dose: 1 mg/day and plasma level: 2.4 
ng/mL
Weeks 4, 8, 12, 16, 20, and 24 
Plasma levels were 3.0, 3.2, 3.4, 3.0, 2.9, 3.3 
ng/mL.
Patient 2: 
Start dose: 1.5 mg/day and plasma level: 
10.9 ng/mL.
Weeks 4 and 8 plasma levels were 5.7 and 
3.4 ng/mL.
Dose increased to 2.0 mg/day.
Weeks 12, 16, 20, 24
Plasma levels were 6.6, 6.4, 6.9, and 5.2 ng/
mL.
Lee et al, 
2010[29].
Case control 35 Peg-IFN alpha 
2a
ribavirin 
(n = 25)
Start of DAA treatment: tacrolimus median 
(IQR) 6.9 (6.0-8.9) ng/mL
End-of-treatment: median (IQR) 3.8 ( 3.6-5.0) 
ng/mL
Dosages adjusted according to AST/ALT.
Fontana et al, 
2013[30].
Case report 1 Daclatasvir, 
sofosbuvir
Tacrolimus dose was not adjusted. 
Plasma concentrations were stable during 
DAA treatment: 4-5 ng/mL.
LT: Liver transplant; DAA: Direct-acting antiviral; Peg-IFN: Peg-interferon; IQR: Interquartile range; AST: Aspartate 
aminotransferase; ALT: Alanine aminotransferase; No: Number.
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thE obSERVED EffECt of GAStRIC byPASS SuRGERy on 
DIRECt-ACtInG AntIVIRAl tREAtMEnt: A CASE REPoRt
Patient and treatment
We describe a 61-year old Brazilian female patient who presented to our outpatient 
clinic in 2011 with chronic HCV genotype 1b infection. She was diagnosed with HCV-
infection in 2008, but the transmission route was unknown. Possible sources of infec-
tion included dental treatment or a caesarean section in Brazil. 
The patient was severely obese with a body mass index (BMI) of 35.4 kg/m2 (weight 
84 kg, height 1.54 meters). Ultrasound demonstrated hepatic steatosis without any 
ultrasonographic signs of cirrhosis. Evaluation of liver stiffness using Fibroscan®[35, 36] 
showed a value of 13.6 kPa, consistent with METAVIR fibrosis score F3 (severe fibrosis)
[37, 38]. A liver biopsy showed moderately active periportal inflammation and moderate 
periportal fibrosis with formation of septae in less than 50% of portal fields (METAVIR 
score A2/F2-3) and macrovascular steatosis in 40-50% of hepatocytes with minimal 
pericellular fibrosis (Brunt score steatosis grade 2, fibrosis stage F1)[39]. Laboratory test-
ing showed mildly elevated liver enzymes with an ALT of 77 U/L, AST of 51 U/L, and γGT 
of 57 U/L. Serum bilirubin, prothrombin time, albumin, creatinine, thrombocytes, and 
fasting blood glucose values were all normal. HCV RNA was 9.56x105 IU/mL and HBsAg 
and anti-HIV 1 & 2 antibodies were negative. 
The patient was a non-responder to treatment with Peg-IFN alfa and ribavirin in 2009. 
In 2013, she was included in a clinical trial and was treated with DAAs daclatasvir and 
asunaprevir for 24 weeks. A relapse occurred after this treatment. 
Whilst waiting for registration and reimbursement of the first DAAs in the Netherlands, 
the patient decided to undergo gastric bypass surgery in 2014 (Roux-and-Y gastric 
bypass). She came back to our outpatient clinic in 2015 for (re-)treatment of the chronic 
HCV-infection. Her weight had reduced to 59 kg (BMI 24.9 kg/m2), and transaminases 
had improved (ALT 48 U/L; AST 39 U/L). Other liver enzymes and liver function tests 
were not altered. HCV RNA load was 5.64 x106 IU/mL and Fibroscan® showed a value of 
7.8 kPa. Sequencing of the viral genome was performed on the regions NS5A and NS3 
(as she had received a NS5A inhibitor and a protease inhibitor), which showed a high 
level of resistance-associated substitutions (RAS) to NS5A inhibitors on the loci L31M/I 
and Y93H. There were no RAS present in the NS3 gene of the viral genome. For these 
reasons, we decided to treat the patient with 400 mg sofosbuvir QD (Sovaldi®, Gilead 
Sciences, Cambridge, United Kingdom), 150 mg simeprevir QD (Olysio®, Janssen-Cilag 
International, Beerse, Belgium), and 1,000 ribavirin per day, for a total of 24 weeks[1, 40, 41].
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Simeprevir and ribavirin in particular must be taken with food for adequate plasma 
concentrations[42]. However, due to the bariatric surgery, the patient was not able 
to eat large meals. To study the exposure of the DAAs and ribavirin in this patient, a 
pharmacokinetic curve was obtained at week 3 of DAA treatment. Blood was sampled 
at t = 0 (pre-dose), 2, 3, 5, 6, 8, and 24 hours after intake of the DAAs. DAA plasma 
concentrations were determined using an in-house made, validated high performance 
liquid chromatography (HPLC)-MS/MS assay. Pharmacokinetic parameters were calcu-
lated using WinNonlin/Phoenix version 6.3, Pharsight Corporation, St. Louis, MO, USA. 
The assay lower limits of quantification for sofosbuvir, GS-331007, and simeprevir were 
2.5 ng/mL, 10 ng/mL, and 10 ng/L respectively. The precision for low, medium, and high 
quality control (QCs) samples was <10% for all analytes. Ribavirin plasma concentra-
tions were determined using validated HPLC assay with ultraviolet detection[43, 44].
At week 3, the AUClast for sofosbuvir was 0.63 h.mg/L, the Cmax was 0.35 mg/L, and the 
Ctrough was 0.0013 mg/L. For the main inactive metabolite of sofosbuvir, GS-331007, the 
AUC0-24 was 21.02 h.mg/L, Cmax was 1.55 mg/L, and the Ctrough was 0.35 mg/L (Figure 4a). 
For simeprevir, at week 3 of treatment, the AUC0-24 was 9.42 h.mg/L, the Cmax was 1.21 
mg/L, and the Ctrough was 0.046 mg/L (Figure 4b). Ribavirin concentration was 2.5 mg/L. 
Sofosbuvir and ribavirin concentrations were considered adequate but simeprevir 
concentrations were subtherapeutic compared with those described in literature[45]. As 
a result, at week 10 of treatment, the simeprevir dose was doubled to 150 mg BID (taken 
together with food). At week 14, trough concentrations of ribavirin and simeprevir were 
determined again and were 0.532 mg/L and 3.5 mg/L, respectively. The hemoglobin 
concentration had dropped from 12.3 g/dL to 9.8 g/dL.
HCV RNA was undetectable during treatment at week 3, 4, 12, 24 (end-of-treatment) 
and 12 weeks after end-of-treatment (SVR12). 
During treatment, the main side effect was extreme fatigue. Liver enzymes, liver func-
tion tests, and renal function were all normal during treatment. Twelve weeks after 
completion of treatment, Fibroscan® showed a value of 4.6 kPa.
For this case report, no formal ethical approval was obtained as all procedures were 
performed for regular health care purposes. The patient did not have to comply with 
certain extra examinations of life style rules. However, the patient gave consent for 
performing the pharmacokinetic curve and publication of this paper. This was recorded 
in the patient chart. 
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figure 4: Plasma concentrations of 400 mg sofosbuvir QD and GS-331007 (A) and 150 mg 
and 300 mg simeprevir QD (b).
A: Sofosbuvir: Ctrough: 0.001 mg/L; Cmax: 0.35 mg/L; Tmax: 2.25 hours; AUClast: 0.63 h.mg/L; T1/2: 0.5 hours. 
GS-331007: Ctrough: 0.35 mg/L; Cmax: 1.55 mg/L; Tmax: 4.91 hours; AUC0-24: 21.02 h.mg/L; T1/2: 10.3 hours. 
Sofosbuvir reference values (400 mg QD treatment-naïve HCV genotype 1-infected subjects without cirrhosis). 
Sofosbuvir: Tmax: 0.5-1.5 hours; Cmax: 0.55 mg/L; AUC0-tau: 1.03 h.mg/L. GS-331007: Tmax: 2-4 hours; Cmax: 582 mg/L; 
AUC0-tau: 7.12 h.mg/L[14].
B: Simeprevir: Ctrough: 0.046 mg/L; Cmax: 1.20 mg/L; Tmax: 3.25 hours; AUC0-24: 9.41 h.mg/L; T1/2: 4.6 hours. 
Week 14: Ctrough: 0.532 mg/L. 
Simeprevir reference values (treatment-experienced patients 150 mg QD): Ctrough: 1.41 mg/L; Cmax: 4.38 mg/L; 
Tmax: 2.03-9.87 hours; AUC0-24: 57.4 h.mg/L[45].
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DISCuSSIon
We are the first to describe a patient who was successfully treated with DAAs includ-
ing an adjusted dose of simeprevir after undergoing gastric bypass surgery. Although 
simeprevir was not deemed ideal in this patient, given the food-dependent uptake, 
there was no alternative due to existing resistance to NS5A inhibitors. 
We treated the patient for 24 weeks, according to national and international guidelines, 
as she relapsed to earlier dual NS3/NS5A DAA therapy[1, 40, 41]. We also tried to enhance 
the potency of the treatment by adding ribavirin (at a weight-based dose). 
According to the simeprevir label, the AUC increases by 60% when administered with 
a fatty meal or normal breakfast[42]. We measured simeprevir Ctrough levels that were 97% 
lower than comparable reference values, and the AUC0-24 was 84% lower. Our patient 
was not able to have large or ‘normal sized’ meals (i.e. a high intake of calories) any-
more and we postulate that this resulted in the extremely low exposure to simeprevir. 
Despite the fact that HCV RNA was undetectable at that time, we doubled the dose of 
simeprevir to increase the plasma exposure and possibly efficacy. This dose was well 
tolerated and the Ctrough plasma concentration at week 14, 4 weeks after doubling the 
dose, was approximately 11-fold higher than the week 3 Ctrough level (62% lower than 
the reference value). This extreme increase is the result of the non-linear pharmacoki-
netics of simeprevir. 
For ribavirin, we strived to attain a plasma concentration of 2.0-3.0 mg/L at steady-
state[46]. At week 3 of treatment the plasma concentration was already 2.5 mg/L, which is 
remarkable as the patient had a low intake of food[47]. These high ribavirin levels caused 
anemia and the patient suffered from extreme fatigue. It was considered to lower the 
dose of ribavirin, but because the hemoglobin levels remained stable throughout 
the whole course of treatment and the patient did not want a dose reduction, so the 
starting dose of 1,000 mg per day was continued. The high plasma concentrations of 
ribavirin (compared to the low plasma concentrations of simeprevir) could also be 
related to the low body weight of <60 kg of the patient after gastric bypass surgery. 
The fact that a large or ‘normal’ meal could not be consumed seems less important for 
an adequate ribavirin level as the initial dose was already relatively high. 
Sofosbuvir pharmacokinetics were not affected by the gastric bypass or the low intake 
of food as the exposure to both sofosbuvir and GS-331007 (the main inactive metabo-
lite of sofosbuvir) were sufficient. This was as expected because it was earlier described 
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that a high-fat meal does not influence the plasma concentration of sofosbuvir or GS-
331007[48].
This case report describes a patient with chronic HCV-infection genotype 1b without liver 
cirrhosis, but with a relapse after earlier dual DAA-treatment, who was successfully treated 
with simeprevir, sofosbuvir, and ribavirin for 24 weeks after undergoing gastric bypass 
surgery. Adequate sofosbuvir and ribavirin plasma concentrations were achieved, however, 
simeprevir plasma concentrations were low when simeprevir was dosed according to the 
drug label (150 mg QD)[42]. Both bariatric surgery and low intake of food can influence drug 
absorption and drug exposure. Awareness is needed when patients who underwent bariatric 
surgery are treated with certain drugs without any experience in this specific condition. This 
is especially the case for simeprevir, as absorption is dependent of food intake; it has non-
linear pharmacokinetics and possibly more severe side effects when given in high dosages. 
Patients with a history of bariatric surgery who are treated with simeprevir should be closely 
monitored using, for example, therapeutic drug monitoring. 
ConCluSIon
A lot of information about the pharmacology of drugs is available when new com-
pounds access the market. However, not every single unique situation has been studied 
and therefore some patients cannot be treated according to (inter)national guidelines. 
An option is to abstain patients in these situations from treatment. However, with good 
cooperation between physicians and pharmacists and knowledge of pharmacology, 
we were able to treat these patients effectively as they all achieved SVR12. Of course, 
this chapter contains experimental data, and therefore, the patients were well informed 
about the risk of their individualized treatment. 
These four case reports were all published in the public domain, so that other health-
care providers can benefit from our experience when they are dealing with a patient in 
a comparable situation.
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GEnERAl DISCuSSIon
The overall objective of this thesis was to address relevant pharmacological issues con-
cerning current hepatitis C virus (HCV) therapy including novel direct-acting antivirals 
(DAAs) and ribavirin. Part 1 focuses on drug-drug interactions (DDIs) with novel DAAs. 
Part 2 discusses the pharmacokinetics (PK) and use of therapeutic drug monitoring 
(TDM) of ribavirin and in Part 3 the use of DAAs in special patient populations is de-
bated. Lastly, Part 4 illustrates the contribution of the expertise of pharmacists in the 
proper use of DAAs by discussing four real-world examples.
This general discussion discusses these four parts combined with future perspectives 
concerning clinical pharmacology for DAAs and HCV therapy. 
Table 1 gives an overview of the aims, main findings, and conclusions of this thesis. 
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table 1: overview of the aims, main findings, and conclusions of the 13 chapters in this 
thesis.
Part Chapter Aim(s) Main findings and 
conclusion
Comments
 D
ru
g-
dr
ug
 in
te
ra
ct
io
ns
 in
vo
lv
in
g 
D
A
A
s
1 •	 Overview of the 
interaction mechanisms 
of DAAs and psychoactive 
agents. 
•	 Overview of DDIs 
between DAAs and 
psychoactive agents.
•	 Identify safe options 
for simultaneous treatment 
of mental illnesses and 
HCV infection.
•	 Only a limited number 
of DDI studies between 
psychoactive agents and 
DAAs are performed.
•	 No studies are done with 
ledipasvir, sofosbuvir, and 
elbasvir.
•	 Safe combinations of 
DAAs and psychoactive 
agents are those without 
any theoretical DDIs or DDIs 
studied in humans.
•	 There is a paucity of 
experimental data on DDIs 
between psychoactive agents 
and DAAs.
•	 More in vivo or in vitro 
interaction studies are 
necessary.
2 •	 To comment  on the 
process of drug licensing 
using the product label 
of velpatasvir/sofosbuvir 
and grazoprevir/elbasvir as 
examples.
•	 There is no clear list of 
strong enzyme inducers 
or inhibitors available and 
there is discrepancy between 
drug labels which of these 
compounds are used.
•	 ‘contra-indicated’, ‘avoid 
use’ or ‘use with caution’ 
are used in the product 
labels, however are these 
recommendations the same?
•	 Only two drugs that are 
listed by the FDA as a drug 
with a narrow therapeutic 
range are discussed in the 
label of grazoprevir/elbasvir.
•	 Of the top 10 most 
frequently used drugs by the 
HCV-infected population, only 
the proton-pump inhibitors 
were mentioned in the labels. 
•	 Is there a need for a 
Consortium for Optimal 
Management of drug-drug 
Interactions in patient Care 
(COMIC)?
3 •	 To evaluate the effect 
of the proposed OCT 
inhibitor daclatasvir on 
the PK and PD of the OCT 
substrate metformin.
•	 Daclatasvir does not 
influence the PK of metformin 
in healthy subjects. 
•	 PD parameters were 
comparable between 
treatments.
•	 The use of PD outcomes 
together with PK outcomes 
remains challenging.
•	 The understanding of 
the role of drug-transporters 
increases however, it must 
become common knowledge 
for pharmacists and 
physicians and implemented 
in daily clinical care. 
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table 1: overview of the aims, main findings, and conclusions of the 13 chapters in this 
thesis. (continued)
Part Chapter Aim(s) Main findings and 
conclusion
Comments
 D
ru
g-
dr
ug
 in
te
ra
ct
io
ns
 in
vo
lv
in
g 
D
A
A
s
4 •	 Determining if 
atazanavir/cobicistat has 
a comparable influence 
on daclatasvir PK as 
atazanavir/ritonavir.
•	 Atazanavir/cobicistat 
and atazanavir/ritonavir had a 
similar influence on daclatasvir 
PK in healthy volunteers. 
•	 Is it possible to predict 
DDIs between comparable 
compounds without any in 
vivo information?
5 •	 Predicting DDIs 
between DAAs and co-
medication used by HCV-
infected patients.
•	 Co-medication use is rich 
in frequency and diversity in 
HCV patients. 
•	 60% of patients are at 
risk for DDIs which may affect 
efficacy or toxicity of DAAs or 
co-medication. 
•	 Many DDIs are predicted 
by the interaction checkers 
and not studied in vivo.
•	 Some DDIs cannot be 
predicted on theoretical 
grounds but do occur in 
clinical practice.
6 •	 Predicting DDIs 
between DAAs and 
non-antiretroviral co-
medication/cART used by 
HIV/HCV-infected patients.
•	 63% of the population 
used non-antiretroviral co-
medication. 
•	 38% of the patients were 
at risk for a DDI between 
DAAs and non-antiretroviral 
co-medication and 75% of the 
patients must alter their cART. 
•	 From the perspective of 
potential DDIs with non-
antiretroviral co-medication 
and/or cART, the most 
favorable regimen seems to 
be sofosbuvir/daclatasvir.
•	 What is the influence 
of all these DDIs on efficacy 
(SVR), HIV viral load, and 
tolerability of co-medication?
7 •	 How do physicians 
manage DDIs 
between DAAs and 
non-antiretroviral co-
medication/cART?
•	 Dutch physicians seem 
well aware of possible DDIs 
and prevent the large majority 
of these.
•	 All patients switch cART 
to non-interacting regimens 
prior to DAA treatment.
•	 Improvement can 
be made for the limited 
number of patients (4/6) who 
continued contra-indicated 
medications.
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table 1: overview of the aims, main findings, and conclusions of the 13 chapters in this 
thesis. (continued)
Part Chapter Aim(s) Main findings and 
conclusion
Comments
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8 •	 Describing the results 
of the first year of the 
ribavirin PT program.
•	 22/28 of the ribavirin 
samples were measured 
accurately.
•	 A part of the ribavirin 
samples measured were 
inaccurate which could 
have clinical consequences. 
For instance, subtherapy or 
unnecessary dose increase. 
9 •	 To assess the influence 
of ribavirin steady-state 
plasma concentrations on 
SVR in HCV patients treated 
with DAAs.
•	 Overall, an SVR-rate of 
89% was achieved.
•	 Multivariable analysis 
showed that ribavirin levels 
are independent predictors of 
SVR.
•	 A steady-state target 
range of 2.3-3.6 mg/L can be 
defined with the novel DAAs.
•	 Do we need to use TDM 
to improve the response rates 
in hard-to-cure patients?
10 •	 Evaluating the 
efficacy and safety of HCV 
treatment with peg-
interferon and ribavirin 
and the PK of ribavirin in 
HIV/HCV co-infected Thai 
patients.
•	 Overall, an SVR-rate of 
56% was achieved.
•	 HIV/HCV patients had 
lower ribavirin exposure 
when compared with mono-
infected HCV patients from 
literature.
•	 To improve response 
rates, do we need to dose 
higher in HIV/HCV patients 
treated with ribavirin?
•	 It is time that oral DAAs 
become available in low and 
middle-income countries.
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table 1: overview of the aims, main findings, and conclusions of the 13 chapters in this 
thesis. (continued)
Part Chapter Aim(s) Main findings and 
conclusion
Comments
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11 •	 Describing treatment 
possibilities in HCV patients 
with hepatic and renal 
impairment. 
•	 All drugs used in HCV 
treatment can be used in 
patients with compensated 
cirrhosis.
•	 All drugs used in HCV 
treatment can be used in 
patients with moderate renal 
insufficiency. 
•	 In patients with GFR ≤29 
mL/min and/or advanced 
liver disease, HCV drugs 
might be contra-indicated or 
dosage adjustments may be 
necessary.
•	 Studies in these special 
populations are challenging 
as these patients are 
vulnerable, however, there 
is a need for information to 
optimally treat these patients.
•	 There is still no answer 
about the use of sofosbuvir in 
patients with decreased renal 
function.
12 •	 Exploring a 
mechanistic model 
to simulate the PK of 
daclatasvir in healthy 
volunteers and cirrhotic 
patients and describing the 
PK of bound and unbound 
daclatasvir in these patient 
populations.
•	 Daclatasvir PK was 
accurately modeled in healthy 
volunteers.
•	 A discrepancy remained 
between the observed 
and simulated daclatasvir 
exposure in cirrhotic patients. 
•	 PBPK modeling is a 
useful tool for understanding 
the PK of drugs; however, 
the use in special patient 
populations needs more 
work. For cirrhotic patients 
we need more information 
about the expression of drug-
transporters.
•	 It is challenging to 
incorporate the influence of 
drug-transporters in a PBPK 
model.
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table 1: overview of the aims, main findings, and conclusions of the 13 chapters in this 
thesis. (continued)
Part Chapter Aim(s) Main findings and 
conclusion
Comments
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13 Patient 1:
Treated with sofosbuvir, 
daclatasvir, plus ribavirin 
while on etravirine and 
darunavir/ritonavir for his 
HIV infection. 
Patient 2: 
Treated with sofosbuvir 
and daclatasvir in 
combination with 
oxcarbazepine for his 
epilepsy.
Patients 3 and 4:
Patients undergoing liver 
transplantations that used 
tacrolimus simultaneously 
with daclatasvir, sofosbuvir, 
and ribavirin. There 
were no DDIs; however, 
decreased tacrolimus 
plasma concentrations 
were reported. 
Patient 5:
A treatment-experienced 
patient with chronic HCV 
infection genotype 1b, 
treated with simeprevir, 
sofosbuvir, and ribavirin 
after a Roux-and-Y gastric 
bypass.
•	 60 mg daclatasvir is the 
right dose in combination 
with etravirine, and darunavir/
ritonavir as the patient 
reached SVR and adequate 
exposure of daclatasvir.
•	 Daclatasvir 90 mg and 
sofosbuvir 400 mg were for 
this specific patient the right 
dosages in combination 
with oxcarbazepine as the 
patient reached SVR, however 
exposure of daclatasvir was 
lower than expected.
•	 Plasma concentrations 
of drugs that are extensively 
metabolized by the liver 
(tacrolimus), might be 
influenced by DAA therapy 
even when there is no DDI. 
•	 The patient was 
successfully treated with 
DAAs after undergoing gastric 
bypass surgery.
•	 Adequate sofosbuvir and 
ribavirin levels were achieved. 
Simeprevir exposure was 
low with a standard dose, for 
which the dose was doubled. 
•	 Despite all the available 
information about DDIs for 
some unique patients, special 
dosages are needed.
•	 More information is 
needed about using strong 
CYP3A4 and P-gp inducers 
in combination with DAAs, 
especially for patients with 
epilepsy.
•	 Rifampicin is not the only 
strong inducer that must be 
studied in phase-I trials.
•	 Physicians treating 
patients with DAAs must 
be aware of the dynamics 
of CYP-substrates, such as 
tacrolimus.
•	 In general, little is known 
about the effects of a Roux-
and-Y gastric bypass on drug 
exposure.
•	 What do we do with drug 
dosing after bariatric surgery?
DDIs: Drug-drug interactions; OCT: Organic cation transporter; HCV: Hepatitis C virus; DAAs: Direct-acting anti-
virals; PT: Proficiency testing; cART: combination antiretroviral therapy; GFR: Glomerular filtration rate; SVR: Sus-
tained virological response; TDM: Therapeutic drug monitoring; PK: Pharmacokinetics; PD: Pharmacodynamics; 
CYP: Cytochrome P450; P-gp: P-glycoprotein; FDA: US Food and Drug Administration.
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DRuG-DRuG IntERACtIonS
In this thesis DDIs are a focus point of discussion. It is important to study DDIs of DAAs, 
as most DAAs are substrates of a large number of drug-transporters and drug-metab-
olizing enzymes. Substrates of enzymes and transporters are prone to be a victim of 
DDIs which might affect the plasma concentration of the substrate. Especially reduced 
plasma concentrations might be a problem in case of the DAAs, since it could possibly 
be that subtherapeutic levels cause therapeutic failure. Secondly, DAAs themselves also 
can influence some of these same drug-transporters and drug-metabolizing enzymes 
which makes them potential perpetrators of DDIs, causing increased or decreased 
plasma concentrations of co-medication (Chapters 5, 6, and 7).
Before drugs are licensed, DDIs are extensively studied, both in vitro and in vivo. 
Drug-metabolizing enzymes and drug-transporters involved in the metabolism and 
distribution of the novel compound are identified in vitro. This in vitro information is, 
among others, used to design DDI studies in humans (in vivo). In addition, DDI studies 
are executed with drugs that are frequently used by the target population. Especially 
the impact and the character of the DDIs are of interest in these in vivo studies.  
In vitro interaction studies
An important aspect of preclinical studies is mapping which drug-metabolizing 
enzymes are involved in the metabolism of a compound, using for example human 
hepatocytes or liver microsomes. These experiments quantify the contribution of a 
certain cytochrome P450 (CYP) or uridine 5’-diphospho-glucuronosyltransferase (UGT) 
enzyme to the metabolism of the compound. Comparably, over expression systems 
can identify possible drug-transporters involved in the disposition of the compound[1]. 
Another important preclinical experiment aims to identify whether a compound is an 
inducer or inhibitor of a certain CYP enzyme. These experiments can be done in human 
hepatocytes measuring the metabolism of a model substrate with and without the 
study compound. Similar studies can be done for drug-transporters. A caveat is that 
experiments studying induction of drug-transporters and enzymes challenging in view 
of the necessity of genetranscription[1].
In vivo interaction studies
In vivo DDI studies (humans) are mostly performed in healthy volunteers giving a good 
impression of the clinical relevance and character of the DDI. These results are used 
to make dose recommendations (increase/decrease) or can even lead to a contra-
indication (do not use simultaneously) for combinations of drugs. Studying DDIs in 
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healthy volunteers (Chapter 3 and 4) gives the researcher the opportunity to control 
parameters such as the use of other co-medication and the existence of co-morbidities. 
However, healthy volunteers are different from the target population, in case of this 
thesis, HCV patients with diabetes (Chapter 3) or HIV/HCV co-infected patients (Chap-
ter 4). For example, drug-metabolism can be altered in patients, resulting in a different 
exposure of a compound when compared with healthy volunteers (Chapter 13). This 
has been described for simeprevir: the exposure of simeprevir was approximately 3-fold 
higher in HCV patients compared with healthy volunteers[2], and this is probably caused 
by altered expression of CYP enzymes and/or drug-transporters. This altered metabo-
lism might also affect the magnitude of a DDI[3]. In addition, healthy volunteers and 
patients have different characteristics such as age, weight, gender, renal, and hepatic 
function, which are known covariates responsible for variation in PK.
In my opinion, the preferable option is to study DDIs in the target population, although, 
it could be unethical to include patients in a DDI study as they can possibly be exposed 
to unnecessary subtherapy or even toxicity. The study with metformin and daclatasvir 
(Chapter 3) could have been conducted in patients with diabetes. However, these 
patients often suffer from many other diseases, making it hard to interpret results as 
there could be many other confounding factors. For example, co-medication used by 
patients would complicate the interpretation of the results of such a DDI study.
The reasoning that supported the design of the interaction study between daclatasvir 
and metformin was that daclatasvir, as an OCT1 and 2 inhibitor might influence the 
excretion of metformin. However, we did not detect a clinically relevant DDI, which was 
bolstered by subsequent published studies showing that the unbound half maximal 
inhibitory concentration (IC50) of daclatasvir for OCT1 and 2, was higher than the in vitro 
maximum plasma concentration (Cmax). One could argue that this DDI study in healthy 
volunteers would have been unnecessary as the IC50 value gave no indication for a 
clinical relevant interaction. However, at time of the study, this information was not 
available in the public domain[4-6]. Now we can state that the in vitro data are consistent 
with the clinical data, which is not always the case.
There are different options to evaluate the outcome parameters (PK values) from an 
in vivo DDI study. Chapter 3 and 4 are randomized, cross-over studies in healthy vol-
unteers. Outcome parameters were evaluated with the bioequivalence approach. This 
approach is most commonly used to determine if the PK profile of a generic drug is 
comparable with the PK profile of a branded drug[7]. Bioequivalence can also be used 
to evaluate DDI studies, resulting in geometric mean ratios (GMR) of PK parameters 
(test versus reference). The GMR must meet acceptance criteria that are defined a priori. 
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In the study protocols of Chapter 3 and 4 it was defined that bioequivalence  was 
established if the GMR, with its 90% confidence interval, was within 80-125%. This range 
of 80-125% takes, among others, the inter-subject variability of the compound into 
account. Of course, for some drugs, for example, with a narrow therapeutic range or 
severe toxicity, other acceptance criteria must be defined.
Drug labels often use a different method when showing interaction data. Frequently 
a percentage increase or decrease in concentration of the substrate in combination 
with the inhibitor or inducer is presented. No acceptance criteria are given. How the 
results from DDI studies are interpreted and presented in the label, is decided by the 
manufactures. This could result in deviating descriptions in the drug labels, which is 
addressed in Chapter 2 of this thesis. For instance, rifampicin causes similar reduced 
exposures of grazoprevir/elbasvir (82%) and velpatasvir/sofosbuvir (90%)[8-11], however, 
the interpretations in the labels are different. The label of grazoprevir/elbasvir lists a 
contra-indication with rifampicin, while velpatasvir/sofosbuvir labels the combination 
with rifampicin as ‘not recommended’. In my opinion, the recommendations should be 
similar and regulatory agencies must be challenged to provide more guidance in these 
situations. 
Which drug-drug interactions must be studied?
Another important question regarding DDI studies is which co-medications must be 
studied in combination with the new drug. A mechanism-based approached is discussed 
earlier. Another approach is to study possible DDIs with frequently used co-medication 
of the target population. Both interaction studies with daclatasvir (atazanavir/ritonavir 
or atazanavir/cobicistat and metformin) are examples of combinations of drugs that 
are frequently used by HCV- or HIV/HCV-infected patients. In Chapters 5, 6, and 7 it is 
presented which drugs are most frequently used by Dutch HCV- and HIV/HCV-infected 
patients. Checking these drugs with the DAA drug labels (January 2017) shows that the 
majority of the top 10 co-medications of both studies are not mentioned in the drug 
labels (Table 2). The label of paritaprevir/ritonavir, ombitasvir with or without dasabuvir 
contains the most information about the listed co-medication.
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table 2: overview of top 10 drugs used by Dutch hCV mono-infected and hIV/hCV co-
infected patients and their presence in the label of the DAA.
  Dacla-
tasvir
[4, 5]
Simepre-
vir
[12, 13]
ledipasvir/
Sofosbuvir
[14, 15]
Paritaprevir/
ritonavir, 
ombitasvir
[16]
Velpatasvir/
sofosbuvir
[10, 11]
Grazoprevir/
elbasvir
[8, 9]
Methadona F/E F/E F/E F/E F/E F/E
Omeprazolea F/E F/E F/E F/E F/E  
Pantoprazolea   E E   E F/E
Oxazepamb            
Hydrochlorothiazideb            
Metforminb       E    
Temazepamb            
Paracetamolb       E    
Salbutamolb            
(Es)citalopramb F/E F/E   F/E    
Calcium supplementsc            
Salbutamolc            
Sulfamethoxazole/
Trimethoprimc
      E    
Valaciclovirc            
Metoprololc       E    
Diazepamc       E    
Lisinoprilc            
aIn top 10 of both mono and co-infection patients.
bIn top 10 of mono-infected patients.
cIn top 10 of co-infected patients.
F: US Food and Drug Administration; E: European Medicine Agency.
It is of particular interest that the drugs listed in the labels are not always comparable 
for US Food and Drug Administration (FDA) and European Medicine Agency (EMA). 
Additionally, in vivo DDI studies have not been performed for all listed co-medications. 
DDIs can be predicted based on the known characteristics of a compound, but can also 
be extrapolated from a DDI study with a drug in the same class. This was for example 
done for the benzodiazepines as Chapter 1 of this thesis describes. However, to which 
extent the results of drugs within a class can be extrapolated is uncertain, especially 
if you take DAAs as an example. For instance, the DDI profile of the NS5A inhibitors 
daclatasvir and ledipasvir are different.
Almost all labels have inserted information of a DDI study with omeprazole (proton 
pomp inhibitor [PPI]). For example, ledipasvir and velpatasvir are dependent on a low 
intra gastric pH for its solubility and therefore acid-reducing agents, such as the PPIs 
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and H2-antagonists, could influence absorption. The European label of ledipasvir states: 
‘PPI doses comparable to omeprazole 20 mg can be administered simultaneously 
with Harvoni® (ledipasvir/sofosbuvir). PPIs should not be taken before Harvoni’ and 
‘H2-receptor antagonists may be administered simultaneously with or staggered from 
Harvoni at a dose that does not exceed doses comparable to famotidine 40 mg twice 
daily’[14]. 
These are also fine examples where the information of a specific drug is extrapolated to 
the total drug class (PPIs and H2-antagonists). In this case, the extrapolation is right as 
all drugs that decrease gastric pH, decrease the solubility of ledipasvir. 
The statement about the acid-reducing agents in the label of ledipasvir/sofosbuvir 
raises a number of questions: 1) What is an equivalent dose of 20 mg omeprazole or 40 
mg famotidine? 2) What if patients use a PPI twice daily? 3) What if the patient uses a 
dosage of 40 mg omeprazole?
As these questions emerged in clinical practice, we tried to enhance the information 
from label. Here, we show our contribution as pharmacists to optimize DAA therapy, by 
translating the information in the drug label to practical recommendations concerning 
ledipasvir and PPIs[17]. 
1. If possible, discontinue the PPI a few weeks prior to ledipasvir treatment.
2. If discontinuing the PPI is not possible: use only 20 mg once daily omeprazole 
together with ledipasvir.
3. If PPI dosages cannot be adapted, switch to another DAA regimen.
The most important question is still unanswered: does a possible reduced ledipasvir 
plasma concentration affect efficacy (sustained virological response [SVR])? This is a 
discussion in the scientific community, and the debate is ongoing[18-20]. 
A last topic I would like to discuss in this section is the interaction between the DAAs and 
strong CYP3A4 and P-gp inducers oxcarbazepine (Chapter 13) and carbamazepine. 
Oxcarbazepine and carbamazepine are used for the treatment of epilepsy and it the 
estimated that in 2010 there were 84,000 epilepsy patients in the Netherlands. About 
50% of these patients were treated with carbamazepine in 2009 (44,000)[21-23]. Patients 
treated with oxcarbazepine and carbamazepine are excluded from HCV treatment as 
these drugs are (strong) CYP3A4/P-gp inducers, and therefore the plasma concentra-
tion of all DAAs decreases when combined (CYP3A4/P-gp substrates). 
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This was among others shown by a DDI study between carbamazepine and parita-
previr/ritonavir, ombitasvir, and dasabuvir showing a decrease in AUC of 31% for pari-
taprevir and 70% for both ombitasvir and dasabuvir. The other DAAs are not studied 
in combination with carbamazepine, and therefore the contra-indication is based on 
studies with rifampicin. Rifampicin is also a strong inducer of CYP3A4 and P-gp, and it 
significantly reduces the plasma concentration of all DAAs[4, 8, 10, 12, 16, 24, 25]. 
This boils down to a clinical issue: how do we treat epilepsy patients that are not able 
to switch their carbamazepine or oxcarbazepine therapy? As there is a paucity of data, 
physicians are struggling how to treat these patients. Therefore, the HepNed (hepatitis 
C Nederland; http://www.hepned.nl) initiative started to collect data on efficacy, safety, 
and PK of patients that are experimentally treated with strong inducers (carbamaze-
pine) and DAAs. The first patient treated with oxcarbazepine and daclatasvir/sofosbuvir 
is discussed in Chapter 13. Four other patients were recently treated with carbamaze-
pine in combination with an increased dose of daclatasvir (60 mg two or three times 
daily [BID or TID]) and 400 mg sofosbuvir. These patients were treated with 1) 400 mg/
day carbamazepine; 60 mg daclatasvir BID and 2) 1,000 mg/day carbamazepine and 60 
mg daclatasvir TID; 3 and 4) 1,200 mg/day carbamazepine and 60 mg daclatasvir TID. 
So far, patient 1 and 2 reached SVR and had daclatasvir trough plasma concentrations 
of approximately 0.1 mg/L, which is 50% lower than previously described[4, 5]. One must 
consider that these are preliminary results and more patients need to be included in 
this study. For now, no recommendations can be formulated.
HepNed is a research cooperation between all academic centers in the Netherlands 
and all disciplines involved in HCV treatment joined: hepatologists, infectious diseases 
specialists, microbiologists, and pharmacists. In my opinion, collaboration between 
these specialists is key to exchange knowledge and to coordinate nationwide research. 
This will probably improve research and answer questions from which patients eventu-
ally will benefit. 
Management of drug-drug interactions
The interaction checkers from the University of Liverpool (http://www.hep-druginter-
actons.org and http://www.hiv-druginteractions.org) are useful tools for the manage-
ment of DDIs and frequently used by physicians, nurse specialists, and pharmacists. 
These websites are part of three chapters in this thesis and contains information about 
possible DDIs between DAAs, cART, and other co-medications. Over 600 drugs are 
available and every combination of drugs is accompanied by an advice:
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• Green: No interaction expected.
• Yellow: Potential interaction, likely to be of weak intensity where additional action/
monitoring or dosage adjustment is unlikely to be required (added to the website 
February 2017).
• Amber: Potential interaction, likely to require additional monitoring, alteration of 
drug dosage or timing of administration.
• Red: Contra-indication; do not co-administer.
The management of DDIs becomes much easier with the use of this tool. Also other 
sources for DDI checking are available online, for example the Epocrates application or 
Fungal Pharmacology. These websites and applications have in common that they are 
developed by pharmacologists to improve the knowledge of DDIs among healthcare 
professionals. Also, pharmacists can use it for medication monitoring. However, part of 
the displayed interactions are predictions, based on what is known of the metabolic 
profile of the drugs, and thus not based on in vivo DDI data. It is simply not feasible to 
study all possible DDIs (costs, time). Consequently, these tools fill in a gap of missing in-
formation. However, the indicated DDIs are not checked by any regulatory agency and 
one could argue how reliable these tools are? I think that these tools are very reliable 
and the recommendations are as evidenced-based as possible, using all information 
available in the public domain: product labels, publications, and poster presentations. 
Still, anybody using these websites must always interpret the information by them-
selves, as the results of the interaction checkers are usually ‘general’ recommendations, 
which must be adapted for an individual patient.
Especially, in case of the ‘amber’ interactions on the websites of the University of Liver-
pool. These DDIs can often be avoided and this is where the pharmacist comes to the 
aid of physicians. Pharmacists can interpret the data presented, give alternatives for 
interacting drugs, or can explain the interaction mechanism. This is where pharmacists 
do best and where they really can contribute to optimize pharmaceutical care of HCV-
infected patients treated with DAA therapy. Two examples where we contribute to 
the treatment of HCV patients with complex DDIs are described in Chapter 13. With 
knowledge of pharmacology and good collaboration with the physicians, we were able 
to treat the patients safely and successfully resulting in clearance of the virus.
As indicated before, many DDIs can be predicted on the basis of already available 
information. There are a number of notable exceptions. There appears to be a DDI of 
daclatasvir/ledipasvir with sofosbuvir and amiodarone[26-30]. The DDI led to mortality 
and this outcome was not predicted and incompletely understood. These examples 
show that despite the fact that the scientific community, manufacturers, and regulatory 
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agencies do their best, DDIs are sometimes unpredictable. Studying novel compounds 
focuses mainly on absorption, metabolism, distribution, and elimination of drugs. How-
ever, Back and Burger suggested that the combination of highly protein-bound drugs 
(DAAs and amiodarone), could have caused this interaction by protein displacement, 
resulting in temporarily increased unbound amiodarone plasma concentrations[28]. It 
may be necessary to study highly protein-bound drugs in more detail. Or must we 
deal with the fact that with the introduction of novel drugs there will always be safety 
concerns, which we must reduce if possible? In my opinion, we must accept that we 
simply do not know everything at the time of drug licensing.
RIbAVIRIn PhARMACoKInEtICS AnD thERAPEutIC DRuG 
MonItoRInG
The exact mechanism of action of ribavirin against the HCV virus remains unclear, but 
as it is a guanine analogue it is expected to interfere with the RNA synthesis of the 
virus. Ribavirin is metabolized through two pathways: 1) a reversible phosphorylation 
pathway; 2) a degradative pathway involving deribosylation and amide hydrolysis to 
yield a triazole carboxyacid metabolite. Because no CYP enzymes are involved, ribavirin 
is not prone to be involved in ‘metabolic’ DDIs. Ribavirin has an absolute bioavailability 
of 45-65%, and this reduced availability is probably caused by first pass metabolism 
and/or saturation of the uptake transporters in the intestine (N1 sodium-dependent 
nucleoside transporters)[31, 32]. Ribavirin accumulates in erythrocytes leading to a volume 
of distribution of 5,000 L, but it does not bind to any plasma proteins. Both ribavirin and 
its metabolite are renally excreted[33].
Combining treatment of peg-interferon (Peg-IFN) and ribavirin (duo-therapy) increased 
response rates compared with Peg-IFN alone (~48 versus 38%, respectively[34-36]). Add-
ing ribavirin reduces among others the risk on viral relapse after treatment[37]. Chapter 
10 describes an HIV/HCV co-infected cohort of Thai patients who were treated with 
Peg-IFN and ribavirin. SVR-rate was 56%, which is comparable with previously published 
studies of genotype 1 and 3 HIV/HCV co-infected patients treated with duo therapy[38]. 
Ribavirin remains part of current DAA therapy. It is recommended to add ribavirin to 
DAAs to increase SVR-rates or to shorten treatment duration[39, 40]. This is particularly 
true for patients with genotype 1a and 3, in patients with cirrhosis, or patients who 
are treatment-experienced. However, other promising DAAs show in phase-II/III studies 
high cure rates in difficult-to-cure patient populations, possibly reducing the need for 
ribavirin in HCV therapy. 
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Chapter 9 shows the importance of ribavirin concentrations in a Dutch cohort treated 
with DAAs and ribavirin. Ribavirin steady-state concentration was a predictor for SVR 
and a therapeutic range of 2.3-3.6 mg/L was defined. The relationship between SVR 
and ribavirin concentration remain controversial, both in combination with Peg-IFN 
and DAA treatment, as conflicting results are published[41-48]. These inconsistent results 
might be caused by differences in treatments, heterogeneity of populations, variation 
in analytical assays, and small sample sizes. 
Ribavirin meets a number of criteria for TDM. For example, it has a high inter-subject 
variation and a low intra-subject variation, which is confirmed in Chapter 9 and 
10[33, 46]. This means that it is hard to predict what the plasma concentration for an 
individual patient will be, but once you know the ribavirin plasma concentration at 
steady-state, the variation within that patient is small (without any dose adjustments 
and stable renal function). 
Secondly, analytical assays are available for determination of ribavirin plasma concen-
trations. Chapter 8 describes the results of a first-year proficiency testing (PT) program. 
These PT programs are important for the quality control of methods developed by 
laboratories. However, not all participating laboratories were able to accurately deter-
mine ribavirin plasma concentrations. Samples were accurately measured when they 
were within 80-120% of the spiked (weighed-in) ‘expert’ concentration. Previously pub-
lished studies showed that methodological problems, technical problems, or clerical 
errors could explain the deviating results[49]. It is of importance that the reported value 
is accurate because pharmacists and clinicians rely on these values for their clinical 
decision making. In my opinion, pharmacists (laboratories) must strive to measure 
ribavirin samples and interpret results as soon as possible, because of the relatively 
short HCV treatment time (12-16 weeks) and possible lack of effect/adverse events can 
be prevented.
The added value of TDM in ribavirin treatment has never been established through a 
randomized controlled trial. The preferred trial design would be one with two random-
ized groups in a multicenter setting. One patient group will be treated with ribavirin 
and dosages will be adjusted based on TDM results; the other group will be treated 
with ribavirin and no TDM is performed. The efficacy and safety results of both groups 
can be compared to show if TDM is beneficial, in terms of higher efficacy (higher SVR-
rates) or less toxicity (less anemia). Probably, this kind of trial will not be conducted as 
efficacy rates of current DAA treatment with or without ribavirin is over 90%. 
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Because we do not have these kinds of studies, we must decide whether we would 
use TDM in patient care. In my opinion, TDM of ribavirin could be useful, especially 
since Chapter 9 shows that in a large prospective cohort adequate ribavirin levels 
were an independent predictor of SVR. So, I believe that physicians must aim to achieve 
a steady-state ribavirin plasma concentration of at least 2.3 mg/L (when tolerated). 
Patients who are nowadays treated with ribavirin are the patients that are hardest to 
cure: patients with liver cirrhosis, resistance-associated substitutions (RAS), genotype 
1a or 3 infection, or those who have failed prior antiviral therapy[37]. Therefore, we must 
balance efficacy with safety. Subtherapy is a risk for patients that are treated with a 
normal dose of ribavirin with the absence of toxicity. It could be that these patients 
have adequate exposure, but it could also be that the ribavirin plasma concentrations 
are not high enough. Using TDM helps tracking down patients with subtherapy fol-
lowed by a ribavirin dosage increase. Another option is to dose based on toxicity. In 
other words, anemia is the dose-limiting factor. With this strategy, also extreme plasma 
concentrations could occur, causing severe anemia with even an indication for blood 
transfusion. Due to the long elimination half-life of ribavirin, plasma concentrations will 
slowly drop in these cases which cannot be accelerated by dialysis. Additionally, dosing 
on toxicity is not an option for vulnerable patients, such as patients with renal impair-
ment and the transplant patients. These patients should be closely monitored and they 
must start with a reduced ribavirin dose according to AASLD guidelines[40]. 
SPECIAl PAtIEnt PoPulAtIonS
After discovery of a potential effective compound (a drug), this compound is extensively 
studied by the manufacturer. The first part of development is the pre-clinical phase, us-
ing in vitro experiments unraveling the characteristics of a drug (e.g., antiviral potency, 
mechanism of action). Next, the studies continue in humans and we can distinguish 
four phases. 
1) First in human trials. Depending on the type of drug, but mostly done in little groups 
of healthy volunteers. During this phase dose finding and safety of the compound 
are main subjects of interest.
2) First in patient trials. Efficacy and safety of a compound are studied in a selected 
target population. In addition, DDIs and dose-response is studied. This is usually a 
small number of patients (<100).
3) Large patient trials (>100 patients) which are used to monitor efficacy and safety 
and compare the treatment with the current standard of care. Again, selected 
patients are included.
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These three phases are needed for market authorization; however, we can add a last 
phase of drug development: 
4) Post approval trials, which are conducted to further evaluate efficacy and safety of a 
compound.
Special patients discussed in this thesis are mainly hepatic and renal impaired patients 
(Chapter 11 and 12). There is no consistency of the data that becomes available about 
the use of these drugs when the DAAs were approved. For instance, in the drug label of 
simeprevir, PK data was available for non-HCV cirrhotic subjects (Child-Pugh (CP) class 
A, B, and C). However, efficacy and safety data are not available for cirrhotic HCV pa-
tients[12]. Another example, patients with an estimated glomerular filtration rate (eGFR) 
below 30 mL/min, patients on hemodialysis, or with end-stage renal disease were not 
discussed in the labels of sofosbuvir, velpatasvir/sofosbuvir, and ledipasvir/sofosbuvir, 
but data is available for daclatasvir, simeprevir, and grazoprevir/elbasvir[4, 8, 10, 12, 14, 25]. 
The efficacy and safety data for these patient groups becomes mostly available during 
post approval studies. Studying these patient groups is important as patients with he-
patic or renal impairment could have altered PK as these two organs are important for 
the metabolism and excretion of drugs (Chapter 11 and 12). Subsequently, patients 
with severe disease might have higher plasma concentrations of some drugs, as there 
could be decreased excretion/metabolism, causing more toxicity. This is relevant for 
HCV-infected patients, as they are at risk for developing cirrhosis and/or declined renal 
function.
As efficacy, safety, and PK data in special patient populations is sometimes missing or 
insufficient, physicians thus treat these patients off-label and based on little informa-
tion. Because they are in need of treatment the risk on a possibly unknown event is 
taken. This may have severe consequences as we have seen with the combination of 
paritaprevir/ritonavir, ombitasvir with or without dasabuvir. After registration, the FDA 
warned for serious liver injury in patients with advanced disease with this combina-
tion[50]. This safety issue was probably caused by the protease inhibitor (paritaprevir). 
The safety and efficacy of this combination was only studied in CP-A patients (PK data 
was available for CP-A/B/C patients[51, 52]), but in real-life the combination of drugs was 
used in patients with more advanced liver disease. 
Often, PK data obtained in pre-approval trials comes from non-HCV cirrhotic patients. 
As discussed above, PK of DAAs can be different between HCV and non-HCV cirrhotic. 
For drugs that are likely to be used in cirrhotic patients (DAAs), a possibility to gather 
more PK information, is to combine PK with safety and efficacy studies. For example, 
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by including cirrhotic patients in phase-III and/or phase-IV trials. Full PK curves could 
be obtained (non-compartmental analysis) or limited sample strategies can be used. 
These samples can be evaluated using population pharmacokinetic modeling. Another 
tool to understand the PK of a compound better in cirrhotic patients is compartmental 
analysis (for example physiology-based pharmacokinetic [PBPK] modeling). This is de-
scribed in Chapter 12, where a cirrhotic model available in Simcyp was used to simu-
late the exposure of daclatasvir in CP-A, B, and C patients[53]. The simulated daclatasvir 
plasma concentrations were not in line with in vivo results. In my opinion, the cirrhotic 
Simcyp model can be useful for all kinds of drugs in explaining and understanding the 
PK of a compound in the cirrhotic population, however improvements of the model 
are needed. These improvements include transporter expression in cirrhotic patients 
and a more physiological classification instead of the use of the CP classification system. 
Patients with decompensated cirrhosis remain hard to treat, but there are several safe 
DAA options. However, it is unknown what the right timing for treatment is, before or 
after transplantation? When treated, these patients can be cured, without improvement 
in hepatic function. A total of 17% of the decompensated patients had an unchanged 
model for end-stage liver disease (MELD) score and 23% of the patients had a wors-
ened MELD score after DAA therapy. The MELD score is used as an indicator for liver 
transplantation (MELD >15). So, we can cure decompensated patients from HCV, but 
treatment may worsen the hepatic disease with risk on further complications. Most pa-
tients (60%), however, had improved MELD scores. The median improvement in MELD 
is +2 points, which means that patients could lose their indication for a transplantation 
(MELD <15) but are still at risk for progression of their liver disease and hepatocellular 
carcinoma[54]. When to treat these patients is under debate. In the Netherlands, we aim 
to treat patients who are on the waiting list before transplantation[17]. 
Patients with renal insufficiency can be treated safely and effectively with paritaprevir/
ritonavir, ombitasvir, with or without dasabuvir or with grazoprevir/elbasvir[16, 24,55]. For all 
the sofosbuvir combinations, efficacy, safety, and PK data in patients with eGFR <30 mL/
min are still pending[10, 14, 25]. However, there are some studies indicating that sofosbuvir 
can be safely and effectively used in patients with all degrees of renal insufficiency[56-61]. 
Ribavirin remains a drug that is difficult to dose in these patients. Ribavirin and its main 
metabolite are primarily eliminated through the kidneys and with decreasing renal 
function the clearance of ribavirin decreases[33]. The Dutch guidelines recommends to 
start with a weight-based loading dose and to adapt the daily dose to 200-400 mg 
dependent on the renal function (eGFR <50 mL)[17]. Despite this advice, Chapter 9 
shows that this is not always done in these patients resulting in anemia and further 
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dose reductions as a consequence. TDM can definitely help optimize ribavirin dosing 
for these patients. In addition, applications such as MwPharm, Dose Me, and InsightRX 
could be helpful, because these programs use population PK models of a compound in 
combination with TDM results and patient characteristics to predict PK in an individual 
patient. These predictions help finding the right dose.
Of course, there are also other special populations who might be treated with DAAs and 
for whom no efficacy, safety, or PK data is available. Two examples are given in Chapter 
13. The patient with gastric bypass surgery had decreased simeprevir exposure when 
treated with 150 once daily (QD). Therefore, the dose was increased to 300 QD. Opti-
mal DAA exposure is important for two reasons 1) subtherapy could cause treatment 
failure and possibly RAS and 2) supratherapy could cause toxicity. The minimum target 
concentration (Cmin), or another PK parameter we must achieve to accomplish SVR and 
to avoid RAS is unknown. Therefore, for all the case reports in this thesis, the area under 
the concentration-time curve (AUC) and Cmax of comparable patient populations were 
used to determine whether the exposure was adequate. Other special populations that 
might be treated for HCV in the future, but without data available are for example: chil-
dren (except ledipasvir/sofosbuvir[62, 63]), pregnant women, and obese patients. Previous 
studies from our department show that dose adaptations in these populations might 
be necessary to accomplish the correct exposure of drugs[64-78].
A PhARMACISt’S ContRIbutIon to ERADICAtE hEPAtItIS C
The four case reports in Chapter 13 present the actual contribution of our work as 
pharmacists to the eradication of HCV. As discussed previously in this general discus-
sion, these patients all needed extra attention prior to DAA treatment. Due to the 
extensive knowledge of (HCV) pharmacology and good collaboration with physicians 
we were able to treat and cure these patients. 
Of course, most of these treatments were off-label and based on predictions rather 
than on evidence, so, together with the treating physicians, we had to make risk assess-
ments prior to treatment initiation. In my opinion, this kind of cooperation between 
physicians, nurses, and pharmacists really improves therapy as DDIs are managed or 
other (experimental) treatment options are evaluated.
For example, the patient with a gastric bypass was an interesting but complex patient 
to treat. Especially in view of the altered absorption together with RAS. I believe that 
these kinds of case reports add significant value to the scientific community and must 
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be published to give insight to these treatments for physicians and pharmacists, be-
cause these cases, represent the gaps in our knowledge. 
ERADICAtIon of hEPAtItIS C VIRuS 
At the end of 2016, the Dutch government released a national plan to reduce transmis-
sion, morbidity, and mortality caused by the hepatitis viruses, using five themes: aware-
ness, identification, diagnostics and adequate treatment, improved organization of the 
chain of care and improved surveillance, and monitoring of HCV in order to gain insight 
in the cascade of care. This strategy focuses on six risk groups: immigrants, children of 
HCV-infected parents, men who have sex with men, (ex)drug users, sex workers, and 
patients who received blood products[69]. 
This strategy is the first step towards eradication of HCV in the Netherlands. Important 
for eradication of HCV is that we must identify all infected patients, as individuals might 
be unaware of their infection. Therefore, screening is advised for the six risk groups. Sec-
ondly, everybody diagnosed must have access to care, treatment must be affordable 
and easy[70]. Probably, in high-income countries we can achieve most of these aspects. 
In the Netherlands identification of the patients is the limiting step in this process. The 
costs of DAAs are also high (see introduction) and under debate. The Dutch Minister of 
Health has negotiated special price arrangements with the pharmaceutical companies, 
which resulted in non-transparent prices, but making all DAAs available for all HCV 
patients.
For governments in low and middle-income countries eradication of HCV will probably 
be much harder to achieve, which is contradictory because most HCV-infected patients 
live in these countries[70]. The costs of the DAAs influence the accessibility to treatment 
around the world. Thai patients (Chapter 10) are still treated with inferior therapy re-
sulting in lower response rates than HIV/HCV co-infected patients treated with DAAs in 
high-income countries. There are several initiatives advocating for reducing the costs. 
For example, in Egypt a combination of ravidasvir and sofosbuvir is developed and will 
be marketed for ~$300[71]. Another example is the use of parallel import of (generic) 
DAAs which first started in Australia, because DAAs were unavailable (http://www.
fixhepc.com). 
We must mention that the costs of DAAs varies extremely among low, middle, and 
high-income countries, which was shown by Andrieux-Meyer et al[72]. Generic sofos-
buvir is available for $343 in Egypt and in India the price of sofosbuvir varies from 
~$160 to $312 (patent sold by Gilead). However, branded sofosbuvir in Malaysia costs 
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$18,000 which is even higher than in some high-income countries. Sofosbuvir was 
the best available DAA throughout the low and middle-income countries questioned. 
The availability of generic sofosbuvir in some of these countries is a result of licensing 
agreements between Gilead and generic companies[72].
Except pricing, other aspects mentioned in the Dutch national plan are also of impor-
tance. One thing that is already achieved is that treatment of HCV is very effective and 
easy. With the introduction of the fixed-dose combination velpatasvir/sofosbuvir, all 
patients can be treated without the need for genotyping when this product is reason-
ably priced and available. NS5A RAS could also be important, especially for genotype 
3, when treatment-experienced patients are re-treated. These patients can for example 
be re-treated with ledipasvir/sofosbuvir (genotype 1, 4, 5, and 6) or velpatasvir/sofos-
buvir with ribavirin for 24 weeks[40]. Other promising studies are done with sofosbuvir, 
velpatasvir, and voxilaprevir, which is a pan-genotypic regimen showing SVR-rates of 
96% in NS5A experienced patients (41% cirrhosis[73]). Also, other manufactures have 
presented data on novel compounds showing high SVR-rates in difficult-to-cure 
patients. For example, glecaprevir/pibrentasvir for compensated genotype 1 and 3 cir-
rhotic patients (SVR 96%)[74]. All these developments and other novel compounds will 
probably result in easier, cheaper, and even more effective therapy, possibly without 
the need for ribavirin. This all will hopefully contribute to the target of the World Health 
Organization to eliminate HCV as a global treat 2030[75]. 
With the introduction of all these highly effective drugs, choices must be made. For 
example, which DAAs are going to be used for which patients? In my opinion, phar-
macists can help in selecting the most suitable regimen for each individual patient 
by interpreting the information from the drug labels. Not only based on efficacy and 
safety but also considering drug-interactions, contra-indications, co-morbidities, and 
recommendations considering special populations. 
ConCluDInG REMARKS
The aim of this thesis was to address pharmacological issues concerning current HCV 
therapy including novel DAAs and ribavirin, which can be used for the optimization of 
HCV treatment. The first part of this thesis focuses on DDIs and showed that patients un-
dergoing DAA treatment are at risk for DDIs. In addition, this part shows that the Dutch 
infectious disease specialists are keen on preventing DDIs. This second part discusses 
the pharmacokinetics and the role of ribavirin in combination with DAA and Peg-IFN 
therapy. The third part of thesis focused on the use of DAAs in patients with renal and 
hepatic disease. With these chapters and the general discussion, the contribution of a 
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pharmacist towards more understanding of the pharmacology of DAAs and ribavirin is 
shown. This will hopefully improve DAA therapy in the future. 
This thesis is finalized with five examples of individual patients that were treated with 
DAAs. These patients all received individualized treatments with DAAs. Adaptations 
were made to therapy, trying to increase the chance of reaching an SVR. These cases 
are the icing on the cake of this thesis and examples of: a pharmacist’s contribution to 
eradicate hepatitis C.
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SuMMARy
IntRoDuCtIon
The hepatitis C virus (HCV) is an RNA virus which replicates in the hepatocyte. Therefore, 
HCV causes liver inflammation and damage which can eventually lead to cirrhosis. HCV 
is transmitted through blood-blood contact and the main risk populations are men who 
have sex with men, patients that received blood products in the past, or intravenous 
drug users. Nowadays, HCV can be treated with direct-acting antivirals (DAAs). These 
oral drugs are highly effective and >95% of the patients treated with these DAAs clear 
the virus. At least two DAAs are combined for the treatment with a duration varying 
from 6 to 24 weeks. Most commonly used regimens are: daclatasvir + sofosbuvir, and 
the fixed-dose products ledipasvir + sofosbuvir, velpatasvir + sofosbuvir, grazoprevir + 
elbasvir, and paritaprevir/ritonavir, ombitasvir, and dasabuvir. 
The first selection criterion for a DAA regimen is the HCV genotype (1-6). Other factors 
influencing the regimen of choice are: whether the patient is treatment-experienced 
(e.g. resistance); the patient has cirrhosis; or if there are any drug-drug interactions 
(DDIs). Because DAAs are substrates/influencers of several drug-transporters and drug-
metabolizing enzymes they are known to cause drug-interactions. Part 1 of this thesis 
focuses on these DDIs with the DAAs. 
Ribavirin is an antiviral drug (not an DAA) that is added to DAA therapy in patient popu-
lations that are hard-to-cure such as patients with cirrhosis, treatment-experienced 
patients, or patients with genotype 1a or 3. Ribavirin is added to improve treatment 
response and to shorten treatment duration. Part 2 discusses the pharmacokinetics of 
ribavirin and the use of therapeutic drug monitoring (TDM) for ribavirin.
Part 3 focuses on special patient populations, such as patients with renal and hepatic 
impairment. These conditions can influence the pharmacokinetics of a drug and there-
fore may lead to dose alterations or increased awareness when treating these patients.
Part 4 describes the contribution of a pharmacist to the eradication of HCV by present-
ing four case reports about patients with special DDIs or adjusted DAA treatment.
The overall aim of this thesis was to answer pharmacological issues concerning current 
HCV therapy including novel DAAs and ribavirin, which can be used for the optimization of 
HCV treatment.
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PART 1:  
Drug-drug interactions involving direct-acting antivirals
Chapter 1 is a review describing DDIs between DAAs and psychoactive medications. 
Mental disorders are highly prevalent in chronic HCV patients. Therefore, these two 
classes of drugs are likely to be combined. Chapter 1 starts with an overview of the 
metabolism of both DAAs and psychoactive agents. Subsequently, the DDI studies per-
formed between DAAs and psychoactive agents are presented. This information was 
combined and used to predict safe options for the simultaneous treatment with DAAs 
and psychoactive agents. We discussed that escitalopram and citalopram have been 
studied with most DAAs and either drugs can be safely combined with HCV treatment. 
Sofosbuvir and ledipasvir are not studied with any psychoactive agents, but based on 
their metabolism we expect no DDIs with most psychoactive agents. Simeprevir and 
the combination of paritaprevir/ritonavir plus ombitasvir with dasabuvir are most likely 
to cause drug-interactions via the inhibition of cytochrome P450 (CYP) 3A4. Therefore, 
caution is needed when CYP3A4 substrates such as midazolam and/or quetiapine are 
co-administered with these DAAs. The conclusion is that the number of in vivo DDI 
studies between DAAs and psychoactive medicines is small and that theoretical predic-
tions of DDIs must be backed with actual in vivo studies.
Chapter 2 is a commentary on how informative drug labels are concerning DDIs. 
These labels are the first source for DDI information when new drugs are marketed. 
Often information is missing (as not everything can be studied before market access) or 
statements in the labels are unclear. Chapter 2 discusses four aspects where the labels 
could be more informative using the labels of velpatasvir + sofosbuvir and grazoprevir 
+ elbasvir as an example.
1. In case a new drug is a CYP3A substrate, with which CYP3A inducers is an interac-
tion mentioned in the label?
2. In case of interaction with CYP3A inducers, when will this lead to a contra-indication 
or labeled as ‘not recommended’; is this the same or not?
3. In case a new drug is a (moderate) CYP3A inhibitor, which CYP3A substrates with a 
narrow therapeutic range are listed in the drug label?
4. New drugs are usually tested with relevant co-medication in the target patient 
population, but how is this set of ‘relevant’ medication selected?
The potential DDI between metformin (diabetes mellitus type 2) and daclatasvir (DAAs) 
is described in Chapter 3 and studied in healthy volunteers. The aim of this study was to 
evaluate the effect of the proposed organic cation transporter (OCT) inhibitor daclatas-
vir on the pharmacokinetics and pharmacodynamics of the OCT substrate metformin. 
A total of 20 subjects received 1,000 mg metformin (treatment A) followed by 1,000 mg 
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metformin and 60 mg daclatasvir (treatment B). Pharmacokinetic curves were recorded 
at steady-state. Geometric mean ratios (GMR) with 90% confidence intervals (CI) of met-
formin area under the concentration-time (AUC) 0-12, maximum plasma concentration 
(Cmax), and last plasma concentration (Clast) (B versus A) were 109% (102-116%), 108% 
(101-116%), and 111% (103-120%). This showed that daclatasvir does not influence the 
pharmacokinetics of metformin in healthy subjects. Pharmacodynamic parameters 
were also comparable between treatments. 
Chapter 4 studies whether the fixed-dose combination of atazanavir/cobicistat 
has a comparable influence on daclatasvir pharmacokinetics as the separate agents 
atazanavir and ritonavir. Atazanavir is an HIV protease inhibitor that is boosted with 
CYP3A4 inhibitor ritonavir. When combined with the CYP3A4 substrate daclatasvir, 
the daclatasvir dosage should be reduced from 60 mg to 30 mg once daily. Recently, 
cobicistat was licensed as a CYP3A booster and used in combination with atazanavir. It 
was unknown whether atazanavir/cobicistat had comparable influence on daclatasvir 
exposure as atazanavir/ritonavir. This interaction study was performed in 16 healthy 
volunteers receiving 300/100 mg atazanavir/ritonavir in combination with 30 mg da-
clatasvir once daily (treatment A), followed by, 300/150 mg of atazanavir/cobicistat plus 
30 mg daclatasvir once daily (treatment B). The GMRs (90% CI) of daclatasvir AUCtau and 
Cmax (B versus A) were 101% (92-111%) and 97% (89-106%), respectively. We showed 
that atazanavir/cobicistat and atazanavir/ritonavir had a similar influence on daclatasvir 
pharmacokinetics in healthy volunteers. Daclatasvir at 30 mg once daily is the correct 
dose when combined with atazanavir/cobicistat.
Chapter 5 studies the risk on DDIs in HCV patients. We predicted the number of DDIs 
with co-medication used by HCV mono-infected patients. We assembled a nationwide 
cohort of HCV patients and collected cross-sectional data on co-medication use. This 
data was used to cross-check for potential DDIs between DAAs and used co-medication 
using the database of the University of Liverpool (http://www.hep-druginteractions.
org). Four DDI categories were defined: (1) no clinically relevant DDI; (2) possible DDI; 
(3) contra-indication; or (4) no information available. We defined category 2 and 3 as 
clinically relevant DDIs. We found that 77% of the 461 patients used co-medication. 
Antidepressants (7.4%), proton pump inhibitors (7.1%), and benzodiazepines (7.1%) 
were most frequently used. We predicted that 60% of the patients were at risk for a 
clinically relevant DDI with at least one of the available DAA regimens. Interactions were 
most common with paritaprevir/ritonavir, ombitasvir ± dasabuvir and least interactions 
were predicted with grazoprevir/elbasvir.
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Chapter 6 described a comparable experiment with HIV/HCV co-infected patients 
from the Netherlands. Information from the ATHENA observational HIV database was 
used. This is a database including all Dutch HIV-infected patients (except if they opt 
out). Patients with an HIV/HCV co-infection at 1 January 2015 were selected and a list of 
non-antiretroviral co-medication and combination antiretroviral therapy (cART) regis-
tered in the ATHENA database was compiled. The potential for DDIs between DAAs and 
co-medication/cART was predicted, using the database of the University of Liverpool. 
A total of 777 HIV/HCV co-infected patients were included of whom 63% used non-
antiretroviral co-medication and 98% were treated with cART. At risk for a category 
2/3 DDI with non-antiretroviral co-medications were 38% of the patients. Concerning 
cART, daclatasvir + sofosbuvir is the most favorable combination as no cART is contra-
indicated with this combination. In genotype 1/4 patients grazoprevir/elbasvir is least 
favorable as 75% of the patients must alter their cART. 
In Chapter 5 and 6, the number of DDIs is predicted and it was shown that ~50% of 
the patients were at risk for a DDI when treated with DAAs. In Chapter 7 we mapped 
how physicians manage these DDIs between DAAs and co-medication including cART. 
Again, the ATHENA cohort was used to select HIV/HCV co-infected patients treated 
with DAAs between January 2015 and May 2016. Interactions were checked using 
the database of the University of Liverpool. Subsequently, analysis was performed to 
determine whether the cART regimen was changed and co-medication discontinued. 
A total of 423 patients were included, of whom 418 (99%) were treated with cART. Of 
these patients 251 (59%) used non-antiretroviral co-medication. Before commencing 
DAA treatment, in 17/84 (20%) patients the non-antiretroviral co-medications, which 
would result in a category 2 or 3 DDI, were discontinued before DAA initiation, includ-
ing 2/6 (33%) prescriptions of category 3 drugs. 
196/418 (47%) patients had a category 2/3 DDI between their DAA regimen and cART. 
Category 2 and 3 DDIs were prevented by switching cART in 78/147 (53%) and 47/49 
(96%) patients, respectively. 367/423 (87%) patients have reached SVR (33 in follow-up). 
We found that the DDIs did not influence the HIV viral load and all patients with a 
clinically relevant DDI achieved SVR. In addition, combined treatment with ledipasvir 
+ sofosbuvir and a proton pump inhibitor, did not influence SVR. We concluded that 
Dutch physicians are well aware of potential DDIs with DAAs, in particular when it con-
cerns cART. Improved awareness is needed for non-antiretroviral co-medication and 
DAA category 3 interactions. 
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PART 2: 
Ribavirin pharmacokinetics and therapeutic drug monitoring
Ribavirin is added to DAA therapy to increase efficacy rates in hard-to-cure patients. 
These patients are among others cirrhotic patients, treatment-experienced patients, or 
patients with genotype 1a or 3.
Ribavirin has a strong concentration-effect relationship, and TDM of ribavirin can be 
used to individualize the dose of ribavirin. Therefore, several laboratories developed 
ribavirin assays. To ensure the accuracy of these bioanalytical methods and to alert lab-
oratories to previously undetected problems an international external quality control 
(QC) or proficiency testing (PT) program for measurement of ribavirin is developed. In 
Chapter 8 we described the results of the first year of this ribavirin PT program (2015). 
Per round two samples were dispatched (2 rounds in total) to the participating labora-
tories. For these samples, bovine serum was spiked with low and high concentrations of 
ribavirin. These samples were freeze-dried and measured by the laboratories. Accuracy 
was considered to be acceptable if measurements were within the 80-120% limits of 
the spiked (weighed-in) ‘expert’ concentrations. Eight laboratories participated in the 
program of which only two participants completed one round. In round 1, 81% of the 
samples (i.e. 13 out of 16 samples) were determined accurately and the variation in ac-
curacy of samples with low concentrations was 86-336%. The samples spiked with high 
ribavirin concentrations varied from 55-160% in accuracy. In round 2, a total of 75% 
samples (i.e. 9 out of 12) were determined accurately within 80-120% of the weighed-in 
concentrations. Accuracy for samples with low and high concentrations varied from 
97-303% and 97-148%, respectively.
The aim of a PT program is to provide external validation of bioanalytical assays to 
assure and improve quality. The laboratories with a poor performance should improve 
their analyses. 
Chapter 9 describes the association between ribavirin steady-state plasma concentra-
tions and SVR in the DAA era. Therefore, HCV patients were included who were treated 
with DAAs and ribavirin in four academic centers in the Netherlands. At steady-state 
(at least week 8 of treatment) ribavirin plasma concentrations were determined. A total 
of 183 patients were included of which the majority was treated with daclatasvir and 
sofosbuvir. The mean ribavirin start dosage was 13.6 mg/kg/day, which was decreased 
to 13.1 mg/kg/day at week 8. The median week 8 ribavirin plasma concentration was 
2.66 mg/L. Multivariable analysis showed that a higher ribavirin plasma concentration 
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was a predictor of SVR. We defined a therapeutic range of 2.28 to 3.61 mg/L. A total of 
89% of the patients reached SVR.
Chapter 10 describes an HIV/HCV co-infected population from Thailand that was 
treated with peg-interferon alfa and ribavirin. With this therapy, HIV/HCV co-infected 
patients have lower response rates than with DAAs. A total of 101 patients were in-
cluded of whom 56% reached SVR. Ribavirin steady-state plasma concentrations (week 
8 of treatment) were 1.81 mg/L and we calculated an inter-subject variability of 29% 
and intra-subject variability of 18%. Patients with anemia (hemoglobin <10 g/dL) had 
higher ribavirin plasma concentrations throughout treatment than patients without 
anemia. However, at week 24, due to dose adaptations ribavirin plasma concentrations 
were comparable in these two groups. No difference in ribavirin plasma concentrations 
was found for patients with and without SVR.
PART 3: 
Treatment of HCV in special patient populations
HCV replicates in the liver and can therefore cause liver inflammation and cirrhosis, which 
is often complicated by renal impairment. Chapter 11 is a review where we describe 
the treatment possibilities in HCV patients with hepatic and/or renal impairment. Dose 
adaptations could be necessary as cirrhosis alters the structure of the liver, which affects 
drug-metabolizing enzymes and drug-transporters. These modifications influence the 
plasma concentration of substrates of drugs metabolized/transported by these enzymes. 
Comparable, drugs that are eliminated by the kidneys might need dose adjustments in 
patients that have decreased renal function. We found that cirrhotic patients with Child-
Pugh class (CP) A can be treated with all DAAs, but that patients with decompensated 
cirrhosis (CP-C) are harder to treat. All drugs used in HCV treatment can be used in pa-
tients with moderate renal insufficiency (Glomerular Filtration Rate [GFR] ≥30 mL/min). 
Grazoprevir + elbasvir can be used in patients with severe renal impairment; ledipasvir 
+ sofosbuvir and velpatasvir + sofosbuvir are both not recommended in patients with 
severe renal impairment as data is still lacking. However, some evidence is available that 
patients with renal insufficiency tolerate a normal dose of sofosbuvir. 
Chapter 12 describes a physiology-based pharmacokinetic (PBPK) model of daclatasvir 
pharmacokinetics in healthy volunteers and cirrhotic patients. Unfortunately, we were 
not able to mimic in vivo exposure with our model in cirrhotic patients. With increasing 
severity, the AUC-ratio of daclatasvir increased, varying from ~2-fold to ~5-fold increase 
in CP-A and CP-C patients. We argue that this issue might be caused by altered intesti-
nal and hepatic transporter expression in cirrhotic patients which was not captured in 
the model. We proposed future studies that must address these issues in more detail.
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PART 4: 
A pharmacist’s contribution to eradicate hepatitis C
Chapter 13 describes four case reports of individual HCV patients treated with DAAs. 
All had adjusted DAA treatment or something unexpected occurred during DAA treat-
ment. With this chapter, we showed the added value of a pharmacist in the treatment 
of HCV patients. 
The first patient was effectively treated with 60 mg daclatasvir in combination with 
etravirine and darunavir/ritonavir. Etravirine is an inducer of CYP3A4 and darunavir/
ritonavir an inhibitor to the same enzyme. In combination with etravirine the dacla-
tasvir dose must be increased to 90 mg, but with darunavir/ritonavir the normal dose 
of 60 mg must be given. Therefore, we treated this patient with 60 mg, as we believed 
that induction of CYP3A4 was mitigated by the inhibition of CYP3A4. Fortunately, the 
patient achieved SVR.
The second patient was treated with oxcarbazepine for epilepsy, which is a strong 
inducer of CYP3A4. As no DDI studies are available, it is unknown what the right dose 
of daclatasvir and sofosbuvir should be. We treated the patient with 90 mg daclatasvir 
in combination with normal dose sofosbuvir. This was effective as the patient reached 
SVR; however, the daclatasvir exposure was somewhat low so caution is needed when 
treating patients with strong inducers.
Thirdly, two patients were described that both had a liver transplantation in the past 
for which they were treated with tacrolimus. During DAA therapy there was a need to 
increase the dose of tacrolimus. There is no DDI between the DAAs and tacrolimus, but 
we hypothesized that the plasma concentration of tacrolimus decreased due to nor-
malization of CYP enzyme activity. Tacrolimus is metabolized by CYP3A4 and we argued 
that patients with HCV have decreased CYP expression. By clearing the HCV virus, there 
will be a normalization of CYP activity, which results in lower plasma concentrations of 
CYP substrates. 
The last patient was a female that underwent a gastric bypass before DAA therapy. 
The patient was treatment-experienced and had resistance-associated substitutions. 
Therefore, the only treatment available was simeprevir plus sofosbuvir with ribavirin. 
We obtained a pharmacokinetic curve of simeprevir, showing decreased plasma con-
centrations. This resulted in an increased simeprevir dose of 300 mg a day. Exposure 
increased and the patient reached SVR. 
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GEnERAl DISCuSSIon
In the general discussion four parts of the thesis are discussed. The discussion starts 
with DDIs: how are DDI studies designed for new compounds (in vitro to in vivo) and 
which drugs must be studied in combination with the new compound. Secondly, the 
use of (online) interaction checkers was discussed in respect to management of drug-
interactions in daily practice. In addition, it is discussed how pharmacist could help in 
managing these DDIs.
Ribavirin pharmacokinetics and the use of TDM for dose adjustment are discussed. 
Especially, TDM of ribavirin remains under debate. We argue that ribavirin is added to 
therapy in the hardest to cure patients and TDM can help to treat these patients opti-
mally, as the dosages can be individualized based on the ribavirin plasma concentra-
tion (decreased or increased). Especially for patients that do not experience any toxicity 
TDM can be useful. 
Lastly, we discuss the use of novel compounds in special populations, focusing on 
patients with renal and hepatic impairment. We discuss that HCV genotype 1 and 4 
patients with renal impairment can be treated with grazoprevir + elbasvir but ribavirin 
treatment remains difficult. Also for these patients, ribavirin TDM could be useful. Sec-
ondly, data are lacking for the sofosbuvir-containing regimens, making patients with 
renal failure and other HCV genotypes harder to treat. 
Compensated cirrhotic patients can be safely treated with most DAAs, however for 
decompensated patients there is a treatment paradigm. When do we need to treat 
these patients? Before or after liver transplantation? The timing could be essential for a 
patient; however, this issue is still under debate. 
The general discussion is finished with a section on what is needed for the eradica-
tion of the HCV virus. First step is to identify the patients, followed by access to care 
and treatment. As treatment remains to be expensive this could be a limiting factor. 
However, some pricing agreements are made which improved the availability of the 
DAAs in low and middle-income countries. 
The discussion of this thesis is ended with a statement that all the chapters in this 
thesis, but especially the chapters concerning the individual patients are examples of a 
pharmacist’s contribution to eradicate hepatitis C.
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SAMEnVAttInG
IntRoDuCtIE
Het hepatitis C-virus (HCV) is een ribonucleïnezuur (RNA) virus dat zich vermenigvuld-
igt in de lever (levercel [hepatocyt]). Doordat het virus zich vermenigvuldigt in de lever 
veroorzaakt het een ontsteking en schade aan de lever. Dit kan uiteindelijk leiden tot 
levercirrose, wat uiteindelijk een indicatie kan zijn voor levertransplantatie. 
HCV is een virus dat wordt overgedragen via bloed-bloed contact, vergelijkbaar met 
het hiv of het hepatitis B-virus. Risicogroepen zijn dan ook mensen die in het verleden 
een bloedtransfusie hebben ondergaan, mensen die intraveneus drugs spuiten, of 
mannen (voornamelijk hiv positieve) die onveilige seks hebben met mannen. 
Door de recente ontwikkeling van uiterst effectieve orale geneesmiddelen, is HCV te 
genezen. Deze geneesmiddelen worden de direct-acting antivirals (DAAs) genoemd. 
Gemiddeld genomen wordt meer dan 95% van de behandelde patiënten genezen. 
De behandeling bestaat altijd uit een combinatie van minimaal twee DAAs. De meest 
voorkomende behandelcombinaties zijn: daclatasvir + sofosbuvir, ledipasvir + sofosbu-
vir, velpatasvir + sofosbuvir, grazoprevir + elbasvir, en paritaprevir/ritonavir, ombitasvir, 
en dasabuvir.
De behandeling is onder andere afhankelijk van het HCV-genotype (genotype 1 tot 
en met 6 en verschillende subtypen). Dit komt doordat niet alle DAAs voldoende 
werkzaam zijn tegen alle genotypen. Andere factoren waar men rekening mee dient 
te houden bij het kiezen van een DAA-regime zijn onder andere: falen van eerdere 
behandeling, de mate van levercirrose en het gebruik van andere medicatie in verband 
met geneesmiddel-geneesmiddel interacties. De DAAs worden gemetaboliseerd door 
verschillende enzymen, maar de DAAs beïnvloeden zelf ook deze enzymen. Door deze 
beide mechanismen zijn de DAAs betrokken bij geneesmiddel-geneesmiddel interac-
ties. Deze wisselwerking tussen geneesmiddelen kan leiden tot een verminderde 
werkzaamheid of tot extra bijwerkingen. Het eerste deel van het proefschrift gaat over 
geneesmiddel-geneesmiddel interacties met HCV-medicatie.
Het tweede deel van het proefschrift wordt de behandeling met ribavirine besproken 
in combinatie met DAAs, evenals of de hoeveelheid ribavirine in het bloed invloed 
heeft op de genezing van het virus. Ribavirine is een oud geneesmiddel, maar wordt 
vandaag de dag nog steeds toegevoegd aan de behandeling met de DAAs. Dit wordt 
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voornamelijk gedaan om de kans op genezing te vergroten bij patiënten met levercir-
rose, patiënten bij wie eerdere behandeling heeft gefaald, of patiënten met genotype 
1a of 3. Dit zijn patiëntengroepen bij wie het virus moeilijk is uit te roeien. Tevens kan 
door het toevoegen van ribavirine de behandeling worden verkort: 12 weken ten 
opzichte van 24 weken behandeling.
Het derde deel van dit proefschrift beschrijft het gebruik van de DAAs en ribavirine 
in speciale populaties. De twee populaties die uitgebreid worden besproken, zijn 
patiënten met verminderde leverfunctie en patiënten met verminderde nierfunctie. 
Beide organen zijn betrokken bij de eliminatie (verwijdering) van geneesmiddelen uit 
het lichaam. Wanneer de lever en nieren minder goed werken, kunnen geneesmid-
delen zich anders gedragen in het lichaam. De concentratie van een geneesmiddel in 
het bloed kan bijvoorbeeld toe- of afnemen wat weer invloed heeft op bijvoorbeeld de 
werkzaamheid of de toxiciteit (bijwerkingen) van geneesmiddelen.
In het laatste deel van het proefschrift wordt ingegaan op vijf speciale patiënten. 
Twee patiënten hadden ingewikkelde interacties, twee patiënten hadden een lever-
transplantatie ondergaan en één patiënt had bariatrische chirurgie (maagverkleining/
gastric bypass) ondergaan. Bij al deze patiënten waren apothekers betrokken om de 
behandeling te optimaliseren.
Het doel van dit proefschrift is om farmacologische vragen met betrekking tot de huidige 
HCV-behandeling te beantwoorden, zodat de behandeling kan worden geoptimaliseerd.
DEEL 1: 
Geneesmiddel-geneesmiddel interacties
Geneesmiddel-geneesmiddel interacties ontstaan wanneer twee of meer geneesmid-
delen tegelijkertijd worden gebruikt door een patiënt. Er is sprake van een interactie 
indien er een wisselwerking tussen twee geneesmiddelen is. Door deze wisselwerking 
kan de geneesmiddelconcentratie in het bloed stijgen, waardoor de kans op bijwerkin-
gen toeneemt. De geneesmiddelconcentratie in het bloed kan ook lager worden. Dit 
kan mogelijk ook leiden tot onder behandeling (sub therapie). hoofdstuk 1 is een 
review waarin geneesmiddelinteractie onderzoeken tussen de DAAs en psychoactieve 
medicatie wordt beschreven. Psychoactieve medicatie wordt veel gebruikt door HCV-
patiënten aangezien mentale stoornissen veelvuldig voorkomen in deze populatie. Bij 
psychoactieve medicatie kan gedacht worden aan slaapmiddelen of geneesmiddelen 
die worden gebruikt bij depressie of psychoses. In hoofdstuk 1 geven we een over-
zicht van het metabolisme van zowel de DAAs als de psychoactieve medicatie. Het 
metabolisme van geneesmiddelen is belangrijk voor het voorspellen van geneesmid-
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delinteracties, omdat het metabolisme essentieel is voor de afbraak van geneesmid-
delen. Daarnaast beïnvloeden de DAAs de enzymen die verantwoordelijk zijn voor het 
metabolisme van andere geneesmiddelen, waardoor interacties ontstaan.
Tevens is er een overzicht gemaakt van de onderzoeken die de wisselwerking tussen de 
DAAs en psychoactieve medicatie hebben bestudeerd. Als er geen onderzoeken naar 
bepaalde combinaties zijn gedaan, werden deze overzichten over het metabolisme 
van de DAAs en psychoactieve medicatie, gebruikt om voorspellingen te doen welke 
geneesmiddelen veilig samen gebruikt kunnen worden. Hieruit blijkt dat escitalopram 
en citalopram (beide geneesmiddelen gebruikt voor onder andere depressie) veilig ge-
bruikt kunnen worden in combinatie met de DAAs. Opvallend was dat met ledipasvir en 
sofosbuvir geen interactie onderzoeken zijn uitgevoerd. Echter, we voorspellen weinig 
tot geen interacties tussen psychoactieve medicatie en ledipasvir en sofosbuvir. Dit 
komt doordat deze middelen een gunstig interactieprofiel hebben. Simeprevir en pari-
taprevir/ritonavir, ombitasvir en dasabuvir zijn de geneesmiddelen waarbij de meeste 
interacties zijn voorspeld. Dit komt doordat ze cytochroom P450 enzymen (CYP3A4) 
in de lever beïnvloeden. Dit zijn de meest belangrijke enzymen betrokken bij genees-
middelmetabolisme. De conclusie van hoofdstuk 1 is dat er weinig onderzoeken in 
mensen zijn gedaan waarin de interacties tussen DAAs en psychoactieve medicatie 
worden onderzocht. Deze onderzoeken zijn nodig om de voorspellingen te verifiëren.
Wanneer geneesmiddelen op de markt komen wordt er een professionele bijsluiter 
gepubliceerd. Dit wordt het geneesmiddel label genoemd. In dit label staan alle onder-
zoeken beschreven, inclusief de informatie over geneesmiddelinteracties. In hoofdstuk 
2 bediscussiëren we hoe informatief dit label eigenlijk is voor artsen en apothekers. Dit 
doen we aan de hand van twee recent geregistreerde DAA combinaties: velpatasvir + 
sofosbuvir en grazoprevir + elbasvir. In dit hoofdstuk stellen we ons vier vragen:
1) In het geval dat een nieuw geneesmiddel wordt gemetaboliseerd door CYP3A4 
(substraat), welke CYP-inductoren (versnellen geneesmiddel afbraak) en remmers 
worden genoemd in het label?
2) In het geval een geneesmiddel een CYP inductor is, wanneer leidt dit tot een 
‘contra-indicatie’ met een ander geneesmiddel en wanneer is een combinatie ‘niet 
aanbevolen’. Zijn beide aanbevelingen hetzelfde of is dit niet het geval?
3) Wanneer een geneesmiddel een CYP3A4 remmer is, welke CYP3A4 substraten met 
een nauwe therapeutische breedte worden genoemd in het geneesmiddel label?
4) Geneesmiddelinteracties worden doorgaans bestudeerd met comedicatie die 
wordt gebruikt door de doelgroep populatie; op basis waarvan is deze lijst samen-
gesteld?
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In hoofdstuk 3 beschrijven we vervolgens een geneesmiddelonderzoek met gezonde 
vrijwilligers, waarbij de interactie tussen metformine (bij diabetes mellitus type 2) en 
daclatasvir (DAA) is bestudeerd. 
Naast interacties waarbij enzymen betrokken zijn, vinden interacties plaats op het 
niveau van geneesmiddeltransporters. Deze transporters zijn betrokken bij de verdel-
ing en de eliminatie van geneesmiddelen in het lichaam.
Metformine is onder andere substraat van organic cation transporters (OCTs). Dacla-
tasvir is een mogelijke remmer van deze transporters. Hierdoor kan de metformine 
concentratie in het bloed stijgen, omdat er minder metformine wordt uitgescheiden 
wanneer OCT wordt geremd. Om dit te onderzoeken zijn 20 vrijwilligers behandeld 
met 1000 mg metformine voor 7 dagen gevolgd door 7 dagen 1000 mg metformine 
en 60 mg daclatasvir (of in omgekeerde volgorde). Op dag 7 van elke behandeling 
werd gedurende 24 uur bloed afgenomen waarin de metformine concentraties zijn 
gemeten. Deze uitslagen zijn gebruikt om farmacokinetische parameters te berekenen. 
De uitslagen zijn gebruikt om een beeld te krijgen van de blootstelling van metformine 
in het lichaam. Uit ons onderzoek bleek dat zowel de totale blootstelling, de maximale 
en minimale plasmaconcentratie van metformine niet waren beïnvloed door dacla-
tasvir. Daarom concluderen we in hoofdstuk 3 dat metformine en daclatasvir veilig 
kunnen worden gecombineerd.
In hoofdstuk 4 wordt een tweede interactie onderzoek met daclatasvir beschreven. In 
dit geval met atazanavir/ritonavir en atazanavir/cobicistat. Beide combinaties worden 
gebruikt voor de behandeling van hiv. Een lage dosering ritonavir en cobicistat zijn 
zelf niet werkzaam tegen hiv, maar zijn toegevoegd om het farmacokinetisch profiel 
van atazanavir te verbeteren. Hierdoor kan atazanavir eenmaal daags worden gebruikt 
en is er minder kans op resistentievorming. Zowel ritonavir als cobicistat zijn sterke 
remmers van CYP3A4. Hierdoor wordt ook het metabolisme van daclatasvir geremd en 
neemt de concentratie van daclatasvir toe in het bloed. In combinatie met atazanavir/
ritonavir moet de dosering van daclatasvir daarom worden verlaagd van 60 mg per 
dag naar 30 mg per dag. De vraag was of dezelfde dosisverlaging ook nodig zou zijn 
wanneer daclatasvir wordt gecombineerd met atazanavir/cobicistat. Daarom kregen 
16 gezonde vrijwilligers 30 mg daclatasvir en 300/100 mg atazanavir/ritonavir voor 10 
dagen gevolgd door 30 mg daclatasvir en 300/150 mg atazanavir/cobicistat voor 10 
dagen (of andersom). Wederom werd op dag 10 bloed afgenomen zodat de farmacoki-
netische parameters berekend konden worden. De totale blootstelling, de maximale en 
minimale plasmaconcentratie van daclatasvir was vergelijkbaar tussen beide groepen. 
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Daarom kan worden geconcludeerd dat 30 mg daclatasvir de juiste dosering is met 
gelijktijdig gebruik van atazanavir/cobicistat.
In hoofdstuk 5 is onderzocht hoe groot het risico voor HCV-patiënten op een ge-
neesmiddelinteractie is. Hiervoor hebben we de medicatiegegevens verzameld die 
Nederlandse HCV-patiënten gebruikten, en dus geen HCV-medicatie. We hebben de 
interacties tussen deze comedicatie en de beschikbare DAA-regimes voorspeld met 
behulp van de database van de Universiteit van Liverpool (http://www.hep-drugin-
teractions.org). Wanneer een combinatie van geneesmiddelen wordt gecontroleerd 
op interacties kunnen er vier adviezen worden gegeven: categorie 1) er is geen inter-
actie, geen actie nodig; categorie 2) er is een mogelijke interactie, verlaag/verhoog 
de dosering of monitor de patiënt; categorie 3) er is een contra-indicatie, gebruik de 
geneesmiddelen niet gelijktijdig; categorie 4) er is geen informatie over de combinatie 
aanwezig. Categorie 2 en 3 werden klinisch relevant beschouwd. In ons onderzoek zijn 
461 patiënten geïncludeerd waarvan 77% geneesmiddelen gebruikten. Antidepressiva 
(7,1%), protonpomp remmers (7,1%) en benzodiazepinen (7,1%) waren de meest ge-
bruikte geneesmiddelgroepen. We voorspelden dat 60% van de patiënten een klinisch 
relevante interactie zou hebben met minimaal een van de DAA-regimes. De meeste 
interacties werden voorspeld met paritaprevir/ritonavir, ombitasvir en dasabuvir; de 
minste interacties met grazoprevir en elbasvir.
In hoofdstuk 6 hebben we een vergelijkbare analyse uitgevoerd met patiënten met 
zowel een hiv als een HCV-infectie. We voorspelden hoeveel patiënten een interactie 
zouden hebben met combinatie antiretrovirale therapie (cART) en andere comedicatie. 
cART wordt gebruikt voor de behandeling van een hiv-infectie. Hiervoor is het ATHENA-
cohort gebruikt, beheerd door de Stichting hiv-monitoring (http://www.hivmonitoring.
nl). Dit is een database waarin alle Nederlandse hiv-patiënten zijn geregistreerd, met 
uitzondering van de patiënten die hebben aangegeven niet te willen deelnemen. Alle 
patiënten met een co-infectie op 1 januari 2015 werden geïncludeerd en informatie 
over zowel de cART en de andere comedicatie werd verzameld. Interacties met de 
verschillende DAA-regimes zijn wederom gecontroleerd met behulp van de database 
van de Universiteit van Liverpool. In totaal konden we de gegevens van 777 patiënten 
evalueren waarvan 98% met cART werd behandeld. 63% van de patiënten gebruikte 
comedicatie. Met deze comedicatie had 38% van de patiënten een klinisch relevante 
interactie met één van de DAA-regimes (categorie 2 of 3). Daclatasvir + sofosbuvir is 
het regime dat het makkelijkst is te combineren met cART. Wanneer daclatasvir wordt 
gebruikt voor de HCV-behandeling behoeft de cART geen aanpassing. Grazoprevir + 
elbasvir is het DAA-regime dat het lastigste is te combineren met cART; 75% van de 
patiënten zou dan hun cART moeten aanpassen.
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In hoofdstuk 5 en 6 hebben we het risico van geneesmiddel-geneesmiddel interacties 
tussen DAAs en comedicatie/cART voorspeld. In hoofdstuk 7 hebben we bestudeerd 
wat er daadwerkelijk voor interacties waren tijdens de behandeling met de DAAs. Dit 
is wederom bestudeerd in hiv/HCV-patiënten waarvan data beschikbaar waren in het 
ATHENA-cohort. Dit waren patiënten die zijn behandeld met DAAs tussen januari 2015 
en mei 2016. Van al deze patiënten verzamelden we informatie over het DAA-regime, 
cART en andere comedicatie. Met behulp van de Liverpool database is gekeken naar 
de interacties tussen het gekozen DAA-regime, cART en andere comedicatie. In totaal 
zijn er 423 patiënten behandeld met DAAs, waarvan 418 (99%) cART gebruikten en 
251 (59%) comedicatie. Voor de gekozen behandeling met DAAs hadden 84 patiënten 
een categorie 2 of 3 interactie met comedicatie en de DAA-behandeling. Bij 17 (20%) 
patiënten is de interactie voorkomen door de comedicatie te stoppen. Wat betreft de 
cART, 196 patiënten gebruikten een cART regime dat een interactie had met het DAA-
regime. Categorie 2 interacties werden voorkomen bij 78/147 (53%) en categorie 3 bij 
47/49 (96%) van de patiënten, doordat bij deze patiënten de cART werd aangepast 
naar een regime zonder een interactie. We hebben in dit hoofdstuk laten zien dat de 
Nederlandse hiv-behandelaren goed op de hoogte zijn van de mogelijke interacties 
tussen DAAs, comedicatie en cART en deze ook goed kunnen voorkómen.
DEEL 2: 
Ribavirine farmacokinetiek en ‘therapeutic drug monitoring’ 
Ribavirine wordt toegevoegd aan de behandeling met DAAs om de effectiviteit te 
bevorderen bij patiënten die moeilijker te genezen zijn. Het gaat dan om patiënten 
met cirrose, bij wie een eerdere behandeling gefaald heeft, of die geïnfecteerd zijn met 
HCV-genotype 1a of 3. 
Ribavirine heeft een sterke concentratie-effect relatie. Dit betekent in het geval van riba-
virine dat zowel de effectiviteit als de toxiciteit (bijwerkingen; anemie [bloedarmoede]) 
gerelateerd zijn aan de plasmaconcentratie van ribavirine. Hoe hoger de plasmacon-
centratie hoe beter de effectiviteit is, maar ook een hogere kans op bijwerkingen. 
Ribavirine is een kandidaat voor zogenaamde therapeutic drug monitoring (TDM). Bij 
TDM worden geneesmiddelconcentraties in het bloed bepaald, welke worden gebruikt 
voor het aanpassen van de dosering. Ribavirine is een kandidaat voor TDM omdat er 
sprake is van een concentratie-effect relatie en er grote inter -patiënt variatie is. Dit betek-
ent dat eenzelfde dosis bij twee patiënten voor verschillende blootstelling kan zorgen. 
Om ribavirine concentraties te meten in het bloed is door verschillende laboratoria een 
methode ontwikkeld om ribavirine te meten. Om de kwaliteit van deze bepalingen 
extern te controleren is er een internationaal kwaliteitsprogramma voor ribavirine 
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ontwikkeld. De resultaten van het eerste jaar van het programma zijn beschreven in 
hoofdstuk 8. Dit kwaliteitsprogramma, uitgevoerd door de sectie Kwaliteitsbewaking 
Klinische Geneesmiddelanalyse en Toxicologie (http://www.kkgt.nl), is onderdeel van 
de Stichting Kwaliteitsbewaking Medische Laboratoriumdiagnostiek (SKML, http://
www.skml.nl). 
Via de post is er kalfsplasma verstuurd waaraan een bekende hoeveelheid ribavirine 
was toegevoegd. Er zijn monsters gemaakt met zowel een lage als een hoge con-
centratie ribavirine. In 2015 hebben er twee rondes plaatsgevonden. De monsters 
zijn op de gebruikelijke manier geanalyseerd door de deelnemende laboratoria. De 
ribavirine concentraties zijn vervolgens gerapporteerd aan de KKGT. Een monster was 
juist geanalyseerd wanneer de gerapporteerde concentratie viel binnen 80-120% van 
de ingemeten concentratie. In totaal hebben 8 laboratoria meegedaan, waarvan twee 
deelnemers maar aan 1 ronde hebben meegedaan. In ronde 1, was 81% (13/16) van de 
monsters juist gemeten. De variatie in de metingen van de lage monsters was 86-336% 
en bij de monsters met hoge concentratie 55-160%. In ronde twee was 75% (9/12) van 
de monsters juist gemeten. De monsters met lage concentratie hadden een variatie 
van 97-303% en monsters 97-148% met de hoge concentratie. Het doel van een kwalit-
eitsprogramma is om analysemethodes extern te valideren zodat de kwaliteit van de 
methodes verbeterd wordt. Laboratoria die ribavirine niet juist hebben bepaald, wordt 
geadviseerd de analysemethode aan te passen.
In hoofdstuk 9 is de relatie tussen ribavirine concentratie en effectiviteit van de HCV-
behandeling bestudeerd. Patiënten die zijn behandeld met de nieuwe DAAs en riba-
virine werden geïncludeerd in deze studie. Tijdens de behandeling is bloed afgenomen 
(week 8, steady-state) om de ribavirine concentratie te bepalen. De gemiddelde 
ribavirine startdosering was 13,6 mg/kg/dag. Op week 8 was de gemiddelde ribavirine 
plasmaconcentratie 2,66 mg/L. In multivariabele analyse hebben we laten zien dat een 
hogere plasmaconcentratie van ribavirine sustained virological response (SVR [genez-
ing van het virus]) voorspelt. Hieruit kon een therapeutisch venster van 2.28-3.61 mg/L 
worden afgeleid. In totaal hebben 89% van de patiënten een SVR behaald, wat betek-
ent dat 89% van de behandelde patiënten was genezen van HCV. 
In hoofdstuk 10 is een vergelijkbare analyse gedaan, echter zijn nu hiv/HCV-patiënten 
uit Thailand geëvalueerd. Deze patiënten zijn behandeld met oude therapie bestaande 
uit peginterferon en ribavirine. Het is bekend dat hiv/HCV-patiënten die met deze 
therapie worden behandeld een lagere kans hebben op respons en dat de hiv/HCV-
patiënten ook lagere ribavirine plasmaconcentraties hebben. In totaal hebben we 101 
patiënten geëvalueerd waarvan 56% een SVR heeft bereikt. De steady-state concentra-
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tie was 1.81 mg/L met een inter-patiënt variabiliteit van ongeveer 29% en intra patiënt 
variabiliteit van 18%. 
DEEL 3: 
Behandeling van HCV in speciale patiënten populaties
Het HCV-virus repliceert zich in de lever waardoor het leverontsteking en levercir-
rose kan veroorzaken. HCV patiënten hebben ook regelmatig nierfunctiestoornissen. 
hoofdstuk 11 is een review waarin de behandelingsmogelijkheden voor patiënten 
met lever- of nierfunctiestoornissen wordt besproken. Dosisaanpassingen kunnen 
nodig zijn aangezien de lever en nieren belangrijk zijn voor de eliminatie van genees-
middelen. 
Patiënten met gecompenseerde (Child-Pugh klasse A) levercirrose kunnen worden 
behandeld met alle DAAs, echter patiënten met gedecompenseerde cirrose (Child-
Pugh klasse C) zijn moeilijker te genezen. Voor patiënten met nierfunctiestoornissen 
(nierfunctie <30 mL/min) geldt dat grazoprevir + elbasvir gebruikt kan worden bij 
patiënten met een genotype 1 of 4 HCV-infectie. Ledipasvir + sofosbuvir en velpatasvir 
+ sofosbuvir wordt afgeraden bij deze patiënten.
In hoofdstuk 12 hebben we een computermodel (physiology-based pharmacoki-
netic [PBPK] model) gebruikt om de farmacokinetiek van daclatasvir te voorspellen 
bij mensen met levercirrose. Helaas waren we niet in staat om het computermodel 
te valideren met humane data. De gesimuleerde en gemeten daclatasvir plasmacon-
centraties kwamen niet overeen. Deze verschillen worden mogelijk veroorzaakt door 
veranderingen in de expressie van transporters die aanwezig zijn in de darm en in de 
lever bij patiënten met levercirrose. 
DEEL 4: 
De bijdrage van een apotheker aan de behandeling van hepatitis C
In het laatste deel van het proefschrift worden vier case reports besproken. Dit zijn vijf 
individuele patiënten die behandelend zijn met DAAs. Bij al deze patiënten was iets 
bijzonders aan de hand. Uit deze casussen blijkt des te meer hoe een apotheker kan 
bijdragen aan de optimale en veilige behandeling van HCV.
De eerste patiënt werd behandeld met 60 mg daclatasvir in combinatie met etravirine 
en darunavir/ritonavir voor zijn hiv-infectie. Etravirine versnelt (induceert) het metabo-
lisme van daclatasvir via CYP3A4 waardoor de geadviseerde dosering voor daclatasvir 
90 mg is in plaats van 60 mg. Darunavir/ritonavir remt dit metabolisme enigszins maar 
de geadviseerde dosering daclatasvir is de normale dosering van 60 mg. De combinatie 
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van daclatasvir, etravirine en darunavir/ritonavir is niet onderzocht. We hebben deze 
patiënt behandeld met 60 mg daclatasvir aangezien we vermoedden dat de remming 
de inductie van CYP3A4 zou opheffen. We hebben de plasmaconcentratie gemeten en 
de blootstelling van daclatasvir was vergelijkbaar met waarden bekend in de literatuur. 
In combinatie met etravirine en darunavir/ritonavir lijkt 60 mg daclatasvir de juiste 
dosering vanwege de blootstelling en omdat de patient het virus heeft geklaard.
De tweede patiënt had epilepsie waarvoor de patiënt werd behandeld met oxcar-
bazepine. Ook oxcarbazepine is een sterke inductor van CYP3A4 en P-gp waardoor de 
plasmaconcentraties van daclatasvir en sofosbuvir mogelijk zouden dalen. Deze patiënt 
is effectief behandeld met 90 mg daclatasvir en een normale dosering sofosbuvir. De 
blootstelling van daclatasvir was lager dan verwacht. Daarom blijft voorzichtigheid 
geboden bij patiënten die worden behandeld met sterke inductoren.
Het derde case report beschrijft twee patiënten die beide in het verleden een levertrans-
plantatie hebben ondergaan. Na een orgaantransplantatie gebruiken deze patiënten 
immunosuppressiva die de weerstand onderdrukken zodat de nieuwe lever niet wordt 
afgestoten door het lichaam. Beide patiënten gebruikten hiervoor tacrolimus (immu-
nosuppressief geneesmiddel). Tacrolimus wordt gemetaboliseerd door CYP3A4. Beide 
patiënten waren ook geïnfecteerd met HCV, waarvoor ze werden behandeld met DAAs. 
Er is geen interactie tussen de door deze patiënt DAAs en tacrolimus. Echter tijdens de 
behandeling hadden beide patiënten een hogere dosering tacrolimus nodig, omdat 
de plasmaconcentratie van tacrolimus lager was dan verwacht. We bediscussiëren dat 
deze verhoogde behoefte aan tacrolimus wordt veroorzaakt door de normalisatie van 
de activiteit van CYP-enzymen in de lever gedurende de behandeling met DAAs. HCV 
zelf heeft invloed op de CYP-enzymen waardoor bij genezing het metabolisme van 
geneesmiddelen kan veranderen.
De laatste patiënt die wordt besproken is eerder behandeld met DAAs. Tijdens deze 
eerdere behandelingen heeft de patiënt resistentie ontwikkeld. Daarnaast heeft de 
patiënt recent bariatrische chirurgie ondergaan. Dit betekent dat er een bypass van de 
maag naar de darm is gecreëerd. Hierdoor worden voedingsstoffen minder goed op-
genomen wat resulteert in gewichtsverlies. Dit heeft echter ook invloed op de blootstel-
ling van geneesmiddelen, deze worden mogelijk ook minder goed opgenomen. Deze 
patiënt is behandeld met simeprevir + sofosbuvir + ribavirine voor de HCV-infectie. Dit 
regime was de enige optie vanwege de resistentie die eerder was ontwikkeld. Tijdens 
de behandeling is bloed afgenomen om de blootstelling van simeprevir te volgen. Het 
bleek dat de blootstelling lager was ten opzichte van de referentiewaarden. Hierom is 
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besloten de dosering van simeprevir te verdubbelen, waardoor de blootstelling toe 
nam. De patiënt heeft SVR behaald en is dus genezen. 
DISCuSSIE
In het laatste hoofdstuk van dit proefschrift worden bovenstaande delen bedis-
cussieerd. De discussie wordt gestart met de geneesmiddelinteracties. We bespreken 
hoe geneesmiddelinteractie onderzoeken worden opgezet (zowel in het laboratorium 
als in de mens) en welke geneesmiddelen er eigenlijk moeten worden bestudeerd in 
combinatie met de nieuwe DAAs. Daarnaast wordt besproken hoe apothekers bijdra-
gen aan het management van geneesmiddelinteracties.
Ten tweede wordt de rol van ribavirine TDM besproken. Wij denken dat moeilijk te 
genezen patiënten (zoals patiënten met levercirrose of nierfunctie problemen) mogelijk 
voordeel hebben van TDM. Vooral patiënten die geen bijwerkingen ervaren van riba-
virine. Deze patiënten hebben mogelijk een te lage plasmaconcentratie en profiteren 
van een dosisverhoging om zo de kans op SVR te verhogen. 
Als laatste worden de patiënten met lever- en nierfunctiestoornissen besproken. Er is 
nog geen geschikte behandeling voor patiënten met nierfunctiestoornissen die niet 
in aanmerking komen voor behandeling met grazoprevir + elbasvir. Tevens is er voor 
de patiënten met gedecompenseerde cirrose een behandelingsdilemma. Wanneer 
moeten deze patiënten worden behandeld? Voor of na de levertransplantatie?
De discussie wordt afgesloten met een sectie waarin de eradicatie van HCV centraal 
staat. HCV is vandaag de dag goed te behandelen, maar het meest belangrijk is dat alle 
patiënten worden opgespoord en dat vervolgens al deze patiënten toegang krijgen tot 
zorg en de geneesmiddelen. Omdat de DAAs op dit moment erg duur zijn, blijft de prijs 
een beperkende factor in veel landen.
De discussie wordt afgesloten met een opmerking dat het hele proefschrift, maar 
vooral het laatste deel waarin de individuele patiënten worden besproken goede 
voorbeelden zijn van a pharmacist’s contribution to eradicate hepatitis C.
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DAnKwooRD 
Na precies 2 jaar en 11 maanden mag ik met trots mijn proefschrift aan u tonen. Dit pro-
efschrift is mede mogelijk gemaakt door vele personen. Als onderzoeker en apotheker 
heb ik veel geleerd en bijzondere mensen ontmoet. Met plezier heb ik met verschil-
lende onderzoekers samengewerkt gedurende dit traject. Daarom wil ik iedereen die 
een bijdrage heeft geleverd hiervoor danken. 
Een speciaal woord van dank voor: 
Prof. dr. D.M. Burger, beste David, het was me een waar genoegen om samen met jou te 
mogen werken aan dit prachtige onderwerp. Ik heb veel van je geleerd. Als onderzoeker 
en als apotheker. De passie die je hebt voor het vak en de parate kennis maken je tot 
een onmisbaar lid van het hiv- en hepatitisbehandelteam. Ik ga onze samenwerking 
missen. Bedankt voor alle kansen die je me hebt gegeven en het eindeloze vertrouwen!
Prof. dr. J.P.H. Drenth, beste Joost, ik ken niemand die zo snel zulke accurate feedback 
kan geven als jij. Ik heb dit altijd enorm gewaardeerd. Je was wat meer op afstand, 
maar toch altijd betrokken bij het onderzoek. De waardering voor mijn werk liet je altijd 
blijken wat me zelfvertrouwen gaf. Het was erg leerzaam om zo’n bevlogen clinicus in 
mijn begeleidingsteam te hebben!
Dr. C.T.M.M. de Kanter, lieve Klaartje, je bent onwijs bescheiden, en dat siert je. Jij bent 
degene geweest die de foutjes uit de manuscripten haalde en altijd kwam met goede, 
andere ideeën. Je stond altijd voor me klaar, al was dat op afstand, toch mocht/mag ik 
je altijd bellen over hepatitis C of over privézaken. Ik bewonder hoe je werk combineert 
met Bram en Roos. Je bent een voorbeeld voor me als ziekenhuisapotheker.
Naast de dagelijkse begeleiding door mijn promotoren en copromotor wil ik graag 
Remco de Jong bedanken, hoofd apotheek, voor het mogelijk maken van onderzoek 
op de afdeling. Daarnaast natuurlijk alle andere ziekenhuisapothekers, apothekers, 
onderzoekers, zeil-genoten en medewerkers van de apotheek voor de fijne tijd in het 
Radboud. Speciale dank gaat uit naar Khalid, Noor, Marga en Kirsten van het lab.
Daarnaast ook de patiënten en gezonde vrijwilligers die hebben deelgenomen aan de 
studies. Evenals de mede-onderzoekers, artsen, verpleegkundigen, coauteurs en pro-
movendi in het land. Of course, I also would like to thank all co-authors and researchers 
from abroad! 
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Dr. A. Colbers, of doen we nu E.P.H Colbers, lieve Angela, bedankt! Je bent koningin van 
de fase 1 onderzoek, GCP en WinNonlin. Ik heb het voorrecht gehad om veel met je te 
mogen samenwerken en op reis te gaan. Zonder jou was ik nog steeds bezig met de 
DATEs, dat is een ding wat zeker is. 
Simon en Karin, bedankt dat ik menig keer met jullie op de poli mocht meekijken. Floor, 
bedankt voor de bijzondere samenwerking, de leuke congressen en alle koffie die we 
samen hebben gedronken. We hebben veel tijd samen doorgebracht, wat voor ons 
beiden leerzaam is geweest. Onze twee verschillende karakters hebben gezorgd voor 
een mooi eindresultaat! Succes met de opleiding, hopelijk kruisen onze wegen elkaar 
nog vaak in de toekomst.
Ook een woord van dank voor de collega’s uit het Isala ziekenhuis te Zwolle. Bedankt 
voor jullie interesse en steun tijdens de laatste loodjes van het onderzoek. Peter, bedankt 
voor het vertrouwen en de vrijheid die je me hebt gegeven in de afrondende fase.
Paradijsvogels, lieve Vincent, Lisa, Lindsey, Stein, Roeland, Krista, Pauline en Mette. Wat 
heb ik geboft met zulke fantastische collega’s. Jullie maakten het promotietraject com-
pleet met heel veel gezelligheid. In het paradijs, Sint Anneke, tijdens congressen, maar 
ook de vele leerzame discussies over NCA, PK, en PD zal ik niet snel vergeten. Vincent, 
eerst schimmels, toen gezellig HCV. In het Radboud of op congres, het is altijd fijn om 
met je bij te kletsen en natuurlijk, heel hard te lachen. Lisa, niemand is zo oprecht als 
jij. Jouw veerkracht in moeilijke tijden is uniek. Ik kijk uit naar onze opleidingsdagen 
samen. Lindsey, als bio medicus heb je me veel bijgebracht over transporters en in vitro 
werk. Altijd geduldig, altijd jezelf, je bent een topper! Stein, co-infectie, bureau-vriend. 
Wat ben je toch een creatieve, slimme kerel. Succes met de laatste loodjes en het moois 
wat de toekomst je gaat brengen. Roeland, je hebt de gave voor het vreemde verhaal. 
Je schoonmaakster zal ik niet snel vergeten. Het was even wennen, maar nu helemaal 
geïntegreerd. 
Lieve paranifmen, lieve Krista, Pauline en Mette. Wat ben ik blij dat jullie naast mij staan! 
Kris, wat heb ik geluk gehad om samen met je te mogen beginnen. Dat schept een 
speciale band. En dan ook nog een paardenmeisje! Jouw soft skills zijn uniek. Jij kunt 
echt met iedereen vrienden worden en ook blijven. Dat doet geen onderzoeker je na. 
Dank dat je mijn vriendinnetje bent geworden.
Pau, wat een fijne collega en vriendin ben jij. Ik bewonder je als ziekenhuisapotheker. 
Zo kundig en altijd doordacht. Ik ga onze reizen missen, wat was het gezellig in Wash-
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ington, Seattle en Chicago. Onze gedeelde passie voor de MAC en lekker eten kwam 
hierbij goed van pas. Hopelijk, mag ik je nog vaak om wijze raad vragen en gaan we snel 
ons spektakelstuk bakken! 
Mettie, met wie het allemaal begon. Na ons bestuursjaar hebben we altijd contact 
gehouden. Toen jij liever prostaatkanker wilde onderzoeken, was er een plekje vrij bij 
het hepatitis-onderzoek. Je hebt een mooie groep mensen om je heen verzameld. Je 
enthousiasme en positivisme zijn aanstekelijk. Bovenal een geweldig lieve vriendin 
die altijd voor me klaar staat. Dank dat je altijd een uurtje vrij hebt om te luisteren en 
te kletsen. Niet meer dagelijks tijdens een koffie, maar gelukkig nog vaak tijdens een 
autorit van Zwolle naar Arnhem.
Lieve vrienden uit Oss, Arnhem, Groningen of waar jullie ook wonen. Hier was het al-
lemaal om te doen! Vaak onbegrijpelijk wat ik nu precies deed, maar bedankt voor jullie 
belangstelling. Het is heerlijk (en noodzakelijk) om af en toe mensen te spreken buiten 
de farmacie.
Scoopies, dank jullie wel voor de afgelopen 10 jaar. Wat is het fantastisch om jullie als 
club te hebben. Eeuwige interesse in het onderzoek en het vieren van elke mijlpaal. Het 
was fijn om dit met jullie te delen. In goede tijden en slechte tijden. 
Adrie, wat is het een heftig jaar geweest. Ik ben trots hoe je alles hebt opgepakt. 
Oma, dit boekje is voor u. Voor al uw hulp, trots, liefde, cappuccino, boerenkool, ijsjes 
en dagjes uit de afgelopen jaren. Wat hebben wij een geluk met zo’n betrokken oma. U 
bent de allerliefste oma van wereld!
Lieve Iris en Simone, mijn twee geweldige zussen. De twee personen op wie ik altijd 
kan rekenen. Jullie zullen er altijd voor mij zijn en andersom. Degene die me beste 
kennen, met dezelfde arbeidsethos, en altijd geïnteresseerd en behulpzaam. Samen 
zijn we opgegroeid, afgestudeerd, hebben we banen en vriendjes gevonden, huizen 
gekocht (of wéér verhuisd) en nu zijn jullie hier om dit bijzondere moment met mij 
mee te maken.
Mam, bedankt voor je steun en goede adviezen. Altijd als ik weer eens geen keuze kan 
maken, ben jij daar om mij te begeleiden naar het juiste pad. Onze reis naar Boston was 
het hoogtepunt van mijn promotie! Bedankt dat je zo spontaan bent meegegaan! Pap, 
bedankt voor je interesse in hepatitis C en het onderzoek. Door jou heb ik geen tele-
visie- of radioprogramma gemist (op de Nederlandse of Duitse televisie) waar iets werd 
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gezegd over hepatitis C. We hebben elk hoogtepunt gevierd met jouw champagne. 
Jullie zijn er allebei altijd voor ons drieën. Dank jullie wel. 
Arjan, dear Arie, hoe kan ik jou nu bedanken. Je bent degene die me altijd steunt in mijn 
ambities, de volste vertrouwen in me heeft en zo trots is als een pauw. Je hebt presen-
taties aangehoord, plaatjes gemaakt, overuren getolereerd. Bedankt dat je bent wie je 
bent en je leven met mij wilt delen. Jij maakt mij gelukkig en laat me lachen. Samen 
met jou is het leven geweldig! Het afgelopen jaar was moeilijk. Veel is er veranderd. 
Omringd door onze lieve vrienden en familie, kunnen we samen de wereld aan. 2018 
wordt ons jaar! To the moon and back, in de groene kia <3. 
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CuRRICuluM VItAE
Elise Smolders werd op 28 maart 1988 geboren in Nijmegen. Op 1-jarige leeftijd ver-
huisde ze naar Oss waar ze opgroeide en in 2001 het vwo ging doen op het Mondriaan 
Collega. In 2006 behaalde ze haar vwo-diploma. Aansluitend begon Elise met haar 
studie Farmacie aan de Rijksuniversiteit in Groningen waar ze in 2009 haar bachelor be-
haalde en in 2013 haar masterdiploma ontving. Elise schreef haar bacheloronderzoek 
over de lokale toediening van amiodaron op de boezem van het hart. Dit onderzoek 
voerde Elise uit de afdeling Farmaceutische Technologie en Biofarmacie onder leiding 
van prof. dr. Erik Frijlink. Het masteronderzoek van Elise richtte zich op het chronische-
vermoeidheidssyndroom welke ze uitvoerde op de afdeling laboratorium geneeskunde 
onder leiding van prof. dr. Frits Muskiet. Na haar afstuderen verhuisde Elise naar Genève, 
Zwitserland, om daar te stage te lopen bij de World Health Organization op de afdeling 
Essential Medicines. Gevolgd door een stage bij Health Action International in Amster-
dam. Hierna is Elise gaan werken in het Amphia ziekenhuis te Breda.
In 2015 begon Elise met haar promotie traject in de apotheek van het Radboud univer-
sitair medisch centrum te Nijmegen, onder leiding van prof. dr. David Burger, prof. dr. 
Joost Drenth en dr. Klaartje de Kanter. Het onderzoek richtte zich op de farmacologie 
van de direct-acting antivirals welke worden gebruikt voor de behandeling van hepati-
tis C. Dit onderzoek is beschreven in dit proefschrift.
Sinds 1 maart 2017 is Elise in opleiding tot ziekenhuisapotheker in het Isala ziekenhuis 
in Zwolle onder de leiding van dr. Peter ter Horst.
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name PhD candidate: E.J. Smolders
Department: Pharmacy
Graduate School: Radboud Institute for 
health Sciences
PhD period: 01-01-2015 – 01-03-2017
Promotor(s): Prof. D.M. burger, prof. J.P.h. Drenth
Co-promotor(s): Dr. C.t.M.M. de Kanter
Year(s) ECTS
tRAInInG ACtIVItIES
Courses & workshops
Introduction day Radboudumc. 2015 0.8
RIHS graduate school specific introductory course. 2015 0.5
Basiscursus Regelgeving en Organisatie voor Klinisch onderzoekers (BROK), 
PAO Heyendaal, Nijmegen.
2015 2.5
Interpretation of population pharmacokinetics, NVZA, Leiden. 2015 0.2
PhD retreat + poster presentation. 2015 0.75
Management for PhD students, PAO Heyendaal, Nijmegen. 2015 2.0
SPSS introduction course, PAO Heyendaal, Nijmegen. 2015 0.6
Academic writing for PhD students, PAO Heyendaal, Nijmegen. 2015-2016 3.0
Hepatitis C masterclass, Virology Education, Utrecht. 2015-2016 1.4
Scientific integrity course, POA Heyendaal, Nijmegen. 2016 1.5
Proficiency English, Radboud in’to Languages, Nijmegen. 2016-2017 2.8
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resistentie - focus op HIV en HCV. Anselmus Colloquium, Utrecht.
2015 0.5
Lecture: Hepatitis C casuïstiek. HCV speakers tour, Nijmegen. 2016 0.45
Lecture: Clinical case presentation: drug-drug interactions in hepatitis C 
patients. 17th International Workshop on Clinical Pharmacology of Antiviral 
Therapy of HIV & Hepatitis, Washington DC, USA.
2016 -
Lecture: Drug-drug interactions, het richtsnoer hepatitis C in de praktijk. 
Zwolle.
2017 0.45
Lecture: Drug-drug interactions in ageing hepatitis C patients. 18th 
International Workshop on Clinical Pharmacology of Antiviral Therapy, Chicago, 
USA.
2017 -
Symposia & congresses
Accepted abstracts
Oral presentation: Ribavirin plasma level is an independent predictor for 
efficacy in hepatitis C patients treated with DAAs and ribavirin (HepNed study 
002). Nederlandse Ziekenhuisfarmaciedagen, Amersfoort.
2015 -
Oral presentation: Ribavirin plasma level is an independent predictor for 
sustained virologic response in difficult-to-treat hepatitis C-infected patients 
treated with direct-acting antivirals + ribavirin combination (HepNed study 
002). Najaarsvergadering Nederlandse Vereniging voor Gastroenterologie, 
Veldhoven.
2016 -
	
	
	
Therapy	of	HIV	&	Hepatitis,	Washington	DC,	USA.	
Poster	presentation:	Evaluation	of	ribavirin	plasma	concentrations	in	HIV/HCV	co-
infected	patients	from.	17
th
	International	Workshop	on	Clinical	Pharmacology	of	
Antiviral	Therapy	of	HIV	&	Hepatitis,	Washington	DC,	USA.	
2016	 -	
Poster	presentation:	Daclatasvir	30	mg/day	is	the	correct	dose	for	patients	taking	
atazanavir/cobicistat.	17
th
	International	Workshop	on	Clinical	Pharmacology	of	
Antiviral	Therapy	of	HIV	&	Hepatitis,	USA.	
2016	 -	
Poster	presentation:	High	risk	on	drug-drug	interactions	during	hepatitis	C	treatment:	a	
nationwide	cohort.	17
th
	International	Workshop	on	Clinical	Pharmacology	of	Antiviral	
Therapy	of	HIV	&	Hepatitis,	Washington	DC,	USA.	
2016	 -	
Poster	presentation:	Pharmacokinetics	of	daclatasvir	in	cirrhotic	patients:	challenges	in	
PBPK	modeling.	18
th
	International	Workshop	on	Clinical	Pharmacology	of	Antiviral	
Therapy,	Chicago,	USA.	
2017	 -	
P ster	pr sentat on:	Treating	the	“untreatable”:	Adjusted	doses	of	daclatasvir	with	the	
anti-epileptic	drug	carbamazepine	(HepNED	study	003).	18
th
	International	Workshop	
on	Clinical	Pharmacology	of	Antiviral	Therapy,	Chicago,	USA.	
2017	 -	
Poster	presentation:	Management	of	drug-interactions	with	DAAs	in	Dutch	HIV/HCV	
co-infected	patients:	adequate	but	not	perfect.	International	Liver	Congress,	European	
Association	for	the	Study	of	the	Liver,	Amsterdam.	
2017	 -	
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Post	EASL,	Virology	Education,	Utrecht.	 2015-2016	 0.4	
Peer-to-peer	review	HCV,	Virology	Education,	Utrecht.	 2015	 0.2	
International	Liver	Congress,	European	Association	for	the	Study	of	the	Liver,	Vienna,	
Austria.	
2015	 1.5	
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2015-2016	 4.5	
HCV	Advances	Workshop,	Virology	Educatio ,	Amsterdam.	 2016	 0.5	
De	behandeling	van	chronische	hepatitis	C	in	Nederland,	Arnhem.	 2016	 0.2	
Pediatric	drug	development:	a	field	in	maturation,	Dutch	Society	of	Toxicology,	
Nijmegen.	
2016	 0.2	
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USA.	
2017	 2.25	
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atazanavir/cobicistat,	Bristol-Myers	Squibb.	
2015	 -	
Clinical	trial	monitoring	during	the	CRUSTRI	trial.	 2015	 -	
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Oral presentation: Steady state ribavirin pharmacokinetics in chronic hepatitis 
C infected patients with moderate renal impairment taking modern DAA 
combinations: are we dosing too high?! 17th International Workshop on Clinical 
Pharmacology of Antiviral Therapy of HIV & Hepatitis, Washington DC, USA.
2016 -
Poster presentation: Ribavirin plasma level is an independent predictor for 
sustained virologic response in difficult-to-treat hepatitis C-infected patients 
treated with direct-acting antivirals + ribavirin combination (HepNed-002 
study). The Liver Meeting, American Association for the Study of Liver Diseases, 
Boston, USA. 
2016 -
Poster presentation: High risk of drug-interactions in hepatitis C treatment: a 
nationwide cohort. Nederlandse Ziekenhuisfarmaciedagen, Den Bosch. 
2016 -
Poster presentation: Measuring plasma concentrations of ribavirin: first report 
from a quality control. 17th International Workshop on Clinical Pharmacology of 
Antiviral Therapy of HIV & Hepatitis, Washington DC, USA.
2016 -
Poster presentation: Evaluation of ribavirin plasma concentrations in HIV/
HCV co-infected patients from. 17th International Workshop on Clinical 
Pharmacology of Antiviral Therapy of HIV & Hepatitis, Washington DC, USA.
2016 -
Poster presentation: Daclatasvir 30 mg/day is the correct dose for patients 
taking atazanavir/cobicistat. 17th International Workshop on Clinical 
Pharmacology of Antiviral Therapy of HIV & Hepatitis, USA.
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Poster presentation: High risk on drug-drug interactions during hepatitis 
C treatment: a nationwide cohort. 17th International Workshop on Clinical 
Pharmacology of Antiviral Therapy of HIV & Hepatitis, Washington DC, USA.
2016 -
Poster presentation: Pharmacokinetics of daclatasvir in cirrhotic patients: 
challenges in PBPK modeling. 18th International Workshop on Clinical 
Pharmacology of Antiviral Therapy, Chicago, USA.
2017 -
Poster presentation: Treating the “untreatable”: Adjusted doses of daclatasvir 
with the anti-epileptic drug carbamazepine (HepNED study 003). 18th 
International Workshop on Clinical Pharmacology of Antiviral Therapy, Chicago, 
USA.
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Poster presentation: Management of drug-interactions with DAAs in Dutch 
HIV/HCV co-infected patients: adequate but not perfect. International Liver 
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Therapy of HIV & Hepatitis, Washington DC, USA.
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